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 Cardiometabolic phenotypes, including diseases such as cardiovascular disease and type 
2 diabetes (T2D) and related traits such as cholesterol levels, obesity, and lipid levels cause 
significant public health burden in many countries. Genetic and environmental factors contribute 
to the etiology of these phenotypes. While genome-wide association studies (GWAS) have 
identified hundreds of loci associated with cardiometabolic phenotypes, progress towards 
elucidating causal variants and genes has been slow. Many associated variants are located in 
noncoding regions, suggesting a regulatory mechanism. Identifying causal GWAS variants is a 
time-consuming and challenging process. Challenges arise from strong linkage disequilibrium 
(LD) at loci requiring multiple variants to be prioritized investigated. Combining statistical fine-
mapping, overlap with genome-wide regulatory datasets, expression quantitative trait loci 
associations (eQTLs) and functional assays elucidates the variant(s) and gene(s) contributing to 
genetic mechanisms at cardiometabolic GWAS loci. I used these approaches to identify 
functional variants at two cardiometabolic GWAS loci and generated open chromatin profiles in 
adipose tissue. At the CDC123/CAMK1D T2D locus, one variant altered binding to FOXA1 and 
FOXA2 and increased transcriptional activity, suggesting it contributes to the mechanism at this 
locus. At the ANGPTL8 high-density lipoprotein cholesterol (HDL-C) GWAS locus, seven 
variants showed allelic differences in functional assays, suggesting a more complex regulatory 
	 iv	
mechanism that may include multiple variants. Finally, open chromatin profiles were generated 
from frozen human subcutaneous adipose samples and a preadipocyte strain to characterize the 
regulatory landscape of adipose tissue and a cellular model system used to test GWAS variants 
in functional assays. Thorough investigations of GWAS loci are necessary for the development 
of new therapies, full elucidation of direction of effect, and better understanding of the genetic 
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CHAPTER 1: INTRODUCTION 
Genome-wide association studies (GWAS) have identified hundreds of loci associated 
with cardiometabolic phenotypes (www.ebi.ac.uk/gwas/). Most of these loci are located in 
noncoding regions and the underlying functional mechanisms remain unknown. Statistical 
analyses and functional experiments are needed to determine the causal variant(s), which gene(s) 
they act on, and how the gene functions to alter cardiometabolic phenotypes. Robust genomic 
regulatory datasets exist to help inform and prioritize candidate variants, but some tissues, such 
as adipose, are under-represented. The aims of my research were to identify the functional 
variant(s) at the CDC123/CAMK1D type 2 diabetes (T2D) GWAS locus, identify the functional 
variant(s) and gene(s) at the ANGPTL8 high-density lipoprotein cholesterol (HDL-C) GWAS 
locus, and to create a more robust regulatory map of adipose tissue by generating open chromatin 
profiles of human adipose tissue using the assay for transposase-accessible chromatin (ATAC-
seq). Generating ATAC-seq open chromatin profiles from adipose tissue will enhance 
identification of functional variants. A thorough understanding of cardiometabolic GWAS loci is 
necessary to the development of therapies for the appropriate genes (1) and direction of effect 
(2), especially given the increasing recognition of allelic heterogeneity at GWAS loci (3-8).  
 
Overview of cardiometabolic phenotypes 
Cardiometabolic phenotypes encompass a wide range of diseases and related traits that 
cause significant public health burden in many countries (9-11). These phenotypes include T2D, 
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cardiovascular disease (CVD), cholesterol and triglyceride levels, and obesity. T2D is 
characterized by impaired glucose tolerance and/or impaired fasting glucose (12,13). These 
impairments can be caused by decreased insulin secretion from the pancreatic beta cells and 
insulin resistance. People affected with T2D can have multiple complications including vascular 
and circulatory abnormalities that can lead to coronary heart disease, congestive heart failure, or 
stroke (14,15).  
CVD is a leading cause of death worldwide (16). CVD includes multiple conditions 
including heart failure, myocardial infarction, stroke, and high blood pressure (12). Risk factors 
for CVD include high levels of low-density lipoprotein cholesterol (LDL-C), high triglyceride 
levels, and low levels of high-density lipoprotein cholesterol (HDL-C) (17-19). LDL-C and 
triglycerides can contribute to the development of plaques in the bloodstream; the buildup of 
plaque in the bloodstream is called atherosclerosis and is a leading cause of CVD (20). HDL-C 
helps clear plaques by collecting LDL-C to take it away from the arteries and back to the liver 
for disposal, thus decreasing plaque buildup and risk for CVD.  
Obesity is a significant public health burden and is extremely prevalent, especially in the 
United States. Approximately 35% of all adults in the U.S. are obese (21,22). Central adiposity, 
or fat deposited around the abdomen, is associated with CVD and general obesity increases risk 
of other comorbid conditions, including T2D, hypertension, dyslipidemia, osteoarthritis, several 
cancers, and many other detrimental phenotypes (21,23,24). CVD, T2D, and their related risk 





Genetics of cardiometabolic diseases and traits 
Cardiometabolic phenotypes are multifactorial and are influenced by environmental and 
genetic factors. Exercise and diet are known to affect lipid and cholesterol levels and increased 
exercise and a healthy diet can decrease the risk of many cardiometabolic diseases. Bowes et al. 
(26) demonstrated that lifestyle intervention including dietician-led education sessions and 
weekly exercise programs led to weight loss and significant improvement in cardiovascular risk 
factors including lipid and triglyceride levels. Strong evidence exists for a genetic component to 
these phenotypes. Heritability estimates range from 30-77% for T2D (27,28), 40-90% for 
cholesterol and lipid levels (29-34), and 31-70% for waist-to-hip ratio, a measure of obesity 
(31,35-37). GWAS have identified hundreds of loci associated with cardiometabolic phenotypes 
(6,7,38). To date, at least 80 loci have been associated with CVD (39-41) and hundreds of loci 
(>250) have been identified for cholesterol and lipid levels and other CVD risk factors (38,42-
46). At least 184 loci have been identified for T2D (47,48), and at least 200 loci have been 
identified for obesity (6,7). While mechanisms are known at a few loci, most mechanisms remain 
unknown. GWAS have been successful in identifying associated loci, but the next step is to 
move past association on to understanding the function of variant(s) and gene(s) at these loci 
(49,50). 
Much more work is needed to elucidate the mechanisms at cardiometabolic GWAS loci. 
Of the hundreds of loci associated with cardiometabolic traits, only a few have been targeted for 
functional validation. One example, near the TRIB1 gene, identified variants associated with 
HDL-C, LDL-C, triglyceride levels, and myocardial infarction (51). Further studies showed a 
connection of TRIB1 gene function and CVD risk factors; Trib1 overexpression in mouse liver 
decreased cholesterol and lipid levels (52). A second example, near JAZF1, identified variants 
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associated with T2D (53). A common variant, rs1635852 increased transcriptional activity in 
pancreatic beta cells by altering binding of the PDX1 transcription factor, suggesting that 
rs1635852 may contribute to T2D susceptibility. A third example described multiple regulatory 
variants at the GALNT2 HDL-C GWAS locus (54). At least two variants, rs4846913 and 
rs2281721 influence GALNT2 expression by altering transcription factor binding. Several other 
mechanisms at cardiometabolic GWAS loci have been elucidated, but hundreds remain 
unsolved. Characterizing functional mechanisms at GWAS loci is challenging and time-
consuming, but is a vital step to understanding the genetics of cardiometabolic diseases and 
traits.  
This dissertation focuses on elucidating novel genetic mechanisms of cardiometabolic 
diseases and related traits. As previously mentioned, GWAS are strong studies for identifying 
loci associated with cardiometabolic phenotypes, but they do not delineate which gene(s) and 
variant(s) are functioning to alter the phenotype. Many loci are located in noncoding regions, 
suggesting a regulatory mechanism. In most cases, multiple genes located near the association 
signals have plausible biological function. Similarly, any of the variants inherited together in 
linkage disequilibrium (LD) could be contributing to the underlying mechanism. Additional 
statistical analyses and functional studies are needed to determine which gene(s) and variant(s) 
are functional at these loci.  
 
Prioritizing candidate variants at GWAS loci 
Multiple approaches exist to prioritize candidate variants at a GWAS locus (55). As a 
first step, variants in LD with the most significantly associated GWAS variant, or lead variant, 
are considered. Variants in pairwise LD are inherited together more frequently than is expected 
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by chance; a statistical measure of LD is r2, where r2=1.0 means that two variant alleles are 
always inherited together. Traditionally, a LD r2 threshold of 0.8 is used to determine candidate 
variants at a GWAS locus; however, various studies use different, less stringent thresholds (i.e.: 
r2>0.5). All variants in strong LD with the lead variant are considered equally likely to be 
functional. 
After determining the number of candidate variants in LD with the lead variant at a locus, 
statistical fine-mapping analyses and overlap with genomic datasets can be used to select 
variants for follow-up in functional experiments (55). Fine-mapping can have multiple 
definitions. For the purposes of this dissertation, I use two types of fine-mapping: to determine 
the number of signals present at an association locus and to statistically predict functional 
variants using association statistics and/or genomic annotations. For fine-mapping to be 
successful, the variants in LD with the lead variant need to be densely genotyped or imputed 
with high confidence in large enough sample sizes to differentiate between variants in strong 
pairwise LD. The first fine-mapping approach is to determine the number of signals present at a 
GWAS locus by performing conditional analysis. If other variants remain significant after 
conditioning on the lead variant, then there are additional signals present at the GWAS locus. 
Conditional analysis is important to ensure all candidate variants are considered. If multiple 
signals exist, there may be multiple mechanisms of action to alter the associated trait.  
The second fine-mapping approach, statistical fine-mapping, predicts which variants are 
more likely to be functional. Statistical fine-mapping analyses fit in two broad categories: 
prioritizing variants based on association statistics and/or LD and Bayesian methods that assign 
posterior probabilities of functionality to each variant. In this dissertation, I employ three 
statistical fine-mapping analyses. CAVIAR (56) is a method that leverages association statistics 
	 6	
including p-values and effect sizes to determine which variants are most likely to be functional. 
PAINTOR (57) also leverages association strength to prioritize variants, but also includes 
functional genomic annotation data. One Bayesian method is MANTRA (58), which compares 
association signals across diverse populations to prioritize shared variants. CAVIAR and 
MANTRA generate a ‘credible set’ of variants most likely to contain the functional variant. 
PAINTOR predicts a set number of functional variants given by the user before analyzing the 
data. Statistical fine-mapping approaches can reach different predictions; it can be beneficial to 
compare variants predicted by multiple approaches to prioritize variants for functional followup.  
Although some GWAS variants alter the protein coding sequence of genes, the majority 
of GWAS loci are located in noncoding regions. The variants underlying these association 
signals likely have regulatory function, by which the variant alters transcription of a gene 
through differential transcription factor binding or other mechanisms. Another approach for 
prioritizing variants for functional assays is to consider overlap with genomic regulatory regions. 
Large consortium efforts including the Encyclopedia of DNA Elements (ENCODE) (59) and the 
Roadmap Epigenomics Project (60) have created robust datasets for many cell and tissue types to 
describe regions characteristic of regulatory activity. These datasets include chromatin 
immunoprecipitation (ChIP-seq) of histone marks often observed at enhancers, promoters, and 
insulators, and transcription factors. Additionally, multiple datasets of open chromatin profiling 
using DNase hypersensitivity (DNase-seq), formaldehyde-assisted isolation of regulatory 
elements (FAIRE-seq), and ATAC-seq provide maps of ‘open’ regions of the genome. 
Regulatory datasets are useful for identifying regions of regulatory activity and the overlap of 
candidate variants with regulatory regions in the cell types of interest.  
	 7	
Regulatory datasets in cell and tissue types relevant to cardiometabolic diseases are 
needed to make the best prioritization of candidate variants because gene expression and 
regulatory regions can be cell-type specific (59). Many tissues, including liver, blood, adipose, 
pancreas, and others are involved in CVD, T2D, and obesity progression. Multiple assays have 
been performed in liver and blood cell types from the ENCODE (59) and the Roadmap 
Epigenomics Project (60), and recent studies have increased the amount of data for pancreatic 
islet (61). The Roadmap Epigenomics Project (60) has generated ChIP-seq data for histone 
marks, but open chromatin profiling in adipose tissue and adipocyte cell models is lacking. 
ATAC-seq is a particularly useful method to determine open chromatin profiles because it 
requires less tissue/cells and less time than DNase-seq and FAIRE-seq (62). In this dissertation, I 
create open chromatin profiles in three human adipose tissue samples and the SGBS 
preadipocyte cell strain. Characterization of the adipose open chromatin profile will help 
prioritize candidate variants at GWAS loci and contribute to a more complete understanding of 
gene regulation in adipose.  
The gene(s) being acted on at regulatory GWAS loci also need to be identified. One 
method is by expression quantitative trait loci (eQTL) associations. eQTL analysis identifies 
variants associated with the RNA levels of nearby (cis-eQTL) or distant (trans-eQTL) genes. 
Further analysis can determine coincidence of a GWAS association signal with an eQTL signal. 
A coincident eQTL signal suggests that the same variants underlying the GWAS trait association 
are acting on the RNA levels of the eQTL-associated gene. In this dissertation, I use eQTL 
associations identified in the METabolic Syndrome in Men (METSIM) study (63). The 
METSIM study consists of ~10,000 Finnish men and includes dense genotyping, ~200 metabolic 
phenotypes, and eQTL associations in 770 adipose samples. The METSIM study is unique 
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because it includes genotypes, expression, and clinical trait data in the same samples. Combining 
these datasets allows us to identify gene expression associations with clinical traits; for example, 
increased PLA2G7 expression level is associated with increased triglyceride levels (63). In the 
METSIM study, we can identify variant-trait, variant-gene, and gene-trait associations in the 
same set of individuals. If a variant is identified as an eQTL with a specific gene, functional 
experiments can be performed to confirm the role of the gene and determine the mechanism of 
action.  
 
Functional assays of regulatory activity 
Many approaches exist to test regulatory variants in functional experiments (64,65). The 
goal of all functional validation is to determine if variants show allelic differences in function, 
usually resulting in allele-specific effects on gene expression levels. Allelic differences can be 
identified in transcriptional reporter assays, protein binding assays, allelic imbalance in 
sequencing reads, genome editing experiments, physical chromatin interaction assays, and other 
experiments. Transcriptional reporter assays test variant alleles located in regulatory regions for 
differences in transcriptional activity. The regulatory region surrounding an associated variant is 
cloned into a vector containing a reporter gene, usually luciferase or GFP, and transfected in a 
cell line or transiently expressed in a model organism. Luciferase activity is measured and the 
variant alleles are compared to determine any allelic differences in transcriptional activity. In this 
dissertation, reporter assays are performed in cell lines, but they can also be performed in mouse, 
zebrafish, and other model organisms. For cardiometabolic disease loci and in this dissertation, I 
use cell lines derived from adipose, liver, and pancreatic islet. For adipose, mouse 3T3L1 
preadipocytes, human SW872 adipocytes, human SGBS preadipocytes are used. I use two 
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human liver carcinoma cell lines: HepG2 and HUH7. Finally, mouse MIN6 and rat 832/13 
insulinoma cells are used to model human pancreatic beta cells.  
Protein binding assays, including electrophoretic mobility shift assays (EMSA), DNA-
affinity pull downs, and ChIP experiments are used to identify variant alleles that bind 
transcription factors differentially. EMSAs are an in vitro approach that visualizes nuclear 
protein complexes that bind to ~20-bp DNA probes surrounding the candidate variant. The 
DNA-protein complexes are visualized on a gel and identity of the transcription factor can be 
determined using antibodies to transcription factors predicted by conserved transcription factor 
binding motifs or identified by ChIP-seq datasets. DNA-affinity pull downs are similar to 
EMSA; all DNA-protein complexes are captured by a ~20-bp probe surrounding the candidate 
variant and visualized on a gel. Proteins in allele-specific bands are identified using mass 
spectrometry.  
Sequencing data generated from ChIP-seq, DNase-seq, FAIRE-seq, or ATAC-seq can be 
used to identify sites of allelic imbalance. A site of allelic imbalance occurs when a sample is 
heterozygous for a candidate variant and has disproportionate sequencing reads for each allele. 
For example, DNase-seq and CEBPB ChIP-seq reads containing rs4846913-A at the GALNT2 
HDL-C GWAS locus showed more reads than rs4846913-C, suggesting that the A allele 
increases CEBPB binding and open chromatin (54). Although not presented in this dissertation, 
genome editing and physical interaction experiments can be used to test candidate variants. 
Functional assays provide supporting evidence for candidate variants; however, it is necessary to 
use multiple assays and approaches to fully delineate the contribution of all variant(s), 
transcription factor(s), and gene(s) at a GWAS locus.  
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Aims and overview 
The aims of this dissertation are to identify the functional variants at the T2D-associated 
CDC123/CAMK1D locus, the HDL-C-associated ANGPTL8 locus, and to create ATAC-seq open 
chromatin profiles to further characterize the regulatory map of human adipose tissue. The 
variants at both CDC123/CAMK1D and ANGPTL8 are located in regulatory regions. The ATAC-
seq open chromatin profiles generated from human adipose tissue and preadipocytes are used to 
better characterize regulatory elements in these cell types and to prioritize variants at 
cardiometabolic GWAS loci.  
In Chapter 2, I demonstrate the allelic effects on regulatory function of a single variant at 
the CDC123/CAMK1D T2D GWAS locus. To gain insight into the molecular mechanisms 
underlying the association signal, we used genomic regulatory overlap to identify SNPs 
overlapping predicted regulatory regions. Two regions containing T2D-associated variants were 
tested for enhancer activity using luciferase reporter assays. One SNP, rs11257655, displayed 
allelic differences in transcriptional enhancer activity in 832/13, MIN6, and HepG2 cells. The 
rs11257655 risk allele T showed greater transcriptional activity then the non-risk allele C in all 
cell types tested. Using EMSAs, the rs11257655 risk allele showed allele-specific binding to 
FOXA1 and FOXA2. FOXA1 and FOXA2 enrichment at the rs11257655 risk allele was 
validated using allele-specific ChIP in human islets. These results suggest that rs11257655 
affects transcriptional activity through altered binding of a protein complex that includes FOXA1 
and FOXA2, providing a potential molecular mechanism at this GWAS locus. 
In Chapter 3, I investigate candidate regulatory variants at the HDL-C-associated 
ANGPTL8 locus. The ANGPTL8 association with HDL-C levels has been identified in multiple 
populations (38,43,66). Given the extensive sharing of GWAS loci across populations (50), I 
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hypothesized that at least one shared variant at this locus affects HDL-C. The HDL-C-associated 
variants are coincident with eQTLs for ANGPTL8 and DOCK6 in subcutaneous adipose tissue; 
however, only ANGPTL8 expression levels are associated with HDL-C. A 400-bp promoter 
region upstream of ANGPTL8 and enhancer regions within 5 kb contribute to regulating 
expression in liver and adipose. To identify variants functionally responsible for the HDL-C 
association, we performed fine-mapping analyses and selected 13 candidate variants that overlap 
putative regulatory regions to test for allelic differences in regulatory function. Of these variants, 
rs12463177-G increased transcriptional activity (1.5-fold, P=0.004) and showed differential 
protein binding. Six additional variants (rs17699089, rs200788077, rs56322906, rs3760782, 
rs737337, and rs3745683) showed evidence of allelic differences in transcriptional activity 
and/or protein binding. Taken together, these data suggest a regulatory mechanism at the 
ANGPTL8 HDL-C GWAS locus involving tissue-selective expression and multiple potentially 
functional variants. 
In Chapter 4, I describe the open chromatin profile of human adipose tissue using ATAC-
seq. ATAC-seq open chromatin profiles were generated using frozen human subcutaneous 
adipose tissue needle biopsies from three individuals and a preadipocyte cell strain. I compared 
heterogeneous adipose tissue ATAC-seq to homogenous preadipocytes and observed 83 gene 
promoters with ATAC-seq peaks specific to adipose tissue and 437 gene promoters with peaks 
specific to SGBS preadipocytes. 17 transcription factors generated footprints using the ATAC-
seq data. Finally, I identified enrichment of cardiometabolic GWAS loci in ATAC peaks, and 
147 variants at 59 cardiometabolic GWAS loci that also harbor colocalized adipose expression 
quantitative trait loci overlapped ATAC peaks. Of the 147 variants, I further investigated 
	 12	
rs1534696 at the SNX10 waist-to-hip ratio GWAS locus and rs7187776 at the ATP2A1-SH2B1 
BMI GWAS locus and identified allelic differences in functional assays.  
Finally, in Chapter 5 I summarize the major findings of Chapters 2, 3, and 4 and discuss 
the scope and future directions of functionally characterizing GWAS signals for complex 
cardiometabolic traits. 
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CHAPTER 2: IDENTIFICATION OF A REGULATORY VARIANT THAT BINDS 
FOXA1 AND FOXA2 AT THE CDC123/CAMK1D TYPE 2 DIABETES GWAS LOCUS1,2 
 
Introduction 
Type 2 diabetes is a complex metabolic disease with a substantial heritable component 
(67). Over the past seven years, genome-wide association studies (GWAS) have successfully 
identified over 70 common risk variants associated with type 2 diabetes (68-71). Association 
signals at many of these loci localize to non-protein-coding intronic and intergenic regions and 
likely harbor regulatory variants altering gene transcription. In recent years great advances have 
facilitated identification of regulatory elements genome-wide using techniques including DNase-
seq and FAIRE-seq (formaldehyde-assisted isolation of regulatory elements), which identify 
regions of nucleosome depleted open chromatin, and ChIP-seq (chromatin immunoprecipitation), 
which identify histone modifications to nucleosomes and transcription factor binding sites. 
Several studies have successfully integrated trait-associated variants at GWAS loci with publicly 
available regulatory element datasets in disease-relevant cell types to guide identification of 
regulatory variants underlying disease susceptibility (53,72-75). 
 The CDC123 (cell division cycle protein 123) / CAMK1D (calcium/calmodulin-
																																																								
1	This chapter previously appeared as an article in PLoS Genetics. The citation is: Fogarty MP, 
Cannon ME, Vadlamudi S, Gaulton KJ, Mohlke KL. 2014. Identification of a regulatory variant 
that binds FOXA1 and FOXA2 at the CDC123/CAMK1D Type 2 Diabetes GWAS locus. PLoS 
Genetics Sep 11;1-(9):e1004633. 
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dependent protein kinase ID) locus on chromosome 10 contains common variants (MAF >  .05) 
strongly associated with type 2 diabetes in Europeans (rs12779790, P = 1.2 x 10-10) (69), East 
Asians (rs10906115, P = 1.5 x 10-8) (70), and South Asians (rs11257622, P = 5.8 x 10-6) (76). 
Fine-mapping using the Metabochip identified rs11257655 as the lead SNP (68). The index 
variant and proxies (r2 > .7) span an intergenic region of at least 45 kb between CDC123 and 
CAMK1D and overlap the 3’ end of CDC123 (69). None of the type 2 diabetes-associated 
variants at this locus are located in exons. Analysis of the beta cell function measurements 
HOMA-B and insulinogenic index, derived from paired glucose and insulin measures at fasting 
or 30 minutes after a glucose challenge, demonstrated association of the risk allele at the 
CDC123/CAMK1D locus with reduced beta cell function, suggesting the beta cell as a candidate 
affected tissue (68,77). Another intronic variant (rs7068966, r2 =0.18 EUR, 1000G Phase 1) 
located 50 kb away from rs12779790 is associated with lung function (78). 
 The transcript(s) targeted by risk variant activity at this locus remain unknown. CDC123 
is regulated by nutrient availability in yeast and is essential to the onset of mRNA translation and 
protein synthesis through assembly of the eukaryotic initiation factor 2 complex (79,80). 
Evidence from previous GWA studies suggest cell cycle dysregulation as a common mechanism 
in type 2 diabetes; for example, type 2 diabetes association signals are found close to the cell 
cycle regulator genes, CDKN2A / CDKN2B and CDKAL1 (50). CAMK1D is a member of the 
Ca2+/calmodulin-dependent protein kinase family which transduces intracellular calcium signals 
to affect diverse cellular processes. Upon calcium influx in granulocyte cells and hippocampal 
neurons, CAMK1D activates CREB-dependent gene transcription (81,82). Given the roles of 
cytosolic calcium in regulation of beta cell exocytotic machinery and of CREB in beta cell 
survival, CAMK1D may have a role in beta cell insulin secretion. In cis-eQTL analyses, the 
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rs11257655 type 2 diabetes risk allele was more strongly and directly associated with increased 
expression of CAMK1D than CDC123 in both blood and lung (83,84).  
 In this study we aimed to identify the variant(s) underlying the association signal at the 
CDC123/CAMK1D locus using genome-wide maps of open chromatin, chromatin state and 
transcription factor binding in pancreatic islets, hepatocytes, adipocytes and skeletal muscle 
myotubes. We measured transcriptional activity of variants in putative regulatory elements using 
luciferase reporter assays, and identified a candidate cis-acting SNP driving allele-specific 
enhancer activity in two mammalian beta cell-lines as well as hepatocellular carcinoma cells. We 
then evaluated DNA-protein binding in sequence surrounding this variant and identified allele-
specific binding to key islet and hepatic transcription factors. Thus, our study provides strong 
evidence of a functional variant underlying the type 2 diabetes association signal at the 
CDC123/CAMK1D locus acting through altered regulation in type 2 diabetes-relevant cell types. 
 
Materials and Methods 
Selection of SNPs for functional study 
 Variants were prioritized for functional study based on linkage disequilibrium (LD) and 
evidence of being in an islet or liver regulatory element based on data from the ENCODE 
consortium (85). Of 11 variants meeting the LD threshold (r2 ≥ .7, EUR, with the GWAS index 
SNP rs12779790, 1000G Phase 1 release), two SNPs showed evidence of open chromatin 
(72,74,86,87), histone modifications (88-90) or transcription factor binding and were tested for 





 Two insulinoma cell lines, rat-derived 832/13 (91) (C.B. Newgard, Duke University) and 
mouse-derived MIN6 (92) were maintained at 37°C with 5% CO2. 832/13 cells were cultured in 
RPMI 1640 (Cellgro/Corning) supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM L-
glutamine, 10 mM HEPES and 0.05 mM β-mercaptoethanol. MIN6 cells were cultured in 
DMEM (Sigma), supplemented with 10% FBS, 1 mM sodium pyruvate, 0.1 mM β-
mercaptoethanol. HepG2 hepatocellular carcinoma cells were cultured in MEM-alpha (Gibco) 
supplemented with 10% FBS, 1 mM sodium pyruvate and 2 mM L-glutamine.  
 
Generation of luciferase reporter constructs, transient DNA transfection and luciferase reporter 
assays 
 Fragments surrounding each of rs11257655 (151 bp) and rs34428576 (179 bp) were 
PCR-amplified (Table 1) from DNA of individuals homozygous for risk and non-risk alleles. 
Restriction sites for KpnI and XhoI were added to primers during amplification, and the resulting 
PCR products were digested with KpnI and XhoI and cloned in both orientations into the 
multiple cloning site of the minimal promoter-containing firefly luciferase reporter vector 
pGL4.23 (Promega, Madison, WI). Fragments are designated as ‘forward’ or ‘reverse’ based on 
their orientation with respect to the genome. Two to five independent clones for each allele for 
each orientation were isolated, verified by sequencing, and transfected in duplicate into 832/13, 
MIN6 and HepG2 cell lines. Missing haplotypes of rs36062557-rs11257655 constructs were 
created using the QuikChange site directed mutagenesis kit (Stratagene).   
 Approximately 1 x 10-5 cells per well were seeded in 24-well plates. At 80% confluency, 
cells were co-transfected with luciferase constructs and Renilla control reporter vector (phRL-
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TK, Promega) at a ratio of 10:1 using Lipofectamine 2000 (Invitrogen) for 832/13, and using 
FUGENE-6 for MIN6 and HepG2 cells (Roche Diagnostics, Indianapolis, IN). 48 h after 
transfection, cells were lysed with passive lysis buffer (Promega), and luciferase activity was 
measured using the Dual-luciferase assay system (Promega). To control for transfection 
efficiency, raw values for firefly luciferase activity were divided by raw Renilla luciferase 
activity values, and fold change was calculated as normalized luciferase values divided by 
pGL4.23 minimal promoter empty vector control values. Data are reported as the fold change in 
mean (± SD) relative luciferase activity per allele. A two-sided t-test was used to compare 
luciferase activity between alleles. All experiments were carried out on a second independent day 
and yielded comparable allele-specific results. 
 
Electrophoretic mobility shift assay (EMSA) 
 Nuclear cell extracts were prepared from 832/13, MIN6, and HepG2 cells using the NE-
PER nuclear and cytoplasmic extraction kit (Thermo Scientific) according to the manufacturer’s 
instructions. Protein concentration was measured with a BCA protein assay (Thermo Scientific), 
and lysates were stored at -80°C until use. 21 bp oligonucleotides were designed to the sequence 
surrounding rs11257655 risk or non-risk alleles:  Sense 5’ biotin- 
GGGCAAGTGT[C/T]TACTGGGCAT 3’, antisense 5’ biotin- 
ATGCCCAGTA[G/A]ACACTTGCCC 3’ (SNP allele in bold). Double-stranded 
oligonucleotides for the risk and non risk alleles were generated by incubating 50 pmol 
complementary oligonucleotides at 95oC for 5 minutes followed by gradual cooling to room 
temperature. EMSA’s were carried out using the LightShift Chemiluminescent EMSA Kit 
(Thermo Scientific). Binding reactions were set up as follows:  1X binding buffer, 50 ng/µL poly 
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(dI•dC), 3 µg nuclear extract, 200 fmol of labeled probe in a final volume of 20 µL. For 
competition reactions, 67-fold excess of unlabeled double-stranded oligonucleotides for either 
the risk or non-risk allele were included. Reactions were incubated at room temperature for 25 
minutes. For supershift assays, 4 µg of polyclonal antibodies against FOXA1 (ab23738; Abcam) 
or FOXA2 (SC6554X; Santa Cruz Biotechnology) was added to the binding reaction and 
incubation proceeded for a further 25 minutes. Binding reactions were subjected to non-
denaturing PAGE on DNA retardation gels in 0.5X TBE (Lonza), transferred to Biodyne nylon 
membranes (Thermo Scientific) and cross-linked on a UV-light cross linker (Stratagene). Biotin 
labeled DNA-protein complexes were detected by chemiluminescence. EMSAs were carried out 
on a second independent day and yielded comparable. 
 
DNA affinity capture assay 
 DNA affinity capture was carried out as previously described (53). Briefly, dialyzed 
nuclear extracts (300 µg) were pre-cleared with 100 µl of streptavidin-agarose dynabeads 
(Invitrogen) coupled to biotin-labeled scrambled control oligonucleotides. For DNA-protein 
binding reactions, 40 pmol of biotin labeled probe for either rs11257655 allele (same probe as 
for EMSA) or for a scrambled control were incubated with 300 µg nuclear extract, binding 
buffer (10 mM Tris, 50 mM KCL, 1 mM DTT), 0.055 µg/µL poly (dI•dC) and H20 to total 450 
µL at room temperature for 30 minutes with rotation. 100 µL (1mg) of streptavidin-agarose 
dynabeads were added and the reaction incubated for a further 20 minutes. Beads were washed 
and DNA-bound proteins were eluted in 1X reducing sample buffer (Invitrogen). Proteins were 
separated on NuPAGE denaturing gels and protein bands stained with SYPRO-Ruby. Protein 
bands displaying differential binding between rs11257655 alleles were excised from the gel and 
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subjected to matrix assisted laser desorption time-of-flight/time-of-flight tandem mass 
spectrometry (MS) and analysis at the University of North Carolina proteomics core facility. For 
peptide identification, all MS/MS spectra were searched against all entries, NCBI non-redundant 
(NR) database, using GPS Explorer TM Software Version 3.6 (ABI) and the Mascot 
(MatrixScience) search algorithm. Mass tolerances of 80 ppm for precursor ions and 0.6 Da for 
fragment ions were used. In addition, two missed cleavages were allowed and oxidation of 
methionine was a variable modification. 
 
Chromatin Immunoprecipitation (ChIP) assays 
 Human islets from non-diabetic organ donors were provided by the National Disease 
Research Interchange (NDRI). Use of human tissues was approved by the University of North 
Carolina Institutional Review Board. Islet viability and purity were assessed by the NDRI. Islets 
were warmed to 37oC and washed with calcium- and magnesium-free Dulbecco’s phosphate-
buffered saline (Life Technologies) prior to crosslinking. For chromatin immunoprecipitation 
(ChIP) studies, approximately 2000 islet equivalents (IEQs) were crosslinked for 10 min in 1% 
formaldehyde (Sigma-Aldrich) at room temperature. Islets were lysed and chromatin was 
sheared on ice using a standard bioruptor (Diagenode; 20–22 cycles of 30 s sonication with 1 
min rest between cycles) to a size of 200–1000 bp. IP dilution buffer (0.01% SDS, 1.1% Triton 
X-100, 1.2 mM EDTA, 16.7 mM Tris at pH 8.1, 167 mM NaCl, protease inhibitors) was added, 
5% of the volume was removed and used as input, and the remainder was incubated overnight at 
4°C on a nutating platform with FOXA1 or FOXA2 antibody or a species-matched IgG as 
control. Antibodies used for ChIP were the same as for EMSA; FOXA1 (Abcam) and FOXA2 
(Santa Cruz). Protein A agarose beads (Santa Cruz) were added and incubated for 3 h at 4°C. 
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Beads were then washed for 5 minutes at 4°C with gentle mixing, using the following solutions: 
Low Salt Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris, 150 mM NaCl); High 
Salt Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris, 500 mM NaCl); LiCl 
buffer (1 mM EDTA, 10 mM Tris, 250 mM LiCl, 1% NP-40, 1% Na-Deoxycholate), twice; and 
TE buffer (Sigma-Aldrich), twice. Chromatin was eluted from beads with two 15-minute washes 
at 65°C using freshly prepared Elution Buffer (1% SDS/0.1 M NaHCO3). To reverse crosslinks, 
5 M NaCl was added to each sample to a final concentration of 0.2 M, and incubated overnight at 
65°C; to remove protein, samples were incubated with 10 uL 0.5 M EDTA, 20 uL 1M Tris (pH 
6.5) and 3 uL of Proteinase K (10 mg/mL) at 45°C for 3 hours. DNA was extracted with 25:24:1 
phenol:choloform:isoamyl alcohol, precipitated with 100% ethanol with 1 m l glycogen as a 
carrier, and resuspended in TE (Sigma). qPCR was performed in triplicate using SYBR Green 
Master Mix. Primers were designed to amplify a 99-bp region surrounding rs112576555; 5′-
CTACTGCTTCTCCGGACTCG ’3′ and 5′- TGGCCTCAAGAGG GAGATAA -3′. Primers for 
a 133-bp control region not overlapping open chromatin and located 27 kb away were 5′-
GCACCCATGGTACTGAAACC -3′ and 5′- CTTTTCCCG AGGAAGGAACT -3′. Dissociation 
curves demonstrated a single PCR product in each case without primer dimers. Fold enrichment 
was calculated as FOXA1/FOXA2 enrichment divided by IgG control. A one-sided t-test was 
performed to compare enrichment based on the direction of binding observed using EMSA. 
 
Effect of glucose on Cdc123 and Camk1d transcript level 
 To measure effects of glucose on expression of Cdc123 and Camk1d, 832/13 cells and 
MIN6 cells were washed with PBS and preincubated for 2.0 h in secretion buffer (114 mm NaCl, 
4.7 mm KCl, 1.2 mm KH2PO4, 1.16 mm MgSO4, 20 mm HEPES, 2.5 mm CaCl2, 0.2% BSA, pH 
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7.2. For GSIS, cells were incubated in secretion buffer for an additional 2 hours or 16 hours in 
the presence of 3 mM or 20 mM glucose and then harvested for RNA. 
 
RNA isolation and quantitative real-time reverse-transcription PCR  
 Total cytosolic RNA was isolated using the RNeasy Mini Kit (Qiagen). RNA 
concentrations were determined using a Nanodrop 1000 (Thermo Scientific, Wilmington, DE, 
USA). For real-time reverse transcription (RT)–PCR, first-strand cDNA was synthesized using 8 
ul of total RNA in a 20 µl reverse transcriptase reaction mixture (Superscript III First strand 
synthesis kit; Life Technologies). cDNA was diluted to contain equivalent to 20-55 ng/µl input 
RNA. To measure total human mRNA levels of CDC123, CAMK1D and B2M, gene-specific 
primers and fast SYBR Green Master Mix (Life Technologies) were used (Table 2). TaqMan 
designed gene expression assays (Life Technologies) were used to measure Cdc123, Camk1D 
and Rsp9 (housekeeping gene) mRNA levels of mouse and rat cells. All PCR reactions were 
performed in triplicate in a 10-µl volume using a STEPOne Plus real-time PCR system (Life 
Technologies). Serial 3-fold dilutions of cDNA from pooled human tissues, 832/13 or MIN6 
cells as appropriate were used as a reference for a standard curve. Statistical significance was 
determined by two-tailed t-tests. 
 
Results 
Prioritization of type 2 diabetes-associated SNPs with regulatory potential at the 
CDC123/CAMK1D locus. 
 To identify potentially functional SNPs at the CDC123/CAMK1D locus, we considered 
variants in high LD (r2 ≥ .7, EUR, 1000G Phase 1 release) with GWAS index SNP rs12779790. 
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To further prioritize variants for functional follow up, we used genome wide maps of chromatin 
state (Figure 1) in available type 2 diabetes-relevant cell types including pancreatic islets, liver 
hepatocytes, skeletal muscle myotubes and adipose nuclei. Variant position was evaluated with 
respect to DNase- and FAIRE-seq peaks and several histone modifications, including H3K4me1 
and H3K9ac. DNase and FAIRE are established methods of identification of nucleosome 
depleted regulatory regions (86), while H3K4me1 and H3K9ac are post-translational chromatin 
marks often associated with enhancer regions (88,89). We also assessed chromatin occupancy by 
transcription factors using available genome wide ChIP-seq data sets. Of 11 variants meeting the 
LD threshold, two SNPs were found to overlap chromatin signals. One SNP, rs11257655 (r2 = 
.74 with GWAS index SNP rs12779790), located 15 kb from the 3’ end of CDC123 and 84 kb 
from the 5’ end of CAMK1D, was a particularly plausible candidate overlapping islet, liver and 
HepG2 cell line DNase peaks, islet and liver FAIRE peaks, H3K4me1 and H3K9ac (data not 
shown) chromatin marks, and FOXA1 and FOXA2 ChIP-seq peaks in HepG2 cells (Figure 6). A 
second SNP, rs34428576 (r2 = .71 with rs12779790), overlapped a HepG2 DNase peak and 
displayed occupancy by FOXA1 and FOXA2 binding in HepG2 cells (Figure 1). No SNPs 
overlapped with DNase peaks in skeletal muscle myotubes (data not shown). 
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Figure 1: Regulatory potential at type 2 diabetes-associated SNPs at the CDC123/CAMK1D 
locus  
A) The 11 SNPs in high LD (r2³.7, EUR) with GWAS index SNP rs12779790. Arrows indicate 
the two SNPs that overlap islet, liver, and HepG2 open chromatin and epigenomic marks and 
that are located near to HepG2 ChIP-seq peaks; these two SNPs were tested for allele-specific 
transcriptional activity. B) DNase hypersensitivity peaks identified in two pooled islet samples 
from the ENCODE Consortium. C) FAIRE peaks identified in one representative islet sample 
from the ENCODE Consortium. D) H3K4me1 histone modifications from the Roadmap 
Epigenomics Consortium. E) FOXA1 and FOXA2 ChIP-seq peaks and signal from ENCODE. 
Image is taken from the UCSC genome browser, February 2009 (GRCh37/hg19) assembly 
(http://genome.ucsc.edu) (93). The 5’ end of CAMK1D begins after position 12,390,000. 
 
Allele-specific enhancer activity of rs11257655 in islet and liver cells.  
 To evaluate transcriptional activity of the SNPs in predicted regulatory regions, 150 – 
200 bp surrounding each SNP allele was cloned into a minimal promoter vector and luciferase 
activity was measured in two beta cell lines, 832/13 rat insulinoma and MIN6 mouse insulinoma 
cells, and in HepG2 liver hepatocellular carcinoma cells. Four to five independent clones for 
each allele were generated and enhancer activity was measured in duplicate for each clone. A 
151-bp region including rs11257655 (and rs36062557 due to proximity, r2 = .38 with 
rs11257655) showed differential allelic enhancer activity in both orientations in all three cell 
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lines (Figure 2). The risk allele rs11257655-T showed significantly increased luciferase activity 
compared to the non-risk allele rs11257655-C (forward: 832/13 P = 6.3 x 10−3, MIN6 P = 1.7 x 
10−5; HepG2 P = 8.0 x 10−5; reverse: 832/13 P = 2.2 x 10−3, MIN6 P = 9.9 x 10−5; HepG2 P = 2.0 x 
10−3). Enhancer activity represents greater than a 1.4-fold (HepG2, MIN6) to 2.1-fold (832/13) 
increase in transcriptional activity relative to the non-risk allele in both the forward and reverse 
orientations. Compared to an empty vector control, enhancer activity was greatest in the islet cell 
lines (risk allele: 832.13, 4-fold; MIN6, 10-fold; HepG2, 1.6-fold).  
Figure 2: Haplotype containing type 2 diabetes-
associated SNPs displays differential 
transcriptional activity  
Enhancer activity was tested in 832/13, MIN6 and 
HepG2 cells for the type 2 diabetes non-risk (white 
bars) and risk (black bars) haplotypes in the forward 
and reverse orientations with respect to the genome. 
Risk refers to the rs11257655 variant; rs36062557 is 
included in the haplotype due to proximity. The 
haplotype containing risk allele rs11257655-T 
shows greater transcriptional activity than the non-
risk allele rs11257655-C in both orientations with 
respect to a minimal promoter vector in 832/13 cells 
(A), MIN6 cells (B) and HepG2 cells (C). Error bars 
represent standard deviation of 4-5 independent 
clones for each allele. Firefly luciferase activity was 
normalized to Renilla luciferase activity, and 
normalized results are expressed as fold change 
compared to empty vector control. P values were 






 A 179-bp region surrounding the second candidate SNP rs34428576 showed only 
moderate allele-specific activity, and only in the reverse orientation, in HepG2 cells (P = .02) 
and no allele-specific activity in islet cells (Figure 7).  
 To verify that rs11257655 and not rs36062557 accounted for allele-specific effects, we 
used site-directed mutagenesis to construct the remaining haplotype combinations. The T risk 
allele of rs11257655 exhibited > 1.8 fold increased transcriptional activity compared to the non-
risk allele C independent of rs36062557 genotype (Figure 3A, B). In contrast, altering alleles of 
rs36062557 on a consistent rs11257655 background showed no significant effect on 
transcriptional activity. Taken together, these data confirm that rs11257655 exhibits allelic 
differences in transcriptional enhancer activity and suggest it functions within a cis-regulatory 
element at the CDC123/CAMK1D type 2 diabetes-associated locus.  
 
Figure 3: rs11257655 drives differential 
transcriptional activity  
Site-directed mutagenesis was carried out to 
separate the effects of rs36062557 from 
rs11257655. Enhancer activity was tested in 
832/13 and MIN6 and cells for the type 2 
diabetes non-risk (white bars) and risk (black 
bars) haplotypes in the forward orientation. 
The risk allele rs11257655-T shows greater 
transcriptional activity than the non-risk allele 
rs11257655-C independent of rs36062557 
genotype in 832/13 cells (A) and MIN6 cells 
(B). Error bars represent standard deviation of 
2-4 independent clones for each allele. Results 
are expressed as fold change compared to 
empty vector control. P values were calculated 





Alleles of rs11257655 differentially bind FOX transcription factors. 
 To assess whether alleles of rs11257655 differentially affect protein-DNA binding in 
vitro, biotin-labeled probes surrounding the T (risk) or C (non-risk) allele were incubated with 
832/13, MIN6 or HepG2 nuclear lysate and subjected to electrophoretic mobility shift assays 
(EMSA). Band shifts indicative of multiple DNA-protein complexes were observed for both 
rs11257655 alleles (Figure 4A, 4B, 4C). In EMSAs from all three cell nuclear extracts, protein 
complexes were observed for the probe containing the T allele that were not present for the probe 
containing the C allele (832/13, arrow a; MIN6, arrows b, c, d; HepG2, arrows e, f) suggesting 
differential protein binding dependent on the rs11257655 allele. Competition of labeled T-allele 
probe with excess unlabeled T-allele probe more efficiently competed away allele-specific bands 
than excess unlabeled C-allele probe, demonstrating allele-specificity of the protein-DNA 
complexes (Figure 4A, 4B, 4C). rs11257655 did not show a differential protein binding pattern 
in EMSA using 3T3-L1 mouse adipocytes (data not shown). To examine transcription factor 
binding to rs11257655, we used a DNA-affinity capture assay. We observed one protein band 
showing allele-specific binding to the T allele (Figure 4D) that was identified as transcription 
factor FOXA2 using MALDI TOF/TOF mass spectrometry.  
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Figure 4: Alleles of rs11257655 differentially bind FOXA proteins in rat 832/13 insulinoma 
cells, mouse MIN6 insulinoma cells and human HepG2 hepatoma cells 
EMSA using 832/13 (A), MIN6 (B) and HepG2 (C) nuclear extract shows differential protein-
DNA binding of rs11257655 alleles. The probe containing risk allele rs11257655 -T shows 
allele-specific protein binding (arrows a - e) compared to the probe containing non-risk allele C. 
Excess unlabeled probe containing the T allele (T-comp) more efficiently competed away allele-
specific bands than unlabeled probe for the C allele (C-comp). Incubation of 832/13 and HepG2, 
nuclear extract with FOXA1 / FOXA2 antibodies disrupt the DNA-protein complex formed with 
T allele-containing DNA probe (arrow a, d, e) and result in band supershifts (asterisks). 
Incubation of MIN6 nuclear extract with FOXA2 antibody decreases the DNA-protein complex 
formed with T allele-containing DNA probe (arrow b) and results in a band supershift. To 
enhance visualization of protein complexes, free biotin-labeled probe is not shown. (D) DNA 
affinity-capture identified differential binding of FOXA2 at rs11257655 alleles in 832/13 cells. 
(E) The T allele of rs11257655 is predicted as a FOXA1 and FOXA2 consensus core-binding 
motif.  
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 A search in the JASPAR CORE database provided further evidence that the rs11257655 
SNP is located within predicted binding sites for FOXA1 and FOXA2, with only the T risk-allele 
predicted to contain a FOXA1 and FOXA2 consensus core-binding motif (Figure 4E) (94). To 
assess binding to FOXA1 and FOXA2, we performed supershift experiments incubating DNA-
protein complexes with antibodies for these factors. Incubation of the T allele-protein complex 
with FOXA1 antibody resulted in a band supershift in 832/13 and HepG2 cells (asterisk, Figure 
4A, 4C) A FOXA2-mediated supershift was observed in 832/13, MIN6 and HepG2 cells 
(asterisk, Figure 4A, 4B, 4C). Differences in antibody species reactivity may account for the lack 
of a visible FOXA1-mediated supershift in MIN6 cells. Collectively, these results suggest that 
rs11257655 is located in binding sites for a transcriptional regulator complex including FOXA1 
and/or FOXA2, which bind preferably to the rs11257655-T allele in beta cell and liver cell lines.  
 
FOXA1 and FOXA2 occupancy at rs11257655 in human islets 
 To evaluate whether FOXA1 and FOXA2 bind differentially to rs11257655 in a native 
chromatin context, we performed allele-specific ChIP in human islets with different rs11257655 
genotypes. FOXA1 was enriched 7.2-fold compared to IgG control in islets carrying a T allele 
while FOXA1 was not enriched in islets homozygous for C allele (Figure 5A). Although less 
robust, FOXA2 was enriched 4.2-fold in islets carrying a T allele compared to IgG control 
(Figure 5B). This direction of enrichment is consistent with the EMSA data (Figure 4). A region 
28 kb downstream of rs11257655 with no evidence of open chromatin (chr10 control) was used 
as a negative control (Figure 8). These findings strengthen the conclusion that rs11257655 is part 
of a bona fide cis-regulatory complex binding FOXA1 and/or FOXA2 in human islets. 
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Figure 5: rs11257655-T allele shows increased 
binding to FOXA1 and FOXA2 in human islets 
FOXA1 (A) and FOXA2 (B) ChIP in human islets 
shows enrichment at rs11257655 compared to IgG 
control. Islets containing one copy of the 
rs11257655-T allele show 7.2-fold greater 
FOXA1 enrichment and 4.2-fold greater FOXA2 
enrichment. rs11257655 CT heterozygotes are 
more significantly enriched than rs11257655 CC 
homozygotes for FOXA1 (one-sided t-test, P = 
.06) and FOXA2 (one-sided t-test,  P = .026). A 
negative control region 28 kb downstream of 
rs11257655 was not enriched in FOXA1- and 
FOXA2- bound chromatin (Figure 8A and 8B). 
Error bars represent standard error of two to three 






CDC123 and CAMK1D transcript levels 
 To determine whether CDC123 or CAMK1D are expressed in type 2 diabetes-relevant 
tissues, we measured and confirmed expression of both transcripts in human islets and 
hepatocytes (Figure 9A, 9B). These data are supported by RNA-seq evidence that both genes are 
expressed in islets (95). Based on our results showing islet beta cells as a target tissue of risk 
variant regulatory activity, we assessed whether glucose treatment regulated CDC123 and 
CAMK1D transcript level. Glucose-mediated transcriptional changes in one of these genes might 
point to the more plausible candidate important in beta cell biology. In MIN6 cells treated with 
low (3 mM) and high (20 mM) concentrations of glucose for 16 hours, CAMK1D expression 
increased (P = .004; Figure 9C) while CDC123 expression remained unchanged (P = .22; Figure 
9D). In 832/13 cells, CDC123 levels were significantly higher in cells stimulated with high 
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glucose (P = 1.6 x 10-5; Figure 9E). We could not assess the effect of glucose on CAMK1D levels 
in 832/13 cells because this transcript level was below detection limits. While we confirm 
expression of CAMK1D and CDC123 in islets and hepatocytes, future studies over-expressing 
the target gene(s) in these tissues would be necessary to establish the mechanisms by which 
increased expression leads to diabetes risk. 
 
Discussion 
 Integration of genome-wide regulatory annotation maps with disease-associated variants 
identified through GWAS has great potential for elucidation of gene-regulatory variants 
underlying association signals. In this study, we expand the lexicon of disease-associated 
functional regulatory variation by examining the type 2 diabetes-association signal at the 
CDC123/CAMK1D locus. We prioritized candidate cis-regulatory variants and tested whether 
prioritized variants exhibited allele-specific transcriptional enhancer activity. We provide 
transcriptional reporter and protein-DNA binding evidence that rs11257655 is part of a cis-
regulatory complex differentially affecting transcriptional activity. Additionally, we validate 
FOXA1 and FOXA2 as components of this regulatory complex in human islets. 
 In recent years, progress has been made in following up mechanistic studies of GWAS 
type 2 diabetes-association signals (53,72,74,96-101), but challenges remain in sifting through 
the many associated variants at a locus to identify those influencing disease. We hypothesized 
that a common variant with modest effect underlies the association at the CDC123/CAMK1D 
locus and evaluated the location of high LD variants (r2 ≥ .7; n = 11) at the locus relative to 
known transcripts and to putative DNA regulatory elements. We identified two variants that 
overlapped putative islet and/or liver regulatory regions and none located in exons. We did not 
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assess variants in lower LD (r2 < .7), and additional functional SNPs may exist at this locus 
acting through alternate functional mechanisms untested in the current study. 
 Based on our observation of type 2 diabetes-associated SNPs in regions of islet and liver 
open chromatin, we measured transcriptional activity in two mammalian islet cell models, rat 
832/13 and mouse MIN6 insulinoma cells and in one hepatocyte cell model, human HepG2 
hepatocellular carcinoma cells. In agreement with our previous observations (53), we found good 
concordance in allelic transcriptional activity of human regulatory elements across the two 
rodent islet cell types. Of the two SNPs predicted to be located in predicted enhancer regions, 
rs11257655 but not rs36062557 demonstrated allele-specific effects in islets and liver, 
suggesting that rs11257655 is a lead functional candidate. The rs11257655-T allele associated 
with type 2 diabetes risk displayed increased enhancer activity relative to the C allele, suggesting 
that increased expression of one or more genes, possibly CAMK1D or CDC123, may be 
associated with type 2 diabetes. Our subsequent analysis of protein binding revealed complexes 
that favored the rs11257655-T allele in 832/13, MIN6 and HepG2 cells. Consistent with 
predictions that the rs11257655-C allele may disrupt binding to the FOXA1 and FOXA2 
transcription factors, we demonstrated that only the T allele of rs11257655 leads to FOXA1- and 
FOXA2-mediated supershifts. The ChIP enrichment of FOXA1 and FOXA2 in human islets 
from carriers of the T allele is concordant with EMSAs using nuclear extract from mouse and rat 
cell lines, further demonstrating the utility of rodent islet cell models to characterize human 
regulatory elements. Our results suggest that a cis-regulatory element surrounding rs11257655 
may act in both islet and liver cells. Although we provide evidence that rs11257655 alleles 
differentially bind FOXA1 and FOXA2 in vivo, it is important to note that this enrichment was 
detected in isolated human islets. Future experiments will be needed to validate effects of 
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rs11257655 within a whole organism environment. For example, recently zebrafish have been 
used to assay the regulatory potential of DNA sequences (102,103).  
 FOXA1 and FOXA2 are members of the FOXA subclass of the forkhead box 
transcription factor family and are essential transcriptional activators in development of 
endodermally-derived tissues including liver and pancreas (104,105). In mature mouse β-cells, 
ablation of both transcription factors compared to ablation of FoxA2 alone leads to more 
pronounced impaired glucose homeostasis and insulin secretion, indicating that both factors are 
important in maintenance of the mature beta cell phenotype (106). In addition, FoxA2 integrates 
the transcriptional response of mouse adult hepatocytes to a state of fasting (107). FOXA1 and 
FOXA2 are thought to act as pioneer transcription factors, scanning chromatin for enhancers 
with forkhead motifs and opening compacted chromatin through DNA demethylation and 
subsequent induction of H3K4 methylation, epigenetic changes that likely render enhancers 
transcriptionally competent by allowing subsequent recruitment of transcriptional effectors (108-
110). Our data demonstrate increased transcriptional activity and increased binding of FOXA1 
and FOXA2 to the rs11257655-T allele, suggesting that rs11257655 may be functioning as part 
of a transcriptional activator complex. Recent experiments in pancreatic islets support a role for 
FOXA transcription factors in activation of islet enhancers (111). This same study also showed 
that FOXA2 binds in pancreatic islets in the T2D-associated region surrounding rs11257655. 
Further experiments, such as ChIP-seq of additional transcription factors, may identify other key 
factors present in the activator complex. 
 Both CAMK1D and CDC123 are candidate transcripts affected by variation at this locus. 
Cis-eQTLs in both blood and lung support an effect on CAMK1D but not CDC123. In blood, 
initial eQTL evidence for both genes were further analyzed by conditional analyses on the T2D 
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lead SNP or rs11257655. The conditional analyses abolished the cis-eQTL signal for CAMK1D 
but not for CDC123, providing evidence that the T2D GWAS signal and the CAMK1D cis-eQTL 
signal are coincident (83). In lung, the GTEx consortium identified an eQTL for CAMK1D with 
rs11257655 as a lead associated variant (P = 1.1 x 10-7); this and other T2D GWAS variants are 
the strongest cis-eQTLs for CAMK1D, while no significant eQTL is observed for CDC123 (84). 
For both eQTLs, the rs11257655 type 2 diabetes risk allele is associated with increased 
CAMK1D transcript level, consistent with the direction of transcriptional activity we observed 
for this allele in islet and liver cells. Many eQTLs are predicted to be shared among tissues 
(112), and a recent study of the beta cell transcriptome reports good concordance of eQTL 
direction (R2 = .74 - .76) between beta cells and blood-derived lymphoblastoid cell lines, fat and 
skin (113), suggesting that the CAMK1D eQTL may also exist in islets. Some eQTLs differ 
across tissues, and evidence of a consistent eQTL in islets would be valuable. Knockout mice 
provide further evidence supporting CAMK1D as a target gene. In FoxA1/FoxA2 beta cell-
specific knockout mice, Camk1d expression was reported to be slightly reduced (1.8 fold, P = 
0.13) (106), consistent with our conclusion that rs11257655 is part of a transcriptional activator 
complex that includes FOXA1 and FOXA2. Together, these data suggest that CAMK1D is a 
more plausible target for differential regulation by rs11257655 alleles. 
 The mechanism by which CAMK1D may act in type 2 diabetes biology is unclear. 
CAMK1D is a serine threonine kinase that operates in the calcium-triggered CaMKK-CaMK1 
signaling cascade (82,114). In response to calcium influx, CAMK1D activates CREB- (cAMP 
response element-binding protein) dependent gene transcription by phosphorylation (82). CREB 
is a key beta cell regulator important in glucose sensing, insulin exocytosis and gene 
transcription and β-cell survival (115), and FOXA2 has been shown to be necessary to mediate 
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recruitment of CREB in fasting-induced activation of hepatic gluconeogenesis (107). CAMK1D 
also has been reported to regulate glucose in primary human hepatocytes (116). It is important to 
note that we cannot rule out cell cycle regulator CDC123 as a target for regulation by 
rs11257655. 
 In conclusion, we extend follow up studies of GWAS-identified type 2 diabetes-
associated variants to the CDC123/CAMK1D locus on chromosome 10. We identify rs11257655 
as part of a cis regulatory complex in islet and liver cells that alters transcriptional activity 
through binding FOXA1 and FOXA2. These data demonstrate the utility of experimentally 
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Figure 6: Regulatory potential at rs11257655 and rs36062557. UCSC genome browser (hg18) 
diagram showing that rs11257655 and rs36062557 overlap regions of open chromatin, detected 
by DNase hypersensitivity and FAIRE, and histone modifications, including H3K4me1 and 
H3K9ac in islet, liver, and HepG2 cells. H3K27ac and H3K4me3 histone modifications are also 
shown. rs11257655 and rs36062557 are also located near to HepG2 ChIP-seq peaks for FOXA1 
and FOXA2. DNA sequences amplified to evaluate transcriptional activity in dual-luciferase 






Figure 7: Transcriptional activity at rs34428576. Enhancer activity was measured in 832/13 
cells (A) and HepG2 cells (B) for alleles of rs34428576. No difference was observed between 
alleles in 832/13 cells. In HepG2 cells, moderate allele-specific activity was observed only in the 
reverse orientation. Error bars represent standard deviation of 4–5 independent clones for each 
allele. Results are expressed as fold change compared to empty vector control. P values were 







Figure 8: Chromosome 10 region not 
overlapping open chromatin does not show 
binding to FOXA1 and FOXA2 in human islets. 
A negative control region 28 kb downstream of 
rs11257655 was not substantially enriched in 
FOXA1- (A) and FOXA2- (B) bound chromatin. 
Error bars represent standard error of two to three 




Figure 9: CDC123 and CAMK1D expression and response to glucose. (A, B) Evidence 
that CAMK1D and CDC123 are expressed in various human tissues. cDNA from human islets, 
hepatocytes, blood and adipocytes was analyzed by real-time PCR using gene-specific primers 
for CAMK1D (A) and CDC123 and B2M (B). mRNA level was normalized to B2M. (C, D, E) 
Effect of glucose stimulus on CAMK1D and CDC123 expression level. 832/13 and MIN6 
insulinoma cells were treated with low (3 mM) and high (15 mM) glucose for 16–18 hours. 
cDNA was analyzed by real-time PCR using TaqMan gene expression assays for CAMK1D (C) 
and CDC123 (D, E). mRNA level was normalized to RSP9. High glucose treatment resulted in a 
significant increase in CAMK1D mRNA level (C) but not CDC123 in MIN6 cells (D). High 
glucose treatment resulted in increased CDC123 mRNA level in 832/13 cells. Error bars 
represent the standard deviation of 4–5 samples for each treatment. P values were calculated by a 
two-sided t-test. 
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Table 1: DNA sequences amplified for luciferase activity assays 
SNP Chromosome position (hg19)              Sequence 5’-3’ 
rs11257655 chr10:12,307,791-12,307,941 GGCCCAGAAATGACACAGAA 
  AACTGGGTAAGGCTCACTTCC 
rs34428576 chr10:12,280,974 -12,281,152 GCGAGACTCTGCCTCAAAAG 
GACAGAGTGAGACCCCATCC 







Table 2: PCR primers for quantitative real-time PCR in human tissues 
Gene Sequence 5’-3’ 
CAMK1D Fwd – ATCTCCACAGAATGGGCATC 
 Rvs  – CAGTTCAACGGCTTTGCTGTA 
CDC123 Fwd – GCAGCTGGAGGATGAAGAAG 
 Rvs –TCATCCCTTCCTGAAACCAC 
B2M Fwd  –TGTCTGGGTTTCATCCATCCGACA 
 Rvs –TCACACGGCAGGCATACTCATCTT 
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CHAPTER 3: TRANS-ANCESTRY FINE MAPPING AND MOLECULAR ASSAYS 
IDENTIFY REGULATORY VARIANTS AT THE ANGPTL8 HDL-C GWAS LOCUS5,6 
 
Introduction 
To date at least 157 loci have been associated with high-density lipoprotein cholesterol 
(HDL-C) in genome-wide association studies (GWAS) (38). Analyses of European, African 
American, Mexican, Pima Indian, and East Asian participants have identified four different lead 
variants associated with HDL-C located in or near angiopoietin-like protein 8 (ANGPTL8) 
(38,43,66,117,118). ANGPTL8 is a small protein of 198 amino acids; the gene is located on 
chromosome 19 within intron 14 of dedicator of cytokinesis 6 (DOCK6) and is transcribed in the 
opposite direction of DOCK6. European GWAS meta-analyses identified rs737337 (P=4.6x10-17, 
N=185,000) (38,119) as the lead variant associated with HDL-C; this variant was also associated 
with total cholesterol (P=4.1x10-5) but not triglycerides (P=0.12) or low-density lipoprotein 
cholesterol (LDL-C, P=0.26). rs737337 is located 2.8 kb upstream of the ANGPTL8 
transcription start site (RefSeq NM_018687) and is a synonymous variant in exon 19 of DOCK6 
(Thr723, RefSeq NM_020812). In an African American population, the lead variant rs12979813 
																																																								
5 This chapter previously appeared as an article in G3: Genes, Genetics, Genomes. The citation 
is: Cannon ME, Duan Q, Wu Y, Zeynalzadeh M, Xu Z, Kangas AJ, Soininen P, Ala-Korpela M, 
Civelek M, Lusis AJ, Kuusisto J, Collins FS, Boehnke M, Tang H, Laakso M, Li Y, Mohlke K. 
2017. Trans-ancestry fine mapping and molecular assays identify regulatory variants at the 
ANGPTL8 HDL-C GWAS locus. G3 7(9):3217-3227. 
 
6 Maren Cannon designed, performed, and analyzed transcriptional reporter luciferase and 
electrophoretic mobility shift assays; prioritized candidate variants based on regulatory overlap; 
analyzed fine-mapping assays; created all figures and wrote the manuscript. Co-authors 
designed, performed, and analyzed clinical trait measurements; genetic and expression 
association data; fine-mapping analyses; and reviewed the manuscript. 
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was only associated with HDL-C (P=1.9x10-9, N=12,157) (43), which is located 7.5 kb upstream 
of ANGPTL8 and in intron 22 of DOCK6. In a joint analysis of Mexican and Pima Indian 
samples, the lead variant rs2278426 was associated with HDL-C (P=3.4x10-9, N=4,361) and total 
cholesterol (P=5.0x10-6) (66,120), which is a nonsynonymous variant in exon 2 of ANGPTL8 
(Arg59Trp) that exhibits relatively high linkage disequilibrium (LD) with the European lead 
rs737337 (r2=.74, 1000G Admixed American (AMR)) and moderate LD with the African 
American lead rs12979813 (r2=.52 AMR). Finally, in recent lipid associations in East Asian 
samples, lead variant rs3760782 was the strongest HDL-C-associated variant (P=8.8x10-11) and 
another variant in strong LD (rs1865063, r2=0.95) is the lead variant for total cholesterol 
(P=1.5x10-15) and LDL-C (P=1.8x10-8) (118). rs3760782 is located 3.5 kb upstream of 
ANGPTL8 and in intron 20 of DOCK6. Given the extensive sharing of GWAS loci across 
populations (50), we hypothesized that at least one shared variant at the ANGPTL8 locus affects 
HDL-C in all of these populations.  
ANGPTL8 is a recently defined gene also called C19orf80, LOC55908, refeeding-induced 
fat and liver (RIFL), TD26, hepatocellular carcinoma-associated gene, lipasin, and betatrophin 
(121-123). Serum ANGPTL8 protein levels have been associated with many metabolic 
phenotypes including type 1 and type 2 diabetes (124-128), obesity (125,129), and non-alcoholic 
fatty liver disease (129). The gene is mainly expressed in liver and adipose tissues, despite being 
entirely contained within one intron of the ubiquitously expressed DOCK6 (121,130). The 
precise mechanisms of action of ANGPTL8 remain unclear. ANGPTL8 is secreted into the 
plasma and is involved in triglyceride storage in adipose tissue; knockout mice gained less fat 
than wildtype (131) mice and Angptl8 knockdown in 3T3L1 mouse adipocytes led to decreased 
triglyceride content (122). ANGPTL8 expression is increased in response to stress, it up-regulates 
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early growth response transcription factor and down-regulates adipose triglyceride lipase, 
suggesting a role in lipid homeostasis (132). ANGPTL8 contains a lipoprotein lipase inhibitory 
motif and inhibits LPL function when co-expressed with ANGPTL3 (133). Additionally, serum 
ANGPTL8 protein is inversely associated with HDL-C levels (134) supporting a role of 
ANGPTL8 in HDL-C metabolism.  
DOCK6 is a member of the dedicator of cytokinesis family of atypical guanine nucleotide 
exchange factors. DOCK6 is expressed in many tissues, with highest levels of expression in the 
lungs, thyroid, and adipose (130). DOCK6 functions as a guanine nucleotide exchange factor for 
RAC1 and CDC42 and has roles in cytoskeletal remodeling and neurite outgrowth (135). 
Mutations in DOCK6 can cause Adams-Oliver syndrome, an actin cytoskeletopathy 
characterized by limb and skin defects (136). DOCK6 does not have functions that obviously 
relate to HDL-C metabolism. 
Two coding variants in ANGPTL8 have been proposed to affect HDL-C levels. A rare 
ANGPTL8 nonsense variant, rs145464906 (MAF=0.001 in >42,000 individuals of European 
ancestry) encoding Gln121Ter, is associated with increased HDL-C (P=5.1x10-13) and increased 
triglycerides (P=0.003) in an exome array-based association analysis (137). Based on 
conditional analysis (137) and LD (r2<.01), rs145464906 is independent of the reported 
ANGPTL8 GWAS variants. The common Mexican and Pima Indian lead variant, rs2278426 
encoding Arg59Trp, has been proposed to increase cleavage of ANGPTL3, leading to decreased 
LPL activity and lower HDL-C (120). Although coding variants have been identified, the 
variants responsible for the common HDL-C association signal at this locus remain unclear, and 
may include regulatory variants. While a simple mechanism involving a single variant that alters 
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transcription of a single gene is straightforward, multiple variants and/or multiple genes may 
contribute to the functional consequences of a GWAS signal (54,138,139).  
In this study, we describe an association between the HDL-C locus variants and 
subcutaneous adipose level of ANGPTL8 RNA. We show that a subset of HDL-C-associated 
variants overlap regions with strong evidence of regulatory activity (59,60), and we use trans-
ancestry fine-mapping and functional assays to identify variants exhibiting allelic differences in 
regulatory activity at the ANGPTL8 HDL-C GWAS locus.  
 
Materials and Methods 
Study population and phenotypes 
The METabolic Syndrome In Men (METSIM) study includes 10,197 men, aged from 45 
to 73 years, randomly selected from Kuopio, Eastern Finland, and examined in 2005 – 2010 
(140,141). The Ethics Committee of the University of Eastern Finland in Kuopio and the Kuopio 
University Hospital approved the METSIM study and it was carried out in accordance with the 
Helsinki Declaration. Triglyceride and lipoprotein characteristics were measured via proton 
nuclear magnetic-resonance (NMR) or enzymatic assays in 10,079 METSIM participants (142). 
DNA samples were genotyped on the Illumina OmniExpress and HumanCoreExome arrays, and 
additional genotypes were imputed using the GoT2D integrated haplotypes reference panel as 
previously described (47). 
We also analyzed a set of 8,421 self-identified African American participants from the 
Women’s Health Initiative SNP Health Association Resource (WHI-SHARe) study. Details of 
the study design, cohort characteristics, written informed consent, and study approval by local 
Human Subjects Committees have been described previously (143). Participants who had 
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consented to genetic research were genotyped on the Affymetrix 6.0 array and additional 
genotypes were imputed using the 1000 Genomes Project data as a reference panel, as previously 
described (144). 
 
Association, conditional, and haplotype analysis 
For METSIM, we performed a preliminary test for association between ~19 million 
genetic variants and 72 lipid and lipoprotein subclasses (145). To better observe the relative 
differences between variants, we use the association of variants with the concentration of 
phospholipids in medium HDL because the association with this trait is stronger (P=1.9x10-7) 
than with HDL-C (P=7.7x10-4). We assumed an additive mode of inheritance and accounted for 
cryptic relatedness between individuals using the EMMAX mixed model (q.emmax test) 
implemented in EPACTS (146). After accounting for age, BMI, smoking status, and lipid-
lowering medication status as covariates trait value residuals were inverse normal transformed. 
We carried out reciprocal conditional analyses with candidate variants within the associated 
signal to evaluate the potential presence of a second association signal by adjusting for specific 
genetic variants including METSIM lead variant rs737337 and WHI lead variant rs4804154. LD 
in locus plots was calculated from the METSIM imputed genotypes, and all chromosome 
coordinates correspond to hg19. 
For WHI, association analysis was performed under an additive genetic model using 
linear regression adjusted for covariates. The imputed allelic dosage at each variant was tested 
via MACH2QTL (147). Genome-wide African ancestry proportion, age, BMI and smoking 
history were included as covariates. Genome-wide African ancestry proportion was derived from 
locus-specific ancestry, which has a correlation of 0.99 with the first principal component of 
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population structure. Ancestry estimation has been described previously (43). To assess the 
potential presence of multiple, independent variants at the same locus influencing HDL-
cholesterol trait, we repeated regression analyses, conditioning on rs4804154. LD in locus plots 
was calculated from WHI imputed genotypes, and all chromosome coordinates correspond to 
hg19. 
We constructed haplotypes based on five variants at ANGPTL8 that were previously 
reported as the GWAS index variants (rs4804154, rs737337, and rs2278426) in studies of 
different ancestry groups (38,43,66,119,120) or are proxies (rs3745683 and rs3760782) in high 
LD with both the European and African American lead variants. We performed haplotype 
analyses using the “haplo.stat” R package (148), estimated haplotypes and haplotype frequencies 
using the haplo.em function, and tested for association between haplotypes and the concentration 
of phospholipids in medium HDL (METSIM) or HDL-C (WHI) level using the haplo.glm 
function. We assumed an additive model in which the regression coefficient represented the 
expected change in inverse normalized HDL level with each additional copy of the specific 
haplotype compared with the reference haplotype. The same covariates used for single variant 
analysis were also used in the haplotype analysis model.  
 
Expression quantitative trait association 
RNA from subcutaneous adipose tissue was extracted and the expression levels of 
probesets were measured using Affymetrix Human Genome U219 Array in 770 METSIM 
participants (63). The expression quantitative trait locus (eQTL) for ANGPTL8 was not 
previously reported because of a gene name difference with RefSeq and Ensembl. Expression 
data were normalized using Robust Multi-Array Average (RMA) analysis (149). eQTL 
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associations were performed as previously described (63). Briefly, we applied PEER analysis 
(150) to account for complex non-genetic factors in the RMA-normalized gene expression levels. 
We adjusted for 35 inferred confounding factors and inverse normal transformed the PEER-
processed residuals. In eQTL analysis, we used genotype dosages imputed using Haplotype 
Reference Consortium data (151) to test for the variant association with expression levels of all 
genes within 1 Mb of rs737337. We assumed an additive mode of inheritance and accounted for 
cryptic relatedness between individuals using the EMMAX mixed model implemented in 
EPACTS (146). Additionally, we performed conditional analysis on the expression level of 
ANGPTL8 by adjusting for rs4804155 and on the expression level of DOCK6 by adjusting for 
rs17699089 to assess the presence of multiple, independent associations. We also performed 
conditional analysis using candidate functional variant rs12463177 to assess the coincidence of 
GWAS and eQTL signals. To examine the relationship between RMA-normalized expression 
levels and HDL-C, we adjusted both traits for age and BMI, inverse normal transformed the 
residuals, and then tested for association in regression analyses. 
 
MANTRA 
To fine-map the ANGPTL8 locus, we performed trans-ancestry meta-analysis using 
MANTRA (58). MANTRA accounts for the shared similarity in closely related populations 
using Bayesian partition model assuming the same underlying allelic effect. It models the effect 
heterogeneity among distant populations by clustering according to the shared ancestry and 
allelic effects. We conducted the analysis based on the association summary statistics from 
GWAS in METSIM and WHI and included variants present in both METSIM and WHI. We 
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constructed a 99% credible set of variants by ranking all variants according to their Bayes 
factors. 
 
CAVIAR and PAINTOR 
To prioritize functional variants, we analyzed variants at the ANGPTL8 locus using both 
CAVIAR (56) and PAINTOR (57). CAVIAR estimates the posterior probability of a variant 
being functional by jointly modeling the p-values and beta association statistics, and PAINTOR 
leverages functional genomic annotation data, in addition to association strength, to prioritize 
functional variants. Both methods allow for multiple functional variants at the risk locus. Using 
consistent alleles for METSIM and WHI African Americans, we calculated Z scores based on p-
values and the sign of betas from GWAS in these studies. For METSIM, the LD matrix was 
calculated based on European data from the 1000 Genomes Project Phase 1. For WHI African 
Americans, LD was calculated based on imputed data as previously described (144). In 
CAVIAR, we returned the credible set that contains all of the true functional variants with 95% 
confidence level. The annotation matrix used in PAINTOR contained data from the ENCODE 
project accessed from the UCSC Genome Browser using the Table Browser tool. The matrix 
included HepG2 H3K4me1, H3K4me2, H3K4me3, and H3K27ac histone marks, DNase 
hypersensitivity clusters (ENCODE v3) and transcription factor binding (ENCODE v2) from the 
Broad Institute. Presence or absence of overlap was determined by the UCSC Table Browser 
intersection with the signal tracks. In PAINTOR, analysis was performed for METSIM alone 
(Finns), WHI alone (African Americans), and the two data sets together. We set the number of 
functional variants as 2, 3, 4 or 5 based on feasible running time. PAINTOR predicted variants to 
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To identify regulatory overlap of HDL-C-associated variants with histone marks, 
transcription factor binding, and DNase hypersensitivity sites, we used data from the ENCODE 
and Roadmap Epigenome projects accessed through the UCSC genome browser (59,60). RNA-
seq data were obtained from the Roadmap Epigenome Project (60)adult liver and adipose tissue) 
or a previous publication(152)HepG2). We evaluated previously published positive correlations 
of DNase hypersensitivity sites with gene expression in liver cell types (153). LD calculations 
for selecting candidate variants were based on 1000 Genomes Phase 1 data. The AFR dataset 
was used for African American LD and EUR for European LD.  
 
Cell culture 
HepG2, SW872, SGBS, 293T, 3T3L1, Huh-7, and MIN6 cell lines were maintained at 
37ºC with 5% CO2. HepG2 cells (ATCC, HB-8065) were cultured in MEM-a (Gibco) 
supplemented with 10% FBS and 1 mM sodium pyruvate. SW872 cells (ATCC, HTB92) were 
cultured in DMEM:F12 (Sigma) supplemented with 10% FBS. SGBS cells (154) were 
generously provided by Dr. Martin Wabitsch (University of Ulm) and cultured in DMEM:F12 
(Sigma) supplemented with 10% FBS and 5% 3.3 mM biotin/1.7 mM panthotenate solution. 
SW872 and SGBS cells were transfected in the undifferentiated, pre-adipocyte state. 293T cells 
(ATCC, CRL-3216) were cultured in DMEM (Sigma) supplemented with 10% FBS and 200 mM 
L-glutamine. 3T3-L1 cells (ATCC, CL-173) were cultured and differentiated as described in the 
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ATCC protocol. Huh-7 cells (JCRB0403, Japanese Collection of Research Bioresources Cell 
Bank, National Institute of Biomedical Innovation), were cultured in DMEM with high glucose 
(Gibco) with 10% FBS, 1 mM sodium pyruvate, 1 mM non-essential amino acids (Sigma), and 1 
mM L-glutamine. MIN6 cells(92) were cultured in DMEM (Sigma), supplemented with 10% 
FBS, 1 mM sodium pyruvate, and 0.1 mM b-mercaptoethanol.  
 
Dual luciferase transcriptional reporter assays 
We PCR-amplified fragments surrounding each regulatory region or variant with 5 
PRIME Mastermix (5 PRIME) or Phusion High-Fidelity Polymerase (New England Biosystems) 
with the primers listed in Table 5 from DNA of individuals homozygous for alleles associated 
with increased or decreased HDL-C. Gateway® attB sites were included in primers and 
Gateway® cloning was used to insert fragments into a Gateway®-compatible pGL4.23 (minimal 
promoter) or pGL4.10 (promoterless) firefly luciferase reporter vector (Promega). Fragments 
containing HDL-C-associated variants are designated as ‘forward’ or ‘reverse’ based on their 
orientation with respect to the genome and the ANGPTL8 gene. The 5-kb and promoter regions 
were only cloned in the forward orientation (pGL4.10) because they include the ANGPTL8 
promoter. Regions were isolated based on epigenetic marks of promoter and/or enhancer regions 
surrounding the HDL-C-associated variants. We isolated three to five independent clones 
(biological replicates) for each allele for each orientation and verified by sequencing. Each clone 
was cotransfected with Renilla luciferase vector in duplicate (HepG2, 293T, Huh-7, SW872) or 
triplicate (SGBS, 3T3L1) wells (technical replicates) using FUGENE 6 (HepG2, 293T, Huh-7, 
SW872, 3T3L1; Promega), Lipofectamine 2000 (Min6; Life Technologies), or Lipofectamine 
3000 (SGBS; Life Technologies). Twenty-four (SGBS) or forty-eight hours (all other cell types) 
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after transfection, we collected cell lysates and assayed for luciferase activity using the Dual-
Luciferase Reporter Assay System (Promega). Firefly luciferase activity of the clones containing 
the PCR fragments was normalized to Renilla luciferase readings to control for differences in 
transfection efficiency. We repeated all luciferase transcriptional reporter experiments on 
independent days and obtained consistent results. Data are reported as fold change in activity 
relative to an empty pGL4.23 or pGL4.10 vector. We used two-sided Student’s t-tests to 
compare luciferase activity between alleles or haplotypes.  
 
Electrophoretic mobility shift assays (EMSA) 
For EMSA, we prepared nuclear cell extracts from HepG2, HuH-7, SGBS, 3T3L1, 
SW872, and MIN6 cells using the NE-PER nuclear and cytoplasmic extraction kit (Thermo 
Scientific). Protein concentration was measured with a BCA assay (Thermo Scientific), and 
lysates were stored at -80ºC until use. We designed 17-19 bp biotin- or IR-Dye® 700-labeled 
oligos around the HDL-C-associated variants (Table 5) for both alleles. We annealed double-
stranded oligos and performed binding reactions as previously described (155). We used 4-6 ug 
of antibody in supershift assays and 100-200 ng CEBPB purified protein for select EMSAs. 
Binding reactions were run on non-denaturing PAGE DNA retardation gels in 0.5X TBE 
(Lonza). For biotin-labeled oligos, we transferred the reactions to Biodyne nylon membranes 
(Thermo Scientific), cross-linked them on a UV cross linker (Stratagene), and detected DNA-
protein complexes by chemiluminescence. For IR-DYE® 700-labeled oligos, we imaged gels on 
a LiCor Odyssey® CLx Imaging System. We repeated all EMSA experiments on another day 





Regulation of tissue-selective expression of ANGPTL8 
ANGPTL8 expression is largely restricted to liver and adipose tissues (121,130). To 
determine drivers of ANGPTL8 tissue specificity, we tested candidate regulatory regions in 
human hepatocyte (HepG2, Huh-7), human pre-adipocyte (SGBS), human adipocyte (SW872), 
mouse adipocyte (3T3-L1), human embryonic kidney (293T), and mouse islet beta (MIN6) cell 
lines. We tested a region extending 400 bp upstream of the transcription start site (TSS) that 
spans epigenetic marks characteristic of promoters, and a regulatory region that extends 5 kb 
upstream of the TSS (regions shown in Figure 10). The 400 bp promoter contains no HDL-C-
associated variants; the 5-kb region contains seven HDL-C-associated variants (rs200788077, 
rs56322906, rs6511729, rs3760782, rs737337, rs737338, and rs3745683). We tested these 
candidate regions in transcriptional reporter luciferase assays. In comparison to empty vector, the 
promoter increased transcriptional activity 5-fold in HepG2 (P<0.0001) and 1.6-fold in Huh-7 
(P=0.04), but not in any other cell type (P>0.5, Figure 11A). The 5-kb region increased 
transcriptional activity in HepG2 by 8-fold in HepG2 (P=0.0007) and 6-fold in Huh-7 (P=0.002) 
compared to empty vector and increased transcriptional activity 2-fold in pre-adipocyte (SW872, 
P=0.0007) and adipocyte (3T3-L1, P=0.023) cells compared to empty vector (Figure 11B). 
Neither region showed transcriptional activity in MIN6 or 293T cells. These data suggest that the 
400-bp region contains promoter regulatory elements contributing to tissue specificity in liver, 
but may be mediated by additional enhancer elements, especially in adipocytes.  
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Figure 10: Thirteen variants overlap predicted regulatory regions. 13 variants overlap 
regulatory regions defined by histone marks, chromatin accessibility, and transcription factor 
binding. The full set of 42 candidate variants span a 39-kb region (Figure 18). Green rectangles 
denote DNase hypersensitivity peaks correlated with ANGPTL8 expression across 112 cell lines 
in a previous study (153). DNase hypersensitivity correlation with DOCK6 expression is not 
indicated because the correlated peaks do not overlap HepG2 or hepatocyte DNase peaks. Gray 
rectangles represent transcription factor binding; the identities of transcription factors are listed 
in Table 9. Data was accessed from ENCODE, the Epigenome Roadmap Atlas, and the UCSC 
Genome Browser. ENCODE ChromHMM: gray, heterochromatin; blue, insulator; green, 
transcription; yellow and orange, enhancer; red and pink, promoter. Roadmap ChromHMM: 
orange, enhancer; light green, genic enhancer; dark green, transcription; blue, heterochromatin; 






Figure 11: Cell-type specificity of 
ANGPTL8 is influenced by nearby 
regulatory regions. Candidate regulatory 
regions were tested in a pGL4.10 vector in 
six cell types to determine drivers of tissue 
specificity. Reporter activity was 
normalized to empty vector (EV) in each 
cell type. Data are represented as the mean 
± standard deviation of 10 biological 
replicates. A) 400-bp promoter B) a 5-kb 
regulatory region including the promoter. 
Comparison of the 400-bp promoter vs. 5-
kb regulatory region P<0.05 for cell types. 
Cell lines include HepG2 human 
hepatocellular carcinoma (liver); Huh-7 
human hepatocellular carcinoma; SGBS 
human preadipocyte; SW872 human 
adipocyte; 3T3L1 mouse adipocyte; MIN6 
mouse pancreatic beta cell; and 293T 




Characterization of the ANGPTL8 HDL-C GWAS locus 
To characterize and determine shared variants of the ANGPTL8 association signal across 
populations, we analyzed the METSIM study of Finns (N=8,380) and the African Americans 
subset (N=8,244) from the Women’s Health Initiative (WHI, (43)). In a preliminary METSIM 
analysis, the variants most strongly associated with HDL-C at the ANGPTL8 locus were 
rs737337 (P=7.7x10-4, ß=-0.09) and its LD proxies; these variants were more strongly associated 
with the concentration of phospholipids in medium HDL particles (P=1.9x10-7, ß=-0.14; Figure 
12A, Table 6) than HDL-C (P=7.7x10-4, ß=-0.14) (145). Association analyses conditioned on 
rs737337 showed no evidence for any additional signals (all P>8.0x10-4, Table 6, Figure 15B). 
In WHI, the lead variant associated with HDL-C is rs4804154 (P=8.4x10-17), located 13 kb from 
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rs737337, and we did not observe evidence of any additional signals (P>4.8x10-4, Figure 12B, 
Table 7, Figure 15D). rs4804154 is in low LD with the reported African American lead variant 
rs12979813 (r2=0.18 AFR). rs12979813 is the most strongly associated genotyped variant in the 
previously reported African American sample (43), which includes the WHI study, but 
rs4804154 is the strongest variant after imputation in WHI. These two lead variants, rs737337 
and rs4804154, are in moderate pairwise LD in Europeans (r2=.67 EUR) and in low pairwise LD 
in Africans (r2=.26 AFR). rs737337 was among the most strongly associated variants in WHI 
(P=9.1x10-10) and the same was true of rs4804154 in METSIM (P=5.7x10-5). The rare coding 
variant rs145464906 in ANGPTL8 (137) is not present in METSIM and was not significantly 
associated with HDL-C in WHI (P=0.30). Conditioning on the common coding variant 
rs2278426 attenuates, but does not abolish, the signal in both populations (METSIM rs737337, 
P=0.03; WHI rs4804154, P=1.82 x 10-4). Conditioning on the lead variant abolished the 
association with rs2278426 (WHI, P=0.78; METSIM, P=0.86), suggesting that the regulatory 
variants capture more of the association signal than rs2278426 alone. Because many GWAS loci 
are shared across populations, the presence of an association signal in both WHI and METSIM 
supports the hypothesis of at least one shared functional variant across populations. 
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Figure 12: Locus plots of HDL-C and eQTL associations near ANGPTL8. A) Concentration 
of phospholipids in medium HDL in the METSIM study of Finnish individuals (N=8,380). 
Variants are colored according to LD (r2) with rs737337 (purple), the lead variant in European 
meta-analyses by GLGC. B) HDL-C association in the WHI subset of African American 
individuals (N=8,244). Variants are colored according to LD (r2) with rs4804154 (purple). C) 
HDL-C-associated variants are also associated with ANGPTL8 expression in 770 subcutaneous 
adipose samples from the METSIM study. The European and African American lead variants 
(rs737337 and rs4804154) are among the most significant variants. Variants are colored 
according to LD (r2) with rs4804154 (purple). 
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To further characterize the locus across populations, we conducted haplotype association 
analyses in METSIM and WHI (Table 3). By comparing variants across haplotypes and 
populations, we can hypothesize which variants represent the inheritance pattern of variants that 
have a functional effect. We included five variants in the analyses: the lead variants from 
European (rs737337), African American (rs4804154), Mexican/Pima Indian (rs2278426), and 
East Asian (rs3760782) studies and the one variant (rs3745683) in high LD (r2>.8) with the leads 
in all four studies. The most common haplotype in both METSIM and WHI contained alleles 
individually associated with increased HDL-C (haplotype 1, Table 3). In both studies, the 
haplotype containing all the alleles individually associated with decreased HDL-C (haplotype 3) 
showed the strongest association with HDL-C (!=-0.044, P<1.0x10-22 in WHI and !=-0.146, 
P=5.3x10-7 in METSIM). Haplotypes 1 and 2 differed only for rs737337 alleles. Haplotype 2 is 
common in African Americans (21% frequency) and nearly absent in Finns (0.02% frequency), 
which explains the different extent of r2-based LD in these populations. The small effect sizes of 
haplotype 2 (!=-0.01 in WHI), 3 (!=-0.044 in WHI, !=-0.146 in METSIM), and 5 (!=-0.009 in 
WHI, !=-0.049 in METSIM) suggest that rs737337, rs2278426, and rs4804154 may contribute 
to, but are not alone responsible for, the association signal. These data are consistent with a 
signal shared across populations driven by one or more functional variants represented by 
rs3745683 and rs3760782, with potential additional contributions from rs737337, rs2278426, 
and/or other proxies. 
	

















Haplotype association analyses in 8,244 African Americans in WHI and 8,380 Europeans in METSIM. Alleles shown in bold differ 
from haplotype 1. In both studies, alleles shown in haplotype 3 were individually associated with decreased HDL-C. Freq, haplotype 
frequency; SE, standard error; N/A, haplotype was too rare to be analyzed; REF, reference haplotype for interpreting association 
analyses
WHI African American participants Haplotype 1 reference Haplotype 3 reference Haplotype 4 reference 
 rs4804154 rs3760782 rs737337 rs3745683 rs2278426 Freq Effect SE P Effect SE P Effect SE P 
1 C C T G C 0.59 REF REF REF 0.042 0.005 8.8E-16 0.019 0.016 0.225 
2 C C C G C 0.21 -0.010 0.055 0.051 0.032 0.006 1.5E-07 0.009 0.016 0.564 
3 T T C A T 0.18 -0.044 0.005 <1E-22 REF REF REF -0.025 0.016 0.126 
4 T T C A C 0.01 -0.035 0.019 0.069 0.006 0.020 0.760 REF REF REF 
5 T C T G C 0.01 -0.009 0.026 0.735 0.040 0.026 0.125 0.014 0.031 0.661 
METSIM Finnish participants Haplotype 1 reference Haplotype 3 reference Haplotype 4 reference 
 rs4804154 rs3760782 rs737337 rs3745683 rs2278426 Freq Effect SE P Effect SE P Effect SE P 
1 C C T G C 0.88 REF REF REF 0.147 0.029 4.4E-07 0.124 0.056 0.029 
2 C C C G C .0002 N/A N/A N/A N/A N/A N/A N/A N/A N/A 
3 T T C A T 0.06 -0.146 0.029 5.3E-07 REF REF REF -0.023 0.063 0.720 
4 T T C A C 0.02 -0.120 0.056 0.034 0.027 0.063 0.660 REF REF REF 
5 T C T G C 0.03 -0.049 0.040 0.210 0.097 0.048 0.041 0.074 0.068 0.280 56	
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eQTL associations with HDL-C-associated variants and nearby genes 
To determine which gene(s) the HDL-C-associated variants may affect, we investigated 
eQTL associations. We observed an eQTL association in subcutaneous adipose tissue from 770 
METSIM study participants for both ANGPTL8 (rs4804154, P=1.0x10-9; Figure 12C, Table 4, 
Figure 16) and DOCK6 (rs17699089, P=7.2x10-7; Table 4, Figure 16, Table 8), but not any other 
gene within 1 Mb of rs737337 (Table 8). The METSIM and WHI HDL-C-associated variants 
were among the variants most strongly associated with both ANGPTL8 and DOCK6 mRNA 
levels (Figure 12, Table 8), suggesting that the same variants associated with HDL-C may act by 
affecting expression level of ANGPTL8 and/or DOCK6. Conditional analyses were performed to 
confirm the coincidence of the GWAS and eQTL signals. For both genes, alleles associated with 
lower HDL-C levels were associated with lower mRNA levels. In addition, ANGPTL8 mRNA 
level was associated with HDL-C level in METSIM samples (P=0.017, Figure 17), whereas 
DOCK6 was not (P=0.42, Figure 17). Evidence that the variants most strongly associated with 
HDL-C are also most strongly associated with ANGPTL8 mRNA levels suggests that a 
regulatory mechanism acts at this GWAS locus. 
	
Table 4: Associations with ANGPTL8 and DOCK6 expression in subcutaneous adipose tissue. 













rs4804155 G/C ANGPTL8 -0.499 0.081 1.04x10-9 - 0.516 - - 
rs737337 C/T ANGPTL8 -0.526 0.098 9.74x10-8 0.244 0.402 0.67 0.40 
rs4804154 T/C ANGPTL8 -0.500 0.081 1.38x10-9 0.762 0.270 1.00 0.48 
rs12463177 C/G ANGPTL8 -0.479 0.080 3.84x10-9 0.570 - 0.94 0.47 
rs17699089 G/A DOCK6 -0.406 0.081 7.21x10-7 - 0.005 - - 
rs737337 C/T DOCK6 -0.298 0.099 2.68x10-3 0.324 0.413 0.74 0.29 
rs4804154 T/C DOCK6 -0.398 0.082 1.65x10-6 0.253 0.267 0.94 0.91 
rs12463177 C/G DOCK6 -0.382 0.081 3.06x10-6 0.029 - 1.00 0.98 
Lead eQTL variants for ANGPTL8 (rs4804155) and DOCK6 (rs17699089), lead GWAS variants (rs4804154 and rs737337) and  
functional candidate variant rs12463177 association with ANGPTL8 and DOCK6 expression in 770 primary subcutaneous adipose  
samples. Conditional analysis on each lead eSNP and the candidate functional variant rs12463177 attenuated both the ANGPTL8 and  
DOCK6 association signals. 
aThe HDL-C-decreasing and eQTL effect alleles are presented first 
bEffect size is shown as the inverse normal transformed expression levels (log2(fluorescence intensity)) with each additional copy of 
the allele. 
cr2 is calculated from 1000 Genomes Phase 1 data
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Selection of variants to test for allelic differences in regulatory activity 
Prioritizing variants at GWAS loci for functional study can be challenging, especially at 
loci with regulatory mechanisms. To narrow variants that may have regulatory function, we 
considered three methods: LD with the lead GWAS variants, three fine-mapping algorithms in 
each of METSIM and WHI, and overlap with predicted regulatory regions (Figure 18). First, we 
considered variants in LD with the lead GWAS variants in European and/or African American 
ancestry individuals (1000 Genomes EUR and AFR). Because the variants in Europeans are of 
moderate allele frequency (MAF~0.07), we considered variants that meet an LD threshold r2>.5. 
In total, 42 variants exhibited r2>.5 with a lead HDL-C-associated variant in at least one study 
and could be considered as candidates for regulatory function (Table 9, Figure 19). As a second 
approach to prioritize candidate variants at this locus, we used the MANTRA, CAVIAR, and 
PAINTOR algorithms to interpret the HDL-C associated variants in the METSIM Finnish and 
WHI African American ancestry groups (Table 10, 11, 12). Finally, we identified candidate 
variants based on simple positional overlap with evidence of predicted regulatory regions, as 
variants overlapping these regions are more likely to be functional (Figure 19, Table 9) 
(59,60,152,153). Nine variants identified in at least one fine-mapping analysis overlapped 
regulatory regions (rs12463177, rs17766692, rs17699089, rs200788077, rs56322906, rs3760782, 
rs737337, rs737338, and rs3745683). We considered these nine variants to represent the most 
plausible candidate variants based both on fine-mapping and regulatory overlap and examined 
them for allelic differences on regulatory function. To compare the set of nine most plausible 
candidate variants to those that only show regulatory overlap, we also examined four additional 
variants in regulatory regions that were not identified by any fine-mapping analysis (rs34692794, 
rs10421795, rs10421382, and rs6511729). Thus, we examined a total of 13 variants in assays 
	 60	
examining allelic effects on regulatory function. All 13 variants are located within 9 kb of the 
ANGPTL8 transcription start site (Figure 10, Table 9).  
 
Functional characterization of candidate variants 
We examined the candidate variants for allelic differences in assays of regulatory 
function in human liver-derived (HepG2, Huh-7), pre-adipocyte (SGBS), and adipocyte 
(SW872) cells. We chose these cell types because ANGPTL8 is expressed in liver and adipose, 
they had the highest transcriptional activity in our cell type-specificity assays, and they have 
roles in HDL-C metabolism. We tested variants individually or as a haplotype in luciferase 
transcriptional reporter assays and/or in electrophoretic mobility shift assays (EMSA, Figure 20, 
21). Among the variants analyzed, rs12463177, which was identified in all three fine-mapping 
analyses and is a candidate at r2>.5 in both populations (r2=0.74 with rs737337 EUR, r2=0.93 
with rs4804154 AFR, and is 8 kb upstream from the ANGPLT8 TSS showed significant (P<.05) 
allelic differences in two assays of regulatory function (Figure 13). In luciferase transcriptional 
reporter assays in HepG2, a 697-bp region containing rs12463177-G showed 1.2 to 1.4-fold 
increased enhancer activity (P=0.02 forward orientation; P=0.004 reverse) compared to 
rs12463177-C. While modest, this allelic difference was replicated in three independent 
experiments. The significant effect on transcriptional activity was not replicated in Huh-7, 
SGBS, and SW872 cells, in which this region showed repressor activity; however, the trend 
between the alleles is consistent with HepG2, at least in the reverse orientation (Figure 20). In 
EMSAs using HepG2 and SGBS nuclear extract, the rs12463177-G allele showed increased 
binding (Figure 13, 21, 22). The direction of effect of rs12463177 transcriptional activity is 
consistent with the eQTL direction. A functional role for rs12463177 is consistent with 
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additional evidence that rs12463177 overlaps a DNase hypersensitivity site that was previously 
correlated to ANGPTL8 expression (153), green rectangle, Figure 10) and that the eQTL 
association signal is attenuated when conditioned on rs12463177 (Figure 16, Table 4).  
 
Figure 13: Allelic differences in regulatory assays of rs12463177 A) 698-bp region containing 
either allele of rs12463177 was cloned into the pGL4.23 vector and transfected in HepG2 cells. 
Data are represented as the mean ± standard deviation of 3-5 biological replicates. Luciferase 
activity was normalized to empty vector (EV) and p-values were determined by t-tests. *P<0.05; 
**P<0.01. B) Differential protein binding was evaluated in vitro using EMSA. IR-labeled probes 
containing either allele of rs12463177 were incubated with 10 ug HepG2 nuclear protein. The 
arrow shows stronger binding for rs12463177-G. Consistent binding was observed with SGBS 
nuclear protein (Figure 21). HDL-C-increasing alleles are presented first.  
 
Six additional variants (rs17699089, rs200788077, rs56322906, rs3760782, rs737337, 
and rs3745683) showed evidence of allelic differences in an assay for regulatory function and 
two (rs17766692 and rs737338) did not (Figure 20, 21, 22, 23). rs56322906 was only tested in 
transcriptional reporter assays as part of the 5-kb haplotype described below (Figure 25). 
rs737337 showed by far the strongest enhancer activity in transcriptional reporter assays, an up 
to 60-fold increase compared to empty vector in HepG2 (Figure 20), and rs737337-C shows 
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strong allele-specific binding in liver cell types (Figure 21). Supershift experiments using HepG2 
nuclear extract identified RXRa as binding to this probe, although not as part of the allele-
specific complex (Figure 24). Interestingly, the four variants that overlap regulatory regions but 
were not predicted by any fine-mapping analysis (rs34692794, rs10421795, rs10421382, and 
rs6511729) did not show allelic differences in protein binding (Figure 23). In total, we observed 
evidence of functional activity for seven of the nine candidate regulatory variants in these assays 
(Figure 14). 
 
Figure 14: Summary of functional results for seven candidate variants. Summary of shared 
LD with lead HDL-C-associated variants reported in European (rs737337), African American 
(rs4804154), and East Asian (rs3760782) populations are shown; variants meeting the r2>0.5 
threshold are marked with a +. Results from transcriptional reporter luciferase assays and 
electrophoretic mobility shift assays (EMSA) for nine candidate variants are shown. Arrows 
show the direction of transcriptional activity in reporter assays. Two arrows at rs12463177-G 
indicate allelic differences in transcriptional activity. Black circles show allele-specific protein 
binding observed in EMSA experiments. The larger and smaller arrows at the ANGPTL8 
promoter indicate higher and lower expression level from adipose eQTL data. Variants are 




To examine the effect on transcriptional activity of multiple variants together with the 
ANGPTL8 promoter, we tested 5-kb haplotypes located immediately upstream of the ANGPTL8 
transcription start site. This region includes five of the seven variants showing allelic differences 
in protein binding and/or transcriptional activity when examined separately (rs200788077, 
rs56322906, rs3760782, rs737337, and rs3745683, Figure 20) and two variants that did not show 
evidence of allelic differences (rs6511729 and rs737338, Figure 23). Transcriptional reporter 
assays of the smaller segments containing individual variants had shown both activator (e.g. 
rs737337) and repressor (e.g. rs3760782 and rs3745683) activity. The 5-kb haplotype acted as an 
enhancer in HepG2, Huh-7, SGBS, and SW872, with intermediate activity observed between the 
individual segments, but did not show significant differences in transcriptional activity between 
the two haplotypes (Figure 25). These results suggest a complex regulatory mechanism involving 
enhancer and repressor regions that work in concert to regulate expression. 
 
Discussion 
In this study, we examined the tissue specificity of ANGPTL8, reported the first eQTL for 
variants at the ANGPTL8 HDL-C GWAS locus in adipose tissue, and identified variants at the 
GWAS locus that exhibit allelic differences in assays of regulatory function. We found that a 
400-bp promoter is the main driver of tissue specificity in liver, and that expression may be 
mediated by additional enhancer elements within 5 kb upstream of ANGPTL8, especially in 
adipocytes. Of 7 candidate regulatory variants that showed allelic differences in transcriptional 
activity and/or protein binding, rs12463177 showed the clearest allelic differences consistent 
with the direction of the ANGPTL8 eQTL. These data suggest that multiple regions and 
potentially multiple variants regulate ANGPTL8 expression in liver and adipose tissue. 
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ANGPTL8 is a strong candidate gene at this GWAS locus. Although we observed coincident 
association between the GWAS variants and transcript level for both ANGPTL8 and DOCK6 in 
subcutaneous adipose tissue samples, ANGPTL8 mRNA level was associated with HDL-C in 
METSIM, whereas DOCK6 mRNA level was not (Figure 17). DNase hypersensitivity sites that 
overlap regulatory variants are correlated to ANGPTL8 expression (Figure 10), providing further 
support for ANGPTL8 as the target gene. ANGPTL8 protein levels have been shown to be 
inversely associated with HDL-C (134). This direction is opposite of the association we observed 
with ANGPTL8 expression and HDL-C; however, others have suggested that ELISA methods 
may not consistently quantify serum ANGPTL8 levels (156). Furthermore, ANGPTL8 inhibits 
lipoprotein lipase when co-expressed with ANGPTL3, giving a direct connection to lipid 
metabolism (133). While we cannot rule out a role for DOCK6, these lines of evidence and a rare 
coding variant in ANGPTL8 associated with HDL-C (137) suggest ANGPTL8 as the most likely 
target gene at this HDL-C GWAS locus.  
The ANGPTL8 HDL-C GWAS locus exhibited unusual characteristics in fine-mapping 
because the associated variants defined by LD r2 with the lead GWAS variants span a larger 
chromosomal region in African Americans than in Europeans, opposite of most loci in the 
genome (157). Our haplotype association analyses showed that the LD differences are due to a 
haplotype with 20% frequency in African Americans from WHI that is essentially not observed 
in Finns from METSIM (0.02% frequency). At this locus, low-frequency haplotypes 
(frequency<.03, Table 3) distinguish r2 thresholds of .8 and .5 in Finns, and the r2 dependence on 
allele frequency suggests that a LD threshold of r2>.8 for selecting candidate variants may be too 
restrictive and miss potentially functional variants. Here, we considered an initial set of 
candidate variants based on a more liberal threshold of r2>.5, resulting in 42 total variants. We 
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then tested nine variants predicted by MANTRA, CAVIAR, and PAINTOR and that overlapped 
regulatory datasets in functional assays. Seven of nine variants showed evidence of allelic 
differences (Figure 14), but only rs12463177 and rs17699089 showed differences consistent with 
the direction of the eQTL association. Of four additional variants that overlapped regulatory 
regions but were not predicted to be functional in fine-mapping assays, none showed evidence of 
regulatory activity. Taken together, these data suggest that the joint use of fine-mapping and 
regulatory overlap can successfully identify variants exhibiting allelic differences in functional 
assays.  
The mechanisms by which the variants that showed allelic differences in functional 
assays may work in concert remains unclear. The effect on transcriptional activity of rs12463177 
was modest and only significant in one cell type (Figure 13, 20). This marginal effect observed 
in cell lines may not represent the physiological effect in vivo. The magnitude of effect of 
rs737337 was much greater (50-fold increased transcriptional activity), but did not show 
significant allelic differences, in contrast to a previous report (158). rs737337 exhibited strong 
liver-specific allele-specific protein binding, but the specific transcription factor(s) remain 
unknown. One possible mechanism is that the regulatory region containing rs737337 is a strong 
enhancer that drives expression of ANGPTL8, but that the region containing rs12463177 is 
important for regulating allele-specific expression. Transcriptional regulators bound at the 
multiple variants may act together via chromosomal looping with the ANGPTL8 promoter. 
Further experiments, especially in vivo, are needed to elucidate the precise roles and interactions 
of the seven variants that showed allelic differences in transcriptional activity and/or protein 
binding.  
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In this study, we identified ANGPTL8 as the target gene at this HDL-C GWAS locus, 
determined regulatory drivers of tissue specificity, and combined fine-mapping approaches and 
regulatory overlap with experimental assays to identify variants that may contribute to the HDL-
C GWAS signal at ANGPTL8. Identifying variants underlying GWAS loci contributes to a 
growing understanding of target genes, their direction of effect, and metabolic phenotypes. Our 
results are consistent with previously described results at other GWAS loci where multiple 
common regulatory variants act together (54,138,139) and continued work on the ANGPTL8 
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Figure 15: HDL association and conditional analysis. A) Variant association with 
concentration of phospholipids in medium HDL in the METSIM study of Finnish individuals  
(N=8380). rs737337 (purple) was among the most significantly associated variants. Variants are 
colored according to LD (r2) with rs737337. B) Conditional analysis on rs737337 attenuated the 
association signal. C) HDL-C association in the WHI study of African American individuals 
(N=8244). Variants are colored according to LD (r2) with rs4804154 (purple). D) Conditional 
analysis on rs4804154 attenuated the signal. 













Figure 16: eQTL association in subcutaneous adipose from 770 individuals in the METSIM 
study. A) HDL-C-GWAS variants are associated with ANGPTL8 expression. B) HDL-C GWAS 
variants are associated with DOCK6 expression. C) Conditional analysis on the top variant 
associated with ANGPTL8 expression, rs4804155, attenuated the signal. D) Conditional analysis 
on the top variant associated with DOCK6 expression, rs17699089, revealed a secondary 
association signal with DOCK6 expression (rs12978266, P=7.33x10-5). E) Conditional analysis 
on candidate functional variant rs12463177 also attenuated the ANGPTL8 association signal and 
reveals the secondary association of rs12978266. F) Conditional analysis on candidate functional 
variant rs12463177 also attenuated the DOCK6 association signal. 
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Figure 17: RNA associations with HDL-C in METSIM. ANGPTL8 RNA levels (A) are 
associated with HDL-C level in 770 Finnish individuals from METSIM. DOCK6 RNA levels (B) 
are not associated with HDL-C. To examine the relationship between RMA-normalized 
expression levels and HDL-C, we adjusted both traits for age and BMI, inverse normal 
transformed the residuals, and then tested for association in regression analysis. Correlation 
coefficients: R=0.086 (ANGPTL8), R=0.029 (DOCK6). 
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Figure 18: Flow chart describing selection of variants to test in functional experiments. 
n=27 n=31
n=10
Variants in LD 
(r2>0.5) with 
rs737337 in METSIM




Variants overlapping regulatory elements defined 
by ENCODE and Epigenome Roadmap histone 
marks, DNase peaks, and/or transcription factor 















12 variants in at least two analyses
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Figure 19: Candidate variants relative to predicted regulatory regions. 27 variants exhibited 
r2>0.5 with rs737337 in METSIM (EUR variants) and 31 variants with rs4804154 in WHI (AFR 
variants). These variants span a 39-kb window within DOCK6. 13 of 42 total variants overlap 
regulatory regions defined by histone marks, chromatin accessibility, and transcription factor 
binding (Figure 10). Green rectangles represent DNase hypersensitivity sites correlated with 
ANGPTL8 expression (153). Consistent with our tissue-specificity experiments, ANGPTL8 is 
highly expressed in liver and adipose RNA-seq datasets (59,60,130). Data was accessed from 
ENCODE, the Epigenome Roadmap Atlas, and the UCSC Genome Browser. Black rectangles 





























Figure 20: Variants tested in transcriptional reporter luciferase assays. Transcriptional 
activity was evaluated for six variants (rs56322906 was evaluated in a 5-kb haplotype, Figure 
25) in HepG2 (A), Huh7 (B), SGBS (C), and SW872 (D) cells. Data are represented as the mean 
± standard deviation of 3-5 biological replicates. Luciferase activity was normalized to empty 
vector (EV). White bars represent the forward orientation with respect to the genome; black are 
reverse. *P<0.05, **P<0.01 ***P<0.001 HDL-C-increasing alleles are presented first. 
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Figure 21: Seven variants show differential protein binding in EMSAs. 
Allelic differences in protein binding were observed for all seven variants with nuclear extract 
from HepG2 cells (A). Six variants (except rs737337) showed allelic differences in protein 



























Figure 22: Competition EMSAs confirm allele-specific effects. 
Competition EMSA experiments using HepG2 nuclear extract were conducted with unlabeled 
competitor probes for each allele. rs12463177 is competed with 100x competition (lanes 2, 3, 7, 
8) and 200x (lanes 4, 5, 9,10) compared to labeled probe. rs17699089 is competed with 100x 
competition, rs200788077 is competed with 100x competition, rs56322906 is competed with 
100x competition, rs3760782 is competed with 192x competition, rs737337 is competed with 
269x competition, and rs3745683 is competed with 50x (lanes 2, 3, 7, and 8) and 100x (lanes 4, 
5, 9, and 10) competition. HDL-C-increasing alleles are presented first. 
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Figure 23: Six variants overlapping regulatory regions did not alter protein binding. 
EMSAs were performed with IR-labeled probes for each allele and incubated with 10 ug of 
HepG2 nuclear protein. rs737338 and rs17766692 were predicted in the CAVIAR causal set. The 
remaining four variants were not predicted in fine-mapping analyses. The prominent band in the 
middle of all gels represents non-specific binding that is observed in all IR-labeled EMSAs. 
HDL-C-increasing alleles are presented first. No allelic differences were observed. 
 
 
Figure 24: RXRα may bind as part of a complex at rs737337. Supershift EMSA assays were 
performed using HepG2 nuclear extract (NE). The allele-specific band (arrow) is not disrupted 
when RXRα antibody is added to the reaction; however, there is a supershift in both alleles 
(asterisks). No disruption or supershift is observed with 36 other transcription factor antibodies 
(data not shown; Table 9). Competitor lanes are competed with 269x unlabeled probe. HDL-C-












Figure 25: A 5-kb haplotype did not show allelic differences in transcriptional activity. 
Transcriptional activity was evaluated for a 5-kb haplotype containing 7 variants in HepG2, 
Huh7, SGBS, and SW872 cells. Data are represented as the mean ± standard deviation of 3-5 
biological replicates. Luciferase activity was normalized to empty vector (EV). P>0.07 The 
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Table 5: Primer and probe sequences for functional assays
 
  















































Table 6: Association of 100 ANGPTL8 locus variants with concentration of phospholipids 
in medium HDL in METSIM 
 
Variant Position Allelesa MAF Effect Std Error P-value Effect Std Error P-value
rs737337 19:11347493 T/C 0.08 -0.137 0.026 1.99E-07 - - -
rs112108870b 19:11345315 G/GA 0.08 -0.138 0.026 1.68E-07 -0.369 0.499 0.460
rs3745683 19:11348521 G/A 0.08 -0.137 0.026 2.39E-07 0.359 0.576 0.533
rs3760782 19:11346550 C/T 0.08 -0.137 0.026 2.40E-07 0.367 0.576 0.525
rs12463177 19:11341680 G/C 0.12 -0.115 0.023 3.88E-07 -0.056 0.039 0.146
rs17699089 19:11343795 A/G 0.12 -0.114 0.023 4.39E-07 -0.055 0.039 0.156
rs3826815 19:11332505 C/T 0.12 -0.114 0.023 5.03E-07 -0.053 0.039 0.178
rs72994363 19:11333358 G/T 0.12 -0.114 0.023 5.14E-07 -0.053 0.039 0.180
rs12974173 19:11333359 A/T 0.12 -0.114 0.023 5.16E-07 -0.052 0.039 0.180
rs3810308 19:11333596 T/C 0.12 -0.114 0.023 5.19E-07 -0.052 0.039 0.181
rs4804155 19:11334295 C/G 0.12 -0.114 0.023 5.24E-07 -0.052 0.039 0.179
rs4804154 19:11334179 C/T 0.12 -0.114 0.023 6.61E-07 -0.049 0.040 0.222
rs4804576 19:11331354 G/T 0.06 -0.142 0.029 1.30E-06 -0.033 0.063 0.599
rs66466742 19:11336444 C/T 0.06 -0.141 0.029 1.45E-06 -0.030 0.063 0.635
rs737338 19:11347657 C/T 0.06 -0.141 0.029 1.58E-06 -0.028 0.063 0.661
rs2278426 19:11350488 C/T 0.06 -0.141 0.029 1.58E-06 -0.028 0.063 0.661
rs56322906 19:11346155 G/A 0.06 -0.141 0.029 1.59E-06 -0.027 0.063 0.662
rs8101801 19:11335477 C/A 0.07 -0.139 0.029 1.84E-06 -0.025 0.062 0.689
rs17766692 19:11342599 C/T 0.10 -0.112 0.024 3.52E-06 -0.049 0.033 0.138
rs1865063 19:11341029 C/T 0.10 -0.112 0.024 3.65E-06 -0.049 0.033 0.140
rs17699030 19:11330942 A/G 0.05 -0.158 0.034 3.72E-06 -0.057 0.051 0.272
rs4804575 19:11329641 G/A 0.10 -0.110 0.024 4.63E-06 -0.046 0.033 0.157
rs4804153 19:11331531 C/T 0.10 -0.111 0.024 4.68E-06 -0.046 0.033 0.166
rs138572354 19:11338309 C/A 0.05 -0.149 0.033 8.66E-06 -0.036 0.053 0.496
rs143466522 19:11318472 G/A 0.02 -0.213 0.056 1.27E-04 -0.103 0.062 0.097
rs79846490 19:11311885 G/C 0.04 -0.146 0.038 1.38E-04 -0.023 0.052 0.661
rs111279811 19:11298369 C/T 0.03 -0.158 0.042 1.49E-04 -0.046 0.052 0.375
rs56048141 19:11317744 C/T 0.02 -0.173 0.051 6.10E-04 -0.056 0.058 0.342
rs12979813 19:11342703 A/G 0.18 -0.062 0.019 8.72E-04 -0.003 0.024 0.883
rs10406522 19:11341635 T/C 0.18 -0.062 0.019 8.81E-04 -0.003 0.024 0.886
rs6511729 19:11346252 A/C 0.18 -0.062 0.019 9.28E-04 -0.003 0.024 0.891
rs3810307 19:11332570 T/A 0.18 -0.061 0.019 1.05E-03 -0.002 0.024 0.941
rs2043302 19:11339396 T/C 0.18 -0.061 0.019 1.16E-03 -0.001 0.024 0.972
rs10418759 19:11340242 A/G 0.18 -0.061 0.019 1.18E-03 -0.001 0.024 0.976
rs7247404 19:11268556 G/A 0.34 0.050 0.015 1.22E-03 0.037 0.016 0.018
rs17001244 19:11340057 A/G 0.18 -0.060 0.019 1.23E-03 0.000 0.024 0.989
rs11672123 19:11194823 G/A 0.09 -0.080 0.025 1.24E-03 -0.075 0.025 0.002
rs10421382 19:11344973 G/C 0.18 -0.060 0.019 1.25E-03 -0.001 0.024 0.980
rs776487142 19:11013429 C/T 0.00 -5.925 1.842 1.31E-03 -5.973 1.840 0.001
rs10409274 19:11273179 G/A 0.29 0.051 0.016 1.34E-03 0.034 0.016 0.035
rs11671937 19:11264514 C/T 0.34 0.049 0.015 1.36E-03 0.036 0.016 0.020
rs7408517 19:11264063 C/T 0.34 0.049 0.015 1.39E-03 0.036 0.016 0.020
rs10421795 19:11344406 C/T 0.18 -0.060 0.019 1.39E-03 0.000 0.024 0.991
rs11670169 19:11266015 T/C 0.34 0.049 0.015 1.41E-03 0.036 0.016 0.020
rs892115 19:11263650 G/T 0.34 0.049 0.015 1.42E-03 0.036 0.016 0.020
rs934424 19:11267613 G/A 0.34 0.049 0.015 1.49E-03 0.036 0.016 0.021
rs9749459 19:11270016 T/C 0.29 0.050 0.016 1.55E-03 0.034 0.016 0.039
Unconditioned Conditioned on rs737337
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rs4804148 19:11270867 C/T 0.29 0.050 0.016 1.60E-03 0.034 0.016 0.040
rs9749257 19:11269960 G/T 0.29 0.050 0.016 1.61E-03 0.033 0.016 0.040
rs17248748 19:11206040 C/T 0.02 -0.175 0.056 1.62E-03 -0.110 0.057 0.056
rs4804579 19:11358700 T/C 0.18 -0.059 0.019 1.65E-03 0.004 0.024 0.882
rs8104261 19:11272585 C/T 0.29 0.050 0.016 1.71E-03 0.033 0.016 0.042
rs9749350 19:11257299 C/G 0.18 -0.059 0.019 1.98E-03 -0.044 0.019 0.023
rs934425 19:11267503 C/T 0.29 0.050 0.016 2.02E-03 0.042 0.016 0.011
rs551841239 19:11671580 G/C 0.00 -1.435 0.465 2.05E-03 -1.371 0.465 0.003
rs150205856 19:11391990 C/T 0.02 -0.180 0.059 2.18E-03 -0.062 0.065 0.338
rs200600677 19:11369440 TC/T 0.23 -0.053 0.017 2.19E-03 -0.022 0.019 0.240
rs17001264 19:11348212 C/T 0.02 -0.181 0.059 2.25E-03 -0.062 0.065 0.340
rs6511728 19:11335597 A/G 0.15 -0.062 0.020 2.37E-03 0.026 0.029 0.361
rs8101802 19:11336182 G/C 0.15 -0.062 0.020 2.38E-03 0.026 0.029 0.360
rs139606057 19:11393073 C/T 0.00 -1.089 0.359 2.40E-03 -1.100 0.358 0.002
rs112550373 19:11071469 G/A 0.01 0.277 0.091 2.41E-03 0.299 0.091 0.001
rs147629608 19:11411726 C/T 0.00 0.862 0.284 2.41E-03 0.953 0.284 0.001
rs34098 19:11539681 A/T 0.10 0.079 0.026 2.45E-03 0.057 0.027 0.031
rs186292971 19:11435015 A/C 0.00 1.608 0.531 2.47E-03 1.598 0.530 0.003
rs187416509 19:11528292 C/T 0.00 -1.387 0.462 2.66E-03 -1.414 0.461 0.002
rs145277768 19:11440420 C/T 0.00 1.595 0.532 2.69E-03 1.586 0.531 0.003
rs541868466 19:11543169 C/T 0.00 -1.384 0.462 2.73E-03 -1.411 0.461 0.002
rs181565096 19:11232702 C/G 0.02 -0.163 0.054 2.75E-03 -0.098 0.056 0.080
rs10423399 19:11273603 T/G 0.29 0.048 0.016 2.78E-03 0.031 0.016 0.057
rs565352617 19:11992491 CAA/C 0.00 -1.488 0.498 2.79E-03 -1.445 0.497 0.004
rs570249721 19:11252163 G/A 0.00 -9.531 3.225 3.13E-03 -9.358 3.221 0.004
rs191370629 19:11569128 C/T 0.00 -1.366 0.463 3.16E-03 -1.394 0.462 0.003
rs182210127 19:11659265 G/A 0.00 -1.352 0.458 3.16E-03 -1.377 0.457 0.003
rs112541805 19:11221946 G/GA 0.03 -0.128 0.045 4.12E-03 -0.087 0.045 0.054
rs386474655 19:11026074 G/C 0.00 -0.486 0.170 4.12E-03 -0.407 0.170 0.017
rs34254024 19:11369433 TTC/T 0.24 -0.049 0.017 4.14E-03 -0.019 0.018 0.311
rs13306513 19:11218226 G/A 0.03 -0.129 0.045 4.25E-03 -0.088 0.046 0.054
rs17242899 19:11216768 T/C 0.03 -0.129 0.045 4.25E-03 -0.088 0.046 0.054
rs145446845 19:11299431 G/A 0.02 -0.164 0.057 4.26E-03 -0.046 0.063 0.467
rs140898392 19:11218361 G/A 0.03 -0.129 0.045 4.28E-03 -0.088 0.046 0.055
rs146559752 19:11264537 A/C 0.03 0.118 0.042 4.42E-03 0.109 0.041 0.008
rs528191740 19:11448303 T/G 0.00 2.902 1.024 4.62E-03 2.889 1.023 0.005
rs200345643 19:11286646 G/C 0.00 -0.619 0.219 4.79E-03 -0.499 0.221 0.024
rs72996217 19:11358966 G/A 0.16 -0.055 0.020 4.81E-03 -0.007 0.023 0.764
rs11085768 19:11370653 G/A 0.24 -0.048 0.017 4.86E-03 -0.017 0.018 0.346
rs7248924 19:11372077 T/C 0.24 -0.047 0.017 5.55E-03 -0.017 0.018 0.352
rs142159985 19:11516368 A/C 0.00 2.395 0.865 5.63E-03 2.367 0.864 0.006
rs199636757 19:11378355 CAG/C 0.24 -0.047 0.017 5.89E-03 -0.017 0.018 0.363
. 19:11798665 A/G 0.00 -3.388 1.231 5.92E-03 -3.429 1.229 0.005
rs2043303 19:11368648 C/T 0.24 -0.047 0.017 5.98E-03 -0.017 0.018 0.366
rs7258016 19:11367353 A/C 0.24 -0.047 0.017 5.98E-03 -0.016 0.018 0.367
rs12462741 19:11365281 C/T 0.24 -0.047 0.017 6.02E-03 -0.016 0.018 0.369
rs2043301 19:11365650 C/A 0.24 -0.047 0.017 6.02E-03 -0.016 0.018 0.369
rs556896609 19:11444804 A/G 0.00 1.369 0.499 6.04E-03 1.358 0.498 0.006
rs322135 19:11379717 A/G 0.24 -0.047 0.017 6.08E-03 -0.016 0.018 0.368
rs7247840 19:11267678 T/C 0.26 0.046 0.017 6.09E-03 0.039 0.017 0.019
rs10422673 19:11265408 C/G 0.26 0.046 0.017 6.09E-03 0.039 0.017 0.019
rs396460 19:11374916 C/T 0.24 -0.047 0.017 6.10E-03 -0.016 0.018 0.368
rs416231 19:11374675 C/T 0.24 -0.047 0.017 6.11E-03 -0.016 0.018 0.369
aNon-effect allele/effect allele
brs112108870 is also known as rs200788077
Evidence of association with the concentration of phospholipids in medium HDL in 8,380 individuals in the 
METSIM study. Effect represents the change in standard-normalized residuals of phospholipids in medium HDL. 
Conditioning on variant rs737337 attenuated the signal. MAF, minor allele frequency
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Table 7: Association of 100 ANGPTL8 locus variants with HDL-C in WHI
Variant Position NEA EA MAF Effect Std Error P-value Effect Std Error P-value
rs4804154 19:11334179 C T 0.19 -0.042 0.005 6.15E-17 - - -
rs3810308 19:11333596 T C 0.19 -0.042 0.005 6.11E-17 0.000 0.005 0.999
rs3826815 19:11332505 C T 0.19 -0.042 0.005 6.20E-17 0.000 0.005 0.996
rs12974173 19:11333359 A T 0.17 -0.046 0.006 1.14E-16 -0.001 0.006 0.923
rs72994363 19:11333358 G T 0.17 -0.046 0.006 1.14E-16 -0.001 0.006 0.923
rs17699089 19:11343795 A G 0.20 -0.043 0.005 1.36E-16 0.000 0.005 0.998
rs12463177 19:11341680 G C 0.20 -0.042 0.005 1.56E-16 0.000 0.005 0.985
rs3760782 19:11346550 C T 0.19 -0.044 0.005 2.01E-16 -0.001 0.005 0.892
rs3745683 19:11348521 G A 0.19 -0.044 0.005 5.22E-16 0.000 0.005 0.955
rs4804153 19:11331531 C T 0.18 -0.044 0.005 5.43E-16 0.001 0.005 0.920
rs4804576 19:11331354 G T 0.18 -0.043 0.005 6.14E-16 0.000 0.005 0.977
rs4804575 19:11329641 G A 0.19 -0.043 0.005 7.50E-16 0.001 0.005 0.861
rs34692794 19:11343547 R I 0.21 -0.041 0.005 1.72E-15 0.001 0.005 0.875
rs56322906 19:11346155 G A 0.18 -0.043 0.005 2.76E-15 0.000 0.005 0.971
rs737338 19:11347657 C T 0.18 -0.043 0.005 5.20E-15 0.001 0.005 0.917
rs17766692 19:11342599 C T 0.20 -0.040 0.005 2.24E-14 0.002 0.005 0.736
rs2278426 19:11350488 C T 0.19 -0.042 0.006 6.22E-14 0.002 0.006 0.780
rs66466742 19:11336444 C T 0.17 -0.040 0.005 7.83E-14 0.002 0.005 0.640
rs4804155 19:11334295 C G 0.31 -0.030 0.004 6.33E-13 -0.004 0.004 0.300
rs35472533 19:11324312 G A 0.34 -0.032 0.004 1.93E-12 -0.005 0.004 0.313
rs62129150 19:11330005 G A 0.52 0.030 0.004 2.12E-12 0.010 0.004 0.017
rs113441245 19:11328383 G A 0.35 -0.031 0.004 2.50E-12 -0.004 0.004 0.356
rs11085764 19:11327227 G C 0.35 -0.031 0.004 2.68E-12 -0.004 0.004 0.350
rs2304154 19:11326125 C T 0.35 -0.031 0.004 3.22E-12 -0.004 0.004 0.357
rs2163830 19:11325417 A G 0.35 -0.031 0.004 3.51E-12 -0.004 0.004 0.359
rs1865063 19:11341029 C T 0.31 -0.030 0.004 4.35E-12 -0.005 0.004 0.256
rs2304155 19:11326119 G A 0.52 0.030 0.004 4.72E-12 0.010 0.004 0.017
rs11673129 19:11325924 C G 0.35 -0.031 0.004 5.06E-12 -0.004 0.004 0.375
rs8113156 19:11321705 T G 0.35 -0.030 0.004 7.63E-12 -0.004 0.004 0.317
rs8101801 19:11335477 C A 0.30 -0.029 0.004 9.08E-12 -0.005 0.004 0.278
rs11666686 19:11323085 T C 0.35 -0.030 0.004 1.26E-11 -0.004 0.004 0.387
rs112108870 19:11345315 R I 0.40 -0.029 0.004 1.67E-11 -0.008 0.004 0.053
rs2116873 19:11325784 A T 0.55 0.030 0.004 4.11E-11 0.008 0.004 0.062
rs4804152 19:11327626 G A 0.39 0.030 0.004 4.28E-11 0.013 0.004 0.004
rs59389322 19:11329394 G A 0.34 -0.029 0.005 9.54E-11 -0.002 0.004 0.578
rs67076391 19:11328617 C T 0.34 -0.029 0.005 1.01E-10 -0.002 0.004 0.582
rs2116875 19:11325764 A G 0.30 -0.032 0.005 1.13E-10 -0.001 0.005 0.777
rs2116874 19:11325767 T C 0.43 -0.030 0.005 1.23E-10 -0.011 0.005 0.017
rs200788077 19:11345320 R I 0.37 -0.028 0.004 1.60E-10 -0.009 0.004 0.051
rs111705028 19:11320494 C T 0.25 -0.036 0.006 3.91E-10 -0.007 0.006 0.215
rs8409 19:11319491 G A 0.37 -0.027 0.004 5.46E-10 -0.003 0.004 0.515
rs737337 19:11347493 T C 0.41 -0.026 0.004 9.09E-10 -0.006 0.004 0.169
rs12981155 19:11320339 G C 0.27 -0.036 0.006 1.20E-09 -0.006 0.006 0.309
rs12979813 19:11342703 A G 0.50 -0.022 0.004 7.01E-09 -0.006 0.004 0.102
rs7252965 19:11309160 G C 0.53 0.024 0.004 8.49E-09 0.006 0.004 0.149
rs8101345 19:11310920 T C 0.45 -0.023 0.004 1.10E-08 -0.005 0.004 0.195
rs4804151 19:11327608 C T 0.36 0.026 0.005 2.44E-08 0.010 0.005 0.033
rs12609620 19:11324890 C T 0.36 0.026 0.005 2.58E-08 0.010 0.005 0.031
rs10406522 19:11341635 T C 0.51 -0.022 0.004 2.62E-08 -0.006 0.004 0.138
rs8110433 19:11316317 A C 0.55 0.023 0.004 2.97E-08 0.005 0.004 0.208
rs138111115 19:11307572 R D 0.50 0.023 0.004 4.66E-08 0.006 0.004 0.171





rs3810307 19:11332570 T A 0.49 -0.022 0.004 8.85E-08 -0.004 0.004 0.277
rs149928810 19:11308475 R D 0.49 0.022 0.004 2.24E-07 0.005 0.004 0.255
rs764304127 19:11314807 D R 0.46 0.021 0.004 2.27E-07 0.006 0.004 0.166
rs11878417 19:11319978 A G 0.52 0.021 0.004 3.19E-07 0.002 0.004 0.615
rs10421795 19:11344406 C T 0.62 -0.022 0.004 3.30E-07 -0.008 0.004 0.075
rs113535966 19:11337269 G A 0.06 -0.051 0.01 5.22E-07 -0.002 0.01 0.822
rs10421382 19:11344973 G C 0.61 -0.021 0.004 5.61E-07 -0.007 0.004 0.100
rs6511728 19:11335597 A G 0.61 -0.021 0.004 5.95E-07 -0.007 0.004 0.086
rs7252976 19:11315343 G A 0.20 0.025 0.005 6.36E-07 0.014 0.005 0.005
rs17001244 19:11340057 A G 0.54 -0.019 0.004 8.72E-07 -0.004 0.004 0.298
rs2043302 19:11339396 T C 0.61 -0.021 0.004 1.09E-06 -0.006 0.004 0.162
rs35248735 19:11312238 G A 0.42 0.019 0.004 1.27E-06 0.005 0.004 0.181
rs56865998 19:11354146 C G 0.07 -0.047 0.01 1.49E-06 -0.002 0.01 0.872
rs59175057 19:11329534 R D 0.44 -0.021 0.004 1.94E-06 -0.004 0.004 0.368
rs184781818 19:11317340 A G 0.00 -1.927 0.413 2.99E-06 -0.492 0.411 0.231
rs114281937 19:11348208 C T 0.02 -0.084 0.018 3.04E-06 -0.034 0.018 0.060
. 19:11323240 D R 0.38 0.020 0.004 3.29E-06 0.005 0.004 0.243
rs7249565 19:11302807 G A 0.60 0.018 0.004 3.44E-06 0.004 0.004 0.300
rs12980863 19:11309871 C T 0.41 0.018 0.004 3.52E-06 0.005 0.004 0.214
rs3745681 19:11303943 A G 0.59 0.018 0.004 3.63E-06 0.003 0.004 0.447
rs7246614 19:11310538 C T 0.24 0.021 0.005 3.87E-06 0.010 0.005 0.024
rs3745682 19:11313256 G A 0.24 0.021 0.005 4.20E-06 0.010 0.004 0.025
rs4804574 19:11317482 A G 0.35 0.019 0.004 4.55E-06 0.007 0.004 0.118
rs7250652 19:11302606 G A 0.40 -0.018 0.004 4.63E-06 -0.004 0.004 0.255
rs145352947 19:11306346 R D 0.58 0.019 0.004 4.86E-06 0.003 0.004 0.478
rs6511727 19:11315817 G T 0.23 0.021 0.005 4.97E-06 0.011 0.005 0.021
rs10421221 19:11316547 T C 0.32 0.019 0.004 6.41E-06 0.007 0.004 0.080
rs10418759 19:11340242 A G 0.64 -0.019 0.004 6.54E-06 -0.005 0.004 0.196
rs8101802 19:11336182 G C 0.62 -0.019 0.004 8.49E-06 -0.006 0.004 0.187
rs8110823 19:11316315 G A 0.23 0.021 0.005 8.52E-06 0.011 0.005 0.019
. 19:11323239 D R 0.38 0.019 0.004 9.08E-06 0.004 0.004 0.341
rs7250778 19:11306265 G A 0.21 0.023 0.005 1.50E-05 0.012 0.005 0.018
rs61045132 19:11303068 C T 0.22 0.020 0.005 1.73E-05 0.013 0.005 0.005
rs58543390 19:11342434 C T 0.00 -1.187 0.279 2.07E-05 -0.328 0.278 0.237
rs73506605 19:11307564 G A 0.44 0.018 0.004 2.10E-05 0.003 0.004 0.442
rs34757881 19:11341462 C T 0.07 -0.039 0.009 2.18E-05 0.012 0.009 0.190
rs200384092 19:11323225 R D 0.41 -0.023 0.005 2.93E-05 -0.006 0.005 0.258
rs79846490 19:11311885 G C 0.01 -0.115 0.028 3.71E-05 -0.030 0.028 0.280
rs6511729 19:11346252 A C 0.65 -0.018 0.004 3.72E-05 -0.004 0.004 0.336
rs57681847 19:11300648 G T 0.21 0.019 0.005 4.02E-05 0.012 0.005 0.009
rs58495388 19:11300312 G C 0.18 0.021 0.005 6.76E-05 0.014 0.005 0.008
rs139048611 19:11321312 R D 0.02 -0.067 0.017 7.34E-05 -0.023 0.017 0.167
rs8111456 19:11301147 A G 0.22 0.018 0.005 7.44E-05 0.013 0.005 0.007
rs147045092 19:11300357 G C 0.00 14.200 3.656 0.000103 10.115 3.641 0.005
rs34301174 19:11348098 G A 0.11 0.034 0.009 0.000115 0.017 0.009 0.054
rs2278013 19:11305429 C A 0.15 0.024 0.006 0.000168 0.014 0.006 0.032
rs148312284 19:11358858 G C 0.02 -0.071 0.019 0.000191 -0.025 0.019 0.182
rs199653227 19:11317508 D R 0.25 0.017 0.005 0.000234 0.007 0.005 0.134
rs73506665 19:11358644 C T 0.05 -0.036 0.01 0.000263 0.000 0.01 0.970
Evidence of association with HDL-C in 8,244 individuals in the WHI study. Effect represents the change in standard-
normalized residuals of phospholipids in medium HDL. Conditioning on lead variant rs4804154 attenuated the 
signal. NEA, non-effect allele; EA, effect allele; MAF, minor allele frequency
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Table 8: Variant associations with gene expression levels in subcutaneous adipose tissue 
 
Gene expression was measured in 770 subcutaneous adipose samples. eQTL data are reported for 
genes within 1 Mb of rs737337 that have at least one variant with p<0.05. Lead eQTL variants 
for ANGPTL8 (rs4804155) and DOCK6 (rs17699089), lead GWAS variants (rs4804154 and 
rs737337) and functional candidate variant rs12463177 are shown. Data are shown for the most 
strongly associated probeset. 
 
Gene rs4804155 rs17699089 rs4804154 rs737337 rs12463177 Probeset ID
ANGPTL8 1.04E-09 1.84E-09 1.38E-09 9.74E-08 3.84E-09 11756040_a_at
DOCK6 2.37E-06 7.21E-07 1.65E-06 2.68E-03 3.06E-06 11719400_a_at
CCDC159 0.071 0.066 0.085 0.092 0.054 11744239_a_at
KANK2 0.056 0.073 0.048 0.565 0.116 11726538_x_at
KRI1 0.052 0.062 0.036 0.348 0.053 11725949_x_at
LDLR 0.303 0.300 0.258 0.616 0.349 11720028_x_at
LPPR2 0.059 0.056 0.054 0.215 0.070 11722506_a_at
S1PR5 0.152 0.202 0.157 0.014 0.247 11752664_a_at
SLC44A2 0.028 0.029 0.028 0.178 0.036 11740973_s_at
TSPAN16 0.050 0.032 0.043 0.288 0.034 11761297_x_at
eQTL p-value
Gene expression was measured in 770 subcutaneous adipose samples. eQTL data are 
reported for genes within 1 Mb of rs737337 that have at least one variant with p<0.05. Lead 
eQTL variants for ANGPTL8 (rs4804155) and DOCK6 (rs17699089), lead GWAS variants 
(rs4804154 and rs737337) and functional candidate variant rs12463177 are shown. Data 
are shown for the most strongly associated probeset.
	
























rs79846490 11311884 0.58 L
rs8409 11319491 0.66 NM











rs4804575 11329641 0.34 0.98 0.240 0.021
rs17699030 11330942 0.45 0.029 Yes
rs4804576 11331354 0.46 0.95 0.450 0.037
rs4804153 11331531 0.3 0.95 0.240
rs3826815 11332505 0.67 0.99 A 0.050 Yes
rs12971537 11333358 A
rs12974173 11333359 0.61 0.81 A 0.049
rs3810308 11333596 0.67 0.98 A 0.290 0.049 Yes
rs4804154 11334179 0.67 1 L:!USF1 0.037
rs4804155 11334295 0.67 0.48 0.050 Yes
rs8101801 11335477 0.46 0.47 0.024
rs6511728 11335597 0.48
rs8101802 11336182 0.53 A
rs66466742 11336444 0.46 0.92 A 0.028
rs138572354 11338309 0.72 ONEBL 0.023
rs12463177 11341680 0.74 0.93 AL AL L 0.320 0.065 Yes
rs17766692 11342599 0.34 0.84 AL L L B:!OCT2,!POU2f2 0.028
rs34692794 11343547 0.74 0.86 AL
rs17699089 11343795 0.74 0.91 AL A 0.290 0.061 Yes
rs10421795 11344406 0.47 AL
rs10421382 11344973 0.47 L A
rs200788077b 11345321 0.96 0.22 L L A L:!JUND,!cJUN 0.066 SMAD4,!HNF4G,!RXRA
rs56322906 11346155 0.54 0.86 AL AL L L L 0.420 0.026
rs6511729 11346252 0.48 M AL AL L L L
rs3760782 11346550 0.98 0.87 AL AL L L L L:HDAC2! 0.430 0.051 Yes SP1,!RXRA,!HNF4A,!HNF4G,!SREBP1,!SREBP2







rs737338 11347657 0.54 0.86 AL AL L L L L:!CEBPb,!TAF1,!ELF1,!HNF4g 0.420 0.026
rs3745683 11348521 0.98 0.82 N AL AL L L L 0.420 0.051 YY1,!SREBP1,!RXRA,!PPARG
















Table 10: Fine-mapping analysis using MANTRA
 
 
Table 11: Fine-mapping analysis using CAVIAR 
 
Variant Position EA NEA logBF PP Direction Bayes Factor Cum(BF) credible set
rs3760782 11,346,550  T C 18.9 0.43 -- 7.57E+18 7.57E+18 0.331
rs3745683 11,348,521  A G 18.8 0.42 -- 6.04E+18 1.36E+19 0.595
rs4804153 11,331,531  T C 18.6 0.24 -- 3.72E+18 1.73E+19 0.757
rs17699089 11,343,795  G A 18.4 0.29 -- 2.28E+18 1.96E+19 0.856
rs4804576 11,331,354  T G 17.9 0.45 -- 7.56E+17 2.04E+19 0.889
rs56322906 11,346,155  A G 17.8 0.42 -- 6.60E+17 2.10E+19 0.918
rs4804575 11,329,641  A G 17.8 0.24 -- 6.48E+17 2.17E+19 0.947
rs737338 11,347,657  T C 17.8 0.42 -- 5.95E+17 2.23E+19 0.973
rs3810308 11,333,596  C T 17.5 0.29 -- 3.14E+17 2.26E+19 0.986
rs12463177 11,341,680  C G 17.3 0.32 -- 2.00E+17 2.28E+19 0.995
MANTRA analysis was conducted in 16624 individuals from METSIM and WHI. Credible set values are the 
cum(BF) divided by the total cumulative Bayes Factor. EA, effect allele; NEA, non-effect allele; logBF, 
log(Bayes Factor); PP, posterior probability





0.066 rs200788077 0.499 rs2116874
























Variants shown are in the 95% causal set.
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Table 12: Fine-mapping analysis using PAINTOR
 
Table S8. Fine-mapping analysis using PAINTOR 
METSIM Finnish
Position Variant Probability Position Variant Probability Position Variant Probability Position Variant Probability
11327571 rs4804150 0.42 11327571 rs4804150 1.00 11327571 rs4804150 1.00 11327571 rs4804150 1.00
11341680 rs12463177 0.29 11313256 rs3745682 1.00 11313256 rs3745682 0.96 11317770 rs56034303 1.00
11343795 rs17699089 0.29 11343795 rs17699089 0.66 11318375 rs116504889 0.86 11313256 rs3745682 0.97
11330942 rs17699030 0.25 11332505 rs3826815 0.34 11343795 rs17699089 0.65 11318375 rs116504889 0.88
11332505 rs3826815 0.23 11332505 rs3826815 0.30 11343795 rs17699089 0.62
11346550 rs3760782 0.20 11332505 rs3826815 0.26
11318235 rs114277401 0.11
WHI African American
Position Variant Probability Position Variant Probability Position Variant Probability Position Variant Probability
11330005 rs62129150 1.00 11334295 rs4804155 1.00 11350086 rs115758240 1.00 11340498 rs73506650 1.00
11321705 rs8113156 1.00 11330005 rs62129150 1.00 11334295 rs4804155 1.00 11340057 rs17001244 1.00
11327571 rs4804150 1.00 11330005 rs62129150 1.00 11334295 rs4804155 1.00
11327571 rs4804150 1.00 11330005 rs62129150 1.00
11327571 rs4804150 1.00
METSIM Finnish and WHI African American
Position Variant Probability Position Variant Probability Position Variant Probability Position Variant Probability
11330005 rs62129150 1.00 N/A N/A N/A 11334295 rs4804155 1.00 N/A N/A N/A 
11321705 rs8113156 1.00 11333596 rs3810308 1.00
11330005 rs62129150 1.00
11327227 rs11085764 1.00
PAINTOR analysis was performed in METSIM, WHI, and METSIM/WHI combined. In each dataset, 2, 3, 4, or 5 causal variants were assumed. Posterior 
probabilities are presented. Positions are on chromosome 19 and hg19. N/A, no variants are predicted.
2 causal variants 3 causal variants 4 causal variants 5 causal variants
2 causal variants 3 causal variants 4 causal variants 5 causal variants
2 causal variants 3 causal variants 4 causal variants 5 causal variants
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CHAPTER 4: OPEN CHROMATIN PROFILING IN ADIPOSE MARKS GENOMIC 
REGIONS WITH FUNCTIONAL ROLES IN CARDIOMETABOLIC TRAITS 
 
Introduction 
Cardiometabolic diseases, including cardiovascular disease, type 2 diabetes (T2D), and 
obesity, are a significant health burden in many populations (9-11). Each of these diseases and 
related traits is regulated by genetic and environmental risk factors (25). Genome-wide 
association studies (GWAS) have identified hundreds of loci associated with cardiometabolic 
diseases and risk factors (www.ebi.ac.uk/gwas/). Many associated variants are located in 
noncoding regions, suggesting a regulatory mechanism of action. The causal variant(s) and target 
gene(s) at noncoding GWAS loci have yet to be fully delineated. A mechanistic understanding of 
loci is necessary to inform the development of therapies for the appropriate genes (1) and 
direction of effect (2), especially given the increasing recognition of allelic heterogeneity at 
GWAS loci (3-8).  
Adipose tissue, especially in subcutaneous depots, is involved in cardiometabolic traits 
and diseases. Subcutaneous adipose tissue serves as a buffering system for lipid energy balance, 
particularly fatty acids (159-161), and may play a protective role in cardiometabolic risk (162). 
Accumulation of fat, particularly in the central abdomen (163), and specifically in the 
subcutaneous depot (164), confers an elevated risk of cardiometabolic diseases and mortality. In 
addition, subcutaneous adipose expression quantitative trait loci (eQTL) studies have identified 
genes involved in central obesity and metabolic traits (63,165-168), and specific GWAS loci for
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type 2 diabetes, lipid levels, measures of obesity, and adiponectin colocalized with subcutaneous 
adipose eQTLs (4-7). In addition, a recent GWAS meta-analysis for waist-hip ratio, a measure of 
obesity, identified loci that were enriched both for putative regulatory elements in adipocyte 
nuclei and for genes expressed in subcutaneous adipose tissue (6), many of which are now linked 
to adipose function (169).  
Adipose tissue is highly complex and composed of many cell types, including adipocytes, 
preadipocytes, nerve cells, immune cells, and vascular cells (170). Characterization of 
heterogeneous whole adipose tissue and its component cell types are both needed to fully 
delineate the role of adipose tissue in cardiometabolic disease. A benefit of using human adipose 
tissue samples is to identify differences in chromatin accessibility due to genotype and link them 
to cardiometabolic traits; however, inherent differences exist between samples due to site of 
tissue extraction, sample handling, tissue storage conditions, genotype, and/or environmental 
contributions such as obesity or T2D. Although cell models do not fully replicate cells within a 
complex tissue, they provide a means to characterize individual cell types and have consistent 
growth, storage, and environmental conditions. The Simpson Golabi-Behmel Syndrome (SGBS) 
human cell strain is an ideal model for studying adipocyte and preadipocyte biology because the 
cells are diploid, easy to grow in culture, can be differentiated to mature adipocytes (171). 
Additionally, using SGBS cells rather than primary human adipocytes from multiple individuals 
decreases experimental variation due to genotype or sample collection differences. 
Variability in chromatin accessibility is heritable and mediates the effects of gene 
expression (172-174). Adipose and adipocytes are poorly represented in open chromatin datasets 
because the high lipid content makes experimental assays challenging. For human adipose and 
adipocytes, three DNase-seq datasets exist: one from in vitro differentiated adipocytes 
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(ENCODE), one SGBS adipocytes (175), and a third from adipose-derived differentiated stem 
cells (176). Accessible chromatin can be assayed in small amounts of tissue or cells using the 
assay for transposase-accessible chromatin followed by sequencing (ATAC-seq) (62). To date, 
only three ATAC-seq datasets have been generated from human adipose tissue or cells: one from 
adipocyte nuclei from subcutaneous adipose tissue (61,177), one from subcutaneous adipose 
tissue (ENCODE), and one from omental fat tissue (ENCODE). In addition to chromatin 
accessibility, regulatory histone marks have been characterized in adipose nuclei from 
subcutaneous adipose tissue and differentiated adipocytes from mesenchymal stem cells in the 
Roadmap Epigenomics Project. The collection of histone marks were integrated into chromatin 
states (178), which predict regulatory function (i.e. promoter or enhancer). Previous studies have 
found that regions of chromatin accessibility occur preferentially in promoters and enhancers 
compared to transcribed and repressed regions of the corresponding cell type (178,179). Adipose 
chromatin states based on histone marks will be strengthened by the addition of open chromatin 
datasets.  
Robust chromatin accessibility data from adipose tissue and adipocytes can identify 
candidate variants at GWAS loci. Allelic differences have been found in accessible chromatin 
and histone marks of chromatin state (172,180-184), and these differences have provided a 
functional context for interpreting GWAS loci for blood and autoimmune diseases (8,173). 
Chromatin accessibility data can also identify sites of transcription factor binding (61). 
Transcription factor motifs predict where a transcription factor may bind; however, only a small 
fraction of predicted motifs show factor binding (185). Transcription factor footprints can 
potentially identify the factor(s) bound at a given site. Cell models such as SGBS may provide a 
more pure population of cells to prioritize candidate variants and identify candidate transcription 
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factors because chromatin accessibility in these cells can identify preadipocyte-specific 
regulatory elements and may help characterize cell-type specificity within heterogeneous adipose 
tissue. Taken together, chromatin accessibility data in adipose tissue and adipocytes will improve 
annotation of candidate regulatory variants and candidate transcription factors at GWAS loci. 
In this study, we use ATAC-seq data from frozen clinical subcutaneous adipose tissue 
needle biopsy samples and SGBS preadipocytes to identify accessible chromatin. We compare 
adipose tissue and preadipocyte open chromatin profiles and identify regulatory regions specific 
to each. We identify cardiometabolic GWAS and transcription factor enrichment within ATAC 
peaks. Finally, we use the ATAC-seq annotations to prioritize candidate variants at 
cardiometabolic GWAS loci with colocalized eQTL associations. Based on ATAC-seq overlap, 
we test candidate variants at two cardiometabolic GWAS loci and identify functional variants. 
 
Materials and Methods 
METSIM study participants 
Subcutaneous adipose tissue needle biopsies were obtained from METabolic Syndrome 
in Men (METSIM) participants as previously described (63). We use three adipose tissue needle 
biopsy samples for ATAC-seq (Table 14). The METSIM study includes 10,197 men, aged from 
45 to 73 years, randomly selected from Kuopio, Eastern Finland, and examined in 2005 – 2010 
(140,141). The Ethics Committee of the University of Eastern Finland in Kuopio and the Kuopio 
University Hospital approved the METSIM study and it was carried out in accordance with the 
Helsinki Declaration. DNA samples were genotyped on the Illumina OmniExpress and 
HumanCoreExome arrays and imputed using the Haplotype Reference Consortium as previously 
described (151).  
	 90	
Sample processing and ATAC-seq library preparation 
Adipose tissue was flash frozen and stored at -80º until use. SGBS cells (154) were 
generously provided by Dr. Martin Wabitsch (University of Ulm) and cultured as previously 
described (186). For adipose tissue samples 1 and 3, we generated libraries using nuclei isolation 
buffers that contained detergent (1% NP-40) or did not contain detergent. For tissue sample 2, 
we generated libraries using ~12 mg and ~36 mg of tissue. For SGBS, we have generated 
profiles using as few as 50,000 cells (data not shown); however, in this study we generated 
profiles with 800,000 cells (SGBS 1) and 400,000 cells (SGBS 2), both with detergent (Table 
15). Tissue was pulverized in liquid nitrogen using a Cell Crusher homogenizer 
(cellcrusher.com). For SGBS cells, cells were trypsinized and pelleted. The tissue powder or cell 
pellet was resuspended in nuclei isolation buffer (20 mM Tris-HCl, 50 mM EDTA, 60 mM KCl, 
40% glycerol, 5 mM spermidine, 0.15 mM spermine, 0.1% mercaptoethanol, 1% NP-40). Tubes 
were rotated at 4º for 5 minutes. The solution was completely homogenized using a tight 
homogenizer (Wheaton) for 10 strokes. Following homogenization, the solution was centrifuged 
at 1500 x g for 10 minutes at 4º. Following removal of the lipid layer from the adipose tissue and 
supernatant, the pellet was resuspended in resuspension buffer (10 mM Tris-HCl, 10 mM NaCl, 
3 mM MgCl2) and centrifuged at 1200 x g for 10 minutes at 4º. The supernatant was removed 
and the pellet was used for the transposase reaction as previously described (62). For SGBS 
libraries, we used 5 ul Tn5 transposase. Following library PCR amplification, we removed 
primer dimers using Ampure Beads (Agencourt) with a 1:1.2 ratio of library to beads. Libraries 
were visualized and quantified using a TapeStation or Bioanalyzer and sequenced at the Duke 
University Genome Sequencing Center (adipose tissue single-end sequencing) or the University 
of North Carolina High-Throughput Sequencing Facility (SGBS paired-end sequencing). 
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ATAC-seq alignment and peak calling 
We obtained previously published adipose ATAC-seq datasets from subcutaneous 
adipose tissue (ENCODE ENCSR540BML) and mature adipocytes (177). The mature adipocyte 
ATAC-seq data was shared by the McGill Epigenomics Mapping Centre and is available from 
the European Genome-phenome Archive of the European Bioinformatics Institute (dataset 
EGAD00001001300). To perform alignments consistently across samples, we merged the mate 
pair fastq files and trimmed reads to 50 nucleotides for each paired-end SGBS, mature adipocyte, 
and ENCODE ATAC-seq samples. We removed sequencing adapters from raw ATAC-seq 
sequence reads using Tagdust (187) with a false discovery rate of 0.001 and selected high quality 
reads with a Phred score of at least 20 for at least 90% of bases using the FASTX toolkit 
(http://hannonlab.cshl.edu/fastx_toolkit). We aligned filtered reads to the hg19 human genome 
using bowtie2 (188), penalizing ambiguous bases as mismatches. We removed any alignments 
with mapping quality less than 20, mitochondrial reads, or blacklisted regions (189,190) and 
shifted the resulting alignments by +4 on the + strand and -5 on the – strand so that the 5’ base of 
each alignment corresponded to the center of the binding site of the Tn5 transposase (62,191). 
We verified sample identity using verifyBamID (192) using genotyped variants with at least 10 
ATAC-seq reads in the sample with the lowest read depth (Tissue 2; 8,683 variants), minimum 
minor allele frequency of 0.01, and call rate of at least 0.5; we used the best-matched genotypes 
for each sample. We called peaks using MACS2 (193) with no background dataset, smoothing 
ATAC signal over a 200 bp window centered on the Tn5 binding site, allowing no duplicates, 




Comparison of adipose ATAC profiles  
We compared ATAC peak genomic positions between our ATAC-seq samples and 
subcutaneous adipose ATAC-seq profiles from ENCODE (ENCSR540BML), and mature 
adipocytes (177) using two metrics in BEDTools: the Jaccard index, which evaluates similarity 
between a pair of samples as the intersection divided by the union of sample set contents, and the 
percent of peak bases in one sample covered by another sample. When comparing peaks between 
library preparations, we used the top 10,000 peaks ranked by peak p value. We used two 
methods to compare peaks between our adipose tissue, SGBS, ENCODE, and mature 
adipocyte.samples. We compared the top 25,000 peaks ranked by peak p value in each individual 
sample and the top 50,000 peaks between the union of our tissue samples, the union of the SGBS 
samples, the union of the mature adipocyte samples, and the ENCODE sample. Results were 
similar between the individual and union comparisons. The p values of overlapping peaks were 
averaged when merging peaks between samples. We generated Venn diagrams showing the 
overlap of the union samples using the Vennerable R package (194). 
 
Chromatin state analyses 
 We obtained chromatin states for the expanded 18-state model consisting of data for 98 
cell and tissue types and 6 histone marks (H3K4me1, H3K4me3, H3K36me3, H3K27me3, 
H3K9me3, and H3K27ac) from the Roadmap Epigenomics Consortium (178). We generated the 
following combined states by merging states of similar genomic context: promoter (1_TssA, 
2_TssFlnk, 3_TssFlnkU, 4_TssFlnkD, 14_TssBiv), transcribed (5_Tx, 6_TxWk), enhancer 
(7_EnhG1, 8_EnhG2, 9_EnhA1, 10_EnhA2, 11_EnhWk, 15_EnhBiv), and polycomb repressed 
(16_ReprPC, 17_ReprPCWk). Using BEDTools (46), we calculated the number of ATAC peak 
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bases overlapped by each chromatin state in each individual ATAC sample, the union of the 
adipose tissue samples, and the union of the SGBS samples. To control for differences in peak 
number and width, we performed overlap using two sets of normalized peaks in the union 
samples: the top 50 thousand peaks ranked by peak p value and the central 200 bases of the top 
50 thousand peaks. We generated stacked bar plots of the percent of ATAC peak bases covered 
by each chromatin state in each cell type using R (195) and ranked the ATAC peak coverage of 
each chromatin state in adipose nuclei (Roadmap epigenome ID = E063) relative to all other cell 
types, where a rank of 1 corresponds to higher coverage than all other cell types. 
 
Comparison of adipose tissue and SGBS specific ATAC peaks 
We classified adipose tissue- or SGBS-specific peaks as those found in at least one tissue 
sample and no SGBS sample, or vice versa. To correct for the greater number of peaks in SGBS, 
we compared the top 10,000 (of 19,757) tissue-specific peaks to the top 10,000 (of 162,414) 
SGBS-specific peaks ranked by peak p value. We identified TF motifs enriched in peaks specific 
to tissue or SGBS relative to peaks shared between tissue and SGBS using 319 vertebrate motifs 
in Homer (188). We classified motifs with an enrichment p value less than 2*10-4 (0.05/319) as 
enriched. For shared peaks, we required that at least 50% of a tissue peak was overlapped by an 
SGBS peak and vice versa (n=45,120). We performed gene ontology enrichment using GREAT 
with default parameters (196) of METSIM and SGBS-specific peaks using the Gene Ontology 
Biological Process ontology (197). We identified transcription start sites (TSSs) of 78,589 
unique TSSs at 43,527 genes TSSs (GENCODE 24lift37 Basic Set) specific to tissue as those 
overlapping one of the top 10,000 tissue-specific peaks and at least 1 kb or 5 kb from any SGBS 
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peak. We defined SGBS-specific TSSs as those overlapping one of the top 10,000 SGBS-
specific peaks and at least 1 kb or 5 kb from any tissue peak.  
 
Transcription factor motif scanning and footprinting 
We scanned the hg19 human genome (SGBS) or haplotypes of personalized reference 
genomes constructed from individual genotypes (adipose tissue samples) for 519 transcription 
factor binding motifs from the JASPAR core 2016 vertebrates database using FIMO (198,199). 
If two motifs for the same factor existed at the exact same genomic coordinates and on the same 
strand on each haplotype, we used the motif with the highest motif score.  
We performed transcription factor footprinting for 35 transcription factor motifs 
corresponding to 34 unique adipose-related transcription factors (Table 16). The 34 transcription 
factors included 21 described as adipose core transcription factors (200), six dimer motifs that 
contained a core transcription factor, CEBPA, CEBPB, CEBPD, ZEB1, SPI1, SPIB, and CTCF. 
For the resulting motifs, we generated windows containing the genomic coordinates of the motif 
and 100 bp flanking both motif edges. We removed motif windows where less than 90% of bases 
uniquely mapped and windows that overlapped blacklisted regions (47). We constructed matrices 
of the number of Tn5 transpositions across the remaining motif windows and predicted which 
motifs were likely bound using CENTIPEDE (185). We used motif scores calculated by FIMO 
for CENTIPEDE priors and classified a motif with a CENTIPEDE posterior binding probability 
greater than 0.99 as bound and less than 0.5 as unbound.  
To determine which transcription factors exhibited an aggregate footprint profile, we 
calculated the average transposition probability at each window position separately for bound 
and the top 10,000 unbound sites to obtain aggregate bound and unbound profiles. We then 
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calculated the transposition probability ratio (TPR) by dividing each position in the bound 
profiles by the corresponding position in the unbound profiles and calculated the average TPR 
across the motifs (mTPR) and the 100 bp flanking regions (fTPR). We considered transcription 
factor motifs to display an aggregate footprint profile if mTPR was less than fTPR.  
  
Enrichment of GWAS variants in ATAC peaks and Roadmap chromatin states 
We tested for enrichment of cardiometabolic GWAS loci in ATAC peaks and Roadmap 
chromatin states using GREGOR with an LD r2 threshold of 0.8 and a window size of 1 Mb 
(158). We used loci from 12 trait categories from the GWAS catalog (December 2016): type 2 
diabetes, insulin, glucose, cardiovascular outcomes, blood pressure traits, low-density lipoprotein 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, total 
cholesterol, body mass index (BMI), waist-hip ratio adjusted for BMI (WHR), and adiponectin. 
Loci that were associated with multiple traits were assigned to each trait. We classified loci as 
enriched in a given region if the enrichment p-value was less than the Bonferroni-corrected 
threshold of 5x10-4 (0.05/(8 regions*12 traits)). To compare enrichment magnitudes between 
regions and traits, we calculated an enrichment z-score: 
 
The expected overlaps and standard deviation were estimated from matched control loci using 
GREGOR. We visualized the enrichment results using the heatmap.2 function in the gplots R 
package (195,201). We computed the percent of loci and proxies for each cardiometabolic trait 
that overlapped adipose tissue and SGBS ATAC peaks using the LD proxies calculated by 
GREGOR (1000 Genomes Phase I) (57). Of the loci and proxies overlapping ATAC peaks, we 
calculated the fraction that overlapped transcription factor motifs from JASPAR (54). 
z-score= observed overlaps-expected overlaps
standard deviation
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Overlap of GWAS-eQTL colocalized loci with ATAC peaks 
eQTL mapping in 770 subcutaneous adipose samples and determination of GWAS-
coincident eQTLs was described previously (63,186). We identified overlap of ATAC peaks 
with any variant in LD (r2>0.8) with the eQTL lead variant at 110 loci using BEDTools (46). LD 
was calculated using the 770 METSIM individuals included in the eQTL analysis. The 110 
GWAS-eQTL colocalized loci contain 6,746 total LD proxies.  
 
Transcriptional reporter luciferase assays 
SGBS and SW872 liposarcoma cells were maintained and transcriptional reporter 
luciferase assays were performed as previously described (186). Table 17 contains primers used 
for amplifying ATAC peaks overlapping the variant of interest. Fragments containing potential 
enhancers are designated as ‘forward’ or ‘reverse’ based on their orientation with respect to the 
genome. Regions were designed to include the entire ATAC peak overlapping the variant of 
interest. Three to five independent clones were cotransfected with Renilla luciferase vector in 
triplicate (SGBS) or duplicate (SW872) wells using Lipofectamine 3000 (SGBS, Life 
Technologies) or FUGENE 6 (SW872, Promega). Firefly luciferase activity of the clones 
containing the PCR fragments was normalized to Renilla luciferase readings to control for 
differences in transfection efficiency. We repeated all luciferase transcriptional reporter 
experiments on independent days and obtained consistent results. Data are reported as fold 
change in activity relative to an empty pGL4.23 vector. We used two-sided Student’s t-tests to 




Electrophoretic mobility shift assays (EMSA) 
For EMSA, we prepared nuclear cell extracts from SGBS and SW872 cells using the NE-
PER nuclear and cytoplasmic extraction kit (Thermo Scientific) as previously described (155). 
Double-stranded oligos (Table 17) were incubated with SGBS or SW872 nuclear extract or 100 
ng purified PU.1 protein (Creative Biomart SPI1-172H) and DNA-protein complex visualization 
as previously described (155). A positive control oligo contained the PU.1 motif from JASPAR 
and a negative control did not contain the motif (Table 17). We repeated all EMSA experiments 
on independent days and obtained consistent results. 
 
Personal genome construction and ATAC-seq allelic imbalance 
We constructed personalized reference genomes with the –create_reference option in the 
AA-ALIGNER pipeline (202). We aligned reads to personalized genomes using the allele-aware 
aligner GSNAP allowing two mismatches, no INDELs, and treating ambiguous bases (encoded 
as Ns) as mismatches (203).We extracted unique alignments and filtered alignments for 
mitochondrial alignments and blacklisted regions (190,204). Using WASP (205), we removed 
alignments that did not uniquely map to each allele at heterozygous sites. Allele count pileup 
files were generated at heterozygous sites with a minimum base quality Phred score of 30 to 
minimize the impact of sequencing errors. We removed heterozygous loci with aligned bases 
other than the two genotyped alleles and selected heterozygous sites with at least 10 total counts 
and at least 1 count per allele. To account for residual biases, we fit allele counts to a beta-
binomial distribution with the probability of success (reference allele ratio) and dispersion 
estimated using maximum likelihood separately for each sample using the VGAM R package 
(195,206). We performed beta-binomial tests of allelic imbalance using VGAM and multiplied 
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the resulting one-tailed p-values by 2 to obtain estimated two-tailed imbalance p-values. We 
tested the significance of overlap between variants exhibiting nominal imbalance (beta-binomial 




Chromatin accessibility in frozen adipose tissue and SGBS preadipocytes 
We generated ATAC-seq open chromatin profiles from three frozen subcutaneous 
adipose tissue needle biopsy samples (Table 14) and two preparations of SGBS preadipocytes. 
We generated ~100-160 million raw ATAC-seq reads for each ATAC profile and ~26-70 million 
high quality aligned reads (Table 13, Methods). Using MACS2 (193) and an FDR of 5%, we 
identified ~29,000-58,000 peaks in the tissue samples and ~180,000 peaks in the SGBS 
preadipocytes (Table 13). We evaluated the use of detergent in library preparation and found that 
including detergent resulted in a greater number of peaks and higher peak similarity compared to 
no detergent (Table 14, 18). The three detergent-treated tissue profiles were similar with 64-80% 
of bases overlapping a peak in another sample and a mean pairwise Jaccard index of 0.58 (Table 
19). The two SGBS replicates showed strong similarity with 82-88% of bases in one replicate 
overlapped the other replicate and a Jaccard index of 0.73 (Table 19). Differences between 
adipose tissue samples may be due to individual variation in tissue collection and storage, 
genotype, or cellular environment. These data demonstrate that ATAC-seq open chromatin 
profiles can be obtained from small amounts (12-36 mg, one-third to two-thirds of a needle 
biopsy) of frozen clinical subcutaneous adipose tissue samples and from SGBS preadipocytes. 
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Table 13: ATAC-seq alignment metrics of human adipose tissue and SGBS preadipocytes 
 
Comparison of adipose tissue, adipocyte, and preadipocyte ATAC profiles 
To determine the differences in genomic distribution and regulatory overlap of our 
adipose tissue, SGBS preadipocyte, and previously published adipose ATAC-seq datasets 
(ENCODE, (177)), we compared the ATAC profiles using three methods: overlap of peak base 
positions, the distribution of ATAC peaks across Roadmap adipose nuclei regulatory regions, 
and the distribution of ATAC peaks across all Roadmap cell types. The ATAC peak bases were 
most similar between adipose tissue and ENCODE or mature adipocytes (mean 52% overlapped 
bases; Jaccard index = 0.33, 0.34 respectively; Figure 26A, Table 19). SGBS preadipocytes 
showed less similarity with mean 42%, 41%, and 48% overlapped bases for adipose tissue, 
mature adipocytes, and ENCODE, respectively (Jaccard index = 0.24, 0.24, and 0.31, 



















Tissue	1 129.5 87.4 8.5 80.0 79.0 70.6 58,279
Tissue	2 131.5 83.6 12.8 72.9 71.8 60.6 36,612
Tissue	3 119.3 70.5 11.9 62.2 61.3 57.1 49,631
SGBS	1a 194.9 168.4 14.2 144.4 126.2 40.5 196,211





Figure 26. Differences in ATAC-seq peaks and overlap with Roadmap adipose nuclei 
chromatin states. A) Venn diagram showing overlap of peak megabases between adipose tissue, 
SGBS preadipocytes, and mature adipocyte (177). B) Overlap of ATAC peaks with Roadmap 
adipose nuclei chromatin states. Adipose tissue ATAC peak bases were mostly located in 
adipose nuclei promoter (49% of total peak bases) and enhancer (40%) chromatin state regions. 
SGBS preadipocyte ATAC peak bases showed less overlap with adipose nuclei promoter (41% 
of total peak bases) and enhancer (25%) states. The ENCODE peaks showed strong overlap with 
promoter states (57%) and less with enhancer (25%) states. Mature adipocytes also showed 
strong overlap with regulatory regions (40% promoter, 34% enhancer). 
 
We next compared the ATAC peak locations to chromatin states in adipose nuclei from 
subcutaneous adipose tissue from the Roadmap Epigenomics Consortium (178). For all four 
ATAC profiles, the majority of peaks were located in adipose nuclei promoter and enhancers 
states with minimal overlap of regions associated with closed chromatin (Figure 26B, Table 19). 
Our adipose tissue samples showed the strongest overlap of peaks with the promoter (49% total 
union bases) and enhancer (40%) chromatin states of adipose nuclei (Figure 26B, Table 20). 
More promoter (57%) and less enhancer (25%) overlap was observed for ENCODE peaks and 
less overlap for mature adipocytes (40% promoter, 34% enhancer) compared to our adipose 
tissue. SGBS preadipocytes showed the least overlap with adipose nuclei promoters (41%) and 
enhancers (25%), suggesting that SGBS preadipocyte ATAC peaks may overlap novel 





































preadipocyte-specific regulatory regions that are not identified in the adipose nuclei chromatin 
states. Multiple peak normalization strategies confirm that results are not due to differences in 
peak number and width between samples (Table 20). The strong overlap of our tissue, ENCODE, 
and mature adipocyte peaks with adipose nuclei promoters and enhancers is surprising given the 
modest peak base overlap between them (Figure 26A, Table 19).  
Finally, we identified which cell types showed the strongest epigenomic similarity to 
each ATAC profile by identifying percent overlap and rank of 98 tissues and cell type chromatin 
states from Roadmap (178). For adipose tissue peaks, enhancers in adipose nuclei rank first of all 
98 cell types and promoters rank 4th behind stomach smooth muscle, chondrocyte cultured cells, 
and foreskin fibroblast cells (Figure 31, Table 20, 21). For SGBS preadipocyte peaks, adipose 
nuclei promoters rank 11th and enhancers rank 25th. 17 of the 24 cell types ranking above adipose 
nuclei in enhancer overlap correspond to cell lines or cultures (Figure 32, Table 20, 21) and 
include five types of fibroblast cells, which may reflect the fibroblast-like nature of 
preadipocytes (207,208). For ENCODE adipose peaks, adipose nuclei promoters rank 8th and 
enhancers rank 18th (Figure 33, Table 20, 21), further demonstrating that differences may exist 
due to adipose tissue collection and processing. For mature adipocyte peaks, adipose nuclei 
promoters rank 7th and enhancers rank 1st (Figure 34, Table 20, 21). Taken together, we identify 
important differences between adipose ATAC profiles, which are likely due to tissue collection 





Open chromatin regions selective to adipose tissue or SGBS preadipocytes exhibit different 
regulatory signatures 
Motivated by the widespread differences in adipose tissue and SGBS peak locations and 
Roadmap adipose nuclei regulatory overlap, we tested if peaks specific to tissue or SGBS 
differed in transcription factor (TF) motif enrichment, biological process enrichment, and 
location near transcription start sites (TSSs). We identified 57 TF motifs enriched in tissue-
specific peaks (Table 22), including TFs known to promote adipogenesis (ie: CEBP family 
members) and adipose core TFs RXR, FLI1, ETS1, FOXO1, and IRF1. We observed 35 motifs 
enriched in SGBS-specific peaks including adipogenesis inhibitors GATA2 and GATA3 
(209,210). Interestingly, SGBS-specific peaks also showed enrichment for AP-1 family 
members, which promote adipogenesis (210). Enhancers for multiple lineages can develop in a 
poised state and poised enhancers are enriched for motifs involved in development of multiple 
endodermal tissues (211), suggesting that a subset of SGBS ATAC peaks may mark poised 
regulatory elements involved in adipogenesis.	
We next tested if peaks specific to tissue or SGBS were enriched for different biological 
processes. Adipose tissue peaks showed significant enrichment for five processes, including both 
adipocyte (brown fat cell differentiation) and endothelial (blood vessel endothelial cell 
differentiation) processes (Figure 35), reflecting the heterogeneous nature of adipose tissue. 
SGBS peaks showed enrichment for eight processes, including processes relevant to cultured 
cells, such as chemotaxis and hippo signaling (Figure 35). However, hippo signaling has also 
been shown to regulate adipogenesis (212). These data suggest that ATAC peaks are marking 
nearby genes with relevant functions to the source cells or tissue.  
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Finally, we identified TSSs with differential chromatin accessibility. We evaluated 
78,589 unique TSSs at 43,527 genes in GENCODE version 24 for overlap with ATAC peaks. 
We identified 346 TSSs at 248 unique genes specific to tissue (Table 23) and 338 TSSs at 247 
genes specific to SGBS. Only two genes (EPS8 and RGS3) with multiple TSSs have both a 
tissue-specific and SGBS-specific TSS.  We identified tissue-specific TSSs at ADIPOQ, which 
encodes adiponectin, a vital metabolic hormone secreted by adipocytes. Adipose-selective 
ATAC peaks overlap the TSS and parts of previously described regulatory elements upstream 
and in intron 1 of ADIPOQ that showed increased transcriptional activity in reporter assays 
(213,214), and additional peaks may mark novel regulatory elements (Figure 27). Consistently, 
there is also an ATAC peak at the ADIPOQ TSS in mature adipocytes (Figure 27) (61,177). 
Interestingly, strong peaks exist in SGBS preadipocytes at the promoter of an isoform of 
ADIPOQ-AS1, the antisense transcript, suggesting that the antisense may be upregulated in 
SGBS preadipocytes. We also observed tissue-specific TSSs at von Willebrand factor (VWF), 
which is expressed in endothelial cells and involved in platelet formation in blood. Notably, 
ATAC peaks are absent in preadipocytes and mature adipocytes, suggesting that VWF is 
functioning in vascular cells within adipose tissue (Figure 36). The presence of tissue-specific 
peaks at VWF and ADIPOQ is consistent with the heterogeneous nature of adipose tissue (25) 
and suggests that open chromatin profiles in heterogeneous tissue can identify regulatory regions 
specific to component cell types. 
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Figure 27. ADIPOQ and FBN2 TSSs show differential ATAC-seq peaks. UCSC genome 
browser image showing the ADIPOQ (A) and FBN2 (B) gene regions. Histone marks from the 
Roadmap Epigenomics project adipose nuclei are shown in green and blue. The three adipose 
tissue (purple) and two SGBS (light blue) ATAC-seq signal tracks and peaks (gray) are shown. 
ATAC-seq signal and peaks from the ENCODE adipose ATAC-seq (light purple, ENCODE ID: 
ENCSR540BML), ATAC-seq from mature adipocytes (177), and signal from SGBS adipocyte 
DNase (175). Chromatin states from the Roadmap Epigenomics Project are shown for adipose 
nuclei. Yellow, enhancer; green, transcribed; orange and red, promoter; light green, genic 
enhancer. Red boxes show adipose tissue-selective (A) or SGBS-selective (B) ATAC-seq peaks 
at TSSs. Blue boxes show intronic ATAC-seq peaks also showing specificity. Data was 


























































We identified SGBS-specific TSSs at fibrillin 2 (FBN2) and lumican (LUM) (Figure 27, 
36), which are involved in the construction and maintenance of the extracellular matrix, 
consistent with previous findings that extracellular matrix genes are upregulated in preadipocytes 
(215). FBN2 is a large glycoprotein involved in creating microfibrils in connective tissues and 
lumican is a extracellular matrix proteoglycan. Another fibrillin family member, FBN1, is 
involved in the transition to adipogenesis by assisting the changing extracellular matrix (216). 
The precise roles of FBN2 and LUM in preadipocytes are unknown, but our data suggests that 
they may be expressed in preadipocytes, perhaps working to maintain or alter the extracellular 
matrix. Taken together, SGBS-specific peaks show both preadipocyte and cell culture regulatory 
signatures, and adipose tissue-specific peaks show regulatory signatures of mature adipocytes 
and non-adipocyte cell types present in adipose tissue. 
 
Cardiometabolic GWAS loci annotation in ATAC peaks  
To identify cardiometabolic traits with a strong genetic link to adipocyte regulatory 
elements, we annotated the ATAC-seq profiles by testing for enrichment of GWAS loci for 12 
cardiometabolic traits (Table 24) and identifying TF motifs and footprints within ATAC peaks at 
these loci. Adipose tissue peaks showed significant enrichment (P<5x10-4) in 9 traits (WHR, 
T2D, insulin traits, triglycerides, HDL-C, LDL-C, total cholesterol, cardiovascular outcomes, 
and blood pressure traits) (Figure 28, 37, Table 25). SGBS preadipocyte peaks showed 
significant enrichment in 5 traits (WHR, adiponectin, T2D, HDL-C, and total cholesterol) 
(Figure 28, 37, Table 25). The enrichment of circulating adiponectin GWAS loci (n=21) in 
SGBS but not tissue peaks is likely due to low power; adipose tissue peaks showed a strong 
enrichment z score (3.99), but the p value (8*10-4) was slightly above the significance threshold  
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(5*10-4) (Figure 28, 37, Table 25). Although adipose tissue peaks showed enrichment for GWAS 
loci for more traits than SGBS peaks, SGBS peaks overlap more loci for all tested traits (Figure 
28, Table 26), likely due to the presence of many more peaks in SGBS preadipocytes than 
adipose tissue.  
 
Figure 28. Cardiometabolic GWAS loci are enriched in ATAC-seq peaks. Heatmap shows 
enrichment of ATAC-seq peaks with cardiometabolic GWAS loci by z-score. We compare all 
peaks in adipose tissue and SGBS preadipocytes, peaks within Roadmap adipose promoters and 
enhancers, and Roadmap adipose promoters and enhancers themselves. Cells with a non-
significant p-value are labeled white. The heatmap colored by p-value is shown in Figure 37. 
 
We next tested if enrichment of cardiometabolic GWAS loci in open chromatin varies 
based on chromatin context by testing for enrichment of GWAS loci in promoter and enhancer 
states from Roadmap adipose nuclei (35) and in ATAC peaks overlapping these promoters and 
enhancers. Roadmap enhancers showed enrichment for loci in 11 traits and promoters in 6 traits. 
Enhancers showed stronger enrichment magnitudes than promoters for all but two traits (total 
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cholesterol and LDL-C). In ATAC peaks overlapping adipose nuclei promoters and enhancers, 
we found that 4 trait loci (WHR, triglycerides, HDL-C, cardiovascular outcomes) were enriched 
in adipose tissue and SGBS preadipocyte enhancer peaks but not promoter peaks, whereas loci 
for 2 traits (total cholesterol, LDL-C) were enriched in tissue and SGBS only in promoter peaks. 
We observed stronger enrichment of WHR loci in tissue (z score=10.6, p=6.4*10-13) and SGBS 
(z score=11.1, p=1.2*10-15) enhancer peaks than in all peaks. Interestingly, loci for WHR and 
insulin and for WHR alone showed stronger enrichment in adipose tissue and SGBS enhancer 
peaks, respectively, compared to all Roadmap enhancers, suggesting that ATAC peaks can 
sometimes pinpoint disease-relevant subsets of enhancers. Taken together, integrating chromatin 
accessibility with chromatin states revealed that enrichment of GWAS loci in chromatin states 
and chromatin accessibility can vary by trait, which may provide trait-specific mechanistic 
insights. 
We next identified transcription factor motifs and footprints within ATAC peaks at 
cardiometabolic GWAS loci to inform functional regulatory assays. The percent of 
cardiometabolic GWAS loci and variants in ATAC peaks that overlapped TF motifs varied 
widely between traits (Table 26). Across all traits, 242 variants at 257 loci overlapped TF motifs 
and ATAC peaks in adipose tissue and 631 variants at 476 loci overlapped TF motifs and ATAC 
peaks in SGBS. We performed transcription factor footprinting using CENTIPEDE to predict 
binding sites for 35 motifs (Table 16) in each of the adipose tissue samples and in one SGBS 
sample, due to sequence duplication (SGBS 2). Using a stringent definition (see Methods), we 
identified aggregate footprint profiles for 9 of 35 tested transcription factor motifs in all three 
adipose tissue samples: CEBPA, CREB3L2, FOXO1, MEF2D, NFIA, SPI1, STAT3, 
STAT5A::STAT5B, and TCF7L2 (Figure 38-44, Table 16). Aggregate footprint profiles for 
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IRF1 and PBX1 were identified in two adipose tissue samples and for ETS1 only in adipose 
tissue sample 2 (Figure 42, Table 16). We identified 17 aggregate footprint profiles in SGBS, 
including all 9 identified in the adipose tissue samples and CEBPB, CEBPD, CTCF, IRF1, 
PBX1, RARA, RREB1, and RXRA::VDR (Figure 38-44, Table 16). Identification of more 
aggregate footprint profiles in SGBS is likely a reflection of deeper read depth in SGBS than the 
adipose tissue samples. 53 cardiometabolic GWAS variants at 46 loci overlap at least one 
footprint (Table 16). Collectively, these results will serve as a useful resource for prioritization of 
variants at GWAS loci and will provide insights into molecular mechanisms of cardiometabolic 
disease. 
 
Functional evaluation of variants at cardiometabolic GWAS with colocalized eQTLs overlapping 
ATAC peaks  
We further examined ATAC-seq signals at the subset of GWAS loci that are also 
associated with subcutaneous adipose gene expression and tested candidate variants in functional 
assays. We evaluated 110 cardiometabolic GWAS loci previously described to have colocalized 
eQTLs (see Methods) (63,186); these loci consist of 6,702 variants (LD r2>0.8 with lead GWAS 
variants). For tissue peaks, 52 loci have at least one proxy variant overlapping an ATAC peak in 
at least one sample (Table 27); 147 of 4,538 total candidate variants overlap an ATAC peak. If 
we more stringently require GWAS variants to overlap an ATAC peak in all three adipose tissue 
samples, then we identify 81 variants at 39 loci (Table 27), of which 13 have only one variant 
that overlaps an ATAC peak, suggesting these variants as strong candidates for a regulatory 
function at these loci. For SGBS, 381 proxies at 86 loci overlap at least one SGBS peak. 
Importantly, 124 of the 147 proxies overlapping tissue peaks also overlap SGBS peaks. Proxies 
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overlapping both tissue and SGBS peaks are more likely to act through regulatory elements 
present in adipose and are not present simply due to tissue heterogeneity or cell culture. We 
identified a previously implicated functional variant at the ANGPTL8 HDL-C GWAS locus 
(186). Of the 147 variants overlapping ATAC peaks in at least one sample, 97 (66%) overlap at 
least one TF motif, two of which overlap a TF footprint (rs7187776 and rs174538).  
rs1534696, located in the second intron of SNX10 (encoding sorting nexin 10) is 
associated with waist-hip ratio (P=2x10-8, ß=0.027, in women) (6) and exhibits a colocalized 
eQTL for SNX10 (P=3.4x10-150, ß=1.12) and CBX3 (P=1.1x10-13, ß=0.39) in adipose tissue (63). 
rs1534696 is the only candidate variant for both the GWAS and eQTL associations based on LD 
(r2>0.8) and overlaps a MEF2C motif. Interestingly, is not located in a predicted regulatory 
region as defined by any adipose-related Roadmap chromatin states. We tested a 250-bp region 
containing either allele of rs1534696 and encompassing the entirety of the surrounding ATAC 
peak in transcriptional reporter luciferase assays in SGBS preadipocytes and SW872 liposarcoma 
cells (Figure 29, 45). In SGBS preadipocytes, the construct containing rs1534696-A showed 
higher transcriptional activity than rs153696-C (P=0.007) in the reverse orientation with respect 
to the genome (Figure 30), and in SW872 cells, the construct containing rs1534696-A showed a 
similar trend (P=.065) in the forward orientation (Figure 45). In EMSA, we observed increased 
protein binding for rs1534696-A using nuclear extract from SGBS preadipocytes but not with 
SW872 nuclear extract (Figure 29, 45).  Taken together, these data suggest that rs1534696-A 
may increase transcription factor binding and transcriptional activity of SNX10 and/or CBX3 and 
contribute to the molecular mechanism at this WHR GWAS locus.   
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Figure 29. A variant at the SNX10 WHR GWAS locus alters transcriptional activity and 
protein binding. A) rs1534696 overlaps an ATAC-seq peak and is located in intron 2 of SNX10 
but is not in a predicted regulatory region based on Roadmap chromatin states or histone marks. 
B) The genomic region containing rs1534696-A shows increased transcriptional activity and 
allelic differences in the reverse orientation (**P=0.007). Bars represent the mean standard 
deviation of three independent clones. C) rs1534696-A shows increased protein binding in 
EMSA using SGBS nuclear extract. Arrow shows allelic differences in protein binding. D) 
Summary of the direction of effect of rs1534696-A. Additional regulatory assays are shown in 
Figure 45. 
 
rs7187776 is located in the 5’UTR of a long isoform of SH2B1 (encoding SH2B adaptor 
protein 1) and is in strong LD (r2 > 0.8) with the lead variant associated with BMI (rs3888190, 
P=3.14x10-23, ß=0.031)(7), which exhibits a colocalized eQTL for SH2B1 (P=4.7x10-15, ß=-
0.39) and ATXN2L (P=2.5x10-11, ß=-0.34) in adipose tissue (63). rs7187776 is one of 124 
candidate variants based on LD (r2>0.8) with the lead GWAS and eQTL variants and one of five 
variants that overlap adipose tissue ATAC peaks at this locus (Table 27). rs7187776 overlaps a 
SPI1 (encodes PU.1 protein) motif and footprint (Figure 30). We tested a 456-bp region 
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peak in transcriptional reporter luciferase assays in SGBS preadipocytes and SW872 cells 
(Figure 30, 46). In both cell types, we observed extremely strong transcriptional activity (>200-
fold compared to background) but no allelic differences between rs7187776 alleles (Figure 46). 
Allelic differences in transcriptional activity may have been masked by the massive 
transcriptional effect of this region. In EMSA, we observed allele-specific binding of rs7187776-
G to purified PU.1 protein and similar binding using nuclear extract from SW872 cells, 
consistent with the predicted motif (Figure 30, Figure 46). One additional variant that overlaps 
an ATAC-seq peak showed allelic differences in protein binding using nuclear extract from 
SW872 cells (Figure 46). These data suggest that rs7187776-G increases PU.1 binding, and may 




Figure 30. A variant at the ATP2A1-SH2B1 BMI GWAS locus alters chromatin 
accessibility and PU.1 binding. A) rs7187776 is located in the promoter of a long SH2B1 
isoform and the 5’-UTR of TUFM. We observe more ATAC-seq reads for rs7187776-A (Table 
29). B) rs7187776-G creates a PU.1 binding motif (JASPAR motif) and we identify a PU.1 
footprint in ATAC-seq reads. C) rs7187776-G shows increased protein binding to purified PU.1 
in EMSA, similar to a positive control containing the PU.1 motif (+). A negative control (-) and 
rs7187776-A show no binding to PU.1. Arrows show allele-specific protein binding. Similar 
protein binding patterns were observed using SW872 nuclear extract (Figure 46). D) Summary of 
the direction of effect of rs7187776-G. 
 
Allelic imbalance in ATAC-seq reads 
Allelic imbalance in ATAC-seq reads, especially at a colocalized GWAS-eQTL locus, 
can suggest that a variant alters chromatin accessibility and may contribute to the underlying 
mechanism at the locus. To find genetic variants that exhibit allelic differences in chromatin 
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imbalance in ATAC-seq reads with at least 10 total reads and at least one read per allele. We 
identified 812 sites showing nominal allelic imbalance (beta-binomial P<0.05) in at least one 
sample (Table 28). Only 40 GWAS-eQTL variants were heterozygous in at least one tissue 
sample and met our threshold of 10 total reads and 1 read per allele. Of these 40 variants, 8 
showed nominal evidence of ATAC allelic imbalance (Table 29), including rs7187776 at the 
SH2B1 locus (chi square p=0.0044 Figure 30). We confirmed that the overlap of nominally 
imbalanced loci with GWAS-eQTLs is still greater than expected by chance when removing 
duplicated reads from the imbalance calculation (chi square p=0.043). These results suggest that 
increased power through higher read depth will enable identification of many more disease-
associated loci exhibiting allelic imbalance in chromatin accessibility. Open chromatin profiling 
in additional samples will also allow the identification of chromatin quantitative trait loci 
(cQTLs), which are not restricted to heterozygous variants. Collectively, these analyses will help 




In this study, we generated high quality ATAC-seq open chromatin profiling from three 
frozen clinical adipose samples and two preparations of SGBS preadipocytes. We identified 
differences between adipose tissue, preadipocyte, and adipocyte open chromatin profiles, 
including adipose tissue-selective peaks at ADIPOQ and VWF and preadipocyte-selective peaks 
at extracellular matrix genes. Adipose tissue open chromatin profiles largely overlapped 
Roadmap adipose nuclei chromatin states and SGBS preadipocytes showed more overlap with 
fibroblast-type cells. Transcription factor motifs and footprints in ATAC peaks overlap GWAS 
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variants and GWAS traits are enriched in ATAC peaks within enhancers. Finally, we used the 
ATAC-seq profiles to annotate potential regulatory variants at GWAS-eQTL colocalized loci 
and provided experimental evidence of allelic differences in regulatory activity for variants at the 
SNX10 and ATP2A1-SH2B1 GWAS loci. Taken together, these data are the deepest 
characterization of chromatin accessibility in adipose tissue and preadipocytes to date. 
Important differences exist between adipose tissue, preadipocyte, and mature adipocyte 
ATAC-seq profiles. Explanations for these differences include cell-type 
composition/heterogeneity, the differentiation state of adipocytes, the cultured nature of SGBS 
preadipocytes, and technical differences that arose when generating the ATAC-seq data, such as 
sequencing depth. At the TSS of VWF, adipose tissue-selective ATAC peaks are present at the 
TSS and very little signal is present in preadipocytes or mature adipocytes (Figure 32), 
suggesting that VWF functions within vascular cells in adipose tissue. At the ADIPOQ gene we 
observed adipose tissue-selective and mature adipocyte ATAC peaks and ATAC peaks specific 
to SGBS preadipocytes at the TSS of ADIPOQ-AS1, the antisense transcript of ADIPOQ. These 
data led us to hypothesize that ADIPOQ-AS1 may be expressed in preadipocytes to stop 
production of ADIPOQ, as antisense transcripts are traditionally thought to interfere with 
production of the sense transcript (217). The accessibility pattern of ADIPOQ is consistent with a 
previous finding that the ADIPOQ promoter is inaccessible until differentiation (218) and it’s 
role in adipocyte differentiation (219-221). Among 98 Roadmap tissue and cell types, SGBS 
preadipocyte ATAC profiles were more similar to fibroblast-like cells and cell lines than to 
adipose nuclei, reflecting differences due to the cultured nature of SGBS preadipocytes. 
Additionally, we identified 17 transcription factor footprints in SGBS, but only 9 in adipose 
tissue due to more read depth in SGBS. We also observed differences between the previously 
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published ENCODE adipose tissue and our adipose tissue ATAC-seq profiles; these differences 
are likely due to technical variation such as such as biopsy location, freezing method, or storage 
conditions could contribute to these differences.  
Adipose ATAC-seq profiles provide insight into the mechanisms of cardiometabolic 
GWAS loci. We found that ATAC peaks can sometimes pinpoint disease-relevant subsets of 
enhancers and that adipose ATAC peaks are enriched in WHR, but not BMI GWAS loci. This 
enrichment is consistent with recent findings that WHR loci are enriched in adipose 
transcriptional regulatory elements (10) and that BMI GWAS loci are enriched in pathways 
involved in central nervous system biology (11). We also identify enrichment of other 
cardiometabolic traits including insulin traits, lipids, cardiovascular outcomes, and blood 
pressure traits that have historically been enriched in liver, islet, and blood cell types more than 
adipose regulatory datasets. Identifying the transcription factor(s) bound to a regulatory variant is 
a challenging part of defining the molecular mechanisms underlying cardiometabolic GWAS 
loci; transcription factor footprints identify factors that are physically occupying the DNA at 
variants or loci with more accuracy than the simple overlap of binding motifs (185). We 
successfully generated transcription factor footprints for 17 transcription factors (Figures 38-44), 
which can be used to identify transcription factor that bind sites overlapping candidate variants at 
cardiometabolic GWAS loci.    
We show two example loci where ATAC peaks helped prioritize candidate variants. At 
the SNX10 waist-hip ratio GWAS and adipose eQTL locus, we identified a potentially functional 
variant. rs1534696 is not located in a predicted regulatory region based on existing chromatin 
state data. However, rs1534696 overlaps an ATAC peak in adipose tissue and shows allelic 
differences in transcriptional reporter and protein-binding assays. At a second example, the 
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ATP2A1-SH2B1 BMI GWAS and adipose eQTL locus, we identified a PU.1 binding motif and 
footprint at rs7187776, as well as allelic imbalance in ATAC-seq reads, and confirmed the allelic 
differences in PU.1 binding in vitro. However, further experiments are needed to confirm that 
PU.1 and/or other ETS family members are binding at this locus in vivo. These data provide an 
excellent example of how to integrate GWAS, eQTL, and ATAC-seq data to identify functional 
variants at GWAS loci. Further experiments are needed to determine if these variants are the sole 
functional variant at each locus, and which gene(s) are contributing to obesity risk.  
ATAC-seq open chromatin profiling can be further improved and future experiments are 
needed to fully characterize chromatin accessibility in adipose. The library preparation methods 
can be further optimized; we considered multiple library preparation conditions and chose 
detergent-treated samples to continue with analyses; however, we note that our sample size is too 
small to make definitive conclusions regarding these choices. The ATAC-seq method is 
relatively new and continues to improve, especially for frozen tissues and cells; a recent update 
to the original protocol, called Omni-ATAC, includes additional detergents for frozen tissues 
(222). Future chromatin profiles from additional individuals will enable detection chromatin 
quantitative trait loci (cQTL) associations, which could provide evidence that a variant allele 
alters chromatin accessibility and would help to prioritize variants for functional followup. 
Cellular environment can alter chromatin state, especially for cardiometabolic phenotypes, where 
both genetic and environmental factors can affect phenotypic outcome. Future work treating the 
cells with various metabolic stimuli and in in different cellular states (e.g. insulin or glucose 
treatment and stages of adipocyte differentiation) will provide needed insight to how chromatin 
changes with metabolic environmental triggers.  	
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Here, we present ATAC-seq open chromatin profiles for frozen adipose tissue and 
cultured preadipocytes. We showed the utility of open chromatin profiles in multiple tissue 
samples and across cell types within heterogeneous tissue. Together, these data add to the 
growing understanding of gene regulation in adipose and the complex genetic mechanisms of 
cardiometabolic traits and diseases.   
	
Supplemental Figures and Tables 
 
Figure 31. Adipose tissue ATAC peak overlap of all chromatin states. ATAC-seq peak base overlap was identified in 98 tissue and  
cell types chromatin states from the Epigenome Roadmap Project (178). Adipose nuclei is boxed in red. Bars are ordered based on  





























































































































































































































Figure 32. SGBS ATAC peak overlap of all chromatin states. ATAC-seq peak base overlap was identified in 98 tissue and cell 
types chromatin states from the Epigenome Roadmap Project (178). Adipose nuclei is boxed in red. Bars are ordered based on 




























































































































































































































Figure 33. ENCODE ATAC peak overlap of chromatin states. ATAC-seq peak base overlap was identified in 98 tissue and cell 
types chromatin states from the Epigenome Roadmap Project (178). Adipose nuclei is boxed in red. Bars are ordered based on 




























































































































































































































Figure 34. Mature adipocyte ATAC peak overlap of all chromatin states. ATAC-seq peak base overlap was identified in 98 tissue 
and cell types chromatin states from the Epigenome Roadmap Project (178). Adipose nuclei is boxed in red. Bars are ordered based on 



























































































































































































































Figure 35. Gene ontology enrichment of adipose tissue- and SGBS- specific ATAC peaks. 
Gene ontology enrichment of genes near adipose tissue- or preadipocyte-specific peaks was 
performed using GREAT with default parameters. 
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Figure 36. VWF and LUM TSSs show differential ATAC-seq peaks. UCSC genome browser 
image showing the VWF (A) and LUM (B) gene regions. Histone marks from the Roadmap 
Epigenomics project adipose nuclei are shown in green and blue. The three adipose tissue 
(purple) and two SGBS (light blue) ATAC-seq signal tracks and peaks (gray) are shown. ATAC-
seq signal and peaks from the ENCODE adipose ATAC-seq (light purple, ENCODE ID: 
ENCSR540BML), ATAC-seq from mature adipocytes (177), and signal from SGBS adipocyte 
DNase (175). Chromatin states from the Roadmap Epigenomics Project are shown for adipose 
nuclei. Yellow, enhancer; green, transcribed; orange and red, promoter; light green, genic 
enhancer. Red boxes show adipose tissue-selective (A) or SGBS-selective (B) ATAC-seq peaks 
























































Figure 37. GWAS loci are enriched in ATAC-seq peaks. Heatmap shows enrichment of 
ATAC-seq peaks with cardiometabolic GWAS loci by p-value. We compare all peaks in adipose 
tissue and SGBS preadipocytes, peaks within Roadmap adipose promoters and enhancers, and 




Figure 38. Aggregate footprint profiles for CEBPA and CREB312 in adipose tissue samples 
and SGBS preadipocytes. Footprints are shown for adipose tissue sample 1, but results were 
similar for the tissue Sample 2 and 3. Bound, unbound, and normalized profiles are shown for 
each factor. 
 













































































































































































































































































Figure 39: Aggregate footprint profiles for FOXO1 and MEF2D in adipose tissue samples 
and SGBS preadipocytes. Footprints are shown for adipose tissue sample 1, but results were 




































































































































































































































































Figure 40: Aggregate footprint profiles for NFIA and SPI1 in adipose tissue samples and 
SGBS preadipocytes. Footprints are shown for adipose tissue sample 1, but results were similar 




































































































































































































































































Figure 41: Aggregate footprint profiles for STAT3A and STAT5A::STAT5B in adipose 
tissue samples and SGBS preadipocytes. Footprints are shown for adipose tissue sample 1, but 
results were similar for the tissue Sample 2 and 3. Bound, unbound, and normalized profiles are 
shown for each factor.  
Adipose tissue Preadipocytes
Adipose tissue Preadipocytes




























































































































































































































































Figure 42: Aggregate footprints for TCFL7, IRF1, PBX1, and ETS1. Aggregate footprints 
for TCFL7 were observed in all three adipose tissue samples and SGBS preadipocytes. 
Aggregate footprint for IRF1 was observed in adipose samples 1 and 3; PBX1 in adipose samples 
1 and 2; and ETS1 in adipose sample 2. For footprints in more than one sample, profiles are 
shown for adipose sample 1. Bound, unbound, and normalized profiles are shown for each factor. 
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Figure 43: Aggregate footprint profiles for CEBPB, CEBPD, CTCF, and IRF1 in SGBS 
preadipocytes. Footprints are shown for SGBS 2. Bound, unbound, and normalized profiles are 
shown for each factor. 
Preadipocytes






































































































































































































































































Figure 44: Aggregate footprint profiles for PBX1, RREB1, RXRA::VDR, and RARA in 
SGBS preadipocytes. Footprints are shown for SGBS 2. Bound, unbound, and normalized 
profiles are shown for each factor. 
Preadipocytes





























































































































































































































































Figure 45. Additional regulatory assays for rs1534696. A) The region containing rs1534696 
was tested in transcriptional reporter luciferase assays in SW872 cells. Each bar represents mean 
standard deviation of three independent clones. Transcriptional activity is greater in SW872, 
and the trend of higher transcriptional activity for rs1534696-A is consistent with results in 
SGBS (Figure 29). B) Allelic differences in protein binding with SW872 nuclear extract are not 
present as with SGBS nuclear extract (Figure 29). Arrow shows where the allele-specific protein 
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Figure 46. Additional regulatory assays for rs7187776. A) rs7187776-G shows increased 
protein binding using SW872 nuclear extract in EMSA. The banding pattern of protein binding is 
similar to protein binding to purified PU.1 (Figure 26). Arrows show allelic differences. B) One 
of four additional variants (rs7198606) overlapping ATAC-seq peaks showed allelic differences 
in protein binding (arrow) using SW872 nuclear extract in EMSA. The remaining three variants 
did not show consistent results across EMSA experiments. C-D) The region containing 
rs7187776 shows extremely strong transcriptional activity in reporter assays in SGBS (C) and 
SW872 (D) cells. Bars represent the mean  standard deviation of 3-5 independent clones. 
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Sample&ID Body&Mass&Index Waist&(cm) WaistDtoDhip&ratio Age&(yrs) Glucose&Tolerance
Tissue&1 28.4 106 1.03 62 impaired
Tissue&2 24.0 91.5 0.94 51 normal
Tissue&3 24.9 100 1.09 55 normal
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Tissue&1 36 No 2.5 160,456,871 103,884,007 4.2 99,514,873 98,503,345 87,261,270 13,073
Tissue&1
a
36 Yes 2.5 129,550,842 87,423,735 8.5 80,036,369 79,034,093 70,607,644 58,279
Tissue&2
a
12 Yes 2.5 131,596,088 83,656,351 12.8 72,952,105 71,836,642 60,612,852 36,612
Tissue&2 36 Yes 2.5 152,103,576 89,636,408 17.0 74,406,166 73,172,989 66,897,385 29,409
Tissue&3 36 No 2.5 156,251,262 97,752,018 10.8 87,234,180 86,077,206 76,890,324 21,016
Tissue&3
a
36 Yes 2.5 119,284,302 70,587,237 11.9 62,214,172 61,339,160 57,119,081 49,631
SGBS&1
b
800,000 Yes 5.0 194,938,464 168,498,157 14.2 144,425,078 126,236,487 40,598,393 196,211
SGBS&2
b









































CEBPA MA0102.3 1,2,3 Yes rs174538,	rs10495712 rs1553832,	rs4812488 10010 0.79 7074 0.53 9343 0.87 16165 0.51
CEBPB MA0466.2 Yes 7062 0.62
CEBPD MA0826.1 Yes 7000 0.62






ETS1 MA0098.3 2 5535 0.99
FLI1 MA0475.2
FOXO1 MA0480.1 1,2,3 Yes rs4149272 8609 0.73 5522 0.51 7622 0.86 19405 0.75
IRF1 MA0050.2 1,3 Yes
rs12128131,	rs662799,	rs7104207,	rs9913522,	
rs17242395,	rs62233075,	rs150111048,	rs55875205,	
rs1401419,	rs1800759 65530 0.09 48881 0.09 70371 0.14
MEF2D MA0773.1 1,2,3 Yes rs35581848 10321 0.35 3547 0.37 6785 0.42 14961 0.66





















SPI1 MA0080.4 1,2,3 Yes rs7187776,	rs1401419 rs1401419,	rs1800759,	rs10790517 10833 0.63 6171 0.38 7982 0.73 20323 0.69
SPIB MA0081.1
STAT3 MA0144.2 1,2,3 Yes rs11097198 16627 0.50 13479 0.36 13079 0.70 32195 0.63
STAT5A::STAT5B MA0519.1 1,2,3 Yes rs11097198,	rs6689393,	rs7178051 rs11041999,	rs6776159 11542 0.70 8490 0.47 9997 0.83 27291 0.71




Table 17: Primer and probe sequences for functional assays 
 
 
Table 18: Comparison of ATAC-seq peak overlap between tissue samples 
 
Table&17:&Primer&and&probe&sequences&for&functional&assays
Primer sequences for 


















PU.1_positive control* CAGAAAAGAGGAAGTGAAACCG N/A
PU.1_negative control TGAGGGGAGAAGGACAGGGTTA N/A
*PU.1 positive control sequence was constructed from the JASPAR motif
Percent	overlap	of	bases	in	peaks
Sample Tissue	1		36	mg		no	det Tissue	1		36	mg		det Tissue	2	36	mg		det Tissue	2		12	mg		det Tissue	3		36	mg		no	det Tissue	3		36	mg		det
Tissue	1 36	mg no	det 100.0 74.3 60.4 65.6 73.5 69.7
Tissue	1 36	mg det 38.7 100.0 56.6 64.4 57.8 71.6
Tissue	2 36	mg det 43.1 77.7 100.0 77.9 61.9 77.2
Tissue	2 12	mg det 43.1 81.3 71.7 100.0 63.6 78.0
Tissue	3 36	mg no	det 56.9 85.9 67.1 74.9 100.0 81.4
Tissue	3 36	mg det 42.0 82.9 65.1 71.5 63.3 100.0
Jaccard	index
Sample Tissue	1		36	mg		no	det Tissue	1		36	mg		det Tissue	2	36	mg		det Tissue	2		12	mg		det Tissue	3		36	mg		no	det Tissue	3		36	mg		det
Tissue	1 36	mg no	det 1.00 0.34 0.34 0.35 0.47 0.36
Tissue	1 36	mg det 1.00 0.49 0.56 0.53 0.63
Tissue	2 36	mg det 1.00 0.60 0.48 0.55
Tissue	2 12	mg det 1.00 0.52 0.59
Tissue	3 36	mg no	det 1.00 0.56
Tissue	3 36	mg det 1.00
	
Table 19: Comparison of ATAC-seq peaks between adipose tissue, mature adipocytes, and SGBS preadipocytes 
Percent	overlap	of	bases	in	peaks Percent	overlap	of	top	50,000	peaks	of	union	sets
Sample Tissue	1 Tissue	2 Tissue	3 SGBS	1 SGBS	2 ENCODE Mature	adipocytes Sample METSIM SGBS Allum ENCODE
Tissue	1 100.0 63.8 71.8 49.9 51.8 67.8 55.5 METSIM 100.0 54.0 54.7 60.0
Tissue	2 80.3 100.0 77.9 48.0 50.0 63.9 60.2 SGBS 30.5 100.0 31.2 41.9
Tissue	3 80.3 69.2 100.0 47.5 49.5 64.0 56.9 Allum 49.9 50.4 100.0 48.7
SGBS	1 30.3 23.2 25.8 100.0 82.0 43.9 29.5 ENCODE 44.3 54.7 39.4 100.0
SGBS	2 33.6 25.8 28.7 87.6 100.0 47.9 32.4
ENCODE 43.8 32.8 37.0 46.7 47.7 100.0 35.9
Mature	adipocytes 57.9 49.8 53.0 50.6 52.1 58.0 100.0
Jaccard	index Jaccard	index	top	50,000	peaks	of	union	sets
Sample Tissue	1 Tissue	2 Tissue	3 SGBS	1 SGBS	2 ENCODE Mature	adipocytes Sample METSIM SGBS Allum ENCODE
Tissue	1 1.00 0.55 0.61 0.23 0.26 0.36 0.40 METSIM 1.00 0.24 0.35 0.34
Tissue	2 1.00 0.58 0.19 0.20 0.28 0.37 SGBS 1.00 0.24 0.31
Tissue	3 1.00 0.20 0.22 0.31 0.38 Allum 1.00 0.28
SGBS	1 1.00 0.73 0.29 0.23 ENCODE 1.00



































Promoter+Enhancer 85.7 1 Promoter+Enhancer 88.9 1 Promoter+Enhancer 84.3 1
Promoter 44.5 4 Promoter 49.3 4 Promoter 38.9 4
Enhancer 41.3 1 Enhancer 39.7 1 Enhancer 45.4 1
Transcribed 3.6 98 Transcribed 2.9 98 Transcribed 4.1 98
Polycomb 2.1 92 Polycomb 1.7 92 Polycomb 2.4 91
Heterochromatin 0.3 91 Heterochromatin 0.2 96 Heterochromatin 0.2 94
ZNF	repeat 0.3 51 ZNF	repeat 0.2 55 ZNF	repeat 0.2 52


























Promoter+Enhancer 49.4 14 Promoter+Enhancer 65.9 17 Promoter+Enhancer 58.0 17
Promoter 24.4 8 Promoter 40.8 11 Promoter 29.9 12
Enhancer 25.0 20 Enhancer 25.2 25 Enhancer 28.1 20
Transcribed 13.3 68 Transcribed 9.1 77 Transcribed 11.1 71
Polycomb 8.6 51 Polycomb 5.3 47 Polycomb 6.0 43
Heterochromatin 1.1 43 Heterochromatin 0.7 49 Heterochromatin 0.9 47
ZNF	repeat 0.3 30 ZNF	repeat 0.3 28 ZNF	repeat 0.3 25


























Promoter+Enhancer 73.9 4 Promoter+Enhancer 81.9 4 Promoter+Enhancer 74.1 4
Promoter 47.5 9 Promoter 57.0 9 Promoter 42.2 9
Enhancer 26.5 17 Enhancer 24.8 18 Enhancer 31.8 17
Transcribed 7.2 92 Transcribed 5.5 91 Transcribed 7.9 91
Polycomb 5.7 56 Polycomb 4.2 61 Polycomb 5.8 58
Heterochromatin 0.7 56 Heterochromatin 0.3 67 Heterochromatin 0.4 62
ZNF	repeat 0.3 45 ZNF	repeat 0.1 57 ZNF	repeat 0.2 54


























Promoter+Enhancer 33.5 1 Promoter+Enhancer 73.8 1 Promoter+Enhancer 73.1 1
Promoter 15.4 5 Promoter 40.0 7 Promoter 34.4 7
Enhancer 18.1 8 Enhancer 33.8 1 Enhancer 38.7 1
Transcribed 12.4 65 Transcribed 5.1 98 Transcribed 5.9 98
Polycomb 16.1 31 Polycomb 4.8 67 Polycomb 4.9 69
Heterochromatin 6.1 35 Heterochromatin 3.0 43 Heterochromatin 2.2 50
ZNF	repeat 3.3 35 ZNF	repeat 1.8 41 ZNF	repeat 1.6 40
























































































































































Table 22: Transcription factor motifs enriched in adipose tissue- and SGBS-specific ATAC 
peaks 
 



































Atf3 DATGASTCATHN 1.00E-923 -2127.0 0 4993 49.9% 8505 20.5% ARE RGRACASNSTGTYCYB 1.00E-136 -313.2 0 911 9.1% 1616 3.6%
Fra1 NNATGASTCATH 1.00E-904 -2083.0 0 4671 46.7% 7624 18.4% GRE,IR3 VAGRACAKWCTGTYC 1.00E-133 -306.4 0 888 8.9% 1571 3.5%
BATF DATGASTCAT 1.00E-887 -2043.0 0 4887 48.9% 8372 20.2% GRE,IR3 NRGVACABNVTGTYCY 1.00E-114 -264.0 0 617 6.2% 955 2.1%
AP-1 VTGACTCATC 1.00E-881 -2030.0 0 5074 50.7% 8989 21.7% PGR AAGAACATWHTGTTC 1.00E-98 -227.5 0 834 8.3% 1660 3.7%
Fosl2 NATGASTCABNN 1.00E-603 -1389.0 0 3276 32.8% 5179 12.5% PPARE TGACCTTTGCCCCA 1.00E-92 -214.0 0 1833 18.3% 5070 11.3%
Jun-AP1 GATGASTCATCN 1.00E-455 -1050.0 0 2610 26.1% 4146 10.0% NF1 YTGCCAAG 1.00E-76 -176.3 0 3888 38.9% 13491 30.2%
Bach2 TGCTGAGTCA 1.00E-206 -475.0 0 1580 15.8% 2834 6.8% RXR,DR1 TAGGGCAAAGGTCA 1.00E-75 -174.2 0 1996 20.0% 5952 13.3%
MafK GCTGASTCAGCA 1.00E-95 -220.4 0 932 9.3% 1836 4.4% PR VAGRACAKNCTGTBC 1.00E-69 -159.9 0 3474 34.7% 11946 26.7%
TEAD4 CCWGGAATGY 1.00E-92 -213.7 0 2266 22.7% 6173 14.9% AR CCAGGAACAG 1.00E-58 -134.8 0 5181 51.8% 19569 43.7%
TEAD YCWGGAATGY 1.00E-87 -202.2 0 2053 20.5% 5513 13.3% CEBPB ATTGCGCAAC 1.00E-33 -76.2 0 2110 21.1% 7367 16.5%
TEAD2 CCWGGAATGY 1.00E-62 -144.5 0 1488 14.9% 3968 9.6% Esrrb KTGACCTTGA 1.00E-23 -55.1 0 907 9.1% 2876 6.4%
RUNX2 NWAACCACADNN 1.00E-54 -125.6 0 1590 15.9% 4455 10.8% ELF5 ACVAGGAAGT 1.00E-21 -50.6 0 1397 14.0% 4843 10.8%
RUNX SAAACCACAG 1.00E-54 -124.5 0 1416 14.2% 3863 9.3% SpiB AAAGRGGAAGTG 1.00E-21 -49.4 0 548 5.5% 1592 3.6%
NF-E2 GATGACTCAGCA 1.00E-53 -122.6 0 496 5.0% 951 2.3% PU.1 AGAGGAAGTG 1.00E-21 -48.8 0 1071 10.7% 3577 8.0%
RUNX1 AAACCACARM 1.00E-52 -121.8 0 1847 18.5% 5390 13.0% Erra CAAAGGTCAG 1.00E-19 -45.1 0 3036 30.4% 11750 26.3%
RUNX-AML GCTGTGGTTW 1.00E-48 -111.0 0 1402 14.0% 3914 9.5% HNF4a,DR1 CARRGKBCAAAGTYCA 1.00E-19 -44.0 0 760 7.6% 2430 5.4%
MafA TGCTGACTCA 1.00E-43 -101.0 0 1581 15.8% 4626 11.2% NPAS2 KCCACGTGAC 1.00E-18 -42.6 0 1381 13.8% 4893 10.9%
Nrf2 HTGCTGAGTCAT 1.00E-43 -100.6 0 412 4.1% 795 1.9% TR4,DR1 GAGGTCAAAGGTCA 1.00E-17 -39.2 0 211 2.1% 496 1.1%
Bach1 AWWNTGCTGAGTCAT 1.00E-42 -97.0 0 478 4.8% 996 2.4% ETV1 AACCGGAAGT 1.00E-15 -36.3 0 2317 23.2% 8881 19.9%
Pdx1 YCATYAATCA 1.00E-31 -71.8 0 1663 16.6% 5210 12.6% Etv2 NNAYTTCCTGHN 1.00E-14 -34.3 0 1833 18.3% 6892 15.4%
GATA3 AGATAASR 1.00E-28 -65.7 0 2162 21.6% 7149 17.3% BMAL1 GNCACGTG 1.00E-14 -33.1 0 2370 23.7% 9175 20.5%
Gata1 SAGATAAGRV 1.00E-22 -52.1 0 906 9.1% 2685 6.5% Nur77 TGACCTTTNCNT 1.00E-14 -33.0 0 315 3.2% 885 2.0%
Gata2 BBCTTATCTS 1.00E-22 -51.8 0 998 10.0% 3016 7.3% THRa GGTCANYTGAGGWCA 1.00E-14 -32.8 0 633 6.3% 2067 4.6%
Gata4 NBWGATAAGR 1.00E-19 -45.6 0 1428 14.3% 4662 11.3% EHF AVCAGGAAGT 1.00E-12 -29.5 0 2175 21.8% 8430 18.8%
Pit1 ATGCATAATTCA 1.00E-10 -23.3 0 514 5.1% 1593 3.9% USF1 SGTCACGTGR 1.00E-12 -28.9 0 705 7.1% 2394 5.4%
Arnt:Ahr TBGCACGCAA 1.00E-09 -21.7 0 612 6.1% 1968 4.8% ETS1 ACAGGAAGTG 1.00E-12 -28.0 0 1906 19.1% 7329 16.4%
PAX3:FKHR ACCRTGACTAATTNN 1.00E-08 -20.6 0 337 3.4% 994 2.4% Max RCCACGTGGYYN 1.00E-11 -27.1 0 930 9.3% 3315 7.4%
Hoxb4 TGATTRATGGCY 1.00E-05 -12.6 0 319 3.2% 1018 2.5% GABPA RACCGGAAGT 1.00E-11 -26.9 0 1574 15.7% 5963 13.3%
NFAT:AP1 SARTGGAAAAWRTGAGTCAB 1.00E-05 -12.2 0.0001 386 3.9% 1269 3.1% Fli1 NRYTTCCGGH 1.00E-11 -26.6 0 1886 18.9% 7278 16.3%
Pit1 ATGMATATDC 1.00E-05 -12.1 0.0001 1302 13.0% 4797 11.6% Usf2 GTCACGTGGT 1.00E-11 -25.5 0 571 5.7% 1915 4.3%
GATA,IR3 NNNNNBAGATAWYATCTVHN 1.00E-05 -12.1 0.0001 309 3.1% 989 2.4% ERG ACAGGAAGTG 1.00E-10 -24.6 0 2701 27.0% 10803 24.2%
PAX5 GTCACGCTCSCTGM 1.00E-04 -10.2 0.0004 130 1.3% 373 0.9% Nr5a2 BTCAAGGTCA 1.00E-09 -22.6 0 893 8.9% 3240 7.2%
OCT:OCT ATGAATWATTCATGA 1.00E-04 -9.7 0.0006 36 0.4% 73 0.2% MITF RTCATGTGAC 1.00E-09 -22.5 0 1407 14.1% 5359 12.0%
Brn2 ATGAATATTC 1.00E-04 -9.7 0.0006 167 1.7% 506 1.2% EWS:ERG ATTTCCTGTN 1.00E-09 -22.0 0 1491 14.9% 5722 12.8%
PAX5 GCAGCCAAGCRTGACH 1.00E-04 -9.5 0.0007 364 3.6% 1230 3.0% CLOCK GHCACGTG 1.00E-09 -21.4 0 733 7.3% 2615 5.8%
EBF1 GTCCCCWGGGGA 1.00E-09 -21.2 0 1754 17.5% 6849 15.3%
VDR,DR3 ARAGGTCANWGAGTTCANNN 1.00E-09 -21.0 0 253 2.5% 757 1.7%
Lhx2 TAATTAGN 1.00E-08 -19.1 0 1121 11.2% 4244 9.5%
Sox2 BCCATTGTTC 1.00E-07 -17.9 0 1045 10.5% 3955 8.8%
c-Myc VVCCACGTGG 1.00E-07 -17.6 0 648 6.5% 2335 5.2%
Ets1 MACAGGAAGT 1.00E-07 -17.1 0 715 7.2% 2615 5.8%
CEBP:AP1 DRTGTTGCAA 1.00E-07 -17.0 0 1719 17.2% 6813 15.2%
n-Myc VRCCACGTGG 1.00E-07 -16.8 0 843 8.4% 3144 7.0%
Nr5a2 BTCAAGGTCA 1.00E-06 -14.6 0 662 6.6% 2447 5.5%
SPDEF ASWTCCTGBT 1.00E-06 -14.4 0 1597 16.0% 6370 14.2%
LXRE,DR4 RGGTTACTANAGGTCA 1.00E-05 -13.5 0 101 1.0% 272 0.6%
ELF1 AVCCGGAAGT 1.00E-05 -13.1 0 738 7.4% 2789 6.2%
bHLHE40 KCACGTGMCN 1.00E-05 -12.9 0 324 3.2% 1116 2.5%
EWS:FLI1 VACAGGAAAT 1.00E-05 -12.7 0 1043 10.4% 4073 9.1%
ETS:E-box AGGAARCAGCTG 1.00E-05 -12.4 0 196 2.0% 627 1.4%
EBF DGTCCCYRGGGA 1.00E-05 -12.0 0 503 5.0% 1848 4.1%
NF1 CYTGGCABNSTGCCAR 1.00E-05 -11.7 0 1039 10.4% 4080 9.1%
ERE VAGGTCACNSTGACC 1.00E-05 -11.6 0.0001 308 3.1% 1071 2.4%
Atoh1 VNRVCAGCTGGY 1.00E-04 -10.5 0.0002 1768 17.7% 7238 16.2%
c-Myc VCCACGTG 1.00E-04 -10.0 0.0003 422 4.2% 1556 3.5%
Foxo1 CTGTTTAC 1.00E-04 -9.9 0.0003 2662 26.6% 11149 24.9%
RORgt AAYTAGGTCA 1.00E-04 -9.8 0.0003 221 2.2% 755 1.7%
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TSS	position	 Transcript	name(s) Gene	name(s) Tissue	samples TSS	position	 Transcript	name(s) Gene	name(s) Tissue	samples TSS	position	 Transcript	name(s) Gene	name(s) SGBS	samples TSS	position	 Transcript	name(s) Gene	name(s) SGBS	samples
10:119235683 ENST00000412075.6 EMX2OS Tissue	1,	Tissue	3 10:60754385 ENST00000432535.1 LINC00844 Tissue	1,	Tissue	2,	Tissue	3 10:115468103 ENST00000452490.3 CASP7 SGBS	1,	SGBS2 10:115464103 ENST00000452490.3 CASP7 SGBS	1,	SGBS2
10:5237797 ENST00000263126.2 AKR1C4 Tissue	1,	Tissue	3 11:104888862
ENST00000260315.7,
ENST00000526056.5,
ENST00000531367.5 CASP5 Tissue	1 10:127660694 ENST00000445458.1 FANK1-AS1 SGBS	1,	SGBS2 10:127656694 ENST00000445458.1 FANK1-AS1 SGBS	1,	SGBS2




00000531367.5 CASP5 Tissue	1 11:104888894
ENST00000393141.6,
ENST00000418434.5 CASP5 Tissue	1 10:35367607 ENST00000584484.1 MIR3611 SGBS	1,	SGBS2 10:35363607 ENST00000584484.1 MIR3611 SGBS	1,	SGBS2
11:104892893 ENST00000444749.6 CASP5 Tissue	1 11:1088317 ENST00000333592.6 MUC2 Tissue	2,	Tissue	3 10:42969990 ENST00000429940.6 LINC00839 SGBS	1,	SGBS2 10:42965990 ENST00000429940.6 LINC00839 SGBS	1,	SGBS2
11:104892894
ENST00000393141.6,EN
ST00000418434.5 CASP5 Tissue	1 1:111410775 ENST00000271324.5 CD53 Tissue	1,	Tissue	3 10:5637080 ENST00000478294.1 RP13-463N16.6 SGBS	1,	SGBS2 10:5633080 ENST00000478294.1 RP13-463N16.6 SGBS	1,	SGBS2
11:1092317 ENST00000333592.6 MUC2 Tissue	2,	Tissue	3 1:112027284 ENST00000414219.5 TMIGD3 Tissue	1,	Tissue	3 10:6820141 ENST00000628989.1 LINC00706 SGBS	1,	SGBS2 10:6816141 ENST00000628989.1 LINC00706 SGBS	1,	SGBS2
1:110967592 ENST00000597455.2 LAMTOR5-AS1 Tissue	1,	Tissue	2,	Tissue	3 11:131235372 ENST00000374791.7 NTM Tissue	1,	Tissue	2,	Tissue	3 10:70991245 ENST00000450995.1 RP11-227H15.4 SGBS	1,	SGBS2 10:70987245 ENST00000450995.1 RP11-227H15.4 SGBS	1,	SGBS2
11:110000728 ENST00000528673.5 ZC3H12C Tissue	1,	Tissue	2,	Tissue	3 11:1869199 ENST00000311604.3 LSP1 Tissue	1 10:81141083 ENST00000438554.2 RP11-342M3.5 SGBS	1,	SGBS2 10:95863231 ENST00000433038.1 PLCE1-AS2 SGBS	1,	SGBS2
1:111414775 ENST00000271324.5 CD53 Tissue	1 1:118722845 ENST00000336338.9 SPAG17 Tissue	1,	Tissue	3 10:95867231 ENST00000433038.1 PLCE1-AS2 SGBS	1,	SGBS2 10:95863292 ENST00000613585.4 PLCE1-AS2 SGBS	1,	SGBS2
1:112031284 ENST00000414219.5 TMIGD3 Tissue	1,	Tissue	3 11:45371921 ENST00000524410.1 RP11-430H10.1 Tissue	1,	Tissue	2,	Tissue	3 10:95867292 ENST00000613585.4 PLCE1-AS2 SGBS	1,	SGBS2 10:95863505 ENST00000453183.5 PLCE1-AS2 SGBS	1,	SGBS2
11:130734455 ENST00000533812.6 RP11-890B15.2 Tissue	1,	Tissue	2,	Tissue	3 11:45372051 ENST00000524565.1 RP11-430H10.1 Tissue	1,	Tissue	2,	Tissue	3 10:95867505 ENST00000453183.5 PLCE1-AS2 SGBS	1,	SGBS2 10:95863536 ENST00000438899.5 PLCE1-AS2 SGBS	1,	SGBS2
11:131239372 ENST00000374791.7 NTM Tissue	1,	Tissue	2,	Tissue	3 11:4659649 ENST00000396952.5 OR51E1 Tissue	1,	Tissue	2,	Tissue	3 10:95867536 ENST00000438899.5 PLCE1-AS2 SGBS	1,	SGBS2 11:107724286 ENST00000375682.8 SLC35F2 SGBS	1,	SGBS2
11:134200767
ENST00000339772.9,EN
ST00000535456.6 GLB1L2 Tissue	1,	Tissue	2,	Tissue	3 11:49224923 ENST00000533034.1 FOLH1 Tissue	2 11:10714098 ENST00000558540.5 MRVI1 SGBS	1,	SGBS2 11:107724913 ENST00000525815.5 SLC35F2 SGBS	1,	SGBS2
11:18286720 ENST00000356524.8 SAA1 Tissue	2 11:49225083 ENST00000356696.7 FOLH1 Tissue	2 11:10714122 ENST00000527509.6 MRVI1 SGBS	1,	SGBS2 11:118281691 ENST00000602598.1 RP11-770J1.7 SGBS	1,	SGBS2
1:118726845 ENST00000336338.9 SPAG17 Tissue	1,	Tissue	3 1:152590578 ENST00000335674.1 LCE3A Tissue	1,	Tissue	2,	Tissue	3 11:10714168 ENST00000541483.5 MRVI1 SGBS	1,	SGBS2 11:126857347 ENST00000531585.1 RP11-688I9.2 SGBS	1,	SGBS2
11:18727083 ENST00000527285.1 RP11-1081L13.4 Tissue	1,	Tissue	3 1:158796106 ENST00000368141.4 MNDA Tissue	1 11:10714298 ENST00000423302.6 MRVI1 SGBS	1,	SGBS2 11:128045321 ENST00000609911.1 RP11-702B10.2 SGBS	1,	SGBS2
11:1873199 ENST00000311604.3 LSP1 Tissue	1 11:67214885 ENST00000438189.6 CABP4 Tissue	1,	Tissue	3 11:10714534 ENST00000547195.5 MRVI1 SGBS	1,	SGBS2 1:117447152 ENST00000610171.1 RP4-753F5.1 SGBS	1,	SGBS2
11:3858096 ENST00000396979.1 RHOG Tissue	1 11:93966315 ENST00000506309.6 RP11-680H20.2 Tissue	1,	Tissue	2,	Tissue	3 11:107728286 ENST00000375682.8 SLC35F2 SGBS	1,	SGBS2 1:117447678 ENST00000393203.2 PTGFRN SGBS	1,	SGBS2
11:45375921 ENST00000524410.1 RP11-430H10.1 Tissue	1,	Tissue	2,	Tissue	3 12:130549869 ENST00000535487.1 RP11-474D1.2 Tissue	1,	Tissue	2,	Tissue	3 11:107728913 ENST00000525815.5 SLC35F2 SGBS	1,	SGBS2 11:1766820 ENST00000340134.4 IFITM10 SGBS	1,	SGBS2
11:45376051 ENST00000524565.1 RP11-430H10.1 Tissue	1,	Tissue	2,	Tissue	3 12:15860926 ENST00000543612.5 EPS8 Tissue	1,	Tissue	2,	Tissue	3 11:118285691 ENST00000602598.1 RP11-770J1.7 SGBS	1,	SGBS2 11:19397030 ENST00000528204.1 NAV2-IT1 SGBS	1,	SGBS2
11:4663649 ENST00000396952.5 OR51E1 Tissue	2,	Tissue	3 12:41081243 ENST00000547702.5 CNTN1 Tissue	1 11:126861347 ENST00000531585.1 RP11-688I9.2 SGBS	1,	SGBS2 11:33769944 ENST00000532057.5 FBXO3 SGBS	1,	SGBS2
11:49228923 ENST00000533034.1 FOLH1 Tissue	2 1:248095492 ENST00000366478.2 OR2L13 Tissue	1,	Tissue	3 11:128049321 ENST00000609911.1 RP11-702B10.2 SGBS	1,	SGBS2 11:33769945 ENST00000531080.5 FBXO3 SGBS	1,	SGBS2
11:49229083 ENST00000356696.7 FOLH1 Tissue	2 12:6228840 ENST00000261405.9 VWF Tissue	1,	Tissue	2,	Tissue	3 1:117451152 ENST00000610171.1 RP4-753F5.1 SGBS	1,	SGBS2 11:4714071 ENST00000396950.3 OR51E2 SGBS	1,	SGBS2
1:152594578 ENST00000335674.1 LCE3A Tissue	1,	Tissue	2,	Tissue	3 12:69737120 ENST00000261267.6 LYZ Tissue	1,	Tissue	3 1:117451678 ENST00000393203.2 PTGFRN SGBS	1,	SGBS2 1:147747854 ENST00000428035.1 RP11-495P10.6 SGBS	1,	SGBS2
1:158800106 ENST00000368141.4 MNDA Tissue	1 12:69737163 ENST00000549690.1 LYZ Tissue	1,	Tissue	3 11:1770820 ENST00000340134.4 IFITM10 SGBS	1,	SGBS2 1:148243103 ENST00000427732.1 RP11-89F3.2 SGBS	1,	SGBS2
11:61015804 ENST00000541528.1 PGA5 Tissue	1,	Tissue	2,	Tissue	3 12:69737165 ENST00000548839.1 LYZ Tissue	1,	Tissue	3 11:19401030 ENST00000528204.1 NAV2-IT1 SGBS	1,	SGBS2 11:4898048 ENST00000380378.1 OR51T1 SGBS	1,	SGBS2
1:161038734 ENST00000368013.7 ARHGAP30 Tissue	1,	Tissue	3 12:7843371 ENST00000329913.3 GDF3 Tissue	1,	Tissue	2,	Tissue	3 11:33773944 ENST00000532057.5 FBXO3 SGBS	1,	SGBS2 11:4898129 ENST00000322049.1 OR51T1 SGBS	1,	SGBS2
1:161038759 ENST00000368015.1 ARHGAP30 Tissue	1,	Tissue	3 12:9263752 ENST00000318602.11 A2M Tissue	1,	Tissue	2,	Tissue	3 11:33773945 ENST00000531080.5 FBXO3 SGBS	1,	SGBS2 1:153343124 ENST00000368737.4 S100A12 SGBS	1,	SGBS2
1:161474219
ENST00000271450.10,E




00000620902.1 MALAT1 Tissue	1 13:23750090 ENST00000218867.3 SGCG Tissue	1,	Tissue	2,	Tissue	3 1:145074881 ENST00000585156.5 PDE4DIP SGBS	1,	SGBS2 1:159919043 ENST00000368093.3 SLAMF9 SGBS	1,	SGBS2
11:67218885 ENST00000438189.6 CABP4 Tissue	1,	Tissue	3 13:24823576 ENST00000430733.1 SPATA13-AS1 Tissue	1 1:145074888 ENST00000620605.4 PDE4DIP SGBS	1,	SGBS2 11:60686947 ENST00000453848.6 TMEM132A SGBS	1,	SGBS2
1:177319721 ENST00000451341.1 RP1-35C21.1 Tissue	1,	Tissue	2,	Tissue	3 14:47807320 ENST00000357362.7 MDGA2 Tissue	1,	Tissue	2,	Tissue	3 1:145074900 ENST00000524974.5 PDE4DIP SGBS	1,	SGBS2 11:60686952 ENST00000005286.8 TMEM132A SGBS	1,	SGBS2







1:192126586 ENST00000367460.3 RGS18 Tissue	1 1:47259717
ENST00000271153.8,
ENST00000371923.8 CYP4B1 Tissue	1,	Tissue	2,	Tissue	3 11:4718071 ENST00000396950.3 OR51E2 SGBS	1,	SGBS2 11:66098872 ENST00000627248.1 RIN1 SGBS	1,	SGBS2
11:93270080 ENST00000527149.1 SMCO4 Tissue	1,	Tissue	2,	Tissue	3 1:47259753
ENST00000371919.8,
ENST00000614163.4 CYP4B1 Tissue	1,	Tissue	2,	Tissue	3 1:1474729 ENST00000624426.1 TMEM240 SGBS	1,	SGBS2 11:66098999 ENST00000311320.8 RIN1 SGBS	1,	SGBS2
11:93970315 ENST00000506309.6 RP11-680H20.2 Tissue	1,	Tissue	2,	Tissue	3 1:49237589 ENST00000371833.3 BEND5 Tissue	1,	Tissue	3 1:1474736 ENST00000378733.8 TMEM240 SGBS	1,	SGBS2 11:66099310 ENST00000530056.1 RIN1 SGBS	1,	SGBS2
1:198607169 ENST00000442510.6 PTPRC Tissue	1 14:94979180 ENST00000341228.2 SERPINA12 Tissue	3 1:1474832 ENST00000425828.1 TMEM240 SGBS	1,	SGBS2 1:17511277 ENST00000412427.1 RP11-380J14.1 SGBS	1,	SGBS2
1:198607224 ENST00000348564.10 PTPRC Tissue	1 15:67346590 ENST00000558071.2 RP11-798K3.2 Tissue	1,	Tissue	2,	Tissue	3 1:147751854 ENST00000428035.1 RP11-495P10.6 SGBS	1,	SGBS2 1:17511283 ENST00000634972.1 RP11-380J14.1 SGBS	1,	SGBS2
1:198607226
ENST00000367364.5,EN
ST00000413409.6 PTPRC Tissue	1 15:69217972 ENST00000455873.7 NOX5 Tissue	1 1:148247103 ENST00000427732.1 RP11-89F3.2 SGBS	1,	SGBS2 11:75922068 ENST00000531538.1 RP11-619A14.3 SGBS	1,	SGBS2
1:209928376 ENST00000400959.7 TRAF3IP3 Tissue	1 16:20415855
ENST00000331849.8,
ENST00000575584.5 ACSM5 Tissue	1,	Tissue	2,	Tissue	3 11:4902048 ENST00000380378.1 OR51T1 SGBS	1,	SGBS2 11:76993462
ENST00000315938.4,
ENST00000376217.6 GDPD4 SGBS	1,	SGBS2
1:209928393 ENST00000367025.7 TRAF3IP3 Tissue	1 16:20415867 ENST00000575070.1 ACSM5 Tissue	1,	Tissue	2,	Tissue	3 11:4902129 ENST00000322049.1 OR51T1 SGBS	1,	SGBS2 1:210106518
ENST00000367019.5,
ENST00000537238.5 SYT14 SGBS	1,	SGBS2
1:209928523 ENST00000367026.7 TRAF3IP3 Tissue	1 16:29752326 ENST00000329410.3 C16orf54 Tissue	1,	Tissue	3 11:5225270 ENST00000418080.1 AC104389.16 SGBS	1,	SGBS2 1:210106595
ENST00000472886.5,
ENST00000629778.2 SYT14 SGBS	1,	SGBS2
12:105626227 ENST00000539978.6 APPL2 Tissue	2 16:31266310 ENST00000287497.12 ITGAM Tissue	1 1:153347124 ENST00000368737.4 S100A12 SGBS	1,	SGBS2 12:104669499 ENST00000549807.1 RP11-818F20.5 SGBS	1,	SGBS2
12:109026734 ENST00000550948.1 SELPLG Tissue	1,	Tissue	3 16:31266314 ENST00000544665.7 ITGAM Tissue	1 11:58671896 ENST00000454512.1 AP001652.1 SGBS	1,	SGBS2 1:210607926 ENST00000367009.2 HHAT SGBS	1,	SGBS2
12:123186889 ENST00000328880.5 HCAR2 Tissue	1,	Tissue	3 16:55352671 ENST00000290552.7 IRX6 Tissue	1,	Tissue	2,	Tissue	3 1:159923009 ENST00000368092.7 SLAMF9 SGBS	1,	SGBS2 12:121194394 ENST00000542620.1 RP11-173P15.7 SGBS	1,	SGBS2
12:130553869 ENST00000535487.1 RP11-474D1.2 Tissue	1,	Tissue	2,	Tissue	3 16:55418611 ENST00000570308.5 MMP2 Tissue	1,	Tissue	2,	Tissue	3 1:159923043 ENST00000368093.3 SLAMF9 SGBS	1,	SGBS2 12:121623670 ENST00000619282.1 RP11-340F14.6 SGBS	1,	SGBS2
12:15864926 ENST00000543612.5 EPS8 Tissue	1,	Tissue	2,	Tissue	3 16:89038611 ENST00000268679.8 CBFA2T3 Tissue	1,	Tissue	3 11:60690947 ENST00000453848.6 TMEM132A SGBS	1,	SGBS2 12:131256090 ENST00000624414.1 RP11-989F5.4 SGBS	1,	SGBS2
1:226861767 ENST00000412918.1 ITPKB-IT1 Tissue	1,	Tissue	2,	Tissue	3 17:18275975 ENST00000399134.4 EVPLL Tissue	1,	Tissue	2 11:60690952 ENST00000005286.8 TMEM132A SGBS	1,	SGBS2 12:133194558 ENST00000623606.1 RP13-554M15.5 SGBS	1,	SGBS2
1:22961998 ENST00000374642.7 C1QA Tissue	1 17:2694731
ENST00000254695.12






NST00000546024.5 FCRLA SGBS	1,	SGBS2 12:15810625 ENST00000540613.5 EPS8 SGBS	1,	SGBS2
12:32637905 ENST00000531134.5 FGD4 Tissue	1,	Tissue	3 17:34308793 ENST00000618404.4 CCL14 Tissue	1 11:66102872 ENST00000627248.1 RIN1 SGBS	1,	SGBS2 1:222658041 ENST00000621440.1 RP11-378J18.9 SGBS	1,	SGBS2
12:41085243 ENST00000547702.5 CNTN1 Tissue	1 17:34309039 ENST00000614009.1 CCL14 Tissue	1 11:66102999 ENST00000311320.8 RIN1 SGBS	1,	SGBS2 12:22847874 ENST00000536744.5 RP11-114G22.1 SGBS	1,	SGBS2
12:45685465 ENST00000441606.2 ANO6 Tissue	1,	Tissue	2,	Tissue	3 17:49512013 ENST00000588341.1 RP11-1018N14.5 Tissue	1 11:66103310 ENST00000530056.1 RIN1 SGBS	1,	SGBS2 12:22847961 ENST00000628326.1 RP11-114G22.1 SGBS	1,	SGBS2
1:248099492 ENST00000366478.2 OR2L13 Tissue	1,	Tissue	3 17:53346013 ENST00000574716.1 RP11-515O17.2 Tissue	1,	Tissue	2,	Tissue	3 1:17515277 ENST00000412427.1 RP11-380J14.1 SGBS	1,	SGBS2 1:225883305 ENST00000448264.1 RP11-145A3.1 SGBS	1,	SGBS2
12:56105194 ENST00000452168.6 ITGA7 Tissue	1,	Tissue	2,	Tissue	3 18:13422478 ENST00000588672.1 LDLRAD4-AS1 Tissue	1,	Tissue	2,	Tissue	3 1:17515283 ENST00000634972.1 RP11-380J14.1 SGBS	1,	SGBS2 1:229571766 ENST00000434311.1 RP5-1068B5.5 SGBS	1,	SGBS2
12:6232840 ENST00000261405.9 VWF Tissue	1,	Tissue	2,	Tissue	3 18:22562645 ENST00000580984.1 RP11-958F21.1 Tissue	1,	Tissue	2,	Tissue	3 11:75926068 ENST00000531538.1 RP11-619A14.3 SGBS	1,	SGBS2 1:240770448 ENST00000318160.4 GREM2 SGBS	1,	SGBS2
12:69741120 ENST00000261267.6 LYZ Tissue	1,	Tissue	3 18:28676550 ENST00000581836.1 DSCAS Tissue	1,	Tissue	2 11:7625968 ENST00000530181.5 PPFIBP2 SGBS	1,	SGBS2 1:244075703 ENST00000440494.1 RP11-278H7.1 SGBS	1,	SGBS2
12:69741163 ENST00000549690.1 LYZ Tissue	1,	Tissue	3 18:29557861 ENST00000624000.1 RP11-326K13.3 Tissue	1,	Tissue	2,	Tissue	3 11:76997462
ENST00000315938.4,E
NST00000376217.6 GDPD4 SGBS	1,	SGBS2 1:246848348 ENST00000442712.1 RP11-439E19.7 SGBS	1,	SGBS2
12:69741165 ENST00000548839.1 LYZ Tissue	1,	Tissue	3 18:30711040 ENST00000581852.5 CCDC178 Tissue	1,	Tissue	2,	Tissue	3 1:179786325 ENST00000415218.1 RP11-12M5.3 SGBS	1,	SGBS2 12:47214779
ENST00000266579.8,
ENST00000447411.5 SLC38A4 SGBS	1,	SGBS2
12:739056 ENST00000537514.1 RP11-218M22.1 Tissue	1,	Tissue	2,	Tissue	3 19:12300831 ENST00000426044.1 CTD-2666L21.1 Tissue	1 1:209740017 ENST00000424696.6 RP1-272L16.1 SGBS	1,	SGBS2 12:72099153 ENST00000549710.1 RP11-498M15.1 SGBS	1,	SGBS2
12:7847371 ENST00000329913.3 GDF3 Tissue	1,	Tissue	2,	Tissue	3 19:12300902 ENST00000451691.2 CTD-2666L21.1 Tissue	1 1:209823678 ENST00000391911.5 LAMB3 SGBS	1,	SGBS2 12:91500607 ENST00000266718.4 LUM SGBS	1,	SGBS2
1:27951750 ENST00000399173.5 FGR Tissue	1 19:22188720 ENST00000597040.1 ZNF208 Tissue	1 1:210110518
ENST00000367019.5,E
NST00000537238.5 SYT14 SGBS	1,	SGBS2 1:30177393 ENST00000422638.1 RP4-656G21.1 SGBS	1,	SGBS2
12:9267752 ENST00000318602.11 A2M Tissue	1,	Tissue	2,	Tissue	3 19:22188744
ENST00000397126.8,
ENST00000601773.5,
ENST00000609966.5 ZNF208 Tissue	1 1:210110595
ENST00000472886.5,E
NST00000629778.2 SYT14 SGBS	1,	SGBS2 13:100100722 ENST00000582220.1 AL583784.1 SGBS	1,	SGBS2
12:94675619 ENST00000547927.1 RP11-1105G2.3 Tissue	1,	Tissue	3 19:22188750 ENST00000599916.5 ZNF208 Tissue	1 12:104673499 ENST00000549807.1 RP11-818F20.5 SGBS	1,	SGBS2 13:31546759 ENST00000433788.1 RP11-252M21.6 SGBS	1,	SGBS2
12:96389121 ENST00000538703.5 HAL Tissue	1,	Tissue	2,	Tissue	3 19:22600147 ENST00000357774.9 ZNF98 Tissue	1 1:210611926 ENST00000367009.2 HHAT SGBS	1,	SGBS2 1:33603830 ENST00000622988.1 RP11-131M11.2 SGBS	1,	SGBS2
12:96389142
ENST00000261208.7,EN
ST00000541929.5 HAL Tissue	1,	Tissue	2,	Tissue	3 19:22600155 ENST00000601553.1 ZNF98 Tissue	1 12:109021462 ENST00000550306.1 RP11-689B22.2 SGBS	1,	SGBS2 13:96362031 ENST00000516092.1 snR65 SGBS	1,	SGBS2
12:96389298 ENST00000551849.1 RP11-256L6.3 Tissue	1,	Tissue	2,	Tissue	3 19:22600314 ENST00000599129.1 AC011516.1 Tissue	1 12:109089177 ENST00000421578.6 CORO1C SGBS	1,	SGBS2 14:105326616 ENST00000556508.5 CEP170B SGBS	1,	SGBS2
13:113632625 ENST00000421756.5 MCF2L Tissue	1,	Tissue	2,	Tissue	3 19:22710427 ENST00000598832.1 LINC01233 Tissue	1 12:121198394 ENST00000542620.1 RP11-173P15.7 SGBS	1,	SGBS2 14:105326649
ENST00000414716.7,
ENST00000453495.2 CEP170B SGBS	1,	SGBS2
1:32041085 ENST00000457433.6 TINAGL1 Tissue	3 19:22710472 ENST00000601708.1 LINC01233 Tissue	1 12:121627670 ENST00000619282.1 RP11-340F14.6 SGBS	1,	SGBS2 1:44509048 ENST00000431800.1 RP5-1198O20.4 SGBS	1,	SGBS2
1:32041135 ENST00000271064.11 TINAGL1 Tissue	3 19:22961908 ENST00000596209.3 ZNF99 Tissue	1,	Tissue	2,	Tissue	3 12:131260090 ENST00000624414.1 RP11-989F5.4 SGBS	1,	SGBS2 1:44509063 ENST00000437643.1 RP5-1198O20.4 SGBS	1,	SGBS2
13:23754090 ENST00000218867.3 SGCG Tissue	1,	Tissue	2,	Tissue	3 19:39821644 ENST00000602185.5 GMFG Tissue	1,	Tissue	3 12:133198558 ENST00000623606.1 RP13-554M15.5 SGBS	1,	SGBS2 1:44851393 ENST00000362515.1 RNU6-369P SGBS	1,	SGBS2
13:24827576 ENST00000430733.1 SPATA13-AS1 Tissue	1 19:39821645 ENST00000598034.5 GMFG Tissue	1,	Tissue	3 12:15814625 ENST00000540613.5 EPS8 SGBS	1,	SGBS2 14:85978277 ENST00000557547.1 CTD-2128A3.2 SGBS	1,	SGBS2
13:44731357 ENST00000415082.1 SMIM2-IT1 Tissue	1,	Tissue	2,	Tissue	3 19:39821656 ENST00000601387.5 GMFG Tissue	1,	Tissue	3 1:21911964 ENST00000457706.1 RP11-63N8.3 SGBS	1,	SGBS2 15:101414580 ENST00000329841.9 ALDH1A3 SGBS	1,	SGBS2
14:105530766
ENST00000329797.7,EN
ST00000539291.6 GPR132 Tissue	1 19:39821663 ENST00000595636.1 GMFG Tissue	1,	Tissue	3 1:222662041 ENST00000621440.1 RP11-378J18.9 SGBS	1,	SGBS2 15:101415043 ENST00000557963.1 ALDH1A3 SGBS	1,	SGBS2
14:105530781 ENST00000392585.2 GPR132 Tissue	1 19:39821667 ENST00000253054.12 GMFG Tissue	1,	Tissue	3 12:22851874 ENST00000536744.5 RP11-114G22.1 SGBS	1,	SGBS2 15:101415079 ENST00000346623.6 ALDH1A3 SGBS	1,	SGBS2
14:24041209 ENST00000544177.1 JPH4 Tissue	1 19:39821678 ENST00000594700.5 GMFG Tissue	1,	Tissue	3 12:22851961 ENST00000628326.1 RP11-114G22.1 SGBS	1,	SGBS2 1:52451435 ENST00000371655.3 RAB3B SGBS	1,	SGBS2
14:47811320 ENST00000357362.7 MDGA2 Tissue	1,	Tissue	2,	Tissue	3 19:39821824 ENST00000597595.5 GMFG Tissue	1,	Tissue	3 1:225887305 ENST00000448264.1 RP11-145A3.1 SGBS	1,	SGBS2 15:29264666 ENST00000560531.1 RP13-126C7.1 SGBS	1,	SGBS2
14:65936819 ENST00000385047.1 MIR625 Tissue	2 19:42050885 ENST00000407170.6 CEACAM21 Tissue	1,	Tissue	2,	Tissue	3 1:229575766 ENST00000434311.1 RP5-1068B5.5 SGBS	1,	SGBS2 15:41311696 ENST00000560178.1 RP11-540O11.4 SGBS	1,	SGBS2
1:47263717
ENST00000271153.8,EN
ST00000371923.8 CYP4B1 Tissue	1,	Tissue	2,	Tissue	3 19:42050887
ENST00000595395.1,
ENST00000601116.5 AC006129.2 Tissue	1,	Tissue	2,	Tissue	3 1:236106104 ENST00000438371.1 RP5-940F7.2 SGBS	1,	SGBS2 15:42714894 ENST00000364207.1 RNU6-188P SGBS	1,	SGBS2
1:47263753
ENST00000371919.8,EN
ST00000614163.4 CYP4B1 Tissue	1,	Tissue	2,	Tissue	3 19:48748027 ENST00000522431.5 CARD8 Tissue	1,	Tissue	2,	Tissue	3 1:240774448 ENST00000318160.4 GREM2 SGBS	1,	SGBS2 15:64158217 ENST00000362286.1 MIR422A SGBS	1,	SGBS2
1:49241589 ENST00000371833.3 BEND5 Tissue	1,	Tissue	3 19:48748082 ENST00000520153.5 CARD8 Tissue	1,	Tissue	2,	Tissue	3 1:244079703 ENST00000440494.1 RP11-278H7.1 SGBS	1,	SGBS2 15:78852861 ENST00000299565.9 CHRNA5 SGBS	1,	SGBS2
14:94983180 ENST00000341228.2 SERPINA12 Tissue	3 19:48748089 ENST00000520015.5 CARD8 Tissue	1,	Tissue	2,	Tissue	3 1:246852348 ENST00000442712.1 RP11-439E19.7 SGBS	1,	SGBS2 15:78852912 ENST00000559554.5 CHRNA5 SGBS	1,	SGBS2
15:100665310 ENST00000560128.1 RP11-90E5.1 Tissue	1,	Tissue	2,	Tissue	3 19:48748103 ENST00000447740.6 CARD8 Tissue	1,	Tissue	2,	Tissue	3 12:47218779
ENST00000266579.8,E
NST00000447411.5 SLC38A4 SGBS	1,	SGBS2 15:79193468 ENST00000624440.1 RP11-16K12.2 SGBS	1,	SGBS2
15:50405700 ENST00000559829.5 ATP8B4 Tissue	1 19:50701884
ENST00000376970.6,
ENST00000425460.5,






15:67350590 ENST00000558071.2 RP11-798K3.2 Tissue	1,	Tissue	2,	Tissue	3 19:50701901 ENST00000601313.5 MYH14 Tissue	1,	Tissue	2,	Tissue	3 12:90340469 ENST00000547094.1 RP11-654D12.3 SGBS	1,	SGBS2 16:18990255
ENST00000304381.9,
ENST00000569532.5 TMC7 SGBS	1,	SGBS2
15:69221838 ENST00000310673.3 SPESP1 Tissue	1 19:54871413 ENST00000474878.5 LAIR1 Tissue	1,	Tissue	3 12:91504607 ENST00000266718.4 LUM SGBS	1,	SGBS2 16:18990608 ENST00000421369.3 TMC7 SGBS	1,	SGBS2
15:69221842 ENST00000557966.1 RP11-809H16.2 Tissue	1 19:54871471 ENST00000348231.8 LAIR1 Tissue	1,	Tissue	3 1:30181393 ENST00000422638.1 RP4-656G21.1 SGBS	1,	SGBS2 16:23676331 ENST00000566996.2 CTD-2196E14.9 SGBS	1,	SGBS2
15:69221863
ENST00000260364.9,EN
ST00000448182.7 NOX5 Tissue	1 19:54871563 ENST00000391742.6 LAIR1 Tissue	1,	Tissue	3 13:100104722 ENST00000582220.1 AL583784.1 SGBS	1,	SGBS2 1:64572887 ENST00000412349.6 ROR1-AS1 SGBS	1,	SGBS2
15:69221972 ENST00000455873.7 NOX5 Tissue	1 19:54871601 ENST00000434277.6 LAIR1 Tissue	1,	Tissue	3 13:31550759 ENST00000433788.1 RP11-252M21.6 SGBS	1,	SGBS2 16:50295426 ENST00000394697.6 ADCY7 SGBS	1,	SGBS2
15:94405337 ENST00000554530.5 RP11-76E17.3 Tissue	1,	Tissue	3 19:57178127 ENST00000537055.3 ZNF835 Tissue	1,	Tissue	2,	Tissue	3 1:33607830 ENST00000622988.1 RP11-131M11.2 SGBS	1,	SGBS2 16:50295461 ENST00000566433.6 ADCY7 SGBS	1,	SGBS2
16:20419855
ENST00000331849.8,EN
ST00000575584.5 ACSM5 Tissue	1,	Tissue	2,	Tissue	3 20:30593252 ENST00000262659.12 CCM2L Tissue	1,	Tissue	2,	Tissue	3 13:96366031 ENST00000516092.1 snR65 SGBS	1,	SGBS2 16:580315 ENST00000581803.1 MIR5587 SGBS	1,	SGBS2
16:20419867 ENST00000575070.1 ACSM5 Tissue	1,	Tissue	2,	Tissue	3 20:30634990
ENST00000534862.5,
ENST00000538448.5 HCK Tissue	1,	Tissue	3 14:105330616 ENST00000556508.5 CEP170B SGBS	1,	SGBS2 16:71455366 ENST00000567469.1 RP11-510M2.1 SGBS	1,	SGBS2
16:29756326 ENST00000329410.3 C16orf54 Tissue	1,	Tissue	3 20:30634999 ENST00000375862.6 HCK Tissue	1,	Tissue	3 14:105330649
ENST00000414716.7,E
NST00000453495.2 CEP170B SGBS	1,	SGBS2 16:71555153 ENST00000539698.3 CHST4 SGBS	1,	SGBS2
16:31270310 ENST00000287497.12 ITGAM Tissue	1 20:30635044
ENST00000520553.5,
ENST00000629881.2 HCK Tissue	1,	Tissue	3 1:44513048 ENST00000431800.1 RP5-1198O20.4 SGBS	1,	SGBS2 16:72816671 ENST00000584072.1 AC004943.1 SGBS	1,	SGBS2
16:31270314 ENST00000544665.7 ITGAM Tissue	1 20:30635063
ENST00000375852.2,
ENST00000518730.5 HCK Tissue	1,	Tissue	3 1:44513063 ENST00000437643.1 RP5-1198O20.4 SGBS	1,	SGBS2 1:6779696 ENST00000432429.5 RP11-242F24.1 SGBS	1,	SGBS2
16:55356671 ENST00000290552.7 IRX6 Tissue	1,	Tissue	2,	Tissue	3 20:31664332 ENST00000375483.3 BPIFB4 Tissue	1,	Tissue	2 1:44855393 ENST00000362515.1 RNU6-369P SGBS	1,	SGBS2 1:6779732 ENST00000635092.1 RP11-242F24.1 SGBS	1,	SGBS2
16:55422611 ENST00000570308.5 MMP2 Tissue	1,	Tissue	2,	Tissue	3 20:34073807 ENST00000453914.1 RP3-477O4.14 Tissue	1 14:71164414 ENST00000553682.1 LINC01269 SGBS	1,	SGBS2 16:81673962 ENST00000398040.8 CMIP SGBS	1,	SGBS2
16:89042611 ENST00000268679.8 CBFA2T3 Tissue	1,	Tissue	3 20:51709190 ENST00000362348.1 RN7SKP184 Tissue	1,	Tissue	3 14:85982277 ENST00000557547.1 CTD-2128A3.2 SGBS	1,	SGBS2 16:82221394 ENST00000516079.1 RN7SKP190 SGBS	1,	SGBS2
17:18279975 ENST00000399134.4 EVPLL Tissue	1,	Tissue	2 20:9961735 ENST00000449270.1 RP5-839B4.8 Tissue	1,	Tissue	2,	Tissue	3 15:101418580 ENST00000329841.9 ALDH1A3 SGBS	1,	SGBS2 16:83018902 ENST00000565238.1 CTD-3253I12.1 SGBS	1,	SGBS2
17:2698731
ENST00000254695.12,E
NST00000366401.8 RAP1GAP2 Tissue	1 2:108140942 ENST00000443205.1 AC096669.3 Tissue	1,	Tissue	2,	Tissue	3 15:101419043 ENST00000557963.1 ALDH1A3 SGBS	1,	SGBS2 16:87835081 ENST00000561567.1 RP4-536B24.3 SGBS	1,	SGBS2
17:34312793 ENST00000618404.4 CCL14 Tissue	1 21:15913661 ENST00000400564.5 SAMSN1 Tissue	1 15:101419079 ENST00000346623.6 ALDH1A3 SGBS	1,	SGBS2 16:9157410 ENST00000562893.1 RP11-473I1.6 SGBS	1,	SGBS2
17:34313039 ENST00000614009.1 CCL14 Tissue	1 21:15913663 ENST00000400566.5 SAMSN1 Tissue	1 1:52455435 ENST00000371655.3 RAB3B SGBS	1,	SGBS2 17:15177793 ENST00000453339.2 AC005703.2 SGBS	1,	SGBS2
17:41002200
ENST00000308423.6,EN
ST00000613571.1 AOC3 Tissue	1,	Tissue	2 21:15913680 ENST00000619120.4 SAMSN1 Tissue	1 15:29268666 ENST00000560531.1 RP13-126C7.1 SGBS	1,	SGBS2 17:39533654 ENST00000394001.1 KRT34 SGBS	1,	SGBS2
17:49516013 ENST00000588341.1 RP11-1018N14.5 Tissue	1 21:29322239 ENST00000433344.1 AJ006995.3 Tissue	1,	Tissue	3 15:41315696 ENST00000560178.1 RP11-540O11.4 SGBS	1,	SGBS2 17:70021794 ENST00000472655.3 LINC01152 SGBS	1,	SGBS2
17:53350013 ENST00000574716.1 RP11-515O17.2 Tissue	1,	Tissue	2,	Tissue	3 2:143881882 ENST00000295095.10 ARHGAP15 Tissue	1 15:42718894 ENST00000364207.1 RNU6-188P SGBS	1,	SGBS2 17:70583942 ENST00000453722.6 LINC00511 SGBS	1,	SGBS2
17:6982625 ENST00000254868.8 CLEC10A Tissue	1,	Tissue	3 21:48020120
ENST00000291700.8,
ENST00000367071.4 S100B Tissue	1,	Tissue	2,	Tissue	3 15:64162217 ENST00000362286.1 MIR422A SGBS	1,	SGBS2 17:79604438 ENST00000611590.1 TSPAN10 SGBS	1,	SGBS2
17:72965798 ENST00000577295.1 HID1-AS1 Tissue	1,	Tissue	3 2:154723425 ENST00000392825.7 GALNT13 Tissue	1,	Tissue	2,	Tissue	3 15:78856861 ENST00000299565.9 CHRNA5 SGBS	1,	SGBS2 17:80535380 ENST00000459591.1 snoU13 SGBS	1,	SGBS2
17:73504968 ENST00000433559.6 CASKIN2 Tissue	1,	Tissue	2,	Tissue	3 2:231085444 ENST00000420434.7 SP140 Tissue	1 15:78856912 ENST00000559554.5 CHRNA5 SGBS	1,	SGBS2 18:32342626 ENST00000596954.1 RP11-138H11.1 SGBS	1,	SGBS2
18:13426478 ENST00000588672.1 LDLRAD4-AS1 Tissue	1,	Tissue	3 2:231085445 ENST00000392045.7 SP140 Tissue	1 15:79197468 ENST00000624440.1 RP11-16K12.2 SGBS	1,	SGBS2 18:61437608 ENST00000540675.5 SERPINB7 SGBS	1,	SGBS2
18:22566645 ENST00000580984.1 RP11-958F21.1 Tissue	1,	Tissue	2,	Tissue	3 2:231085456 ENST00000417495.7 SP140 Tissue	1 16:15595122 ENST00000452191.6 C16orf45 SGBS	1,	SGBS2 18:61437643 ENST00000398019.6 SERPINB7 SGBS	1,	SGBS2
18:28680550 ENST00000581836.1 DSCAS Tissue	1,	Tissue	2 2:231085459 ENST00000343805.10 SP140 Tissue	1 16:18994255
ENST00000304381.9,E
NST00000569532.5 TMC7 SGBS	1,	SGBS2 18:68046826 ENST00000582251.1 RP11-41O4.2 SGBS	1,	SGBS2
18:29561861 ENST00000624000.1 RP11-326K13.3 Tissue	1,	Tissue	2,	Tissue	3 2:231085478 ENST00000373645.3 SP140 Tissue	1 16:18994608 ENST00000421369.3 TMC7 SGBS	1,	SGBS2 18:73114992 ENST00000579386.2 RP11-321M21.3 SGBS	1,	SGBS2
18:30715040 ENST00000581852.5 CCDC178 Tissue	1,	Tissue	2,	Tissue	3 22:50046077 ENST00000405854.5 C22orf34 Tissue	1,	Tissue	2,	Tissue	3 16:23680331 ENST00000566996.2 CTD-2196E14.9 SGBS	1,	SGBS2 19:14043877 ENST00000254320.7 PODNL1 SGBS	1,	SGBS2
18:3450590 ENST00000551541.5 TGIF1 Tissue	1 22:50046151 ENST00000414287.5 C22orf34 Tissue	1,	Tissue	2,	Tissue	3 1:64576887 ENST00000412349.6 ROR1-AS1 SGBS	1,	SGBS2 19:14044288 ENST00000339560.9 PODNL1 SGBS	1,	SGBS2
18:59414408 ENST00000567801.2 LINC01544 Tissue	1,	Tissue	2,	Tissue	3 2:50196292 ENST00000635519.1 NRXN1 Tissue	1,	Tissue	2,	Tissue	3 16:50299426 ENST00000394697.6 ADCY7 SGBS	1,	SGBS2 19:33550793 ENST00000254260.7 RHPN2 SGBS	1,	SGBS2
19:1173254 ENST00000587024.5 SBNO2 Tissue	1,	Tissue	3 2:50196336 ENST00000412315.5 NRXN1 Tissue	1,	Tissue	2,	Tissue	3 16:50299461 ENST00000566433.6 ADCY7 SGBS	1,	SGBS2 19:35891508 ENST00000536898.5 LINC01531 SGBS	1,	SGBS2
19:1173281 ENST00000361757.7 SBNO2 Tissue	1,	Tissue	3 2:50196340 ENST00000378262.7 NRXN1 Tissue	1,	Tissue	2,	Tissue	3 16:584315 ENST00000581803.1 MIR5587 SGBS	1,	SGBS2 19:36159192 ENST00000443196.1 UPK1A-AS1 SGBS	1,	SGBS2
19:12304831 ENST00000426044.1 CTD-2666L21.1 Tissue	1 2:7213010
ENST00000415520.5,
ENST00000428379.1 AC019048.1 Tissue	1,	Tissue	2,	Tissue	3 16:58532950 ENST00000566192.5 NDRG4 SGBS	1,	SGBS2 19:44759032 ENST00000592581.5 ZNF233 SGBS	1,	SGBS2
19:12304902 ENST00000451691.2 CTD-2666L21.1 Tissue	1 2:9241721 ENST00000565044.1 RP11-734K21.5 Tissue	1,	Tissue	2,	Tissue	3 16:58533010 ENST00000568640.5 NDRG4 SGBS	1,	SGBS2 19:44759075 ENST00000391958.6 ZNF233 SGBS	1,	SGBS2





NST00000570248.5 NDRG4 SGBS	1,	SGBS2 19:55876740 ENST00000264563.6 IL11 SGBS	1,	SGBS2
19:17374532 ENST00000431146.6 USHBP1 Tissue	3 3:178979789 ENST00000497599.5 KCNMB3 Tissue	1,	Tissue	2,	Tissue	3 16:67310412 ENST00000360461.9 PLEKHG4 SGBS	1,	SGBS2 19:55876830
ENST00000585513.1,
ENST00000590625.5 IL11 SGBS	1,	SGBS2
19:17374604 ENST00000252597.7 USHBP1 Tissue	3 3:183268476 ENST00000341319.7 KLHL6 Tissue	1,	Tissue	2,	Tissue	3 1:66819064 ENST00000480109.2 PDE4B SGBS	1,	SGBS2 1:96203651 ENST00000603401.1 RP11-286B14.2 SGBS	1,	SGBS2
19:18507420 ENST00000595840.1 LRRC25 Tissue	1 3:18782235 ENST00000453361.1 SATB1-AS1 Tissue	1 16:71459366 ENST00000567469.1 RP11-510M2.1 SGBS	1,	SGBS2 19:7948389
ENST00000306708.10
,ENST00000618098.4 LRRC8E SGBS	1,	SGBS2
19:18507426 ENST00000339007.3 LRRC25 Tissue	1 3:40802697 ENST00000412811.1 RP11-761N21.1 Tissue	3 16:71559153 ENST00000539698.3 CHST4 SGBS	1,	SGBS2 19:9512730 ENST00000634951.1 CTC-325H20.8 SGBS	1,	SGBS2




00000609966.5 ZNF208 Tissue	1 4:15424537 ENST00000502344.5 RP11-665G4.1 Tissue	1,	Tissue	2,	Tissue	3 1:6783696 ENST00000432429.5 RP11-242F24.1 SGBS	1,	SGBS2 20:24477980 ENST00000458461.1 RP11-526K17.2 SGBS	1,	SGBS2
19:22192750 ENST00000599916.5 ZNF208 Tissue	1 5:160360632 ENST00000518580.5 RP11-109J4.1 Tissue	1,	Tissue	2,	Tissue	3 1:6783732 ENST00000635092.1 RP11-242F24.1 SGBS	1,	SGBS2 20:32600554 ENST00000451556.2 RP5-1125A11.4 SGBS	1,	SGBS2
19:22604147 ENST00000357774.9 ZNF98 Tissue	1 5:23502723 ENST00000296682.3 PRDM9 Tissue	1,	Tissue	3 16:81642911 ENST00000566513.5 CMIP SGBS	1,	SGBS2 20:49634665 ENST00000371571.4 KCNG1 SGBS	1,	SGBS2
19:22604155 ENST00000601553.1 ZNF98 Tissue	1 5:42543144 ENST00000618088.4 GHR Tissue	1,	Tissue	3 16:81677962 ENST00000398040.8 CMIP SGBS	1,	SGBS2 20:5887075 ENST00000378961.8 CHGB SGBS	1,	SGBS2
19:22604314 ENST00000599129.1 AC011516.1 Tissue	1 5:42543314 ENST00000612382.4 GHR Tissue	1,	Tissue	3 16:82225394 ENST00000516079.1 RN7SKP190 SGBS	1,	SGBS2 20:60007602 ENST00000616819.1 RP5-827E24.1 SGBS	1,	SGBS2
19:22714427 ENST00000598832.1 LINC01233 Tissue	1 5:76430073 ENST00000515356.2 ZBED3-AS1 Tissue	1,	Tissue	2,	Tissue	3 16:83022902 ENST00000565238.1 CTD-3253I12.1 SGBS	1,	SGBS2 2:113964098 ENST00000456685.5 PAX8-AS1 SGBS	1,	SGBS2
19:22714472 ENST00000601708.1 LINC01233 Tissue	1 6:15990174 ENST00000451285.1 RP11-401E14.2 Tissue	1,	Tissue	2,	Tissue	3 16:87839081 ENST00000561567.1 RP4-536B24.3 SGBS	1,	SGBS2 2:114595932 ENST00000446401.1 AC104653.1 SGBS	1,	SGBS2
19:22965908 ENST00000596209.3 ZNF99 Tissue	1,	Tissue	2,	Tissue	3 6:166183673 ENST00000431017.1 RP11-252P19.2 Tissue	1,	Tissue	2,	Tissue	3 16:9161410 ENST00000562893.1 RP11-473I1.6 SGBS	1,	SGBS2 2:121619977 ENST00000603720.1 RP11-297J22.1 SGBS	1,	SGBS2
19:29458803 ENST00000587998.5 LINC00906 Tissue	1,	Tissue	2,	Tissue	3 6:32186843 ENST00000375023.3 NOTCH4 Tissue	1,	Tissue	3 17:15181793 ENST00000453339.2 AC005703.2 SGBS	1,	SGBS2 2:122543019 ENST00000438722.5 AC018737.3 SGBS	1,	SGBS2
19:3177765 ENST00000246115.4 S1PR4 Tissue	1 6:32552581 ENST00000611060.4 HLA-DRB1 Tissue	3 17:39537654 ENST00000394001.1 KRT34 SGBS	1,	SGBS2 2:122543040 ENST00000435895.5 AC018737.3 SGBS	1,	SGBS2
1:9337449 ENST00000517032.1 Z98044.1 Tissue	3 6:32552624 ENST00000360004.5 HLA-DRB1 Tissue	3 17:52976873 ENST00000575882.5 TOM1L1 SGBS	1,	SGBS2 21:27757454 ENST00000421771.1 AP001596.6 SGBS	1,	SGBS2
19:39825644 ENST00000602185.5 GMFG Tissue	1,	Tissue	3 6:32629428 ENST00000399082.7 HLA-DQB1 Tissue	1,	Tissue	2,	Tissue	3 17:52977112 ENST00000445275.6 TOM1L1 SGBS	1,	SGBS2 21:30718954 ENST00000504298.1 BACH1-IT1 SGBS	1,	SGBS2
19:39825645 ENST00000598034.5 GMFG Tissue	1,	Tissue	3 6:32629440 ENST00000399079.7 HLA-DQB1 Tissue	1,	Tissue	2,	Tissue	3 17:52977166 ENST00000348161.8 TOM1L1 SGBS	1,	SGBS2 21:35823534 ENST00000408471.1 SNORA11 SGBS	1,	SGBS2
19:39825656 ENST00000601387.5 GMFG Tissue	1,	Tissue	3 6:32629460 ENST00000374943.8 HLA-DQB1 Tissue	1,	Tissue	2,	Tissue	3 17:52977194 ENST00000572405.5 TOM1L1 SGBS	1,	SGBS2 2:167992464 ENST00000525330.1 XIRP2-AS1 SGBS	1,	SGBS2
19:39825663 ENST00000595636.1 GMFG Tissue	1,	Tissue	3 6:32629470 ENST00000434651.6 HLA-DQB1 Tissue	1,	Tissue	2,	Tissue	3 17:52977196 ENST00000572158.5 TOM1L1 SGBS	1,	SGBS2 2:175647655 ENST00000416004.1 AC018890.4 SGBS	1,	SGBS2
19:39825667 ENST00000253054.12 GMFG Tissue	1,	Tissue	3 6:32631159 ENST00000399084.5 HLA-DQB1 Tissue	1,	Tissue	2,	Tissue	3 17:52977213 ENST00000536554.5 TOM1L1 SGBS	1,	SGBS2 2:207073351 ENST00000621141.4 GPR1 SGBS	1,	SGBS2
19:39825678 ENST00000594700.5 GMFG Tissue	1,	Tissue	3 6:46866207 ENST00000451135.1 RP3-365O12.2 Tissue	3 17:52977217 ENST00000575333.5 TOM1L1 SGBS	1,	SGBS2 22:19863686 ENST00000485358.5 TXNRD2 SGBS	1,	SGBS2
19:39825824 ENST00000597595.5 GMFG Tissue	1,	Tissue	3 6:62991131 ENST00000281156.4 KHDRBS2 Tissue	1,	Tissue	2,	Tissue	3 17:70025794 ENST00000472655.3 LINC01152 SGBS	1,	SGBS2 22:19863891 ENST00000462330.5 TXNRD2 SGBS	1,	SGBS2
19:42054885 ENST00000407170.6 CEACAM21 Tissue	1,	Tissue	2,	Tissue	3 6:6583340 ENST00000379953.6 LY86 Tissue	1,	Tissue	3 17:70334707 ENST00000581183.1 LINC00511 SGBS	1,	SGBS2 2:223158464 ENST00000409828.7 PAX3 SGBS	1,	SGBS2
19:42054887
ENST00000595395.1,EN
ST00000601116.5 AC006129.2 Tissue	1,	Tissue	2,	Tissue	3 7:150259364 ENST00000255945.3 GIMAP4 Tissue	1,	Tissue	3 17:70587942 ENST00000453722.6 LINC00511 SGBS	1,	SGBS2 2:223158470 ENST00000350526.8 PAX3 SGBS	1,	SGBS2
19:4539078 ENST00000586020.1 CTB-50L17.14 Tissue	1 7:150259456 ENST00000461940.5 GIMAP4 Tissue	1,	Tissue	3 17:79608438 ENST00000611590.1 TSPAN10 SGBS	1,	SGBS2 2:223158583 ENST00000258387.5 PAX3 SGBS	1,	SGBS2
19:48752027 ENST00000522431.5 CARD8 Tissue	1,	Tissue	2,	Tissue	3 7:150408644 ENST00000307194.5 GIMAP1 Tissue	1,	Tissue	2,	Tissue	3 17:80539380 ENST00000459591.1 snoU13 SGBS	1,	SGBS2 2:223158613 ENST00000409551.7 PAX3 SGBS	1,	SGBS2
19:48752082 ENST00000520153.5 CARD8 Tissue	1,	Tissue	2,	Tissue	3 7:150408755 ENST00000611999.4 GIMAP1-GIMAP5 Tissue	1,	Tissue	2,	Tissue	3 18:12418931 ENST00000592149.5 PRELID3A SGBS	1,	SGBS2 2:223158699 ENST00000392069.6 PAX3 SGBS	1,	SGBS2








00000440075.6 MYH14 Tissue	1,	Tissue	2,	Tissue	3 7:157642276 ENST00000438047.1 AC011899.9 Tissue	1,	Tissue	3 18:61441608 ENST00000540675.5 SERPINB7 SGBS	1,	SGBS2 2:228730769 ENST00000373666.6 DAW1 SGBS	1,	SGBS2
19:50705901 ENST00000601313.5 MYH14 Tissue	1,	Tissue	2,	Tissue	3 7:37388271 ENST00000442504.5 ELMO1 Tissue	1,	Tissue	2,	Tissue	3 18:61441643 ENST00000398019.6 SERPINB7 SGBS	1,	SGBS2 2:228731322 ENST00000309931.2 DAW1 SGBS	1,	SGBS2
19:54326570 ENST00000391775.7 NLRP12 Tissue	1 7:57467422 ENST00000624231.1 RP11-114G11.4 Tissue	1,	Tissue	2,	Tissue	3 18:68050826 ENST00000582251.1 RP11-41O4.2 SGBS	1,	SGBS2 22:29422463 ENST00000325660.3 ZNRF3-AS1 SGBS	1,	SGBS2




00000391773.5 NLRP12 Tissue	1 7:63356445 ENST00000585312.1 AC092634.1 Tissue	1,	Tissue	2,	Tissue	3 19:14047877 ENST00000254320.7 PODNL1 SGBS	1,	SGBS2 2:239031030 ENST00000409506.1 ESPNL SGBS	1,	SGBS2
19:54875413 ENST00000474878.5 LAIR1 Tissue	1,	Tissue	3 7:63382213 ENST00000582948.1 AC092634.2 Tissue	1,	Tissue	2,	Tissue	3 19:14048288 ENST00000339560.9 PODNL1 SGBS	1,	SGBS2 22:40919136 ENST00000516315.1 AL031594.1 SGBS	1,	SGBS2
19:54875471 ENST00000348231.8 LAIR1 Tissue	1,	Tissue	3 7:63500820
ENST00000456806.2,
ENST00000550760.3 ZNF727 Tissue	1,	Tissue	2,	Tissue	3 19:33554793 ENST00000254260.7 RHPN2 SGBS	1,	SGBS2 2:70909273 ENST00000457851.1 AC007395.3 SGBS	1,	SGBS2
19:54875563 ENST00000391742.6 LAIR1 Tissue	1,	Tissue	3 7:75236019 ENST00000616821.4 HIP1 Tissue	1,	Tissue	2,	Tissue	3 19:35895508 ENST00000536898.5 LINC01531 SGBS	1,	SGBS2 3:11173778 ENST00000438284.2 HRH1 SGBS	1,	SGBS2
19:54875601 ENST00000434277.6 LAIR1 Tissue	1,	Tissue	3 8:101310486 ENST00000519449.5 RNF19A Tissue	1,	Tissue	2 19:36163192 ENST00000443196.1 UPK1A-AS1 SGBS	1,	SGBS2 3:113928159 ENST00000481773.1 RP11-553L6.2 SGBS	1,	SGBS2
19:57182127 ENST00000537055.3 ZNF835 Tissue	1,	Tissue	2,	Tissue	3 8:112383867 ENST00000521904.5 RP11-1101K5.1 Tissue	1,	Tissue	2,	Tissue	3 19:44763032 ENST00000592581.5 ZNF233 SGBS	1,	SGBS2 3:113928237 ENST00000493033.1 RP11-553L6.2 SGBS	1,	SGBS2
19:6771724 ENST00000304076.6 VAV1 Tissue	1 8:112383891 ENST00000521753.5 RP11-1101K5.1 Tissue	1,	Tissue	2,	Tissue	3 19:44763075 ENST00000391958.6 ZNF233 SGBS	1,	SGBS2 3:115337170 ENST00000305124.10 GAP43 SGBS	1,	SGBS2
19:6771736 ENST00000602142.5 VAV1 Tissue	1 8:40005973 ENST00000315792.4 C8orf4 Tissue	1,	Tissue	2,	Tissue	3 19:52075580 ENST00000436511.2 ZNF175 SGBS	1,	SGBS2 3:115337356 ENST00000393780.3 GAP43 SGBS	1,	SGBS2
19:6771738 ENST00000596764.5 VAV1 Tissue	1 8:56428535 ENST00000522918.1 RP11-628E19.2 Tissue	2,	Tissue	3 19:55880740 ENST00000264563.6 IL11 SGBS	1,	SGBS2 3:120621918 ENST00000273666.10 STXBP5L SGBS	1,	SGBS2
20:1471041 ENST00000359801.7 SIRPB2 Tissue	1,	Tissue	2 8:61875333 ENST00000525556.1 AC022182.3 Tissue	1,	Tissue	3 19:55880830
ENST00000585513.1,E
NST00000590625.5 IL11 SGBS	1,	SGBS2 3:120622051 ENST00000471454.5 STXBP5L SGBS	1,	SGBS2
20:1471126 ENST00000444444.2 SIRPB2 Tissue	1,	Tissue	2 8:93676115 ENST00000521307.1 RP11-100L22.1 Tissue	1,	Tissue	2,	Tissue	3 1:96207651 ENST00000603401.1 RP11-286B14.2 SGBS	1,	SGBS2 3:120622135 ENST00000472879.5 STXBP5L SGBS	1,	SGBS2
20:17942588 ENST00000390930.1 SNORD17 Tissue	1,	Tissue	2 9:116258706
ENST00000343817.9,
ENST00000394646.7 RGS3 Tissue	1,	Tissue	3 19:7952389
ENST00000306708.10
,ENST00000618098.4 LRRC8E SGBS	1,	SGBS2 3:120622160
ENST00000492541.5,
ENST00000497029.5 STXBP5L SGBS	1,	SGBS2
20:30597252 ENST00000262659.12 CCM2L Tissue	1,	Tissue	3 9:130519696 ENST00000429553.5 SH2D3C Tissue	1,	Tissue	2,	Tissue	3 19:9516730 ENST00000634951.1 CTC-325H20.8 SGBS	1,	SGBS2 3:146666864 ENST00000515991.1 U3 SGBS	1,	SGBS2
20:30638990
ENST00000534862.5,EN
ST00000538448.5 HCK Tissue	1,	Tissue	3 9:268001 ENST00000429661.1 RP11-59O6.3 Tissue	1 20:18294754 ENST00000436848.1 RP4-568F9.3 SGBS	1,	SGBS2 3:155388827
ENST00000340059.11
,ENST00000447496.6 PLCH1 SGBS	1,	SGBS2
20:30638999 ENST00000375862.6 HCK Tissue	1,	Tissue	3 9:66531443 ENST00000609749.1 RP11-262H14.3 Tissue	2,	Tissue	3 20:24481980 ENST00000458461.1 RP11-526K17.2 SGBS	1,	SGBS2 3:155389204 ENST00000494598.5 PLCH1 SGBS	1,	SGBS2
20:30639044
ENST00000520553.5,EN
ST00000629881.2 HCK Tissue	1,	Tissue	3 9:93559068
ENST00000375751.8,
ENST00000375754.8 SYK Tissue	1 20:2794613 ENST00000380593.4 RP5-860F19.8 SGBS	1,	SGBS2 3:178131910 ENST00000614557.1 RP11-385J1.3 SGBS	1,	SGBS2
20:30639063
ENST00000375852.2,EN
ST00000518730.5 HCK Tissue	1,	Tissue	3 9:93559208 ENST00000375747.5 SYK Tissue	1 20:2794632 ENST00000603872.1 C20orf141 SGBS	1,	SGBS2 3:178131988 ENST00000455307.5 LINC01014 SGBS	1,	SGBS2
20:31668332 ENST00000375483.3 BPIFB4 Tissue	1,	Tissue	2 X:136643300 ENST00000287538.9 ZIC3 Tissue	1,	Tissue	2,	Tissue	3 20:2794656 ENST00000380589.4 C20orf141 SGBS	1,	SGBS2 3:183261522 ENST00000491676.1 KLHL6-AS1 SGBS	1,	SGBS2
20:34077807 ENST00000453914.1 RP3-477O4.14 Tissue	1 X:78617855 ENST00000373298.6 ITM2A Tissue	1,	Tissue	2,	Tissue	3 20:32604554 ENST00000451556.2 RP5-1125A11.4 SGBS	1,	SGBS2 3:21979057 ENST00000448980.5 ZNF385D-AS2 SGBS	1,	SGBS2
20:36973758 ENST00000217407.2 LBP Tissue	1,	Tissue	2,	Tissue	3 X:78618048 ENST00000434584.2 ITM2A Tissue	1,	Tissue	2,	Tissue	3 20:49638665 ENST00000371571.4 KCNG1 SGBS	1,	SGBS2 3:52877568 ENST00000624222.1 RP11-894J14.2 SGBS	1,	SGBS2
20:51713190 ENST00000362348.1 RN7SKP184 Tissue	1,	Tissue	3 20:52198635 ENST00000302342.3 ZNF217 SGBS	1,	SGBS2 4:100060426 ENST00000505590.5 ADH4 SGBS	1,	SGBS2
20:589909 ENST00000621005.1 TCF15 Tissue	1,	Tissue	2,	Tissue	3 20:5891075 ENST00000378961.8 CHGB SGBS	1,	SGBS2 4:100060431 ENST00000629236.2 ADH4 SGBS	1,	SGBS2
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20:590041 ENST00000246080.3 TCF15 Tissue	1,	Tissue	2,	Tissue	3 20:60011602 ENST00000616819.1 RP5-827E24.1 SGBS	1,	SGBS2 4:100060447
ENST00000265512.11
,ENST00000508393.5 ADH4 SGBS	1,	SGBS2
20:9965735 ENST00000449270.1 RP5-839B4.8 Tissue	2,	Tissue	3 2:113968098 ENST00000456685.5 PAX8-AS1 SGBS	1,	SGBS2 4:113189471 ENST00000610220.1 RP11-73K9.3 SGBS	1,	SGBS2
2:102607305 ENST00000332549.7 IL1R2 Tissue	1 2:114599932 ENST00000446401.1 AC104653.1 SGBS	1,	SGBS2 4:119269157 ENST00000296498.3 PRSS12 SGBS	1,	SGBS2
2:108144942 ENST00000443205.1 AC096669.3 Tissue	1,	Tissue	2,	Tissue	3 2:121623977 ENST00000603720.1 RP11-297J22.1 SGBS	1,	SGBS2 4:129517554 ENST00000487657.2 RP11-184M15.2 SGBS	1,	SGBS2
2:113930547 ENST00000245796.10 PSD4 Tissue	1 2:122547019 ENST00000438722.5 AC018737.3 SGBS	1,	SGBS2 4:145951283 ENST00000410662.1 RN7SKP235 SGBS	1,	SGBS2
2:113930573 ENST00000441564.7 PSD4 Tissue	1 2:122547040 ENST00000435895.5 AC018737.3 SGBS	1,	SGBS2 4:154173554 ENST00000482578.2 TRIM2 SGBS	1,	SGBS2
21:15917661 ENST00000400564.5 SAMSN1 Tissue	1 21:27761454 ENST00000421771.1 AP001596.6 SGBS	1,	SGBS2 4:157602815 ENST00000512609.1 RP11-171N4.4 SGBS	1,	SGBS2
21:15917663 ENST00000400566.5 SAMSN1 Tissue	1 21:30722954 ENST00000504298.1 BACH1-IT1 SGBS	1,	SGBS2 4:3366605 ENST00000338806.4 RGS12 SGBS	1,	SGBS2
21:15917680 ENST00000619120.4 SAMSN1 Tissue	1 21:35827534 ENST00000408471.1 SNORA11 SGBS	1,	SGBS2 4:74859495 ENST00000296027.4 CXCL5 SGBS	1,	SGBS2
21:29326239 ENST00000433344.1 AJ006995.3 Tissue	1,	Tissue	3 21:40297103 ENST00000623098.3 AF064858.6 SGBS	1,	SGBS2 4:81182752 ENST00000312465.11 FGF5 SGBS	1,	SGBS2
21:36420594 ENST00000437180.5 RUNX1 Tissue	1 21:40297200 ENST00000613045.1 AF064858.6 SGBS	1,	SGBS2 4:81182792 ENST00000456523.3 FGF5 SGBS	1,	SGBS2
21:36420640 ENST00000300305.7 RUNX1 Tissue	1 2:167996464 ENST00000525330.1 XIRP2-AS1 SGBS	1,	SGBS2 5:10474482 ENST00000416930.2 LINC01513 SGBS	1,	SGBS2
2:138858453 ENST00000446520.1 AC069394.1 Tissue	1,	Tissue	2,	Tissue	3 2:175651655 ENST00000416004.1 AC018890.4 SGBS	1,	SGBS2 5:111328160 ENST00000450761.6 NREP SGBS	1,	SGBS2
21:39869399 ENST00000453032.6 ERG Tissue	1,	Tissue	2,	Tissue	3 2:197123747 ENST00000430904.1 AC020571.3 SGBS	1,	SGBS2 5:112819526 ENST00000408903.6 MCC SGBS	1,	SGBS2
21:39869406 ENST00000288319.11 ERG Tissue	1,	Tissue	2,	Tissue	3 2:197123837 ENST00000433933.1 AC020571.3 SGBS	1,	SGBS2 5:121460207 ENST00000296600.4 ZNF474 SGBS	1,	SGBS2
2:143885882 ENST00000295095.10 ARHGAP15 Tissue	1 2:207077351 ENST00000621141.4 GPR1 SGBS	1,	SGBS2 5:127868295 ENST00000619499.4 FBN2 SGBS	1,	SGBS2
21:44898413 ENST00000441283.1 LINC00313 Tissue	1,	Tissue	2,	Tissue	3 2:208117975 ENST00000432413.2 AC007879.5 SGBS	1,	SGBS2 5:127868513 ENST00000508989.5 FBN2 SGBS	1,	SGBS2
21:48024120
ENST00000291700.8,EN
ST00000367071.4 S100B Tissue	1,	Tissue	2,	Tissue	3 22:19867686 ENST00000485358.5 TXNRD2 SGBS	1,	SGBS2 5:127868734 ENST00000262464.8 FBN2 SGBS	1,	SGBS2
2:154727425 ENST00000392825.7 GALNT13 Tissue	1,	Tissue	2,	Tissue	3 22:19867891 ENST00000462330.5 TXNRD2 SGBS	1,	SGBS2 5:127868915 ENST00000620257.1 FBN2 SGBS	1,	SGBS2
2:158299653 ENST00000264192.7 CYTIP Tissue	1 2:220324976 ENST00000396686.1 SPEG SGBS	1,	SGBS2 5:140863687 ENST00000252087.2 PCDHGC5 SGBS	1,	SGBS2
2:204570197 ENST00000374481.7 CD28 Tissue	1 2:220325106 ENST00000396689.2 SPEG SGBS	1,	SGBS2 5:140863733 ENST00000610789.1 PCDHGC5 SGBS	1,	SGBS2
2:204570246 ENST00000458610.6 CD28 Tissue	1 2:223162464 ENST00000409828.7 PAX3 SGBS	1,	SGBS2 5:171981016 ENST00000517916.1 CTB-54I1.1 SGBS	1,	SGBS2
2:204570270 ENST00000324106.8 CD28 Tissue	1 2:223162470 ENST00000350526.8 PAX3 SGBS	1,	SGBS2 5:19881380 ENST00000506372.5 CDH18 SGBS	1,	SGBS2
2:209223437 ENST00000617735.4 PTH2R Tissue	1,	Tissue	2 2:223162583 ENST00000258387.5 PAX3 SGBS	1,	SGBS2 5:19983293 ENST00000502796.5 CDH18 SGBS	1,	SGBS2
22:18246024 ENST00000583102.1 MIR3198-1 Tissue	1 2:223162613 ENST00000409551.7 PAX3 SGBS	1,	SGBS2 5:19983315 ENST00000511273.1 CDH18 SGBS	1,	SGBS2
2:219124737
ENST00000519574.1,EN
ST00000522678.5 GPBAR1 Tissue	1,	Tissue	2,	Tissue	3 2:223162699 ENST00000392069.6 PAX3 SGBS	1,	SGBS2 5:19983338 ENST00000382275.5 CDH18 SGBS	1,	SGBS2
2:219124756 ENST00000521462.1 GPBAR1 Tissue	1,	Tissue	2,	Tissue	3 2:223162714
ENST00000336840.10
,ENST00000344493.8,






2:219245751 ENST00000233202.10 SLC11A1 Tissue	1 22:24911475 ENST00000432032.1 AP000355.2 SGBS	1,	SGBS2 5:41789684 ENST00000510634.5 OXCT1 SGBS	1,	SGBS2
2:231089444 ENST00000420434.7 SP140 Tissue	1 2:227049086 ENST00000423838.1 AC068138.1 SGBS	1,	SGBS2 5:72739186 ENST00000615637.1 FOXD1 SGBS	1,	SGBS2
2:231089445 ENST00000392045.7 SP140 Tissue	1 2:228734769 ENST00000373666.6 DAW1 SGBS	1,	SGBS2 5:75914237 ENST00000504899.1 F2RL2 SGBS	1,	SGBS2
2:231089456 ENST00000417495.7 SP140 Tissue	1 2:228735322 ENST00000309931.2 DAW1 SGBS	1,	SGBS2 5:75914258 ENST00000296641.4 F2RL2 SGBS	1,	SGBS2
2:231089459 ENST00000343805.10 SP140 Tissue	1 22:29426463 ENST00000325660.3 ZNRF3-AS1 SGBS	1,	SGBS2 5:95540930 ENST00000384270.1 RNU6-524P SGBS	1,	SGBS2
2:231089478 ENST00000373645.3 SP140 Tissue	1 2:231772566 ENST00000454890.1 AC012507.4 SGBS	1,	SGBS2 6:132401223 ENST00000430428.1 RP3-523C21.2 SGBS	1,	SGBS2
22:37256029
ENST00000248899.10,E
NST00000397147.6 NCF4 Tissue	1 2:239035030 ENST00000409506.1 ESPNL SGBS	1,	SGBS2 6:150341606 ENST00000367341.5 RAET1L SGBS	1,	SGBS2
22:37308669 ENST00000403662.7 CSF2RB Tissue	1 22:40923136 ENST00000516315.1 AL031594.1 SGBS	1,	SGBS2 6:150341667 ENST00000286380.2 RAET1L SGBS	1,	SGBS2
22:37308674 ENST00000262825.9 CSF2RB Tissue	1 2:38373556 ENST00000362733.1 RNU6-951P SGBS	1,	SGBS2 6:166396401 ENST00000581850.1 LINC00473 SGBS	1,	SGBS2
22:50050077 ENST00000405854.5 C22orf34 Tissue	1,	Tissue	2,	Tissue	3 2:42251441 ENST00000451514.1 AC013480.2 SGBS	1,	SGBS2 6:166396409 ENST00000444465.1 LINC00473 SGBS	1,	SGBS2
22:50050151 ENST00000414287.5 C22orf34 Tissue	1,	Tissue	2,	Tissue	3 2:70913273 ENST00000457851.1 AC007395.3 SGBS	1,	SGBS2 6:166396478 ENST00000584179.1 LINC00473 SGBS	1,	SGBS2
2:32488948 ENST00000402280.5 NLRC4 Tissue	1 2:75144274 ENST00000435984.1 LINC01291 SGBS	1,	SGBS2 6:166396535 ENST00000584911.1 LINC00473 SGBS	1,	SGBS2
2:43328828 ENST00000434020.1 AC093609.1 Tissue	1,	Tissue	2,	Tissue	3 3:11177778 ENST00000438284.2 HRH1 SGBS	1,	SGBS2 6:28758811 ENST00000577570.1 AL662890.3 SGBS	1,	SGBS2
2:50200292 ENST00000635519.1 NRXN1 Tissue	1,	Tissue	2,	Tissue	3 3:113932159 ENST00000481773.1 RP11-553L6.2 SGBS	1,	SGBS2 6:5049656 ENST00000606227.1 RP11-428J1.4 SGBS	1,	SGBS2
2:50200336 ENST00000412315.5 NRXN1 Tissue	1,	Tissue	2,	Tissue	3 3:113932237 ENST00000493033.1 RP11-553L6.2 SGBS	1,	SGBS2 6:56502657 ENST00000518935.5 DST SGBS	1,	SGBS2
2:50200340 ENST00000378262.7 NRXN1 Tissue	1,	Tissue	2,	Tissue	3 3:115341170 ENST00000305124.10 GAP43 SGBS	1,	SGBS2 6:56502693 ENST00000370765.10 DST SGBS	1,	SGBS2
2:68591304 ENST00000234313.7 PLEK Tissue	1 3:115341356 ENST00000393780.3 GAP43 SGBS	1,	SGBS2 6:56502793 ENST00000244364.10 DST SGBS	1,	SGBS2
2:69000932
ENST00000409030.7,EN
ST00000409220.5 ARHGAP25 Tissue	1,	Tissue	2,	Tissue	3 3:11609397 ENST00000424529.6 VGLL4 SGBS	1,	SGBS2 7:114866408 ENST00000419883.1 LINC01392 SGBS	1,	SGBS2
2:69001071 ENST00000497079.5 ARHGAP25 Tissue	1,	Tissue	2,	Tissue	3 3:120625918 ENST00000273666.10 STXBP5L SGBS	1,	SGBS2 7:137023519 ENST00000393083.2 PTN SGBS	1,	SGBS2
2:7217010
ENST00000415520.5,EN
ST00000428379.1 AC019048.1 Tissue	1,	Tissue	2,	Tissue	3 3:120626051 ENST00000471454.5 STXBP5L SGBS	1,	SGBS2 7:137023610 ENST00000348225.6 PTN SGBS	1,	SGBS2
2:9245721 ENST00000565044.1 RP11-734K21.5 Tissue	1,	Tissue	2,	Tissue	3 3:120626135 ENST00000472879.5 STXBP5L SGBS	1,	SGBS2 7:143627258 ENST00000408955.2 OR2F2 SGBS	1,	SGBS2
3:111851097 ENST00000460387.6 GCSAM Tissue	1 3:120626160
ENST00000492541.5,E
NST00000497029.5 STXBP5L SGBS	1,	SGBS2 7:224556 ENST00000514988.1 AC145676.2 SGBS	1,	SGBS2
3:111851100 ENST00000484193.5 GCSAM Tissue	1 3:141084978 ENST00000507698.1 RP11-438D8.2 SGBS	1,	SGBS2 7:23431064 ENST00000390962.1 SNORD65 SGBS	1,	SGBS2
3:111851151 ENST00000308910.8 GCSAM Tissue	1 3:146670864 ENST00000515991.1 U3 SGBS	1,	SGBS2 7:30003682 ENST00000631335.1 SCRN1 SGBS	1,	SGBS2
3:128293928 ENST00000356020.2 LINC01565 Tissue	3 3:155392827
ENST00000340059.11
,ENST00000447496.6 PLCH1 SGBS	1,	SGBS2 7:30003886 ENST00000409497.5 SCRN1 SGBS	1,	SGBS2
3:150995254 ENST00000309170.7 P2RY14 Tissue	1 3:155393204 ENST00000494598.5 PLCH1 SGBS	1,	SGBS2 7:50855665 ENST00000403097.5 GRB10 SGBS	1,	SGBS2
3:167587764 ENST00000470523.2 RP11-298O21.3 Tissue	1,	Tissue	2,	Tissue	3 3:178135910 ENST00000614557.1 RP11-385J1.3 SGBS	1,	SGBS2 7:50856132 ENST00000402497.5 GRB10 SGBS	1,	SGBS2
3:178983758 ENST00000349697.2 KCNMB3 Tissue	1,	Tissue	2,	Tissue	3 3:178135988 ENST00000455307.5 LINC01014 SGBS	1,	SGBS2 7:50856158 ENST00000335866.7 GRB10 SGBS	1,	SGBS2
3:178983789 ENST00000497599.5 KCNMB3 Tissue	1,	Tissue	2,	Tissue	3 3:183265522 ENST00000491676.1 KLHL6-AS1 SGBS	1,	SGBS2 7:75396574 ENST00000005180.8 CCL26 SGBS	1,	SGBS2
3:183272476 ENST00000341319.7 KLHL6 Tissue	1,	Tissue	2,	Tissue	3 3:187663008 ENST00000413056.1 RP11-44H4.1 SGBS	1,	SGBS2 7:75711761 ENST00000515989.1 RNU6-863P SGBS	1,	SGBS2
3:186559478 ENST00000320741.6 ADIPOQ Tissue	1,	Tissue	2,	Tissue	3 3:21983057 ENST00000448980.5 ZNF385D-AS2 SGBS	1,	SGBS2 8:102133385 ENST00000524369.1 KB-1460A1.1 SGBS	1,	SGBS2
3:186559492 ENST00000444204.2 ADIPOQ Tissue	1,	Tissue	2,	Tissue	3 3:52881568 ENST00000624222.1 RP11-894J14.2 SGBS	1,	SGBS2 8:125278923 ENST00000517482.1 RP11-383J24.1 SGBS	1,	SGBS2
3:18786235 ENST00000453361.1 SATB1-AS1 Tissue	1 3:66118284 ENST00000354883.10 SLC25A26 SGBS	1,	SGBS2 8:16983689 ENST00000513892.2 RP11-468H14.2 SGBS	1,	SGBS2
3:40806697 ENST00000412811.1 RP11-761N21.1 Tissue	3 4:100064426 ENST00000505590.5 ADH4 SGBS	1,	SGBS2 8:18739543 ENST00000523619.5 PSD3 SGBS	1,	SGBS2
3:56949498 ENST00000496106.5 ARHGEF3 Tissue	1,	Tissue	2,	Tissue	3 4:100064431 ENST00000629236.2 ADH4 SGBS	1,	SGBS2 8:32618642 ENST00000607314.1 RP11-1002K11.1 SGBS	1,	SGBS2
3:9920934 ENST00000423850.5 CIDEC Tissue	1,	Tissue	2,	Tissue	3 4:100064447
ENST00000265512.11
,ENST00000508393.5 ADH4 SGBS	1,	SGBS2 8:37346430 ENST00000522718.5 LINC01605 SGBS	1,	SGBS2
3:9920937 ENST00000618572.4 CIDEC Tissue	1,	Tissue	2,	Tissue	3 4:113193471 ENST00000610220.1 RP11-73K9.3 SGBS	1,	SGBS2 8:40750343 ENST00000297737.10 ZMAT4 SGBS	1,	SGBS2
4:100241555
ENST00000305046.12,E
NST00000625860.2 ADH1B Tissue	2 4:119273157 ENST00000296498.3 PRSS12 SGBS	1,	SGBS2 8:40750351 ENST00000315769.11 ZMAT4 SGBS	1,	SGBS2
4:100241557 ENST00000506651.5 ADH1B Tissue	2 4:129521554 ENST00000487657.2 RP11-184M15.2 SGBS	1,	SGBS2 8:41650139
ENST00000289734.11
,ENST00000347528.8 ANK1 SGBS	1,	SGBS2
4:123804866 ENST00000609680.1 RP11-170N16.3 Tissue	1,	Tissue	2,	Tissue	3 4:145955283 ENST00000410662.1 RN7SKP235 SGBS	1,	SGBS2 8:68653577 ENST00000518549.1 CPA6 SGBS	1,	SGBS2
4:15428537 ENST00000502344.5 RP11-665G4.1 Tissue	1,	Tissue	2,	Tissue	3 4:154177554 ENST00000482578.2 TRIM2 SGBS	1,	SGBS2 8:68653579 ENST00000297770.8 CPA6 SGBS	1,	SGBS2
4:185725941 ENST00000513317.5 ACSL1 Tissue	1,	Tissue	2,	Tissue	3 4:157606815 ENST00000512609.1 RP11-171N4.4 SGBS	1,	SGBS2 8:69532693 ENST00000325233.3 C8orf34 SGBS	1,	SGBS2
4:8320902 ENST00000509453.1 RP11-774O3.2 Tissue	1,	Tissue	2,	Tissue	3 4:3370605 ENST00000338806.4 RGS12 SGBS	1,	SGBS2 8:70373858
ENST00000260128.8,
ENST00000458141.6 SULF1 SGBS	1,	SGBS2
4:88243037 ENST00000302219.10 HSD17B13 Tissue	1,	Tissue	3 4:74863495 ENST00000296027.4 CXCL5 SGBS	1,	SGBS2 8:74263695 ENST00000514599.5 RDH10-AS1 SGBS	1,	SGBS2
4:88243057 ENST00000328546.4 HSD17B13 Tissue	1,	Tissue	3 4:81186752 ENST00000312465.11 FGF5 SGBS	1,	SGBS2 9:102126195 ENST00000605377.5 NAMA SGBS	1,	SGBS2
5:160364632 ENST00000518580.5 RP11-109J4.1 Tissue	1,	Tissue	2,	Tissue	3 4:81186792 ENST00000456523.3 FGF5 SGBS	1,	SGBS2 9:116322233 ENST00000342620.9 RGS3 SGBS	1,	SGBS2
5:180466224
ENST00000327705.13,E
NST00000376841.6 BTNL9 Tissue	1,	Tissue	2,	Tissue	3 5:10478482 ENST00000416930.2 LINC01513 SGBS	1,	SGBS2 9:119046047 ENST00000438048.1 PAPPA-AS2 SGBS	1,	SGBS2
5:180466265 ENST00000515271.1 BTNL9 Tissue	1,	Tissue	2,	Tissue	3 5:111332160 ENST00000450761.6 NREP SGBS	1,	SGBS2 9:125160184 ENST00000439471.2 RP11-542K23.10 SGBS	1,	SGBS2
5:23506723 ENST00000296682.3 PRDM9 Tissue	1,	Tissue	3 5:112823526 ENST00000408903.6 MCC SGBS	1,	SGBS2 9:132510325 ENST00000340607.4 PTGES SGBS	1,	SGBS2
5:36724274 ENST00000510740.1 CTD-2353F22.1 Tissue	1,	Tissue	3 5:121464207 ENST00000296600.4 ZNF474 SGBS	1,	SGBS2 9:132929856 ENST00000372398.5 NCS1 SGBS	1,	SGBS2
5:36724277 ENST00000512329.1 CTD-2353F22.1 Tissue	1,	Tissue	3 5:127872295 ENST00000619499.4 FBN2 SGBS	1,	SGBS2 9:21554667 ENST00000304425.3 MIR31HG SGBS	1,	SGBS2
5:36724296 ENST00000508745.1 CTD-2353F22.1 Tissue	1,	Tissue	3 5:127872513 ENST00000508989.5 FBN2 SGBS	1,	SGBS2 9:32640023 ENST00000413291.1 RP11-555J4.3 SGBS	1,	SGBS2
5:38447357 ENST00000514476.1 EGFLAM Tissue	1,	Tissue	2,	Tissue	3 5:127872734 ENST00000262464.8 FBN2 SGBS	1,	SGBS2 9:71814926 ENST00000535702.5 TJP2 SGBS	1,	SGBS2
5:42547144 ENST00000618088.4 GHR Tissue	1,	Tissue	3 5:127872915 ENST00000620257.1 FBN2 SGBS	1,	SGBS2 9:71815077 ENST00000539225.1 TJP2 SGBS	1,	SGBS2
5:42547314 ENST00000612382.4 GHR Tissue	1,	Tissue	3 5:135393537 ENST00000508076.5 TGFBI SGBS	1,	SGBS2 X:40117169 ENST00000452690.1 RP11-320G24.1 SGBS	1,	SGBS2
5:42810993
ENST00000507920.5,EN
ST00000511224.5 SEPP1 Tissue	1,	Tissue	2,	Tissue	3 5:140704776 ENST00000606901.1 AC005618.6 SGBS	1,	SGBS2 X:51234447 ENST00000375992.3 NUDT11 SGBS	1,	SGBS2
5:42811180 ENST00000514985.5 SEPP1 Tissue	1,	Tissue	2,	Tissue	3 5:140704806 ENST00000606674.1 AC005618.6 SGBS	1,	SGBS2 X:77909824 ENST00000321110.1 ZCCHC5 SGBS	1,	SGBS2
5:55411777 ENST00000434982.2 ANKRD55 Tissue	1 5:140867687 ENST00000252087.2 PCDHGC5 SGBS	1,	SGBS2 X:96867257 ENST00000445414.1 DIAPH2-AS1 SGBS	1,	SGBS2
5:59316075 ENST00000502993.1 CTD-2254N19.1 Tissue	1 5:140867733 ENST00000610789.1 PCDHGC5 SGBS	1,	SGBS2
5:60932534 ENST00000507461.1 C5orf64 Tissue	1,	Tissue	2,	Tissue	3 5:141999906 ENST00000359370.10 FGF1 SGBS	1,	SGBS2
5:60932635 ENST00000505642.5 C5orf64 Tissue	1,	Tissue	2,	Tissue	3 5:167717655 ENST00000265293.8 WWC1 SGBS	1,	SGBS2
5:7325176 ENST00000512746.1 RP11-404K5.4 Tissue	1,	Tissue	2,	Tissue	3 5:167718154 ENST00000521089.5 WWC1 SGBS	1,	SGBS2
5:76434073 ENST00000515356.2 ZBED3-AS1 Tissue	1,	Tissue	2,	Tissue	3 5:171985016 ENST00000517916.1 CTB-54I1.1 SGBS	1,	SGBS2
6:107831639 ENST00000441532.5 RP1-67A8.3 Tissue	1,	Tissue	2,	Tissue	3 5:19885380 ENST00000506372.5 CDH18 SGBS	1,	SGBS2
6:107831924 ENST00000437040.1 RP1-67A8.3 Tissue	1,	Tissue	2,	Tissue	3 5:19987293 ENST00000502796.5 CDH18 SGBS	1,	SGBS2
6:11381580 ENST00000504387.5 NEDD9 Tissue	1 5:19987315 ENST00000511273.1 CDH18 SGBS	1,	SGBS2
6:134860129 ENST00000606039.1 RP11-557H15.4 Tissue	1,	Tissue	2,	Tissue	3 5:19987338 ENST00000382275.5 CDH18 SGBS	1,	SGBS2






6:154676899 ENST00000265198.8 IPCEF1 Tissue	1 5:41793684 ENST00000510634.5 OXCT1 SGBS	1,	SGBS2
6:15994174 ENST00000451285.1 RP11-401E14.2 Tissue	1,	Tissue	2,	Tissue	3 5:72743186 ENST00000615637.1 FOXD1 SGBS	1,	SGBS2
6:166187673 ENST00000431017.1 RP11-252P19.2 Tissue	1,	Tissue	2,	Tissue	3 5:75918237 ENST00000504899.1 F2RL2 SGBS	1,	SGBS2
6:166800623 ENST00000623222.1 RP1-168L15.6 Tissue	1,	Tissue	2,	Tissue	3 5:75918258 ENST00000296641.4 F2RL2 SGBS	1,	SGBS2
6:31147507 ENST00000441888.7 POU5F1 Tissue	1,	Tissue	2,	Tissue	3 5:95544930 ENST00000384270.1 RNU6-524P SGBS	1,	SGBS2
6:32190843 ENST00000375023.3 NOTCH4 Tissue	1,	Tissue	3 6:132405223 ENST00000430428.1 RP3-523C21.2 SGBS	1,	SGBS2
6:32556581 ENST00000611060.4 HLA-DRB1 Tissue	3 6:150345606 ENST00000367341.5 RAET1L SGBS	1,	SGBS2
6:32556624 ENST00000360004.5 HLA-DRB1 Tissue	3 6:150345667 ENST00000286380.2 RAET1L SGBS	1,	SGBS2
6:32633428 ENST00000399082.7 HLA-DQB1 Tissue	2,	Tissue	3 6:166400401 ENST00000581850.1 LINC00473 SGBS	1,	SGBS2




Table 24: GWAS loci used in GREGOR enrichment analyses
 
6:32633460 ENST00000374943.8 HLA-DQB1 Tissue	2,	Tissue	3 6:166400478 ENST00000584179.1 LINC00473 SGBS	1,	SGBS2
6:32633470 ENST00000434651.6 HLA-DQB1 Tissue	2,	Tissue	3 6:166400535 ENST00000584911.1 LINC00473 SGBS	1,	SGBS2
6:32635159 ENST00000399084.5 HLA-DQB1 Tissue	2,	Tissue	3 6:28762811 ENST00000577570.1 AL662890.3 SGBS	1,	SGBS2
6:32783824 ENST00000438763.6 HLA-DOB Tissue	1 6:31081607 ENST00000259881.9 PSORS1C1 SGBS	1,	SGBS2
6:46870207 ENST00000451135.1 RP3-365O12.2 Tissue	3 6:41884263 ENST00000384641.1 Y_RNA SGBS	1,	SGBS2
6:62995131 ENST00000281156.4 KHDRBS2 Tissue	1,	Tissue	2,	Tissue	3 6:5053656 ENST00000606227.1 RP11-428J1.4 SGBS	1,	SGBS2
6:6587340 ENST00000379953.6 LY86 Tissue	1,	Tissue	3 6:56506657 ENST00000518935.5 DST SGBS	1,	SGBS2
6:74103470 ENST00000370336.4 DDX43 Tissue	1,	Tissue	2,	Tissue	3 6:56506693 ENST00000370765.10 DST SGBS	1,	SGBS2
6:74103815 ENST00000370363.5 OOEP Tissue	1,	Tissue	2,	Tissue	3 6:56506793 ENST00000244364.10 DST SGBS	1,	SGBS2
7:139527951 ENST00000414508.6 TBXAS1 Tissue	1 6:71947300 ENST00000612512.1 RP11-154D6.1 SGBS	1,	SGBS2
7:139528022 ENST00000448866.5 TBXAS1 Tissue	1 7:114870408 ENST00000419883.1 LINC01392 SGBS	1,	SGBS2
7:139528052
ENST00000455353.5,EN
ST00000458722.5 TBXAS1 Tissue	1 7:137027519 ENST00000393083.2 PTN SGBS	1,	SGBS2
7:139528062 ENST00000411653.5 TBXAS1 Tissue	1 7:137027610 ENST00000348225.6 PTN SGBS	1,	SGBS2
7:150037748 ENST00000482669.1 RARRES2 Tissue	1,	Tissue	2,	Tissue	3 7:142510083 ENST00000417977.2 TRBV30 SGBS	1,	SGBS2
7:150037762 ENST00000223271.7 RARRES2 Tissue	1,	Tissue	2,	Tissue	3 7:143631258 ENST00000408955.2 OR2F2 SGBS	1,	SGBS2
7:150037859 ENST00000563946.1 RP4-584D14.7 Tissue	1,	Tissue	2,	Tissue	3 7:228556 ENST00000514988.1 AC145676.2 SGBS	1,	SGBS2
7:150146717 ENST00000307271.3 GIMAP8 Tissue	1,	Tissue	2,	Tissue	3 7:23435064 ENST00000390962.1 SNORD65 SGBS	1,	SGBS2
7:150263364 ENST00000255945.3 GIMAP4 Tissue	1,	Tissue	3 7:30007682 ENST00000631335.1 SCRN1 SGBS	1,	SGBS2
7:150263456 ENST00000461940.5 GIMAP4 Tissue	1,	Tissue	3 7:30007886 ENST00000409497.5 SCRN1 SGBS	1,	SGBS2
7:150412644 ENST00000307194.5 GIMAP1 Tissue	1,	Tissue	2,	Tissue	3 7:30959914 ENST00000441328.6 AQP1 SGBS	1,	SGBS2
7:150412755 ENST00000611999.4 GIMAP1-GIMAP5 Tissue	1,	Tissue	2,	Tissue	3 7:30960048 ENST00000409899.5 AQP1 SGBS	1,	SGBS2
7:150418340 ENST00000498181.6 GIMAP5 Tissue	1,	Tissue	2,	Tissue	3 7:30960104 ENST00000409611.1 AQP1 SGBS	1,	SGBS2
7:153108318 ENST00000454441.2 LINC01287 Tissue	2 7:50859665 ENST00000403097.5 GRB10 SGBS	1,	SGBS2
7:157646276 ENST00000438047.1 AC011899.9 Tissue	1,	Tissue	3 7:50860132 ENST00000402497.5 GRB10 SGBS	1,	SGBS2
7:30600131 ENST00000578293.6 AC005154.6 Tissue	1 7:50860158 ENST00000335866.7 GRB10 SGBS	1,	SGBS2
7:37392271 ENST00000442504.5 ELMO1 Tissue	1,	Tissue	2,	Tissue	3 7:75400574 ENST00000005180.8 CCL26 SGBS	1,	SGBS2









8.4,ENST00000615491.4 IKZF1 Tissue	1 8:102137385 ENST00000524369.1 KB-1460A1.1 SGBS	1,	SGBS2
7:57471422 ENST00000624231.1 RP11-114G11.4 Tissue	1,	Tissue	2,	Tissue	3 8:125282923 ENST00000517482.1 RP11-383J24.1 SGBS	1,	SGBS2
7:63360200 ENST00000450544.1 RP11-340I6.8 Tissue	1,	Tissue	2,	Tissue	3 8:129439161 ENST00000520206.5 LINC00824 SGBS	1,	SGBS2
7:63360445 ENST00000585312.1 AC092634.1 Tissue	1,	Tissue	2,	Tissue	3 8:16987689 ENST00000513892.2 RP11-468H14.2 SGBS	1,	SGBS2
7:63386213 ENST00000582948.1 AC092634.2 Tissue	1,	Tissue	2,	Tissue	3 8:18743543 ENST00000523619.5 PSD3 SGBS	1,	SGBS2
7:63504820
ENST00000456806.2,EN
ST00000550760.3 ZNF727 Tissue	1,	Tissue	2,	Tissue	3 8:32622642 ENST00000607314.1 RP11-1002K11.1 SGBS	1,	SGBS2




00000544133.5 CD36 Tissue	1,	Tissue	2,	Tissue	3 8:40754343 ENST00000297737.10 ZMAT4 SGBS	1,	SGBS2
7:80266991
ENST00000394788.7,EN
ST00000447544.6 CD36 Tissue	1,	Tissue	2,	Tissue	3 8:40754351 ENST00000315769.11 ZMAT4 SGBS	1,	SGBS2
8:101314486 ENST00000519449.5 RNF19A Tissue	1,	Tissue	2 8:41654139
ENST00000289734.11
,ENST00000347528.8 ANK1 SGBS	1,	SGBS2
8:112387867 ENST00000521904.5 RP11-1101K5.1 Tissue	1,	Tissue	2,	Tissue	3 8:68657577 ENST00000518549.1 CPA6 SGBS	1,	SGBS2
8:112387891 ENST00000521753.5 RP11-1101K5.1 Tissue	1,	Tissue	2,	Tissue	3 8:68657579 ENST00000297770.8 CPA6 SGBS	1,	SGBS2
8:144294067 ENST00000622500.1 GPIHBP1 Tissue	1,	Tissue	2,	Tissue	3 8:69536693 ENST00000325233.3 C8orf34 SGBS	1,	SGBS2
8:22784420 ENST00000256404.7 PEBP4 Tissue	1,	Tissue	3 8:70377858
ENST00000260128.8,E
NST00000458141.6 SULF1 SGBS	1,	SGBS2
8:27467873 ENST00000523500.5 CLU Tissue	1,	Tissue	2,	Tissue	3 8:74267695 ENST00000514599.5 RDH10-AS1 SGBS	1,	SGBS2
8:27467947 ENST00000405140.7 CLU Tissue	1,	Tissue	2,	Tissue	3 9:102130195 ENST00000605377.5 NAMA SGBS	1,	SGBS2
8:40009973 ENST00000315792.4 C8orf4 Tissue	1,	Tissue	2,	Tissue	3 9:116326233 ENST00000342620.9 RGS3 SGBS	1,	SGBS2
8:56432535 ENST00000522918.1 RP11-628E19.2 Tissue	2,	Tissue	3 9:119050047 ENST00000438048.1 PAPPA-AS2 SGBS	1,	SGBS2
8:61879333 ENST00000525556.1 AC022182.3 Tissue	1,	Tissue	3 9:125164184 ENST00000439471.2 RP11-542K23.10 SGBS	1,	SGBS2
8:74963574 ENST00000519323.1 RP11-6I2.3 Tissue	1 9:132514325 ENST00000340607.4 PTGES SGBS	1,	SGBS2
8:93680115 ENST00000521307.1 RP11-100L22.1 Tissue	1,	Tissue	2,	Tissue	3 9:132933856 ENST00000372398.5 NCS1 SGBS	1,	SGBS2
9:116262706
ENST00000343817.9,EN
ST00000394646.7 RGS3 Tissue	1,	Tissue	3 9:21558667 ENST00000304425.3 MIR31HG SGBS	1,	SGBS2
9:130523696 ENST00000429553.5 SH2D3C Tissue	1,	Tissue	2,	Tissue	3 9:32644023 ENST00000413291.1 RP11-555J4.3 SGBS	1,	SGBS2
9:133768224 ENST00000343079.1 QRFP Tissue	1 9:6565424 ENST00000516301.1 snoU13 SGBS	1,	SGBS2
9:134144879 ENST00000372269.7 FAM78A Tissue	1,	Tissue	2,	Tissue	3 9:71818926 ENST00000535702.5 TJP2 SGBS	1,	SGBS2
9:139556378 ENST00000308874.11 EGFL7 Tissue	1,	Tissue	2,	Tissue	3 9:71819077 ENST00000539225.1 TJP2 SGBS	1,	SGBS2
9:139556381 ENST00000406555.7 EGFL7 Tissue	1,	Tissue	2,	Tissue	3 X:40121169 ENST00000452690.1 RP11-320G24.1 SGBS	1,	SGBS2
9:139926461 ENST00000314412.6 FUT7 Tissue	1 X:51238447 ENST00000375992.3 NUDT11 SGBS	1,	SGBS2
9:272001 ENST00000429661.1 RP11-59O6.3 Tissue	1 X:77913824 ENST00000321110.1 ZCCHC5 SGBS	1,	SGBS2
9:66535443 ENST00000609749.1 RP11-262H14.3 Tissue	2,	Tissue	3 X:96871257 ENST00000445414.1 DIAPH2-AS1 SGBS	1,	SGBS2




9:93563208 ENST00000375747.5 SYK Tissue	1




X:50385682 ENST00000460112.3 SHROOM4 Tissue	1,	Tissue	2,	Tissue	3
X:78621855 ENST00000373298.6 ITM2A Tissue	1,	Tissue	2,	Tissue	3







Cardiovascular,outcomes 76 2049 Coronary,artery,disease,,coronary,heart,disease,,large,artery,atherosclerosis,,myocardial,infarction,,stroke
HDL,cholesterol 250 5084 HDL,cholesterol,,HDL,cholesterol:triglycerides
Blood,pressure,traits 57 2184 Diastolic,blood,pressure,,hypertension,,mean,arterial,pressure,,pulse,pressure,,systolic,blood,pressure
Body,mass,index 91 3188 Body,mass,index
Type,2,diabetes 154 3046 Type,2,diabetes
LDL,cholesterol 291 3941 LDL,cholesterol
Waist,to,hip,ratio,adjusted,for,BMI 64 1385 Waist,to,hip,ratio,adjusted,for,BMI
Insulin 31 735 Fasting,insulin,,fasting,insulin,adjusted,for,BMI
Triglycerides 159 2753 Triglycerides
Adiponectin 21 424 Adiponectin
Total,cholesterol 231 3801 Total,cholesterol
Glucose 63 1135 1,hour,glucose,,2,hour,glucose,,2,hour,glucose,adjusted,for,BMI,,fasting,glucose,,fasting,glucose,adjusted,for,BMI
GWAS,loci,are,from,the,GWAS,catalog,(www.ebi.ac.uk/gwas,,accessed,December,2016)
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Adiponectin Adipose	tissue	all	peaks 8 2.46 1.39 3.25 3.99 8.03E-04 21 38.1 424 12 2.8
Adiponectin Adipose	tissue	enhancer	peaks 5 0.82 0.88 6.07 4.76 8.66E-04 21 23.8 424 8 1.9
Adiponectin Adipose	tissue	promoter	peaks 2 1.05 0.96 1.91 0.99 2.82E-01 21 9.5 424 3 0.7
Adiponectin Roadmap	adipose	enhancers 20 5.66 1.92 3.53 7.47 4.94E-12 21 95.2 424 70 16.5
Adiponectin Roadmap	adipose	promoters 7 2.91 1.5 2.41 2.72 1.41E-02 21 33.3 424 18 4.2
Adiponectin SGBS	all	peaks 13 5.99 1.86 2.17 3.78 4.37E-04 21 61.9 424 21 5.0
Adiponectin SGBS	enhancer	peaks 9 1.28 1.07 7.06 7.22 5.78E-07 21 42.9 424 11 2.6
Adiponectin SGBS	promoter	peaks 4 1.42 1.1 2.82 2.35 4.11E-02 21 19.0 424 4 0.9
Blood	pressure	traits Adipose	tissue	all	peaks 25 10.45 2.69 2.39 5.41 9.96E-07 57 43.9 2184 36 1.6
Blood	pressure	traits Adipose	tissue	enhancer	peaks 13 3.75 1.79 3.47 5.16 2.82E-05 57 22.8 2184 11 0.5
Blood	pressure	traits Adipose	tissue	promoter	peaks 16 5.16 2.03 3.1 5.34 6.45E-06 57 28.1 2184 17 0.8
Blood	pressure	traits Roadmap	adipose	enhancers 38 19.84 3.33 1.92 5.45 1.23E-07 57 66.7 2184 162 7.4
Blood	pressure	traits Roadmap	adipose	promoters 21 11.45 2.77 1.83 3.44 1.00E-03 57 36.8 2184 51 2.3
Blood	pressure	traits SGBS	all	peaks 32 22.86 3.28 1.4 2.78 4.57E-03 57 56.1 2184 110 5.0
Blood	pressure	traits SGBS	enhancer	peaks 13 5.02 2.08 2.59 3.84 7.70E-04 57 22.8 2184 23 1.1
Blood	pressure	traits SGBS	promoter	peaks 16 6.57 2.25 2.44 4.2 1.77E-04 57 28.1 2184 19 0.9
Body	mass	index Adipose	tissue	all	peaks 19 15.31 3.16 1.24 1.17 1.56E-01 91 20.9 3188 39 1.2
Body	mass	index Adipose	tissue	enhancer	peaks 3 5.28 2.15 0.57 -1.06 9.12E-01 91 3.3 3188 4 0.1
Body	mass	index Adipose	tissue	promoter	peaks 15 7.66 2.4 1.96 3.05 4.08E-03 91 16.5 3188 27 0.8
Body	mass	index Roadmap	adipose	enhancers 33 29.62 4.11 1.11 0.82 2.40E-01 91 36.3 3188 181 5.7
Body	mass	index Roadmap	adipose	promoters 27 16.6 3.3 1.63 3.16 2.05E-03 91 29.7 3188 80 2.5
Body	mass	index SGBS	all	peaks 38 32.5 4.03 1.17 1.37 1.08E-01 91 41.8 3188 97 3.0
Body	mass	index SGBS	enhancer	peaks 9 7.58 2.51 1.19 0.56 3.42E-01 91 9.9 3188 11 0.3
Body	mass	index SGBS	promoter	peaks 15 9.7 2.67 1.55 1.98 4.13E-02 91 16.5 3188 35 1.1
Cardiometabolic	outcomes Adipose	tissue	all	peaks 26 12.91 2.92 2.01 4.47 3.49E-05 76 34.2 2049 40 2.0
Cardiometabolic	outcomes Adipose	tissue	enhancer	peaks 16 4.37 1.95 3.66 5.97 1.76E-06 76 21.1 2049 19 0.9
Cardiometabolic	outcomes Adipose	tissue	promoter	peaks 10 6.84 2.28 1.46 1.38 1.24E-01 76 13.2 2049 16 0.8
Cardiometabolic	outcomes Roadmap	adipose	enhancers 49 25.91 3.83 1.89 6.03 5.60E-09 76 64.5 2049 267 13.0
Cardiometabolic	outcomes Roadmap	adipose	promoters 21 15.41 3.09 1.36 1.81 5.34E-02 76 27.6 2049 67 3.3
Cardiometabolic	outcomes SGBS	all	peaks 39 27.49 3.65 1.42 3.15 1.54E-03 76 51.3 2049 129 6.3
Cardiometabolic	outcomes SGBS	enhancer	peaks 20 7 2.39 2.86 5.43 3.45E-06 76 26.3 2049 41 2.0
Cardiometabolic	outcomes SGBS	promoter	peaks 12 8.45 2.51 1.42 1.42 1.14E-01 76 15.8 2049 28 1.4
Glucose Adipose	tissue	all	peaks 15 8.98 2.6 1.67 2.31 2.14E-02 63 23.8 1135 21 1.9
Glucose Adipose	tissue	enhancer	peaks 5 2.97 1.65 1.68 1.23 1.71E-01 63 7.9 1135 5 0.4
Glucose Adipose	tissue	promoter	peaks 10 4.15 1.87 2.41 3.14 5.08E-03 63 15.9 1135 13 1.1
Glucose Roadmap	adipose	enhancers 36 20.22 3.52 1.78 4.48 1.43E-05 250 14.0 5084 48 0.9
Glucose Roadmap	adipose	promoters 22 10.38 2.78 2.12 4.17 1.23E-04 63 34.9 1135 40 3.5
Glucose SGBS	all	peaks 29 21.33 3.43 1.36 2.24 1.97E-02 63 46.0 1135 57 5.0
Glucose SGBS	enhancer	peaks 5 5.08 2.11 0.98 -0.04 5.85E-01 63 7.9 1135 7 0.6
Glucose SGBS	promoter	peaks 12 5.27 2.09 2.28 3.23 3.48E-03 63 19.0 1135 19 1.7
HDL	cholesterol Adipose	tissue	all	peaks 78 36.77 5.18 2.12 7.96 4.92E-13 250 31.2 5084 90 1.8
HDL	cholesterol Adipose	tissue	enhancer	peaks 42 12.34 3.33 3.4 8.92 6.17E-13 250 16.8 5084 35 0.7
HDL	cholesterol Adipose	tissue	promoter	peaks 24 17.82 3.82 1.35 1.62 7.26E-02 250 9.6 5084 36 0.7
HDL	cholesterol Roadmap	adipose	enhancers 167 79.42 6.88 2.1 12.72 3.62E-34 250 66.8 5084 720 14.2
HDL	cholesterol Roadmap	adipose	promoters 80 43.23 5.52 1.85 6.67 5.04E-10 250 32.0 5084 136 2.7
HDL	cholesterol SGBS	all	peaks 122 86.54 6.66 1.41 5.32 1.42E-07 250 48.8 5084 218 4.3
HDL	cholesterol SGBS	enhancer	peaks 35 19.21 4.07 1.82 3.88 2.73E-04 63 55.6 1135 144 12.7
HDL	cholesterol SGBS	promoter	peaks 38 23.45 4.32 1.62 3.37 1.09E-03 250 15.2 5084 59 1.2
Insulin Adipose	tissue	all	peaks 14 4.97 1.9 2.82 4.75 3.21E-05 31 45.2 735 19 2.6
Insulin Adipose	tissue	enhancer	peaks 9 1.65 1.23 5.47 5.99 1.32E-05 31 29.0 735 14 1.9
Insulin Adipose	tissue	promoter	peaks 0 NA 1.39805 NA NA NA 31 NA 735 0 NA
Insulin Roadmap	adipose	enhancers 23 10.56 2.47 2.18 5.03 1.33E-06 31 74.2 735 142 19.3
Insulin Roadmap	adipose	promoters 5 6.3 2.05 0.79 -0.63 8.08E-01 31 16.1 735 12 1.6
Insulin SGBS	all	peaks 20 11.44 2.44 1.75 3.51 5.87E-04 31 64.5 735 33 4.5
Insulin SGBS	enhancer	peaks 7 2.76 1.54 2.54 2.76 1.41E-02 31 22.6 735 11 1.5
Insulin SGBS	promoter	peaks 1 3.2 1.59 0.31 -1.39 9.73E-01 31 3.2 735 1 0.1
LDL	cholesterol Adipose	tissue	all	peaks 54 34.04 5.05 1.59 3.95 1.42E-04 291 18.6 3941 58 1.5
LDL	cholesterol Adipose	tissue	enhancer	peaks 11 11.53 3.23 0.95 -0.16 6.10E-01 291 3.8 3941 12 0.3
LDL	cholesterol Adipose	tissue	promoter	peaks 35 15.99 3.68 2.19 5.17 3.83E-06 291 12.0 3941 33 0.8
LDL	cholesterol Roadmap	adipose	enhancers 118 81.97 7.2 1.44 5 8.85E-07 291 40.2 3941 327 8.3
LDL	cholesterol Roadmap	adipose	promoters 76 42.41 5.58 1.79 6.02 1.93E-08 291 26.1 3941 138 3.5
LDL	cholesterol SGBS	all	peaks 98 82.31 6.85 1.19 2.29 1.42E-02 291 33.7 3941 180 4.6
LDL	cholesterol SGBS	enhancer	peaks 25 17.84 3.96 1.4 1.81 5.14E-02 291 8.6 3941 29 0.7
LDL	cholesterol SGBS	promoter	peaks 41 21.99 4.22 1.86 4.5 2.93E-05 291 14.1 3941 52 1.3
Total	cholesterol Adipose	tissue	all	peaks 55 32.63 4.75 1.69 4.71 8.06E-06 231 23.8 3801 56 1.5
Total	cholesterol Adipose	tissue	enhancer	peaks 10 11.07 3.14 0.9 -0.34 6.80E-01 231 4.3 3801 8 0.2
Total	cholesterol Adipose	tissue	promoter	peaks 33 15.39 3.53 2.14 4.98 6.96E-06 231 14.3 3801 34 0.9
Total	cholesterol Roadmap	adipose	enhancers 101 69.46 6.51 1.45 4.84 1.84E-06 231 43.3 3801 346 9.1
Total	cholesterol Roadmap	adipose	promoters 68 38.71 5.17 1.76 5.67 9.71E-08 231 29.4 3801 154 4.1
Total	cholesterol SGBS	all	peaks 96 73.05 6.2 1.31 3.7 1.95E-04 231 41.6 3801 194 5.1
Total	cholesterol SGBS	enhancer	peaks 25 17.04 3.81 1.47 2.09 2.98E-02 231 10.8 3801 31 0.8
Total	cholesterol SGBS	promoter	peaks 40 20.65 4.03 1.94 4.81 9.12E-06 231 17.3 3801 59 1.6
Triglycerides Adipose	tissue	all	peaks 64 27.45 4.3 2.33 8.51 1.81E-14 159 40.3 2753 57 2.1
Triglycerides Adipose	tissue	enhancer	peaks 28 9.53 2.88 2.94 6.4 7.70E-08 159 17.6 2753 22 0.8
Triglycerides Adipose	tissue	promoter	peaks 22 13.49 3.26 1.63 2.61 9.85E-03 159 13.8 2753 18 0.7
Triglycerides Roadmap	adipose	enhancers 115 54.22 5.58 2.12 10.9 3.70E-26 159 72.3 2753 390 14.2
Triglycerides Roadmap	adipose	promoters 58 31.27 4.63 1.86 5.78 5.52E-08 159 36.5 2753 88 3.2
Triglycerides SGBS	all	peaks 77 59.35 5.41 1.3 3.26 8.49E-04 159 48.4 2753 127 4.6




Table 26: GWAS loci and variants overlapping transcription factor motifs 
Triglycerides SGBS	promoter	peaks 25 17.4 3.66 1.44 2.08 3.01E-02 159 15.7 2753 26 0.9
Type	2	diabetes Adipose	tissue	all	peaks 39 22.17 3.92 1.76 4.3 5.09E-05 154 25.3 3046 48 1.6
Type	2	diabetes Adipose	tissue	enhancer	peaks 15 7.13 2.53 2.1 3.1 4.30E-03 154 9.7 3046 13 0.4
Type	2	diabetes Adipose	tissue	promoter	peaks 12 11.25 2.9 1.07 0.26 4.51E-01 154 7.8 3046 19 0.6
Type	2	diabetes Roadmap	adipose	enhancers 72 48.74 5.37 1.48 4.33 1.93E-05 154 46.8 3046 403 13.2
Type	2	diabetes Roadmap	adipose	promoters 33 26.75 4.2 1.23 1.49 8.74E-02 154 21.4 3046 86 2.8
Type	2	diabetes SGBS	all	peaks 73 50.29 5.11 1.45 4.44 1.22E-05 154 47.4 3046 170 5.6
Type	2	diabetes SGBS	enhancer	peaks 24 11.8 3.15 2.03 3.88 3.76E-04 154 15.6 3046 44 1.4
Type	2	diabetes SGBS	promoter	peaks 18 14.9 3.28 1.21 0.95 2.10E-01 154 11.7 3046 34 1.1
Waist	to	hip	ratio	adjusted	for	BMI Adipose	tissue	all	peaks 26 7.37 2.39 3.53 7.79 1.16E-10 64 40.6 1385 45 3.2
Waist	to	hip	ratio	adjusted	for	BMI Adipose	tissue	enhancer	peaks 19 2.59 1.54 7.33 10.63 6.43E-13 64 29.7 1385 32 2.3
Waist	to	hip	ratio	adjusted	for	BMI Adipose	tissue	promoter	peaks 4 3.25 1.67 1.23 0.45 4.11E-01 64 6.3 1385 6 0.4
Waist	to	hip	ratio	adjusted	for	BMI Roadmap	adipose	enhancers 44 18.03 3.38 2.44 7.69 9.42E-13 64 68.8 1385 294 21.2
Waist	to	hip	ratio	adjusted	for	BMI Roadmap	adipose	promoters 22 9.2 2.58 2.39 4.96 9.21E-06 64 34.4 1385 65 4.7
Waist	to	hip	ratio	adjusted	for	BMI SGBS	all	peaks 36 19.38 3.28 1.86 5.07 1.43E-06 64 56.3 1385 124 9.0
Waist	to	hip	ratio	adjusted	for	BMI SGBS	enhancer	peaks 25 4.09 1.89 6.12 11.09 1.15E-15 64 39.1 1385 52 3.8




















Adipose	tissue Waist	to	hip	ratio	adjusted	for	BMI 64 26 23 88.5 45 34 75.6
Adipose	tissue Body	mass	index 91 19 13 68.4 39 23 59.0
Adipose	tissue Adiponectin 21 8 6 75.0 12 6 50.0
Adipose	tissue Type	2	diabetes 154 39 28 71.8 48 28 58.3
Adipose	tissue Insulin 31 14 14 100.0 19 14 73.7
Adipose	tissue Glucose 63 15 13 86.7 21 15 71.4
Adipose	tissue HDL	cholesterol 250 78 61 78.2 90 62 68.9
Adipose	tissue LDL	cholesterol 291 54 43 79.6 58 38 65.5
Adipose	tissue Total	cholesterol 231 55 46 83.6 56 38 67.9
Adipose	tissue Triglycerides 159 64 33 51.6 57 33 57.9
Adipose	tissue Cardiovascular	outcomes 76 26 21 80.8 40 25 62.5
Adipose	tissue Blood	pressure	traits 57 25 16 64.0 36 22 61.1
Adipose	tissue All	traits 1245 345 257 74.5 371 242 65.2
SGBS Waist	to	hip	ratio	adjusted	for	BMI 64 36 33 91.7 124 71 57.3
SGBS Body	mass	index 91 38 30 78.9 97 51 52.6
SGBS Adiponectin 21 13 10 76.9 21 15 71.4
SGBS Type	2	diabetes 154 73 63 86.3 170 90 52.9
SGBS Insulin 31 20 12 60.0 33 16 48.5
SGBS Glucose 63 29 23 79.3 57 33 57.9
SGBS HDL	cholesterol 250 122 101 82.8 218 132 60.6
SGBS LDL	cholesterol 291 98 81 82.7 180 99 55.0
SGBS Total	cholesterol 231 96 77 80.2 194 108 55.7
SGBS Triglycerides 159 77 58 75.3 127 73 57.5
SGBS Cardiovascular	outcomes 76 39 39 100.0 129 74 57.4
SGBS Blood	pressure	traits 57 32 26 81.3 110 58 52.7
SGBS All	traits 1245 575 476 82.8 1123 631 56.2
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Table 27: Variants at GWAS-eQTL colocalized loci that overlap ATAC peaks 
 
 












Abdominal	aortic	aneurysm DAB2IP rs7025486 DAB2IP rs885150 rs10818578 0.254191 0.989032 16 SGBS	1,	SGBS	2
Adiponectin ARL15 rs4311394 FST rs59061738 rs255757 0.234005 0.983153 85 SGBS	1,	SGBS	2 STAT1,Stat4,ZNF410
Adiponectin ARL15 rs4311394 FST rs59061738 rs6876198 0.233905 0.983699 85 SGBS	1 Stat6
Adiponectin CDH13 rs12051272 CDH13 rs12051272 rs12051272 0.106983 N/A 9 SGBS	1,	SGBS	2 NFYA,NFYB,RREB1 RREB1
Adiponectin GNL3 rs2590838 GNL3,NEK4 rs35212380,rs7612511 rs1108842 0.472473 1 21 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Adiponectin,WHRadjBMI,HDL	cholesterol CMIP rs2925979 CMIP rs56823429 rs2925979 0.314007 N/A 2 SGBS	1,	SGBS	2 DUX4
Body	mass	index DMXL2 rs3736485 CYP19A1 rs930920 rs11070860 0.470241 0.81589 194 SGBS	1
Body	mass	index DMXL2 rs3736485 CYP19A1 rs930920 rs2278989 0.47034 0.815551 194 Tissue	1 SGBS	1,	SGBS	2
Body	mass	index DMXL2 rs3736485 CYP19A1 rs930920 rs2278990 0.47034 0.815551 194 Tissue	1 NFKB1,NFKB2 SGBS	1,	SGBS	2 NFKB1,NFKB2
Body	mass	index DMXL2 rs3736485 CYP19A1 rs930920 rs7183479 0.463694 0.82174 194 Tissue	1 SGBS	1,	SGBS	2
Body	mass	index FOXO3 rs9400239 FOXO3 rs3800228 rs4946936 0.386122 0.948583 48 SGBS	1,	SGBS	2 Tcf7




















rs9972866 rs6565173 0.436961 0.827771 87 SGBS	1,	SGBS	2 IRF1 IRF1
Body	mass	index MTCH2 rs10838738 MTCH2 rs11604825 rs2293578 0.294862 0.823474 99 SGBS	1,	SGBS	2 EWSR1-FLI1,ZNF263
Body	mass	index USP37 rs492400 PLCD4,RQCD1,ZNF142 rs4674320,rs62182125,rs832810 2:219446813 0.425156 0.995336 262 SGBS	1,	SGBS	2 FOXP1,IRF1
Body	mass	index USP37 rs492400 PLCD4,RQCD1,ZNF142 rs4674320,rs62182125,rs832810 rs2241527 0.398968 0.893145 262 Tissue	1 SGBS	1,	SGBS	2
Body	mass	index USP37 rs492400 PLCD4,RQCD1,ZNF142 rs4674320,rs62182125,rs832810 rs2556391 0.398076 0.889009 262 SGBS	1,	SGBS	2
Body	mass	index USP37 rs492400 PLCD4,RQCD1,ZNF142 rs4674320,rs62182125,rs832810 rs3731867 0.398919 0.893358 262 SGBS	1,	SGBS	2
Body	mass	index USP37 rs492400 PLCD4,RQCD1,ZNF142 rs4674320,rs62182125,rs832810 rs4674319 0.427438 0.985675 262 SGBS	1 Vdr
Body	mass	index USP37 rs492400 PLCD4,RQCD1,ZNF142 rs4674320,rs62182125,rs832810 rs4674324 0.425305 0.994729 262 SGBS	1,	SGBS	2
Body	mass	index USP37 rs492400 PLCD4,RQCD1,ZNF142 rs4674320,rs62182125,rs832810 rs500317 0.424958 0.994524 262 Tissue	1,	Tissue	2,	Tissue	3 GLIS3,ZBTB33 SGBS	1,	SGBS	2 ZBTB33
Body	mass	index USP37 rs492400 PLCD4,RQCD1,ZNF142 rs4674320,rs62182125,rs832810 rs500422 0.432546 0.966107 262 Tissue	1,	Tissue	2,	Tissue	3 IRF8,Spz1 SGBS	1,	SGBS	2 IRF8













Body	mass	index USP37 rs492400 PLCD4,RQCD1,ZNF142 rs4674320,rs62182125,rs832810 rs526897 0.398919 0.893358 262 Tissue	1,	Tissue	2,	Tissue	3
FOXP1,NFATC1,NFATC3,POU6F
2,SRY,Sox6 SGBS	1,	SGBS	2 FOXP1,SRY,Sox6
Body	mass	index USP37 rs492400 PLCD4,RQCD1,ZNF142 rs4674320,rs62182125,rs832810 rs611203 0.425007 0.993916 262 SGBS	1,	SGBS	2
Body	mass	index USP37 rs492400 PLCD4,RQCD1,ZNF142 rs4674320,rs62182125,rs832810 rs689116 0.425206 0.995539 262 SGBS	1,	SGBS	2








Cardiac	hypertrophy COL17A1 rs1320448 OBFC1,RP11-541N10.3 rs79342925 rs73329737 0.0609067 0.996543 57 SGBS	1,	SGBS	2
Cardiac	hypertrophy COL17A1 rs1320448 OBFC1,RP11-541N10.3 rs79342925 rs805702 0.0611546 0.999136 57 SGBS	1
Cardiac	hypertrophy COL17A1 rs1320448 OBFC1,RP11-541N10.3 rs79342925 rs805703 0.061105 1 57 SGBS	1,	SGBS	2
Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 17:46970081 0.458089 0.994809 116 Tissue	1,	Tissue	2,	Tissue	3 Sox1 SGBS	1,	SGBS	2 Sox1
Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 17:46970083 0.45804 0.993412 116 Tissue	1,	Tissue	2,	Tissue	3 Sox1 SGBS	1,	SGBS	2 Sox1
Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 rs12601672 0.457693 0.999201 116 SGBS	1 Zfx
Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 rs12602746 0.493155 0.866593 116 SGBS	1
Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 rs12603612 0.457693 0.999201 116 SGBS	1
Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 rs2270574 0.457693 0.999201 116 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 rs2291725 0.493056 0.866553 116 SGBS	1,	SGBS	2
Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 rs2411375 0.457693 0.999201 116 SGBS	1 SP2
Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 rs3744608 0.456602 0.994816 116 SGBS	1,	SGBS	2
GLIS2,KLF14,KLF16,NR2C2,SP3,
SP4,SP8,ZIC3,ZNF740
Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 rs4378658 0.457693 0.999201 116 SGBS	1,	SGBS	2





Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 rs62075824 0.457544 0.989822 116 SGBS	1,	SGBS	2 ZNF263
Coronary	heart	disease ATP5G1-GIP-SNF8-UBE2Z rs46522 CALCOCO2,UBE2Z rs62075846,rs9904645 rs9904645 0.456998 0.992018 116 Tissue	1,	Tissue	2,	Tissue	3 ZNF143 SGBS	1,	SGBS	2
Coronary	heart	disease CDKN2A-CDKN2B rs1333048 CDKN2B rs1333046 rs10757279 0.404821 0.989115 53 SGBS	2
Coronary	heart	disease CDKN2A-CDKN2B rs1333048 CDKN2B rs1333046 rs1333042 0.410178 0.948515 53 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1
Coronary	heart	disease CDKN2A-CDKN2B rs1333048 CDKN2B rs1333046 rs1537372 0.371987 0.8594 53 SGBS	1,	SGBS	2 RREB1,ZNF263
Coronary	heart	disease CDKN2A-CDKN2B rs1333048 CDKN2B rs1333046 rs1537373 0.410078 0.948102 53 Tissue	1,	Tissue	2,	Tissue	3 GCM2 SGBS	1,	SGBS	2
Coronary	heart	disease CDKN2A-CDKN2B rs1333048 CDKN2B rs1333046 rs2383206 0.420792 0.929841 53 SGBS	1
Coronary	heart	disease CDKN2A-CDKN2B rs1333048 CDKN2B rs1333046 rs2891168 0.422875 0.89792 53 Tissue	1
Coronary	heart	disease CDKN2A-CDKN2B rs1333048 CDKN2B rs1333046 rs4977575 0.416328 0.943139 53 SGBS	1,	SGBS	2
Coronary	heart	disease CDKN2A-CDKN2B rs1333048 CDKN2B rs1333046 rs7341786 0.42223 0.925536 53 SGBS	1,	SGBS	2 Gfi1b,MYBL2
Coronary	heart	disease LIPA rs1412444 LIPA rs1412445 rs1332328 0.402837 0.948118 8 Tissue	3 EGR2,EGR4,GCM1,GCM2,ZEB1 SGBS	1,	SGBS	2 EGR2,EGR4,GCM1,GCM2,ZEB1







Coronary	heart	disease MRAS rs2306374 MRAS rs34905952 rs9872754 0.100784 0.999453 15 SGBS	1,	SGBS	2 HIC2,Vdr
Coronary	heart	disease WDR12 rs6725887 ICA1L rs72928613 2:203736202 0.117697 0.910861 286 Tissue	1,	Tissue	2 NRF1,Tcfl5 SGBS	1,	SGBS	2 NRF1,Tcfl5
Coronary	heart	disease WDR12 rs6725887 ICA1L rs72928613 rs143035655 0.111348 0.989983 286 SGBS	1,	SGBS	2 Nr2f6(var.2),Rarb,SP2,THAP1
Coronary	heart	disease WDR12 rs6725887 ICA1L rs72928613 rs144505847 0.1111 0.990467 286 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Coronary	heart	disease WDR12 rs6725887 ICA1L rs72928613 rs149846585 0.11358 0.966107 286 Tissue	1,	Tissue	2 SP2,SP8,TFAP2A(var.2),TFAP2B SGBS	1,	SGBS	2 SP2,SP8,TFAP2A(var.2),TFAP2B
Coronary	heart	disease WDR12 rs6725887 ICA1L rs72928613 rs72932575 0.110555 0.997986 286 SGBS	1,	SGBS	2
Coronary	heart	disease WDR12 rs6725887 ICA1L rs72928613 rs72932770 0.11115 0.990971 286 Tissue	1 MEF2A,TBP SGBS	1,	SGBS	2 MEF2A,TBP
Coronary	heart	disease WDR12 rs6725887 ICA1L rs72928613 rs72932777 0.111001 0.992467 286 SGBS	1,	SGBS	2 NRF1,TP53,Zfx
Coronary	heart	disease WDR12 rs6725887 ICA1L rs72928613 rs72934512 0.110654 0.996979 286 SGBS	1,	SGBS	2
Coronary	heart	disease WDR12 rs6725887 ICA1L rs72928613 rs72936309 0.110207 0.991444 286 SGBS	1,	SGBS	2
Coronary	heart	disease WDR12 rs6725887 ICA1L rs72928613 rs75869289 0.110555 0.997986 286 SGBS	1,	SGBS	2
Coronary	heart	disease WDR12 rs6725887 ICA1L rs72928613 rs79642273 0.110455 0.996979 286 SGBS	1
Fasting	insulin-related	traits IRS1 rs2943634 IRS1 rs1515098 2:227052396 0.350461 0.989772 107 SGBS	1
FOXA1,FOXB1,FOXC1,FOXC2,R
ARA
Fasting	insulin-related	traits IRS1 rs2943634 IRS1 rs1515098 rs2943646 0.375608 0.882662 107 Tissue	2 Dux
Fasting	insulin-related	traits IRS1 rs2943634 IRS1 rs1515098 rs2943654 0.37526 0.879829 107 SGBS	1 HMBOX1,IRF2,IRF8
Fasting	insulin-related	traits IRS1 rs2943634 IRS1 rs1515098 rs2943656 0.393066 0.81567 107 SGBS	1,	SGBS	2 FOXP1,Sox3,Sox6
Fasting	insulin-related	traits PDGFC rs4691380 PDGFC rs4568281 4:157656410 0.267583 0.930021 94 SGBS	1,	SGBS	2
Fasting	insulin-related	traits PDGFC rs4691380 PDGFC rs4568281 rs10857295 0.280925 0.869658 94 SGBS	1
Fasting	insulin-related	traits PDGFC rs4691380 PDGFC rs4568281 rs6819797 0.26049 0.998456 94 SGBS	1
Glycated	hemoglobins ANK1 rs4737009 IKBKB rs4737010 rs552904 0.288215 0.897496 15 SGBS	1
Glycated	hemoglobins ANK1 rs4737009 IKBKB rs4737010 rs7461534 0.284347 0.923446 15 SGBS	1,	SGBS	2 RFX5
Glycated	hemoglobins C1orf85-CCT3-TMEM79 rs6684514 CCT3,GLMP	(C1orf85) rs12022657,rs2273832 1:156308031 0.282412 0.984018 111 Tissue	1,	Tissue	2,	Tissue	3 HSF1,HSF2,HSF4 SGBS	1,	SGBS	2 HSF1,HSF2,HSF4
Glycated	hemoglobins C1orf85-CCT3-TMEM79 rs6684514 CCT3,GLMP	(C1orf85) rs12022657,rs2273832 1:156329883 0.284446 0.990044 111 SGBS	1,	SGBS	2
Glycated	hemoglobins C1orf85-CCT3-TMEM79 rs6684514 CCT3,GLMP	(C1orf85) rs12022657,rs2273832 rs10908498 0.285537 0.999757 111 SGBS	1,	SGBS	2 ZNF143
Glycated	hemoglobins C1orf85-CCT3-TMEM79 rs6684514 CCT3,GLMP	(C1orf85) rs12022657,rs2273832 rs12132794 0.285537 0.999757 111 Tissue	1,	Tissue	3 JUN(var.2),MAF::NFE2,Nr2e3
Glycated	hemoglobins C1orf85-CCT3-TMEM79 rs6684514 CCT3,GLMP	(C1orf85) rs12022657,rs2273832 rs2075166 0.281619 0.97968 111 SGBS	1 NRF1
Glycated	hemoglobins C1orf85-CCT3-TMEM79 rs6684514 CCT3,GLMP	(C1orf85) rs12022657,rs2273832 rs2273832 0.282908 0.985945 111 SGBS	1,	SGBS	2
Glycated	hemoglobins C1orf85-CCT3-TMEM79 rs6684514 CCT3,GLMP	(C1orf85) rs12022657,rs2273832 rs2273833 0.282908 0.985945 111 SGBS	1,	SGBS	2
ID4,NHLH1,NRF1,SNAI2,TCF3,T
CF4
Glycated	hemoglobins C1orf85-CCT3-TMEM79 rs6684514 CCT3,GLMP	(C1orf85) rs12022657,rs2273832 rs28372828 0.285339 0.998784 111 SGBS	1,	SGBS	2 Pou5f1::Sox2,RFX5,Rfx1,Stat6
Glycated	hemoglobins C1orf85-CCT3-TMEM79 rs6684514 CCT3,GLMP	(C1orf85) rs12022657,rs2273832 rs3806408 0.285339 0.997812 111 SGBS	2 Nr2e3







HDL	cholesterol ANGPTL8 rs4804154 ANGPTL8 rs12463177 0.117895 0.971939 11 Tissue	3
HDL	cholesterol CETP rs1532624 CETP rs4784741 rs12720926 0.411864 0.989602 10 Tissue	2,	Tissue	3 SGBS	1,	SGBS	2




HDL	cholesterol CETP rs1532624 CETP rs4784741 rs1532625 0.413848 0.999796 10 SGBS	1,	SGBS	2




HDL	cholesterol GSK3B rs6805251 GSK3B rs334533 rs334558 0.368366 0.899155 61 Tissue	1,	Tissue	2,	Tissue	3 INSM1,NR2C2 SGBS	1,	SGBS	2
HDL	cholesterol LCAT rs2271293 GFOD2,NUTF2 rs6499143,rs7199443 rs1124324 0.169775 1 92 Tissue	1,	Tissue	3 SOX21,ZBTB7A,ZBTB7B,ZBTB7C SGBS	1,	SGBS	2 ZBTB7A,ZBTB7B,ZBTB7C
HDL	cholesterol LCAT rs2271293 GFOD2,NUTF2 rs6499143,rs7199443 rs20549 0.200278 0.814092 92 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
HDL	cholesterol LCAT rs2271293 GFOD2,NUTF2 rs6499143,rs7199443 rs56047901 0.162335 0.947686 92 SGBS	1
HDL	cholesterol LCAT rs2271293 GFOD2,NUTF2 rs6499143,rs7199443 rs58588228 0.164319 0.961546 92 SGBS	1,	SGBS	2
BHLHE22,BHLHE23,NEUROD2,
Neurog1,OLIG2,OLIG3









HDL	cholesterol MMAB-MVK rs7134594 MMAB rs3782894 rs10850358 0.460817 0.999202 57 SGBS	1 ESR2
HDL	cholesterol MMAB-MVK rs7134594 MMAB rs3782894 rs7308864 0.491072 0.831764 57 SGBS	2 JUND(var.2),Sox17
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs11538549 0.0864498 0.88805 158 Tissue	1,	Tissue	2,	Tissue	3 NR2C2,REST,ZIC3 SGBS	1,	SGBS	2 REST
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs11555809 0.0870945 0.904682 158 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs12737946 0.0856562 1 158 Tissue	1,	Tissue	2,	Tissue	3 PLAG1,RUNX1 SGBS	1,	SGBS	2 PLAG1
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs12738345 0.0856562 1 158 Tissue	1,	Tissue	2,	Tissue	3 REST,ZBTB33 SGBS	1,	SGBS	2 REST,ZBTB33
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs12742115 0.0856562 1 158 Tissue	1,	Tissue	2,	Tissue	3 SOX8 SGBS	1,	SGBS	2 SOX8
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs12760759 0.085805 0.995576 158 Tissue	1,	Tissue	2
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs17162387 0.0864498 0.88805 158 Tissue	1 ZNF410
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs34618114 0.0856562 1 158 SGBS	1,	SGBS	2 PLAG1,ZNF263,Zfx
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs35108146 0.0867473 0.884653 158 Tissue	1 SGBS	1,	SGBS	2
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs57217461 0.0856562 1 158 SGBS	1,	SGBS	2 SOX21,Sox1
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs58421016 0.0856562 1 158 SGBS	1,	SGBS	2
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs71636779 0.0856562 1 158 SGBS	1,	SGBS	2 Foxd3
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs71636780 0.0859538 0.996213 158 Tissue	1,	Tissue	2,	Tissue	3 HES5,HES7,NRF1,Zfx SGBS	1,	SGBS	2 NRF1,Zfx
HDL	cholesterol NR0B2-PIGV rs12748152 ARID1A,PIGV rs34217609,rs6656815 rs71640337 0.102024 0.824543 158 Tissue	1 SGBS	1,	SGBS	2






HDL	cholesterol PMVK-HDGF rs12145743 RRNAD1 rs3806415 rs11264533 0.323777 0.99932 18 SGBS	1,	SGBS	2
HDL	cholesterol PMVK-HDGF rs12145743 RRNAD1 rs3806415 rs12030654 0.323579 0.998414 18 SGBS	1
EGR1,INSM1,KLF16,NR2C2,Ppa
rg::Rxra,SP1,SP2,SP3,THAP1
HDL	cholesterol PMVK-HDGF rs12145743 RRNAD1 rs3806415 rs3806415 0.325017 0.969816 18 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
HDL	cholesterol PMVK-HDGF rs12145743 RRNAD1 rs3806415 rs4501833 0.323777 0.99932 18 Tissue	1,	Tissue	3 RFX2,RFX4 SGBS	1,	SGBS	2 RFX2,RFX3,RFX4,RFX5,Rfx1
HDL	cholesterol RBM5 rs2013208 RBM6 rs11130233 3:50138580 0.452187 0.977931 96 SGBS	1,	SGBS	2 PHOX2A,PROP1,Phox2b





HDL	cholesterol RBM5 rs2013208 RBM6 rs11130233 rs2252833 0.450749 0.972485 96 SGBS	1 Six3,Spz1
HDL	cholesterol RBM5 rs2013208 RBM6 rs11130233 rs2526754 0.447178 0.995191 96 Tissue	1 GLIS3 SGBS	2
HDL	cholesterol RBM5 rs2013208 RBM6 rs11130233 rs2883057 0.450749 0.972485 96 SGBS	1,	SGBS	2
HDL	cholesterol RBM5 rs2013208 RBM6 rs11130233 rs35065728 0.450749 0.972485 96 SGBS	1
HDL	cholesterol RBM5 rs2013208 RBM6 rs11130233 rs6772095 0.450699 0.972284 96 Tissue	1 SGBS	1,	SGBS	2
HDL	cholesterol STAB1 rs13326165 PBRM1 rs13326165 rs13326165 0.172453 N/A 1 SGBS	1
HDL	cholesterol STARD3 rs11869286 PGAP3,STARD3 rs11869286,rs2517951 rs1053651 0.273981 0.82125 62 SGBS	1
HDL	cholesterol STARD3 rs11869286 PGAP3,STARD3 rs11869286,rs2517951 rs2271308 0.27408 0.82166 62 Tissue	3
HDL	cholesterol STARD3 rs11869286 PGAP3,STARD3 rs11869286,rs2517951 rs2952151 0.287124 0.831459 62 SGBS	1,	SGBS	2
NR1H2::RXRA,Pparg::Rxra,RXR
G,Rxra
HDL	cholesterol STARD3 rs11869286 PGAP3,STARD3 rs11869286,rs2517951 rs881844 0.314751 0.991042 62 SGBS	1 PPARG,Znf423
HDL	cholesterol UBE2L3 rs181362 UBE2L3,YDJC rs11089620,rs12158299 rs11089620 0.324769 0.884579 91 SGBS	1,	SGBS	2 NRF1,TFAP2A(var.2)
HDL	cholesterol UBE2L3 rs181362 UBE2L3,YDJC rs11089620,rs12158299 rs140491 0.352892 0.995228 91 SGBS	1,	SGBS	2 Klf12,SP4
HDL	cholesterol UBE2L3 rs181362 UBE2L3,YDJC rs11089620,rs12158299 rs140492 0.3519 0.999565 91 SGBS	1,	SGBS	2
HDL	cholesterol UBE2L3 rs181362 UBE2L3,YDJC rs11089620,rs12158299 rs181360 0.3519 0.999565 91 SGBS	1,	SGBS	2
HDL	cholesterol UBE2L3 rs181362 UBE2L3,YDJC rs11089620,rs12158299 rs2266959 0.324769 0.885437 91 SGBS	1,	SGBS	2
HDL	cholesterol UBE2L3 rs181362 UBE2L3,YDJC rs11089620,rs12158299 rs3747093 0.341335 0.831789 91 Tissue	1,	Tissue	2,	Tissue	3 SP4,Zfx SGBS	1,	SGBS	2 SP4
HIPadjBMI KLHL31 rs7739232 KLHL31 rs113505085 6:53538019 0.0757861 0.997168 52 SGBS	2
HIPadjBMI KLHL31 rs7739232 KLHL31 rs113505085 rs75582203 0.0757861 0.997168 52 SGBS	2 CEBPA
HIPadjBMI KLHL31 rs7739232 KLHL31 rs113505085 rs76936629 0.0750918 0.991498 52 Tissue	1,	Tissue	3 SGBS	1,	SGBS	2
HIPadjBMI KLHL31 rs7739232 KLHL31 rs113505085 rs77162760 0.0751414 0.992206 52 SGBS	1,	SGBS	2 Stat6
HIPadjBMI KLHL31 rs7739232 KLHL31 rs113505085 rs77597023 0.0757861 0.997168 52 SGBS	2
HIPadjBMI KLHL31 rs7739232 KLHL31 rs113505085 rs77937059 0.0757861 0.997168 52 SGBS	2 EWSR1-FLI1
HIPadjBMI KLHL31 rs7739232 KLHL31 rs113505085 rs79823138 0.0750918 0.991498 52 Tissue	1 SGBS	1,	SGBS	2
HIPadjBMI KLHL31 rs7739232 KLHL31 rs113505085 rs80087193 0.0757861 0.997168 52 SGBS	2 ZNF263
HIPadjBMI KLHL31 rs7739232 KLHL31 rs113505085 rs80271463 0.0756373 0.999291 52 Tissue	1
HIPadjBMI VPS53 rs2034088 FAM101B,VPS53 rs10153248,rs2289620 rs2289620 0.369755 0.832991 22 SGBS	1
Intracranial	aneurysm PLCL1-BOLL rs700651 SF3B1 rs2564383 2:198540701 0.410178 0.949014 296 SGBS	1,	SGBS	2 IRF1 IRF1
Intracranial	aneurysm PLCL1-BOLL rs700651 SF3B1 rs2564383 2:198692686 0.39138 0.962402 296 SGBS	1,	SGBS	2
Intracranial	aneurysm PLCL1-BOLL rs700651 SF3B1 rs2564383 rs1116734 0.427686 0.859539 296 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Intracranial	aneurysm PLCL1-BOLL rs700651 SF3B1 rs2564383 rs4850812 0.3889 0.957302 296 Tissue	1 Hic1,NFIA,NFIX,Sox1
Intracranial	aneurysm PLCL1-BOLL rs700651 SF3B1 rs2564383 rs700674 0.39133 0.962612 296 SGBS	1,	SGBS	2
Intracranial	aneurysm PLCL1-BOLL rs700651 SF3B1 rs2564383 rs770659 0.39133 0.962201 296 SGBS	1,	SGBS	2 PAX5
Intracranial	aneurysm PLCL1-BOLL rs700651 SF3B1 rs2564383 rs787983 0.428033 0.858292 296 SGBS	1,	SGBS	2





Intracranial	aneurysm STARD13 rs9315204 KL,STARD13 rs1998728,rs614691 rs671937 0.36792 0.882484 22 SGBS	2
Intracranial	aneurysm STARD13 rs9315204 KL,STARD13 rs1998728,rs614691 rs9315204 0.344013 N/A 22 SGBS	1,	SGBS	2
Pou5f1::Sox2,TEAD1,TEAD3,TE
AD4
Intracranial	aneurysm STARD13 rs9315204 KL,STARD13 rs1998728,rs614691 rs9527098 0.355967 0.948381 22 SGBS	1
LDL	cholesterol HMGCR rs12916 HMGCR rs34341 rs1423527 0.462206 0.919682 54 SGBS	1 CEBPA
LDL	cholesterol HMGCR rs12916 HMGCR rs34341 rs2878417 0.457048 0.940258 54 SGBS	1 EWSR1-FLI1,ZNF263
LDL	cholesterol HMGCR rs12916 HMGCR rs34341 rs7703282 0.451394 0.860682 54 SGBS	1,	SGBS	2
LDL	cholesterol PLEC rs11136341 PLEC rs10107388 8:145030900 0.361075 0.918912 26 SGBS	1,	SGBS	2 INSM1,RUNX1
LDL	cholesterol PLEC rs11136341 PLEC rs10107388 8:145030903 0.350164 0.874653 26 SGBS	1,	SGBS	2 INSM1
LDL	cholesterol PLEC rs11136341 PLEC rs10107388 rs62523994 0.394554 0.801675 26 SGBS	1,	SGBS	2 GLI2,SP4
LDL	cholesterol PLEC rs11136341 PLEC rs10107388 rs7832643 0.394455 0.802827 26 SGBS	1,	SGBS	2 EGR1
LDL	cholesterol,CHD PSRC1 rs599839 CELSR2 rs1277930 rs12740374 0.216794 0.980703 11 SGBS	1,	SGBS	2 TFAP2A(var.2),TFAP2B,TFAP2C
LDL	cholesterol,CHD PSRC1 rs599839 CELSR2 rs1277930 rs646776 0.216794 0.980703 11 SGBS	1,	SGBS	2
LDL	cholesterol,CHD PSRC1 rs599839 CELSR2 rs1277930 rs660240 0.215901 0.975547 11 SGBS	1,	SGBS	2 RREB1
Lipid	metabolism	phenotypes	(VLDL-D) MLXIPL rs13247874 MLXIPL rs35493868 rs55747707 0.157772 0.959112 33 Tissue	1,	Tissue	2,	Tissue	3
Lipoprotein-associated	phospholipase	A2	activity	and	mass PLA2G7 rs7756935 PLA2G7 rs3757241 rs7767605 0.246503 0.976309 25 Tissue	3





Metabolic	traits ACADM rs211718 ACADM rs12094842 rs61797339 0.27165 0.990489 142 Tissue	1,	Tissue	2,	Tissue	3
NR2F1,NR4A2,Nr2e1,Pparg::Rx
ra,Sox3 SGBS	1,	SGBS	2
Metabolic	traits ENPEP rs2087160 ENPEP rs9997379 rs10033071 0.208957 0.991914 33 SGBS	2
Metabolic	traits ETFDH rs8396 ETFDH rs17843929 rs2070629 0.232963 0.994457 22 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Metabolic	traits ETFDH rs8396 ETFDH rs17843929 rs2070630 0.232963 0.994457 22 Tissue	1,	Tissue	2,	Tissue	3 TFAP2A(var.3),TFAP2C(var.3) SGBS	1,	SGBS	2 TFAP2A(var.3),TFAP2C(var.3)
Metabolic	traits LACTB rs2652822 LACTB rs2652822 rs2292038 0.478871 0.965617 16 Tissue	1,	Tissue	2,	Tissue	3 HIC2,MTF1,RARA::RXRA SGBS	1,	SGBS	2 MTF1,RARA::RXRA
Metabolic	traits LACTB rs2652822 LACTB rs2652822 rs7170846 0.476143 0.976409 16 Tissue	1,	Tissue	3 USF1 SGBS	1,	SGBS	2 USF1
Metabolic	traits NAT8 rs13391552 ALMS1 rs6740766 rs11903916 0.234253 0.880665 180 SGBS	1 EHF,ELF3,ELF4,ELF5
Metabolic	traits NAT8 rs13391552 ALMS1 rs6740766 rs4547554 0.180091 0.813533 180 Tissue	1,	Tissue	2,	Tissue	3 GCM1,Hic1
Metabolic	traits NAT8 rs13391552 ALMS1 rs6740766 rs73947808 0.212281 0.99911 180 SGBS	1 Crx,Znf423
Metabolic	traits NAT8 rs13391552 ALMS1 rs6740766 rs7564890 0.212082 0.996738 180 SGBS	1,	SGBS	2
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 8:145134151 0.0729094 1 114 SGBS	1,	SGBS	2 Nr1h3::Rxra,Sox2,Sox3,Sox6
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 8:145136999 0.0729094 1 114 SGBS	1 RARA,RHOXF1
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 8:145159708 0.0862018 0.833673 114 Tissue	1,	Tissue	2 Klf12 SGBS	1,	SGBS	2 Klf12
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 8:145181859 0.0707271 0.93719 114 SGBS	1
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 rs11136254 0.0736534 0.989105 114 SGBS	1,	SGBS	2




Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 rs11541475 0.0787124 0.920478 114 Tissue	1 Tcfl5 SGBS	1,	SGBS	2
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 rs11986647 0.0727606 0.882018 114 SGBS	1,	SGBS	2 CTCF,HINFP CTCF
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 rs12549149 0.0737526 0.987669 114 SGBS	1,	SGBS	2
EGR1,EGR3,EGR4,KLF16,KLF5,N
R2C2,RREB1,SP1,SP2,SP3,SP8 RREB1
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 rs13255347 0.0805972 0.897114 114 Tissue	1
CTCF,GCM1,GCM2,NR2C2,THA
P1 SGBS	1,	SGBS	2 CTCF,EGR4,NR2C2 CTCF
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 rs13256214 0.073951 0.984808 114 Tissue	1,	Tissue	2,	Tissue	3 Bach1::Mafk,GLIS1 SGBS	1,	SGBS	2 EGR4,SP2,ZNF740
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 rs144843136 0.0687432 0.938639 114 SGBS	1,	SGBS	2
TFAP2A(var.3),TFAP2B(var.3),T
FAP2C(var.3)
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 rs180768286 0.0724135 0.992666 114 SGBS	1,	SGBS	2 Sox2,Sox3,Sox6
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 rs6984764 0.084813 0.848611 114 Tissue	1,	Tissue	2,	Tissue	3 NRF1,REST SGBS	1,	SGBS	2
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 rs73379171 0.0687432 0.938639 114 SGBS	1
Metabolic	traits OPLAH rs6558295 CYC1 rs7836836 rs75361772 0.073703 0.988386 114 Tissue	1,	Tissue	2,	Tissue	3 GLIS1 SGBS	1,	SGBS	2 GLIS1
Metabolic	traits PDXDC1 rs7200543 PDXDC1 rs35574015 rs16966953 0.345105 0.999781 37 SGBS	1,	SGBS	2
Metabolic	traits,Phospholipid SCD rs603424 SCD rs603424 rs603424 0.11611 N/A 1 Tissue	1,	Tissue	2,	Tissue	3 TBX2,TBX20,TBX21 SGBS	1,	SGBS	2
Moyamoya	disease RNF213 rs6565681 RNF213 rs9901680 rs35096485 0.191449 0.93418 14 SGBS	1,	SGBS	2 MAFF,MAFK,NRL
Obesity ATP2A1-SH2B1 rs7498665 ATXN2L,SH2B1 rs11863370,rs62037367 16:28851377 0.431306 0.997174 107 Tissue	1 NFIC::TLX1 SGBS	1,	SGBS	2 NFIC::TLX1
Obesity ATP2A1-SH2B1 rs7498665 ATXN2L,SH2B1 rs11863370,rs62037367 rs11864750 0.429471 0.989334 107 Tissue	1,	Tissue	2,	Tissue	3 EGR1,RREB1,SP2,ZNF263 SGBS	1,	SGBS	2 EGR1,SP2,ZNF263
Obesity ATP2A1-SH2B1 rs7498665 ATXN2L,SH2B1 rs11863370,rs62037367 rs62037367 0.432001 1 107 SGBS	1,	SGBS	2 MTF1,Nr5a2
Obesity ATP2A1-SH2B1 rs7498665 ATXN2L,SH2B1 rs11863370,rs62037367 rs7187776 0.448715 0.933628 107 Tissue	1,	Tissue	2,	Tissue	3 SPI1,SPIB SPI1 SGBS	1,	SGBS	2
Obesity ATP2A1-SH2B1 rs7498665 ATXN2L,SH2B1 rs11863370,rs62037367 rs7193733 0.429422 0.988327 107 SGBS	1,	SGBS	2
Obesity ATP2A1-SH2B1 rs7498665 ATXN2L,SH2B1 rs11863370,rs62037367 rs7198606 0.432001 1 107 Tissue	1,	Tissue	2,	Tissue	3 ZNF263 SGBS	1,	SGBS	2 ZNF263
Obesity ATP2A1-SH2B1 rs7498665 ATXN2L,SH2B1 rs11863370,rs62037367 rs8055138 0.432001 1 107 Tissue	1 NR2C2,Nr2f6 SGBS	1,	SGBS	2 NR2C2,Nr2f6,ZNF263
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs10883504 0.220514 0.896472 240 SGBS	1,	SGBS	2 Nr1h3::Rxra,Vdr
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs10883505 0.220514 0.896472 240 SGBS	1,	SGBS	2 ZIC3
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs10883506 0.220067 0.894783 240 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs11190587 0.220365 0.8961 240 SGBS	1,	SGBS	2
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs11190599 0.220514 0.897046 240 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs17113137 0.218332 0.862079 240 SGBS	1,	SGBS	2 OTX1,OTX2,PITX3,Zfx
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs1800662 0.220514 0.897046 240 SGBS	1,	SGBS	2
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs2295776 0.220514 0.897046 240 Tissue	1,	Tissue	2,	Tissue	3 Klf1,RREB1,SP3 SGBS	1,	SGBS	2 Klf1,RREB1,SP3 RREB1
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs2495758 0.20246 0.999079 240 Tissue	1,	Tissue	3 SGBS	1,	SGBS	2
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs28522614 0.203055 0.983788 240 SGBS	1
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs3750626 0.220365 0.8961 240 SGBS	1,	SGBS	2
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs4919466 0.221803 0.882931 240 SGBS	1
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs7080356 0.220365 0.8961 240 SGBS	1,	SGBS	2
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs7099913 0.20251 0.999386 240 SGBS	1,	SGBS	2 Ddit3::Cebpa
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs7900678 0.221803 0.882931 240 SGBS	1,	SGBS	2
Palmitoleic	acid	(16:1n-7) NDUFB8-SCD-SEC31B-WNT8B-HIF1AN rs11190604 HIF1AN,SEC31B rs2489041,rs7071271 rs9420796 0.20241 0.999386 240 SGBS	1,	SGBS	2 RREB1






Phospholipid C11orf10 rs174538 TMEM258	(C11orf10) rs108499 rs174538 0.336723 N/A 6 Tissue	1,	Tissue	3 Creb3l2,XBP1 Creb3l2 SGBS	1,	SGBS	2 XBP1
Proinsulin LARP6 rs1549318 LARP6 rs4777325 rs7175862 0.477234 0.911488 32 SGBS	1,	SGBS	2 NFIA,NFIC::TLX1,NFIX,REST NFIA
Proinsulin MADD rs10501320 ACP2,FNBP4 rs10501320,rs11039149 rs11039149 0.179546 0.97985 7 Tissue	1,	Tissue	2,	Tissue	3 PLAG1,Pparg::Rxra SGBS	1,	SGBS	2 PLAG1,Pparg::Rxra
Stearic	acid	(18:0) RWDD3 rs6671200 RWDD3 rs34266846 rs35917978 0.089624 0.881211 87 SGBS	1 TP53,TP63,TP73
Total	Cholesterol DOCK7-ANGPTL3 rs2131925 DOCK7 rs631106 1:63153199 0.241147 0.995938 237 SGBS	1,	SGBS	2
Total	Cholesterol DOCK7-ANGPTL3 rs2131925 DOCK7 rs631106 rs10889356 0.228499 0.911899 237 SGBS	1,	SGBS	2
ELK3,ELK4,ERF,ERG,ETS1,ETV2,
ETV6,FEV,FLI1
Total	Cholesterol DOCK7-ANGPTL3 rs2131925 DOCK7 rs631106 rs1168042 0.241246 0.999729 237 SGBS	1
Total	Cholesterol DOCK7-ANGPTL3 rs2131925 DOCK7 rs631106 rs1168114 0.228846 0.910518 237 SGBS	1,	SGBS	2
Total	Cholesterol DOCK7-ANGPTL3 rs2131925 DOCK7 rs631106 rs2131925 0.241296 N/A 237 SGBS	1
Total	Cholesterol DOCK7-ANGPTL3 rs2131925 DOCK7 rs631106 rs630144 0.241494 0.997834 237 SGBS	1,	SGBS	2 Gata1
Total	Cholesterol DOCK7-ANGPTL3 rs2131925 DOCK7 rs631106 rs631106 0.241444 0.997022 237 Tissue	1 SGBS	1,	SGBS	2





Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs113119264 0.13213 0.999568 132 SGBS	1,	SGBS	2
Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs113575110 0.131336 0.905992 132 SGBS	1,	SGBS	2
Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs113642700 0.132229 0.991799 132 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs11763793 0.132923 0.99097 132 SGBS	1 GLIS2,ZIC1,ZIC4
Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs118132455 0.132179 0.999135 132 SGBS	1,	SGBS	2
Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs140138013 0.132229 0.999568 132 SGBS	2 Stat4,ZIC3
Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs1881123 0.132179 1 132 SGBS	1,	SGBS	2




Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs28522260 0.135899 0.959189 132 Tissue	1,	Tissue	3 Nr1h3::Rxra SGBS	1,	SGBS	2 Nr1h3::Rxra
Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs61753396 0.132527 0.994394 132 SGBS	1,	SGBS	2 TP53,TP63,TP73,ZIC1,Znf423
Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs74360401 0.131882 0.995678 132 SGBS	1,	SGBS	2
KLF14,KLF5,Klf1,Klf4,SP1,SP2,S
P8
Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs77760339 0.132279 0.999136 132 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs77943789 0.13585 0.961279 132 SGBS	1,	SGBS	2
Total	Cholesterol GPR146 rs1997243 GPR146 rs11764937 rs78628466 0.133221 0.990132 132 SGBS	1
Total	Cholesterol PXK rs13315871 PXK rs35557787 3:58311576 0.097411 0.983296 184 SGBS	1 IRF1,MEF2A,MEF2D
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs11708590 0.0987005 0.998885 184 SGBS	1,	SGBS	2
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs13066269 0.0977582 0.983849 184 SGBS	1,	SGBS	2
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs13317400 0.0987005 1 184 SGBS	1,	SGBS	2
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs13320620 0.0987005 1 184 SGBS	1,	SGBS	2
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs13327709 0.0987005 1 184 SGBS	1,	SGBS	2 Znf423
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs36037390 0.101379 0.963081 184 SGBS	1,	SGBS	2
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs71311853 0.0978574 0.978297 184 SGBS	1,	SGBS	2 Spz1
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs71311854 0.0976094 0.981069 184 SGBS	1,	SGBS	2
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs77825960 0.102916 0.914103 184 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs78578590 0.103462 0.919208 184 Tissue	1,	Tissue	2,	Tissue	3
EGR1,EGR4,Klf4,SP1,SP2,SP4,Z
NF740 SGBS	1,	SGBS	2 EGR1,Klf4,SP2,SP4
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs78946071 0.0993453 0.96196 184 Tissue	1,	Tissue	2,	Tissue	3 GLIS2,GLIS3 SGBS	1,	SGBS	2 GLIS2,GLIS3





Total	Cholesterol PXK rs13315871 PXK rs35557787 rs9818581 0.0973614 0.98274 184 SGBS	1,	SGBS	2 ZNF263
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs9864325 0.0987005 0.998885 184 SGBS	1
Total	Cholesterol PXK rs13315871 PXK rs35557787 rs9871725 0.0973614 0.98274 184 SGBS	1,	SGBS	2
Total	Cholesterol TMEM57 rs10903129 RHCE,TMEM50A,TMEM57
rs3093578,rs35343405,
rs78809829 rs1053438 0.485765 0.865797 179 SGBS	1,	SGBS	2
Total	Cholesterol TMEM57 rs10903129 RHCE,TMEM50A,TMEM57
rs3093578,rs35343405,
rs78809829 rs10903129 0.46538 N/A 179 SGBS	1,	SGBS	2
Total	Cholesterol TMEM57 rs10903129 RHCE,TMEM50A,TMEM57
rs3093578,rs35343405,
rs78809829 rs35172831 0.458337 0.965725 179 SGBS	1,	SGBS	2 CTCF
Total	Cholesterol TMEM57 rs10903129 RHCE,TMEM50A,TMEM57
rs3093578,rs35343405,
rs78809829 rs35260034 0.458337 0.965725 179 SGBS	2 ZNF263
Total	Cholesterol TMEM57 rs10903129 RHCE,TMEM50A,TMEM57
rs3093578,rs35343405,
rs78809829 rs35850196 0.465232 0.999003 179 SGBS	1,	SGBS	2
Total	Cholesterol TMEM57 rs10903129 RHCE,TMEM50A,TMEM57
rs3093578,rs35343405,
rs78809829 rs599691 0.485864 0.865437 179 SGBS	1,	SGBS	2
Total	Cholesterol TMEM57 rs10903129 RHCE,TMEM50A,TMEM57
rs3093578,rs35343405,
rs78809829 rs61776810 0.457693 0.963206 179 SGBS	1,	SGBS	2 RARA
Total	Cholesterol TMEM57 rs10903129 RHCE,TMEM50A,TMEM57
rs3093578,rs35343405,
rs78809829 rs631133 0.465628 0.993427 179 SGBS	1,	SGBS	2
BATF3,Creb5,JDP2(var.2),JUND
(var.2)
Total	Cholesterol TMEM57 rs10903129 RHCE,TMEM50A,TMEM57
rs3093578,rs35343405,
rs78809829 rs9438904 0.462553 0.972424 179 Tissue	1,	Tissue	2,	Tissue	3 Bach1::Mafk,CREB3L1,XBP1 SGBS	1,	SGBS	2
Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs138728 0.343468 0.88858 130 Tissue	1,	Tissue	2,	Tissue	3 EWSR1-FLI1,ZNF263 SGBS	1,	SGBS	2 EWSR1-FLI1,ZNF263
Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs138733 0.336227 0.860215 130 Tissue	3 SGBS	1,	SGBS	2
Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs138774 0.369259 1 130 SGBS	1,	SGBS	2 ATF4,RUNX1
Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs138775 0.369457 0.999149 130 SGBS	1,	SGBS	2 ZIC1
Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs1534877 0.369557 0.991919 130 SGBS	1,	SGBS	2 RXRA::VDR
Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs2235145 0.369507 0.992131 130 SGBS	1 RFX5,TFAP2B(var.2)




Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs4461 0.368565 0.991492 130 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs4462 0.36911 0.993829 130 SGBS	1,	SGBS	2
Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs4463 0.372384 0.979502 130 Tissue	3 SP1,SP2 SGBS	1,	SGBS	2 RREB1,SP1,SP2 RREB1
Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs4465 0.369259 1 130 SGBS	1,	SGBS	2 Spz1,TFAP4
Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs5755674 0.330771 0.835501 130 Tissue	1,	Tissue	2,	Tissue	3 Rfx1 SGBS	1,	SGBS	2
Total	Cholesterol TOM1 rs138777 HMGXB4 rs9306298 rs67921523 0.370747 0.988118 130 SGBS	1,	SGBS	2 Stat5a::Stat5b Stat5a--Stat5b







Triglycerides FADS1 rs174548 FADS1 rs174555 11:61594920 0.427438 0.887534 48 SGBS	1,	SGBS	2
Triglycerides FADS1 rs174548 FADS1 rs174555 11:61596322 0.427587 0.888178 48 SGBS	1,	SGBS	2 Pparg::Rxra
Triglycerides FADS1 rs174548 FADS1 rs174555 rs174529 0.426991 0.899905 48 SGBS	1,	SGBS	2 REST
Triglycerides FADS1 rs174548 FADS1 rs174555 rs174535 0.425305 0.906955 48 SGBS	1
Triglycerides FADS1 rs174548 FADS1 rs174555 rs174561 0.395496 0.968415 48 Tissue	1,	Tissue	2,	Tissue	3 EGR3,NFKB1 SGBS	1,	SGBS	2 EGR3
Triglycerides FADS1 rs174548 FADS1 rs174555 rs97384 0.434977 0.870961 48 SGBS	2
ESRRB,NFIC::TLX1,NR4A2,Nr5a
2,RUNX1
Triglycerides JMJD1C rs10761731 JMJD1C,NRBF2 rs10761739,rs7896518 rs10761731 0.366531 N/A 16 SGBS	1,	SGBS	2
Triglycerides JMJD1C rs10761731 JMJD1C,NRBF2 rs10761739,rs7896518 rs7073753 0.366333 0.998719 16 SGBS	1 HSF1,HSF2,HSF4,IRF7,IRF8
Triglycerides MLXIPL rs3812316 BCL7B,TBL2 rs2240466,rs799166 7:73022934 0.117597 0.996183 55 SGBS	1
IRF1,PRDM1,SPIC,STAT1::STAT
2
Triglycerides MLXIPL rs3812316 BCL7B,TBL2 rs2240466,rs799166 rs13231516 0.116209 0.964795 55 Tissue	1,	Tissue	3 SGBS	1,	SGBS	2
Triglycerides MLXIPL rs3812316 BCL7B,TBL2 rs2240466,rs799166 rs13233571 0.118143 0.984322 55 Tissue	1 MEIS2 SGBS	1,	SGBS	2 MEIS2
Triglycerides MLXIPL rs3812316 BCL7B,TBL2 rs2240466,rs799166 rs13246490 0.118143 0.984322 55 SGBS	1 EWSR1-FLI1
Triglycerides MLXIPL rs3812316 BCL7B,TBL2 rs2240466,rs799166 rs34430945 0.116853 0.907456 55 SGBS	1,	SGBS	2
Triglycerides MLXIPL rs3812316 BCL7B,TBL2 rs2240466,rs799166 rs799165 0.117399 0.901648 55 Tissue	1
ELK3,ELK4,ERF,ERG,ETS1,ETV2,
ETV6,FEV,FLI1,Gabpa
Triglycerides MPP3 rs8077889 DUSP3,MPP3 rs2342310,rs55768269 rs15359 0.246801 0.822301 97 SGBS	2
CTCF,Myod1,ZIC1,ZIC3,ZIC4,ZN
F410
Triglycerides MPP3 rs8077889 DUSP3,MPP3 rs2342310,rs55768269 rs2074143 0.243875 0.847199 97 Tissue	1 SGBS	1,	SGBS	2





Triglycerides MPP3 rs8077889 DUSP3,MPP3 rs2342310,rs55768269 rs746742 0.191896 0.808194 97 Tissue	1,	Tissue	2,	Tissue	3 EWSR1-FLI1,ZNF263
Triglycerides MPP3 rs8077889 DUSP3,MPP3 rs2342310,rs55768269 rs9894873 0.213917 0.985647 97 Tissue	1,	Tissue	3 NFATC1,NFATC2 SGBS	1,	SGBS	2 NFATC1,NFATC2









Type	2	diabetes AP3S2 rs2028299 ARPIN	(C15orf38) rs7174878 15:90371590 0.255729 0.986212 58 Tissue	1 SGBS	1,	SGBS	2
Type	2	diabetes AP3S2 rs2028299 ARPIN	(C15orf38) rs7174878 rs12910992 0.256225 0.995061 58 SGBS	1 CTCF
Type	2	diabetes AP3S2 rs2028299 ARPIN	(C15orf38) rs7174878 rs2165069 0.254389 0.989056 58 SGBS	1,	SGBS	2
Type	2	diabetes AP3S2 rs2028299 ARPIN	(C15orf38) rs7174878 rs4932143 0.255778 0.996875 58 Tissue	1,	Tissue	3 SGBS	1,	SGBS	2
Type	2	diabetes AP3S2 rs2028299 ARPIN	(C15orf38) rs7174878 rs4932144 0.254538 0.989316 58 SGBS	1,	SGBS	2 Rfx1
Type	2	diabetes AP3S2 rs2028299 ARPIN	(C15orf38) rs7174878 rs6496609 0.255282 1 58 SGBS	1 EHF,ELF4,ELF5
Type	2	diabetes AP3S2 rs2028299 ARPIN	(C15orf38) rs7174878 rs8031576 0.255282 1 58 SGBS	1,	SGBS	2
Type	2	diabetes AP3S2 rs2028299 ARPIN	(C15orf38) rs7174878 rs986505 0.256473 0.977689 58 Tissue	1 SGBS	1,	SGBS	2






























rs28583837 rs949142 0.19507 0.99369 215 SGBS	2
Type	2	diabetes SDHAF4	(C6orf57) rs1048886 SDHAF4	(C6orf57) rs6901232 6:71224414 0.248041 0.932155 303 Tissue	1,	Tissue	2,	Tissue	3 PAX7
Type	2	diabetes SDHAF4	(C6orf57) rs1048886 SDHAF4	(C6orf57) rs6901232 rs112809632 0.224581 0.877106 303 Tissue	2 EGR1,NR2C2,NRF1,SP2,SP8 SGBS	1,	SGBS	2 EGR1,NR2C2,NRF1,SP2,SP8
Type	2	diabetes SDHAF4	(C6orf57) rs1048886 SDHAF4	(C6orf57) rs6901232 rs12526164 0.224531 0.920498 303 SGBS	1,	SGBS	2
Type	2	diabetes SDHAF4	(C6orf57) rs1048886 SDHAF4	(C6orf57) rs6901232 rs2293297 0.224581 0.920218 303 SGBS	1,	SGBS	2
Type	2	diabetes SDHAF4	(C6orf57) rs1048886 SDHAF4	(C6orf57) rs6901232 rs4283855 0.248041 0.932155 303 Tissue	1
Type	2	diabetes SDHAF4	(C6orf57) rs1048886 SDHAF4	(C6orf57) rs6901232 rs55968813 0.224531 0.920498 303 Tissue	1
Type	2	diabetes SDHAF4	(C6orf57) rs1048886 SDHAF4	(C6orf57) rs6901232 rs6455370 0.248041 0.932682 303 SGBS	2 MEIS2,MEIS3
Type	2	diabetes SDHAF4	(C6orf57) rs1048886 SDHAF4	(C6orf57) rs6901232 rs6911983 0.224482 0.920778 303 SGBS	1,	SGBS	2
Type	2	diabetes SDHAF4	(C6orf57) rs1048886 SDHAF4	(C6orf57) rs6901232 rs75589353 0.221109 0.902394 303 SGBS	1
Type	2	diabetes SDHAF4	(C6orf57) rs1048886 SDHAF4	(C6orf57) rs6901232 rs77554252 0.221109 0.902394 303 SGBS	1
Type	2	diabetes SDHAF4	(C6orf57) rs1048886 SDHAF4	(C6orf57) rs6901232 rs9455144 0.24809 0.932432 303 SGBS	1
Venous	thromboembolism F5 rs6427196 F5 rs2420371 rs6427194 0.0470687 1 16 SGBS	1,	SGBS	2 Gfi1b,MYF6
Venous	thromboembolism F5 rs6427196 F5 rs2420371 rs6427195 0.0470687 1 16 SGBS	1,	SGBS	2 LEF1,T
Venous	thromboembolism F5 rs6427196 F5 rs2420371 rs6427196 0.0470687 N/A 16 SGBS	1,	SGBS	2 MEF2C
Venous	thromboembolism intergenic rs10504130 PCMTD1 rs80143499 rs10504130 0.253199 N/A 94 SGBS	1,	SGBS	2 STAT1::STAT2
Venous	thromboembolism intergenic rs10504130 PCMTD1 rs80143499 rs11781330 0.253199 1 94 SGBS	1,	SGBS	2
Venous	thromboembolism intergenic rs10504130 PCMTD1 rs80143499 rs12681203 0.279536 0.872865 94 SGBS	1,	SGBS	2 ZNF143
Venous	thromboembolism intergenic rs6695223 WDR63 rs10782538 rs6681402 0.0905168 0.996397 20 Tissue	1,	Tissue	2,	Tissue	3 Hoxc9,MEF2A,MEF2B SGBS	1,	SGBS	2
Venous	thromboembolism intergenic rs6695223 WDR63 rs10782538 rs6681619 0.0910624 0.989825 20 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Venous	thromboembolism intergenic rs10504130 PCMTD1 rs80143499 rs76649221 0.2531 0.999475 94 SGBS	1
Waist-hip	ratio CPEB4 rs6861681 CPEB4 rs72812818 5:173315416 0.446087 0.893898 79 Tissue	1,	Tissue	3 CTCF,EGR1,EGR3,SP2 SGBS	1,	SGBS	2 CTCF,EGR1,EGR3,SP2 CTCF
Waist-hip	ratio CPEB4 rs6861681 CPEB4 rs72812818 rs10516107 0.465331 0.999801 79 SGBS	1
RARA(var.2),RXRA::VDR,Rarb(v
ar.2)
Waist-hip	ratio CPEB4 rs6861681 CPEB4 rs72812818 rs17695555 0.465331 0.999801 79 SGBS	1,	SGBS	2
Waist-hip	ratio CPEB4 rs6861681 CPEB4 rs72812818 rs17763772 0.462851 0.981536 79 SGBS	1
Waist-hip	ratio CPEB4 rs6861681 CPEB4 rs72812818 rs55946741 0.465331 0.999801 79 Tissue	1,	Tissue	3 SGBS	1,	SGBS	2
Waist-hip	ratio CPEB4 rs6861681 CPEB4 rs72812818 rs72810974 0.452733 0.947975 79 SGBS	1,	SGBS	2 CLOCK,MYF6,SCRT1,TFEB
Waist-hip	ratio CPEB4 rs6861681 CPEB4 rs72812818 rs72812811 0.465331 0.999801 79 SGBS	1,	SGBS	2 REL,RELA
Waist-hip	ratio CPEB4 rs6861681 CPEB4 rs72812818 rs747472 0.465182 0.999203 79 SGBS	1,	SGBS	2
Waist-hip	ratio NISCH-STAB1 rs6784615 NISCH rs728408 3:52505756 0.0309493 0.937835 99 Tissue	1,	Tissue	2,	Tissue	3
Waist-hip	ratio NISCH-STAB1 rs6784615 NISCH rs728408 3:52505758 0.0309493 0.937835 99 Tissue	1,	Tissue	2,	Tissue	3
Waist-hip	ratio NISCH-STAB1 rs6784615 NISCH rs728408 rs13065677 0.0306517 0.885413 99 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
Waist-hip	ratio NISCH-STAB1 rs6784615 NISCH rs728408 rs13076508 0.0319413 0.848076 99 SGBS	1
Waist-hip	ratio NISCH-STAB1 rs6784615 NISCH rs728408 rs13096571 0.0302053 0.899079 99 SGBS	1 ATF4
Waist-hip	ratio NISCH-STAB1 rs6784615 NISCH rs728408 rs34827613 0.0300069 0.905284 99 SGBS	1,	SGBS	2
Waist-hip	ratio NISCH-STAB1 rs6784615 NISCH rs728408 rs3774409 0.0309493 0.937835 99 SGBS	1
Waist-hip	ratio NISCH-STAB1 rs6784615 NISCH rs728408 rs4312651 0.0309493 0.937835 99 SGBS	1
Waist-hip	ratio NISCH-STAB1 rs6784615 NISCH rs728408 rs758800 0.0310485 0.934718 99 Tissue	3 GATA1::TAL1
Waist-hip	ratio NISCH-STAB1 rs6784615 NISCH rs728408 rs929529 0.0309493 0.937835 99 Tissue	3 ZNF263
Waist-hip	ratio NISCH-STAB1 rs6784615 NISCH rs728408 rs9863753 0.0329332 1 99 SGBS	1,	SGBS	2





Weight AIF1 rs115963686 CSNK2B rs114899308 rs114167507 0.289803 0.949383 31 SGBS	1,	SGBS	2








Weight AIF1 rs115963686 CSNK2B rs114899308 rs116665625 0.323133 0.815493 31 Tissue	1,	Tissue	2,	Tissue	3 TBP SGBS	1,	SGBS	2
WHRadjBMI ADAMTS9 rs2371767 ADAMTS9 rs4616635 rs66815886 0.220811 0.995977 9 Tissue	3 FIGLA,TCF3,TCF4
WHRadjBMI ADAMTS9 rs2371767 ADAMTS9 rs4616635 rs7433808 0.189912 0.817086 9 Tissue	3 HSF4,SMAD3 SGBS	1 SMAD3





Table 28: Allelic imbalance in ATAC peaks
WHRadjBMI GDF5 rs224333 UQCC rs2425055 rs224331 0.399564 0.939297 104 SGBS	1
WHRadjBMI GDF5 rs224333 UQCC rs2425055 rs2425066 0.426247 0.911495 104 SGBS	1,	SGBS	2
WHRadjBMI GDF5 rs224333 UQCC rs2425055 rs3795159 0.458536 0.822012 104 SGBS	1,	SGBS	2 ESR1,RREB1 RREB1
WHRadjBMI GDF5 rs224333 UQCC rs2425055 rs6088791 0.458437 0.822343 104 SGBS	1,	SGBS	2 Stat4,ZNF263
WHRadjBMI GDF5 rs224333 UQCC rs2425055 rs6579234 0.430017 0.923435 104 SGBS	1
WHRadjBMI GDF5 rs224333 UQCC rs2425055 rs78110303 0.41603 0.984763 104 SGBS	1,	SGBS	2 EGR1,IRF2,KLF16,PRDM1,SP8
WHRadjBMI GORAB rs10919388 PRRX1 rs6427242 rs10753805 0.233161 0.941605 27 SGBS	1,	SGBS	2
WHRadjBMI GORAB rs10919388 PRRX1 rs6427242 rs6427242 0.23336 0.934523 27 SGBS	1,	SGBS	2 Nkx2-5(var.2)
WHRadjBMI GORAB rs10919388 PRRX1 rs6427242 rs824840 0.234054 0.946186 27 SGBS	2
GSX2,HNF1A,HNF1B,HOXB13,H
OXD13,SRY
WHRadjBMI JUND rs12608504 JUND rs7247222 rs10416600 0.341633 0.998457 19 SGBS	1,	SGBS	2
KLF5,Klf1,Klf12,Klf4,RREB1,SP3,
SP4
WHRadjBMI JUND rs12608504 JUND rs7247222 rs7247222 0.347981 0.939994 19 Tissue	1,	Tissue	2,	Tissue	3 PAX1,PAX5,PAX9 SGBS	1,	SGBS	2 PAX1,PAX5,PAX9
WHRadjBMI LEKR1 rs17451107 TIPARP rs10049090 rs13322435 0.315346 0.936043 16 Tissue	1,	Tissue	2,	Tissue	3 ZEB1 SGBS	1,	SGBS	2 ZEB1














WHRadjBMI LEKR1 rs17451107 TIPARP rs10049090 rs9854955 0.315296 0.936258 16 Tissue	1,	Tissue	2,	Tissue	3 SGBS	1,	SGBS	2
WHRadjBMI MACROD1 rs11231693 VEGFB rs56271783 rs2701540 0.0958734 0.902817 12 SGBS	1,	SGBS	2 ALX3,Dlx4
WHRadjBMI MACROD1 rs11231693 VEGFB rs56271783 rs2845885 0.0958734 0.902817 12 SGBS	1,	SGBS	2
ATF7,JDP2(var.2),JUN,JUND(var
.2),NR2F1,Rarg(var.2),Vdr
WHRadjBMI NKX3-6 rs7830933 STC1 rs6983481 rs11986562 0.196607 0.910969 37 Tissue	1,	Tissue	3 SGBS	1,	SGBS	2
WHRadjBMI NKX3-6 rs7830933 STC1 rs6983481 rs13273073 0.208908 0.99191 37 SGBS	2
WHRadjBMI NKX3-6 rs7830933 STC1 rs6983481 rs57220043 0.209057 1 37 SGBS	1,	SGBS	2 Bcl6,STAT1
WHRadjBMI NKX3-6 rs7830933 STC1 rs6983481 rs6983481 0.196607 0.910969 37 Tissue	1,	Tissue	3 SGBS	1,	SGBS	2
WHRadjBMI NT5DC2 rs12489828 NT5DC2,SMIM4	(C3orf78) rs6778735,rs7639267 3:52552922 0.474556 0.846162 18 SGBS	2
KLF14,KLF16,KLF5,Klf1,Klf12,Klf
4,SP1,SP2,SP3,SP4,SP8
WHRadjBMI NT5DC2 rs12489828 NT5DC2,SMIM4	(C3orf78) rs6778735,rs7639267 rs12489828 0.456453 N/A 18 SGBS	1
WHRadjBMI NT5DC2 rs12489828 NT5DC2,SMIM4	(C3orf78) rs6778735,rs7639267 rs66782572 0.452832 0.916749 18 SGBS	1
WHRadjBMI NT5DC2 rs12489828 NT5DC2,SMIM4	(C3orf78) rs6778735,rs7639267 rs7614981 0.456552 0.999201 18 SGBS	1 Stat5a::Stat5b
WHRadjBMI NT5DC2 rs12489828 NT5DC2,SMIM4	(C3orf78) rs6778735,rs7639267 rs7639267 0.448071 0.965537 18 SGBS	2
WHRadjBMI RSPO3 rs72959041 RSPO3 rs72961007 6:127440047 0.0682968 0.947962 5 SGBS	1,	SGBS	2
WHRadjBMI SNX10 rs1534696 CBX3,SNX10 rs1534696 rs1534696 0.464041 N/A 1 Tissue	1 MEF2C
WHRadjBMI TNFAIP8 rs1045241 TNFAIP8 rs7703744 rs1045241 0.326753 N/A 11 SGBS	1,	SGBS	2




WHRadjBMI TNFAIP8 rs1045241 TNFAIP8 rs7703744 rs11064 0.313213 0.939215 11 SGBS	1,	SGBS	2 MYF6,RREB1 RREB1












Tissue&1 58,279 1,894,559 6,461 381
Tissue&2 29,409 1,890,071 3,631 230
Tissue&3 49,631 1,885,394 3,836 220
Sites&in&at&least&2&samples N/A 1,451,379 2,267 18


















rs11662724 0.22 C/T 20 5 0.02 N/A Phospholipids ESCO1 70.63 Promoter EGR3,@EGR4,@PAX5,@PAX9,@TFAP2A,@TFAP2B,@TFAP2C
rs7187776 0.45 A/G 25 3 7.05E704 N/A Obesity SH2B1,*ATXN2L 0.40,@0.34 Promoter SPI1,@SPIB
rs9854955 0.32 G/A 15 5 0.04 14 3 0.01 Obesity TIPARP 0.41 Enhancer
rs13322435 0.32 G/A 18 1 3.13E704 15 3 3.23E703 Obesity TIPARP 0.41 Enhancer ZEB1
rs56406311 0.30 T/C 12 3 0.04 N/A Obesity TIPARP 0.41 Enhancer NFIC::TLX1,@NR5A2,@PLAG1,@TFAP2A,@TFAP2B,@TFAP2C
rs9817452 0.30 T/G 14 4 0.04 N/A Obesity TIPARP 0.41 Enhancer NFIC::TLX1,@NR5A2,@TFAP2A,@TFAP2B,@TFAP2C
rs111447985 0.06 C/A 17 5 0.04 11 6 0.33 Cardiac@hypertrophy RP113541N10.3,*OBFC1 0.49,@1.04 Promoter ELK1,@ELK3,@ELK4,@ERF,@ETS1,@ETV1,@ETV4,@ETV5,@FEV,@FLI1,@GABPA,@TFAP2A,@TFAP2B,@TFAP2C












CHAPTER 5: DISCUSSION 
GWAS have identified hundreds of loci associated with cardiometabolic diseases and 
traits (www.ebi.ac.uk/gwas/). To date, relatively few mechanisms have been identified at these 
loci. GWAS are powerful studies that identify many associated loci; however, functionally 
characterizing these loci presents a multi-faceted challenge and can be time consuming. 
Challenges include the noncoding nature of many GWAS loci, multiple variants in LD at each 
locus, the complexity of the underlying mechanisms themselves, and the time and cost of 
evaluating each locus individually. Statistical fine-mapping, overlap of predicted genomic 
regulatory elements, and functional assays can be combined to prioritize and identify causal 
variants. Genome-wide approaches are needed to better characterize the regulatory landscape of 
cardiometabolic tissues. Identifying causal variants is a critical step in understanding the genetic 
mechanisms and etiology of complex cardiometabolic diseases.  
The noncoding nature of many GWAS loci makes characterizing biological function 
challenging. The most probable mechanism is that variants act by altering gene regulation (223). 
Thus, understanding the regulatory landscape of cardiometabolic-relevant tissues is necessary to 
prioritize candidate variants. The regulatory landscape includes regions of open chromatin, sites 
of transcription factor binding, and histone marks; these data can be combined to create predicted 
chromatin states such as promoters, enhancers, and repressors. The ENCODE and Roadmap 
Epigenomics projects (59,60) have generated a wealth of regulatory datasets in diverse cell 
types; however, data for some cell types is still limited, particularly for adipose tissue and 
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pancreatic islets. In Chapter 4, we generated ATAC-seq open chromatin profiles from human 
subcutaneous adipose tissue and the preadipocyte cell strain, SGBS. By interrogating the open 
chromatin profiles of adipose tissue and preadipocytes, we can better prioritize candidate 
variants for functional experiments and identify disease-relevant regulatory regions. As shown in 
Chapter 4, ATAC-seq open chromatin alone identified a regulatory variant at the SNX10 WHR 
GWAS locus, and ATAC-seq peaks were enriched in disease-relevant adipose enhancers. 
Cellular environment can alter chromatin state, especially for cardiometabolic phenotypes, where 
both genetic and environmental factors contribute to phenotype; additional experiments are 
needed to characterize regulatory landscapes across various cellular conditions (e.g. mature 
adipocytes and insulin or glucose treatment). Together, the ATAC-seq data generated from both 
adipose tissue and preadipocytes add to the growing understanding of gene regulation and the 
genetics of cardiometabolic traits and diseases.  
Variants at a GWAS locus can be prioritized using statistical fine-mapping analyses such 
as MANTRA, CAVIAR, and PAINTOR and annotation with evidence of regulatory elements. 
While statistical fine-mapping analyses are informative and can help the variant prioritization 
process, several limitations exist. Most statistical fine-mapping analyses return a list of variants, 
or “credible set”, that could contribute to the association signal, which requires all or a subset of 
variants to be tested in functional assays requiring significant time and resources. Another 
limitation of statistical fine-mapping are the inconsistent results that can arise by comparing 
existing statistical methods. Each method makes different assumptions about the contributions of 
underlying variants and applies different strategies incorporating genetic association, LD, and 
functional annotation. At the ANGPTL8 locus, we used three fine-mapping methods (MANTRA, 
CAVIAR, and PAINTOR) to prioritize candidate variants. MANTRA identified a credible set of 
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ten variants. CAVIAR identified 24 variants in the Finnish credible set and two in the African 
American credible set. PAINTOR identified ten, seven, and five variants in Finnish, African 
American, and the combined studies, respectively. Of the 39 variants identified in at least one 
fine-mapping analysis, only 12 were identified in at least two analyses, and only 4 in all three 
analyses. From my experience, current fine-mapping analyses are most informative when 
combined with regulatory overlap and functional testing of all probable variants. 
The genetic mechanisms at GWAS loci can complicate the identification of causal 
variants. Identifying the target gene(s) at a GWAS locus is a fundamental part of elucidating the 
molecular mechanism; however, these genes remain largely unknown for most GWAS loci. 
GWAS loci in noncoding regions can have multiple genes that appear to be good functional 
candidates based on gene function and expression, rare coding variant effects, chromosome 
interactions, and/or literature review. To complicate matters further, multiple genes can be 
targeted at a single locus (224). eQTL data can be used to identify which gene(s) are most likely 
to be targeted at a given locus. In Chapter 3, we showed a subcutaneous adipose eQTL 
association for both ANGPTL8 and DOCK6. Biological roles and a stronger eQTL association 
suggest ANGPTL8 is the target gene; however, further experiments are needed to fully delineate 
the role of ANGPTL8 and/or DOCK6. When we published the CDC123/CAMK1D work, eQTL 
associations had been identified for both CDC123 and CAMK1D in whole blood and lung tissue 
(84,225). Since our publication, in conjunction with collaborators, we have published a large 
pancreatic islet eQTL study, which identified an eQTL association with GWAS variants, 
including rs11257655, for CAMK1D (P=4.2x10-9) but not CDC123 (61). The eQTL association 
in pancreatic islets provides strong evidence that CAMK1D is a target gene and that CAMK1D 
plays a role in T2D biology. eQTL studies in additional tissues with larger sample sizes, 
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especially in liver and other cardiometabolic tissues, are needed to help delineate additional 
target genes at these and other GWAS loci. Additionally, variants may only affect expression in 
a specific cellular environment (e.g. when transcriptional regulators are induced); thus, context-
specific eQTL studies may be necessary to identify the missing variant-gene connections. 
Understanding how associated variants act on gene expression is a vital piece to the complex 
genetics puzzle. 
While a single functional variant is the simplest explanation of a GWAS signal, and such 
mechanisms exist (53,226,227), many loci consist of multiple functional variants (54,138). At a 
single locus, variants may be acting in concert in promoters, enhancers, and repressors to alter 
gene expression, which adds to the complexity of determining mechanisms at GWAS loci. At the 
CDC123/CAMK1D T2D GWAS locus, we identified a straightforward molecular mechanism 
with one functional variant, rs11257655, which displayed allelic differences in both 
transcriptional activity and binding of FOXA1 and FOXA2 (Chapter 2). At the ANGPTL8 HDL-
C GWAS locus, the mechanism was more complex (Chapter 3). What began as a straightforward 
locus with only four candidate regulatory variants (r2>0.8 in European populations), turned into 
an extremely complex locus with 42 candidate regulatory variants (r2>0.5 in African and/or 
European populations), in which I identified seven variants that exhibited allelic differences in 
regulatory activity in cells or in vitro. Evaluating variants at individual GWAS loci allows for the 
most thorough and accurate identification of potentially functional variants. 
The functional assays described in this dissertation (i.e. transcriptional reporter and in 
vitro DNA-protein binding assays) elucidate limitations to and effort involved in experimentally 
validating candidate variants. Transcriptional reporter luciferase assays are limited in that they 
do not represent the native chromatin context. The cloned plasmid does not contain nucleosomes 
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and cannot loop to form the proper chromatin structure present in the cell. We identified 
functional variants at the CDC123/CAMK1D and ANGPTL8 GWAS loci, but we may have 
missed potentially functional variants. In addition, regulatory regions tested may show a stronger 
effect if investigated within the native chromatin context. EMSA experiments determine if 
proteins are binding to the region of DNA containing a variant; however, they are in vitro assays 
and transcription factors may bind in vitro more readily than in cells. Additionally, it is often 
difficult to determine the identity/identities of the transcription factor(s) responsible for 
regulatory mechanisms. Transcription factor binding motifs and chromatin immunoprecipitation 
(ChIP-seq) data can be informative for identifying proteins binding to variant alleles. Moreover, 
transcription factor footprints identified in sequencing data can be more informative than motifs 
alone, as demonstrated in Chapter 4 using ATAC-seq data. Even with motifs, ChIP-seq data, and 
footprints, identifying the correct factor remains challenging. For example, at the ANGPTL8 
locus (Chapter 3), I performed supershift assays using ~40 antibodies for candidate transcription 
factors, many of which had predicted binding motifs or previous evidence of at least indirect 
binding from ChIP-seq data, to attempt to determine the identity of the allele-specific protein 
complex binding to rs737337-C. Only one antibody (RXRa) showed a supershift; however, the 
supershift was observed in both alleles, suggesting RXRa is not the allele-specific protein. The 
lack of supershifts may be due to poor antibody specificity, insufficient length of the probe, 
incorrect assay conditions, or simply not testing for binding of the correct target protein/factor. 
Once a transcription factor is identified using in vitro assays, allelic differences in binding can be 
confirmed by performing ChIP assays in cells or tissues of differing genotypes. Elucidating the 
effects of variants on transcriptional activity and protein binding provide strong evidence of 
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potentially functional variants at GWAS loci and are among the best initial experiments to 
examine GWAS variant function. 
Additional experiments will be necessary to fully characterize the mechanism at the 
CDC123/CAMK1D and ANGPTL8 GWAS loci. At ANGPTL8, the transcription factors binding 
to variant alleles need to be identified. Additionally, at both loci, physical chromatin interaction 
and/or genome editing experiments would confirm the target genes, effect on transcription, and 
downstream phenotype effects. Physical interaction experiments are used to identify chromatin 
loops between promoters, enhancers, and other regulatory regions. Chromatin conformation 
assays would solidify the relationship of the identified regulatory regions in Chapters 2 and 3 and 
target gene promoters. In addition, entire regulatory regions can be deleted or specific variants 
mutated using CRISPR-Cas9 genome editing to evaluate the effect of altered regulatory elements 
in vivo (228-230). After isolating edited clones, RNA levels of nearby genes are measured and 
downstream metabolites or other phenotypes can be quantified to determine the effect of the 
variant or regulatory region. Such experiments were conducted at the ADCY5 T2D GWAS locus 
(227), where deletion of the regulatory region containing rs11708067 resulted in decreased 
ADCY5 expression levels and decreased insulin secretion in pancreatic islet beta cells. Physical 
chromatin interaction and genome editing experiments are robust approaches because the 
chromatin remains in its native context throughout the experiment. Future experiments will 
further solidify the mechanism at the CDC123/CAMK1D and ANGPTL8 GWAS loci.  
Future experiments will increase the power of ATAC-seq; we are currently expanding to 
include ~400 clinical subcutaneous adipose samples from the METSIM study. As mentioned 
previously, the METSIM study contains genotypes, expression, and clinical trait data in the same 
samples. With ~400 ATAC-seq profiles, we will have reasonable statistical power to identify 
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chromatin quantitative trait loci associations (cQTL). Similar to allelic imbalance in open 
chromatin sequencing reads, these cQTL associations will delineate where in the genome a 
variant allele alters chromatin accessibility. Variants that alter chromatin accessibility are more 
likely to be functional variants (172) and cQTL associations will add to strength our ability to 
prioritize candidate GWAS variants.  
Since the advent of GWAS, we have gained significant insight to the genetics of complex 
cardiometabolic traits. One model to explain the hundreds of GWAS loci suggests an 
“omnigenic” mode of inheritance, where gene regulatory networks are so highly interconnected 
that all genes expressed in relevant tissues contribute to all cardiometabolic traits (231). 
Regardless of whether this or other hypotheses are true, significant work is needed to understand 
how the thousands of noncoding variants alter gene expression and downstream phenotypes. 
Given the small effect sizes of most GWAS loci, significant work is needed to understand the 
network of genes contributing to cardiometabolic phenotypes and how these genes interact 
together to increase risk for cardiometabolic diseases. Although some massively-parallel 
regulatory assays exist (232,233), fully elucidating the mechanism of each locus will require 
locus-specific analysis. Testing candidate variants locus-by-locus is time-consuming and 
expensive. However, new methods including CRISPR-Cas9 genome editing can improve the 
speed of regulatory element identification and allow for testing variants in the native chromatin 
context (227,228). In this set of studies, I have tested candidate variants at two GWAS loci and 
generated open chromatin profiles for adipose tissue and preadipocyte cells. Together, these 
results contribute to a broad understanding of genetic regulation of the human genome and 
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